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disease risk. These studies aim to address what reprogramming events these 
stressors initiate in the womb and what the implications of these outcomes are for 
the onset and severity of childhood and adult diseases; such as insulin resistance 
and associated non-communicable diseases including obesity, cardiovascular 
disease and hypertension. More importantly, the research sets out to understand 
the degree of plasticity of these changes by investigating if they are locked after 
being reprogrammed, or are there windows of opportunity for intervention and 






Preface to “Nutrition in Pregnancy” 
Maternal nutrition during pregnancy, and how this impacts placental and 
fetal growth and metabolism, is of considerable interest to women, their partners 
and their health care professionals. In developing countries, maternal 
undernutrition is a major factor contributing to adverse pregnancy outcomes and 
an increased adverse metabolic health risk in postnatal life. Conversely, with the 
increased prevalence of high calorie diets and resulting overweight and obesity 
issues in developed countries, the impact of overnutrition on pregnancy outcome 
is highlighted as a contributing factor for adverse metabolic outcomes in offspring 
later in life. Both epidemiological and animal studies now highlight that 
undernutrition, overnutrition, and diet composition negatively impact 
fetoplacental growth and metabolic patterns, having adverse later-life metabolic 
effects for the offspring. This Special Issue Book aims to highlight new research in 
a number of these abovementioned areas across the early life course. 
A great deal of data now highlights the periconceptional period as a critical 
period upon which insults may generate later-life physiological and metabolic 
changes in the resulting offspring. In the review submitted by Padhee and 
colleagues, the procedures of ARTs are examined, specifically in terms of how 
common procedures associated with the handling and preparation of gametes and 
embryos may impact later-life metabolism, particularly impacting offspring 
cardiometabolic health. These later-life poor metabolic outcomes are also 
understood to be established during pregnancy. In surveying preconceptional 
women, pregnant and lactating women and women of reproductive age, Cuervo 
et al. report that these groups are not consuming appropriate foods for their 
physiological status, based upon the Spanish dietary guidelines and highlight a 
real need for improved education and community outreach programs to these 
groups of women to ensure adequate maternal and thus fetal nutrition. 
Poor maternal nutritional intake after the periconceptional period during 
pregnancy can also negatively impact fetal growth trajectory and can result in 
fetal growth restriction. Vonnahme et al., describe the effects of maternal 
undernutrition on vascularity of nutrient transferring tissue during different 
stages of pregnancy. In addition to maternal nutrient supply, the effectiveness of 
the placenta in transporting nutrients and oxygen to the fetus is important in 
determining fetal growth. A range of adaptations to placental development occur 
when the fetus is growth-restricted and these are described by Zhang et al. 
Regardless of the cause of low birth weight, Zheng et al. show a relationship 
between the placental microbiome and fetal growth. Zohdi et al. describe the 
effects of maternal protein restriction during pregnancy on fetal development that 
increase the risk of cardiovascular disease later in life. Davis et al. illustrate the 





highlighting the important role of norepinephrine in regulating fetal growth but 
not pancreatic mass in the growth-restricted fetus. Wood-Bradley and team 
provide a review of the literature surrounding the potential mechanisms by which 
maternal nutrition (focusing on malnutrition due to protein restriction, 
micronutrient restriction and excessive fat intake) influences offspring kidney 
development and thereby function in later life. In the same light, Blumfield et al. 
detail evidence that a maternal diet during pregnancy that is low in protein is 
related to higher systolic blood pressure in childhood. Furthermore, Colon-Ramos 
and colleagues investigated the potential association between maternal dietary 
patterns during pregnancy and birth outcomes in a diverse population with a 
historically high burden of low birth weight and other adverse birth outcomes. 
Experiences in the perinatal period also play a key role in defining how 
offspring respond to stress(es) in postnatal life. On this point, Tsuduki and 
colleagues report upon the impact of a high fat diet during mouse lactation, where 
it appears to increase the susceptibility of later-life obesity induced through 
postnatal social stress. This paper highlights the importance of understanding 
how an early life environment predisposes offspring to potential detrimental 
responses to postnatal adverse situations. In a review by Dunlop et al., the impact 
of fetal growth restriction on postnatal metabolism in skeletal muscle, but also the 
effect of a “second hit”, such as a Western diet in postnatal life, is presented. 
While meeting dietary guidelines is important, overall maternal health status 
also plays a pivotal role in determining fetal nutrient supply. In situations of 
maternal disease, such as infection with human immunodeficiency virus (HIV), 
the ability of the mother to consume sufficient substrates to maintain herself and 
meet fetal demands is often compromised. Also in situations of HIV, resting 
energy expenditure is increased and the disease may limit dietary intake and 
reduce nutrient absorption, in addition to influencing the progression of HIV 
disease as reported by Ramlal and colleagues. Their study described typical diets 
of HIV-infected, pregnant Malawian women and highlighted that poor quality 
maternal diets should be enhanced to meet demands of this particular group of 
pregnant women, vulnerable to both HIV and malnutrition. 
While deficiencies in nutrition during pregnancy can result in adverse 
offspring outcomes, once pregnant, maternal weight gain during and after 
pregnancy are critical issues both for maternal and fetal health. In the pilot RCT 
report led by Martin et al., a cohort of women were recruited with the aim of 
reducing postpartum weight retention and improving breastfeeding outcomes. 
The findings indicate that the approach reported is feasible and acceptable to 
pregnant women and that the methodology, including the collection of blood for 
biomarker assessment, could be adapted based on qualitative feedback to a larger, 
adequately powered RCT. Assessing maternal body composition, as part of 





estimate the requirements for dietary energy during gestation and when 
investigating relationships between maternal nutritional status and offspring 
development. Forsum and co-workers investigate the possibility of estimating 
body density and the use of a two-component model (2CM) to calculate total body 
fat, concluding it may present a new clinically appropriate methodology. 
Many nutritional studies in pregnancy have focused on the impact of changes 
in total or macronutrient intake. This current issue features several studies that 
expand our knowledge regarding nutrient uptake during pregnancy, but have 
focused on changes in micronutrients during pregnancy. Grieger and Clifton, 
provide updated evidence from epidemiological and RCTs on the impact of 
dietary and supplemental intakes of omega-3 long-chain polyunsaturated fatty 
acids, zinc, folate, iron, calcium, and vitamin D, as well as dietary patterns, on 
infant birth weight. Additionally, in studying maternal intakes of polyunsaturated 
fatty acids (PUFAs), Bascuñán et al. report a Chilean study that highlights the 
need for new strategies to improve n-3 PUFA intake throughout pregnancy and 
breastfeeding periods and the need to develop dietary interventions to improve 
the quality of consumed foods with particular emphasis on n-3 PUFA for 
adequate fetal development. Fish intake during pregnancy is recognized as an 
important source of PUFAs. Starling and co-workers present a systematic review 
of fish intake during pregnancy and fetal neurodevelopment. The review covers 
approximately a 14 year period of publications between January 2000 and  
March 2014 involving over 270 papers, of which only eight were selected for a 
qualitative comparison of study findings. 
Deficiencies in a range of micronutrients in low vs. middle income countries 
that may act through epigenetic mechanisms to influence fetal development and 
risk of chronic disease in adult life are identified by Darnton-Hill et al. They also 
discuss supplementation programs. One particular micronutrient that is important 
for sulphonation of steroids and hormones is sulphate. Dawson et al. describe the 
requirements for sulphate during pregnancy, the consequences of reduced 
sulphonation capacity and the use of animal models to adequately understand the 
role of sulphate in human pregnancy. Folic acid and Vitamin B12, are crucial 
factors for metabolic pathways, and have been extensively studied and 
demonstrated to play important roles in preventing the development of neural 
tube defects (NTDs). Wang et al. present data that in a local Chinese population 
consumption of non-staple foods such as milk, fresh fruits, and nuts were 
associated with decreasing NTDs risk in offspring. Further independent roles for 
folate and Vitamin B12 deficiency amongst pregnant women are presented in this 
Issue. The relationship between maternal Vitamin B12 and neonatal HDL is 
presented by Adaikalakotwewari et al. Further, folate deficiency resulting in birth 
defects is highlighted by Li et al., who present a mouse model to provide evidence 





The importance of adequate Vitamin D in women of reproductive age and its role 
in fetal development is of great interest and importance. A review of calcitrol 
biosynthesis during pregnancy, particularly in the placenta is presented by 
Olmos-Ortiz et al. Additionally, Choi et al. describe the high prevalence of 
Vitamin D deficiency in Korean women during pregnancy, particularly in the 
winter, while Yu et al. report the cord blood Vitamin D in babies born in Shanghai. 
Finally regarding Vitamin D, the impact of sun exposure and Vitamin D 
supplementation on achieving appropriate Vitamin D status in women whom are 
breastfeeding is explored by Dawodu and colleagues. 
In this Special Issue Book, several new studies highlighted the importance of 
diet intake and composition upon maternal and fetal well-being parameters in 
human population and animal studies. Many of these studies show that 
deficiencies in consumption/delivery of components (e.g., protein, vitamins, 
PUFAs) of a diet can lead to adverse fetal/offspring development and detail how 
consumption of certain foods may have beneficial effects on fetal/offspring growth 
and development. We hope that the articles contained within this Special Issue 
Book, and the material they reference and describe, are of interest to women, their 
partners and their health care professionals in promoting continual and informed 
dialogue about nutrition in pregnancy. 
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The Periconceptional Environment and
Cardiovascular Disease: Does In Vitro
Embryo Culture and Transfer Influence
Cardiovascular Development and Health?
Monalisa Padhee, Song Zhang, Shervi Lie, Kimberley C. Wang,
Kimberley J. Botting, I. Caroline McMillen, Severence M. MacLaughlin and
Janna L. Morrison
Abstract: Assisted Reproductive Technologies (ARTs) have revolutionised reproductive
medicine; however, reports assessing the effects of ARTs have raised concerns about
the immediate and long-term health outcomes of the children conceived through
ARTs. ARTs include manipulations during the periconceptional period, which
coincides with an environmentally sensitive period of gamete/embryo development
and as such may alter cardiovascular development and health of the offspring in
postnatal life. In order to identify the association between ARTs and cardiovascular
health outcomes, it is important to understand the events that occur during the
periconceptional period and how they are affected by procedures involved in ARTs.
This review will highlight the emerging evidence implicating adverse cardiovascular
outcomes before and after birth in offspring conceived through ARTs in both human
and animal studies. In addition, it will identify the potential underlying causes
and molecular mechanisms responsible for the congenital and adult cardiovascular
dysfunctions in offspring whom were conceived through ARTs.
Reprinted from Nutrients. Cite as: Padhee, M.; Zhang, S.; Lie, S.; Wang, K.C.;
Botting, K.J.; McMillen, I.C.; MacLaughlin, S.M.; Morrison, J.L. The Periconceptional
Environment and Cardiovascular Disease: Does In Vitro Embryo Culture and Transfer
Influence Cardiovascular Development and Health?. Nutrients 2015, 7, 1378–1425.
1. Introduction
In recent years, the use of Assisted Reproductive Technologies (ARTs) have
increased rapidly as a result of increasing infertility rates in humans and increasing
demand for the reproduction of livestock with desired genetic characteristics. There
are, however, a range of controversial issues surrounding in vitro embryo culture and
embryo transfer, both of which are important processes in ARTs. These processes
occur during the periconceptional period and are known to involve manipulation
of the nutritional environment. Hence, to understand the link between ARTs and
their effects on cardiovascular health, we need to understand and address these
major questions:
3
(1) When is the periconceptional period?
(2) Why is the periconceptional period a critical window of embryonic development?
(3) What are the different procedures involved in ARTs and how do these impact
the periconceptional environment?
(4) What is the evidence that the periconceptional environment influences
cardiovascular health in fetal life and in adulthood?
(5) What is the evidence that ARTs influence cardiovascular health before and
after birth?
(6) What are the most likely mechanisms linking ARTs and risk of cardiovascular
disease in fetal and adult life?
2. When Is the Periconceptional Period?
ARTs involve manipulations that occur during oocyte maturation, fertilization
and preimplantation, each of which is part of the periconceptional period and are
likely to involve changes in the nutritional environment during this period [1,2].The
term “periconceptional” is defined as the period before and immediately after the
time of conception and is a critical period during early development [3]. Most human
studies have included different time frames in defining the periconceptional period
and these depend on the specific research questions (Figure 1). For example, a
study of maternal multivitamin supplementation in the periconceptional period
on congenital abnormalities, included from one month prior to conception to
about two months after conception [4]. Another study investigating the effect of
periconceptional maternal characteristics on embryonic development has defined
14 weeks prior to conception as the periconceptional period [5].
Similar to human studies, animal studies have used different timings around
conception to define the periconceptional period (Figure 1). For example, the
periconceptional period is defined as 3–6 days before and 1 day after conception
in one study and 3.5 days before and after conception in another study in mice
(term, 19 days) [6,7]. In rats (term, 21 days), the periconceptional period is defined
as 3 weeks prior to and 5 days after conception, whereas in another study, it is
defined as 4.25 days after conception [8,9]. In sheep (term, 145–150 days), different
definitions of the periconceptional period have been used to investigate the impact
of maternal nutrition in the periconceptional period on the development and health
of the offspring (Figure 1). The Auckland model defines the periconceptional
period as extending from 60 days prior to conception until 30 days gestation
(term, 145 days) [10,11]. This period includes oocyte maturation, preimplantation
and postimplantation of the embryo as well as early placentation [12], because
implantation occurs on day 16 of gestation in sheep [12]. The Nottingham model
includes the period between day 0 till day 30 of gestation (term, 147 days), which
covers embryo/blastocyst development, preimplantation development of the embryo
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and the period of implantation [13]. A commonality between these models is
that the period of intervention extends beyond the periconceptional period to the
postimplantation period and thus includes processes such as development of the
uterine glands which provide nutrition (uterine histotroph) to the developing embryo
and the process of placentation [14] Thus extension into the postimplantation period
may not provide evidence of changes that are specific to manipulations during
oocyte maturation and embryo development [15]. In contrast, the Adelaide model
is restricted to the critical windows of oocyte maturation and preimplantation
embryo development (60 days prior conception to 7 days after conception; term,
150 days) [16]. Similarly, the Southampton model also includes 15 days before
until 15 days after conception (term, 147 days), which includes oocyte maturation
and blastocyst formation [17].Therefore, isolating the impact of perturbations
during oocyte maturation and the preimplantation period alone from those of the
postimplantation and placentation periods [18–20].
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Figure 1. Different models of the periconceptional period in studies in humans,
rodents and ruminants include different stages of oocyte and embryo development.
Note: Implantation occurs at different days after conception across species (Human,
7–9 days; Rodents, 6–7 days; Sheep 16 days) [4–10,13,16,17].
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3. Why Is Periconceptional Period a Critical Window of Development?
3.1. Oogenesis Occurs Early in Life
A women’s reproductive function is determined in fetal life because the
specialized cells known as primordial germ cells (PGCs), that give rise to gametes,
are present within the wall of the yolk sac at 4–6 weeks gestation [21–23]. PGCs
migrate from the yolk sac to the genital ridge between 6 and 12 weeks gestation
and differentiate into oogonia after becoming invested by somatic support cells [21].
By 12 weeks gestation, oogonia commence the first meiotic prophase and are called
primary oocytes. Immediately after this, they become dormant in the early diplotene
stage [23]. When the nuclei of these primary oocytes enlarge and become watery, the
primary oocytes are known as germinal vesicles. The primary oocyte, surrounded by
a single layered, squamous capsule of epithelial follicles is the primordial follicle [24].
At ~5 months gestation, the pool of these follicles reaches its peak of ~7 million,
however, most of these follicles degenerate and the maximum number of oocytes a
female will have in her lifetime is set at birth, ranging from 700,000 to 2 million [25,26],
with only 400,000 follicles remaining at puberty [23,25]. Any changes in the maternal
nutritional environment such as under- or overnutrition can affect oogenesis and
other reproductive functions and hence can have an impact on the granddaughter’s
reproductive health [27–30]. Studies have also shown that nutritional manipulations
during pregnancy can have transgenerational effects, since they not only alter
cardiovascular outcomes in the offspring but can also result in cardiovascular
dysfunction and alter glucose and insulin control in the next generation [31–34].
Thus, in addition to understanding the impact of ARTs on the cardiovascular health
of the offspring, it will be of interest to understand the impact on the grandchildren.
During and after puberty, hormonal secretions from the hypothalamus, anterior
pituitary gland and ovary regulate the menstrual cycle, which averages 28 days
in humans, 17 days in sheep and 4–5 days in rodents [35–38]. A small group
of primordial follicles are converted into primary follicles with a decrease in
inhibitory signals and/or an increase in stimulatory factors which remain largely
unknown [39–41]. The granulosa cells undergo a squamous to cuboidal epithelial
morphology from primordial to primary, and then several layers of granulosa cells
begin to develop to form secondary follicle and the theca cells emerge in the transition
from primary to secondary follicle [23,40]. A thick glycoprotein layer surrounds the
surface of the oocyte known as zona pellucida [42]. Some of these follicles degenerate,
but a few enlarge in response to rising levels of follicle stimulating hormone (FSH)
and develop a fluid filled cavity known as the antrum from fluid generated by
granulosa cell secretions and by plasma transudate (antral follicle) [43,44]. Eventually,
one of the antral follicles becomes dominant (mature Graafian follicle), while the
others degenerate [41]. At ~13–14 days of the menstrual cycle in humans, the primary
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oocyte resumes meiosis under the influence of the ovulatory surge of luteinizing
hormone (LH) caused by positive feedback of estrogen, produced by the dominant
follicle, on the pituitary gland and hypothalamus [23]. At the end of the first
meiotic division, a small polar body containing a set of chromosomes is released
into the perivitelline space [24]. Then the oocyte progresses to the second meiotic
division, where it is again arrested in metaphase ~3 h before ovulation. Follicular
rupture and ovulation occurs ~38 h after the beginning of the ovulatory surge [23].
The oocyte then moves into the ampulla of the oviduct and remains viable for
fertilization for 24 h. Fusion of the sperm enables the oocyte to resume meiosis [45].
At the end of the second meiosis, the oocyte divides into two unequal cells: a polar
body and the female pronucleus. The sperm loses its nuclear envelope, undergoes
chromatin decondensation and replacement of the sperm specific protamine by
histones. The DNA from the sperm binds to the histones in the oocyte and is
surrounded by a new nuclear envelope of maternal origin, which forms the male
pronucleus. The fusion of the pronuclei of sperm and oocyte results in a zygote [46].
Perturbations during oocyte maturation, such as those that may occur during parts
of ART (ovarian hyperstimulation, in vitro maturation and in vitro fertilization (IVF))
have been shown to reduce the quality of oocytes and embryo viability as well as alter
energy metabolism of the oocytes [47,48]. This has been shown to result in delayed
embryonic development, increased abnormal blastocyst formation, fetal growth
retardation, increased fetal loss, congenital malformations, imprinting disorders,
and a range of postnatal growth and development disorders such as poor cognitive
development, increased risk for neurological problems, cardiovascular diseases and
respiratory tract infections [47,49–54]. In addition, superovulation can also perturb
proper placental and fetal development by altering trophoblast differentiation and
distribution of cell types in the placenta [55].
3.2. Key Events in Embryonic Development during the Periconceptional Period in
Different Species
Studies in humans and animals have shown that nutritional manipulations
during blastocyst formation, such as culturing the embryo in media, have been
associated with cleavage anomalies, improper embryo development, an altered
placental transcriptome, fetal and birth defects, increased blood pressure, vascular
dysfunctions, poor neuromotor development, behavioural disorders and imprinting
disorders [56–63]. In addition, the maturation of endometrium in human also
takes place before implantation and studies have shown that ovarian stimulation
could alter endometrial receptivity and impair implantation rate [64,65]. There
is variation between species in the timing of ovulation after the beginning of
estrous, completion of the second cleavage, hatching from the zona pellucida and
implantation [66]. The steps from fertilization to implantation of the embryo include
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several major processes such as decondensation of parental genomes and cleavage to
blastomere formation which includes an equal first cleavage (2 cell), and subsequent
asynchronous division resulting in 4, 8, 16, 32 cell stages; (Table 1) [23,46]. With the
development of a fluid filled cavity by the process of compaction, a blastocyst is
formed [23]. The inner cell mass of the blastocyst will give rise to the embryo, the
yolk sac, amnion and allantois while the outer cell mass develops into the chorion.
As the hydrostatic pressure of the fluid increases within the cavity of the blastocyst,
it expands and the zona pellucida is digested by enzymes which allow hatching
of the embryo. This is followed by implantation of the embryo in the uterine wall
(Table 1).
3.2.1. Humans
Ovulation occurs in the middle of the menstrual cycle i.e., around the 14th day
of the cycle [67]. After fertilization, the formation of 2 cell (first cleavage), 4 cell, 8 cell
and 16 cell (morula) stages take place at 24, 40, 50, 72 h, respectively. By the 5th day,
the blastocyst is formed, followed by zona hatching at 5–7 days and implantation at
7–9 days (Table 1).
Table 1. Timing of important events in the periconceptional period in relation to
ovulation [66,68,69].
Timing of events during the
periconceptional period Human Mouse Rat Sheep
Time between ovulations 28 days 4–5 days 4–5 days 17 days
Time to 2 cell stage (first cleavage) 24 h 21–23 20.6 h 24–26 h
Time to 4 cell stage 40 h 38–50 72 h 30–36 h
Time to 8 cell stage 50 h 50–60 78 h 42–45 h
Time to 16–32 cells (morula stage) 72 h 60–70 84 h 63–86 h
Formation of blastocyst 5 days 3–4 days 4–5 days 5–6 days
Zona hatching 5–7 days 3.5 6 days 8 days
Implantation 7–9 days 4–5 days 6–7 days 16 days
Zygotic gene activation 40–50 h 24 h 24 h 30–45 h
3.2.2. Rats
Ovulation in rats and mice occurs after the first two stages (proestrus and estrus)
of estrous cycle, which is ~10 h after the start of estrus [70,71]. The embryo divides
to form the 4 cell stage (second cleavage) by 38–50 h in mice and 72 h in rats, which
is at a later time point than in humans. The blastocyst is formed at around 3–4 days
in mice and 4–5 days in rats followed by hatching at day 3–3.5 in mice and at day 6
in rats. Implantation occurs at days 4–5 in mice and 6–7 in rats [72,73] (Table 1).
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3.2.3. Sheep
Ovulation occurs 20–30 h after the beginning of estrus [35]. After the fertilization,
the first cleavage division occurs 24 h after ovulation (Table 2), followed by the 4, 8
and 16 cell stages at 30–36 h, 42–45 h and 63–86 h, respectively. The formation of the
blastocyst occurs between 5 and 6 days after ovulation in sheep [12,74]. Hatching
takes place at day 8, so that elongation can occur prior to implantation at day 16 [12].
3.3. Zygotic Gene Activation Occurs during Early Embryogenesis
One of the major events after fertilization is the transition of control of the
developmental program of the zygote/embryo from maternally derived transcripts
and proteins accumulated in the oocyte during the process of oogenesis to embryonic
transcripts and proteins [75]. This transition is known as zygotic gene activation
or embryonic gene activation [76]. Zygotic gene activation is associated with three
main functions: (i) to degrade maternally inherited transcripts; (ii) to replace the
oocyte specific transcripts that are common to both the oocyte and early embryo
with zygotic transcripts; and (iii) to promote the generation of novel embryo specific
transcripts by reprogramming the pattern of gene expression [68]. In humans and
sheep the maternal-zygotic transition occurs between 4–8 cell stage and 8–16 cell
stage respectively and is associated with the developmental loss of totipotency and
in mice and rats, this occurs by the 2 cell stage (Table 1) [77]. The initiation of zygotic
transcription also coincides with demethylation during embryogenesis, which is
an important event in epigenetic programming that can affect chromatin structure
and gene expression [78]. Nutritional manipulations such as culturing embryos
in various media have been shown to delay the transcription of important growth
factors such as platelet-activating factor-receptor in mouse preimplantation embryos,
which can affect the viability of the embryo [79]. Studies have shown that IVF has
differential effects on growth factors by either delaying the first onset of expression
of some of growth factors after the activation of zygotic genome or by decreasing the
expression, which can hamper proper embryogenesis in mice [80].
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3.4. Epigenetics Reprogramming Is an Important Event in Both Gametogenesis
and Embryogenesis
Epigenetics is defined as all meiotically and mitotically heritable changes in gene
expression that occur without changes in the DNA sequence [83,84]. One of the main
mechanisms involved is DNA methylation (other mechanisms involved are histone
modifications such as acetylation, phosphorylation, methylation, ubiquitination
and sumoylation) [85,86]. During mammalian development, gametogenesis and
embryogenesis are the two critical periods where epigenetic reprogramming
occurs (Figure 2) [87]. This begins with demethylation when PGCs migrate
along the genital ridge followed by sex-specific pattern of remethylation before
fertilization [88,89]. There is a second wave of whole genomic demethylation in
the male pronucleus within hours of fertilization whereas the female pronucleus
undergoes complete demethylation after several cleavage divisions [90]. During
implantation, genome-wide methylation takes place in a lineage-specific pattern [89].
However, there are certain genes, known as imprinted genes, that undergo erasure
of methylation marks during PGC development and the methylation marks are
re-established during gametogenesis but escape the second wave of demethylation
that occurs after fertilization and thus maintain their methylation of CpG islands
that was established during gametogenesis [91,92]. Imprinted genes are expressed
differentially depending on their inheritance from maternal or paternal origin [93].
During development, one of the alleles of a particular gene is expressed only in
the zygote and the other allele is silenced, and this process is known as genomic
imprinting [87].
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This epigenetic reprogramming is essential for proper development because it
controls expression of early embryonic genes, cell cleavage and cell determination [95].
Imprinted genes, in particular, play an important role in embryonic and fetal
development as well as placental function [96–98]. Any defects during epigenetic
reprogramming, including the imprinting process, may affect genotype and
phenotype and are linked to embryonic abnormalities and diseases in later life [99].
As such, the periconceptional period, which involves the crucial process of epigenetic
remodelling, makes the early oocyte or the preimplantation embryo vulnerable to
perturbations that can have immediate and long-term consequences on the health of
the offspring. For example, there is compelling evidence for a link between ARTs,
manipulations in the periconceptional period, and epigenetic disorders (imprinting
defects) [100]. A recent study has also shown that maternal nutritional status during
the periconceptional period was associated with persistent epigenetic changes at
human metastable epialleles [101].
This section has provided evidence that the periconceptional period encompasses
many important events that determine health of the embryo and that any
manipulation during this period, such as ART, can impact the processes of oocyte
maturation, embryogenesis, fetal and postnatal development. It is important to
understand that different types of ARTs are being used and thus that each type of
ART involves different manipulations to the periconceptional period.
4. What Are the Different Procedures Involved in ARTs and How Do These
Impact the Periconceptional Environment?
4.1. History, Procedures and Current Status of ARTs
ARTs are manipulations during the periconceptional period in which the oocyte,
sperm and/or zygote develop that apply laboratory or clinical techniques to gametes
(sperm and ova) and/or embryos to establish pregnancy [102–104]. The history
of ARTs dates back to 1890 when the first successful embryo transfer occurred in
rabbits [105]. A live calf was successfully produced from embryo transfer 60 years
later [106]. In 1973, two of the earliest human pregnancies occurred at the Queen
Victoria Hospital in Melbourne but they lasted for less than a week [107]. These were
chemical pregnancies identified by increasing plasma human chorionic gonadotropin
(hCG) concentrations and provided the evidence that embryos produced from IVF
could develop to the blastocyst stage and initiate implantation. The birth of the
world’s first test-tube baby, Louise Brown, occurred on 25 July 1978 at Oldham
hospital in England, UK [108,109]. This was a landmark in the area of reproductive
medicine and paved the way for scientific developments to improve implantation
and pregnancy rates.
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The use of ARTs has increased rapidly around the globe in recent years. In
2011, 588,629 treatment cycles were performed at clinics in 33 European countries,
151,923 cycles in the US and 66,347 cycles in Australia and New Zealand [110].
According to the European Society of Human Reproduction and Embryology,
an estimated 5 million children have been conceived as result of ARTs [110].
The extensive usage of ARTs is attributed to increasing infertility rates in the
population [111,112]. One of the reasons could be that women are considering
pregnancy later in life. The average age of a first pregnancy has increased from
26.9 years in 1983 to 30.1 years in 2012 in Australia [113,114]. In 1991, around 23%
of new mothers were aged over 30 years but this has risen to 37% in 2001 and 43%
in 2011 [115]. Similar trends were observed in the USA and Canada where the
average age of women having their first child increased from 21.4 years in 1970 to
25.8 years in 2012 and from 23.5 in mid 1960s to 28.1 in 2008, respectively [116,117].
There is evidence to suggest that fertility as well as fecundity declines with increasing
age for both men and women [112,118–120]. Delayed child-bearing also results in
increased time to conception and complications during pregnancy [121]. With recent
advancements in both ARTs and clinical practice, coupled with the widespread
availability of ART and improved success rates, there has been a rise in the number
of couples that are experiencing problems with conception seeking treatment [122].
The improvements in ARTs have also benefited the livestock industry, which
have resulted in great advancements in livestock production [123,124]. The
introduction of reproductive technologies has increased production as well as
reproduction of livestock animals with desired genetic characteristics [124,125]. They
have also helped in overcoming reproductive problems, such as reducing generation
intervals and preventing the spread of vertically transmitted diseases [126,127].
Livestock industries as a whole have scaled to new heights in terms of economic
gains with the help of these reproductive technologies [125,128].
The most widely used ART is IVF because it has the highest success rate per
cycle, irrespective of the cause of the infertility [81]. It was developed to treat
infertility associated with blocked Fallopian tubes and to treat other disorders related
to infertility such as endometriosis, unexplained infertility, ovarian failure, ovulatory
disorders and male infertility [129,130]. Gamete intraFallopian transfer (GIFT) and
zygote intraFallopian transfer (ZIFT) were developed as alternative treatments to
IVF in specific circumstances [82,131]. GIFT involves introduction of both egg and
sperm in the Fallopian tube where fertilization and subsequent embryo development
occurs [132–135]. GIFT treatment can be used as a treatment for sperm dysfunction,
endometriosis or unknown infertility [136,137], but requires that at least one Fallopian
tube is open. ZIFT involves removal of eggs followed by IVF with subsequent transfer
of the embryo at the 2 cell stage into the Fallopian tube [138]. It can be used in cases
of severe male infertility, immunologic infertility or unexplained infertility [138–141].
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Other ARTs include artificial insemination (AI), intrauterine insemination (IUI) and
intracytoplasmic sperm injection (ICSI), which are generally used in cases of male
infertility and can be coupled with other ARTs, such as IVF, depending on the severity
of the infertility (Table 2) [142,143].
4.2. Periconceptional Manipulations Associated with ARTs
A typical IVF treatment involves administration of FSH for controlled ovarian
hyperstimulation over several days to induce the development of multiple follicles
and the maturation of oocytes is induced by administration of hCG. This is followed
by aspiration of mature oocytes from the ovarian follicles and insemination with
a prepared sperm sample in vitro. The zygote that forms after fertilization of the
oocyte and sperm is cultured in a nutritional medium for either 2–3 days to form a
cleavage stage embryo or 5–6 days to form a blastocyst, which is then transferred
to the uterine cavity for implantation (Table 2) [144,145]. In the past, more than
one embryo was transferred to increase the chance of pregnancy and this has been
associated with multiple pregnancies [146]. Twin pregnancies are at an increased risk
of premature birth and its associated complications [147,148]. Therefore, transfer of a
single embryo has been advocated to reduce the risk of multiple pregnancies [149].
With the transfer of a single embryo, a desirable pregnancy rate with fewer multiple
pregnancies has been achieved [150]. However, even with the transfer of a single
embryo, there are reports of increased twinning [151].
4.3. In Vitro Embryo Culture: A Periconceptional Manipulation of the Nutritional
Environment of the Gametes and/or Zygote Associated with ARTs
An important component of many ARTs is the nutritional medium used
for culturing the embryo [152,153]. The nutritional medium contains essential
components required for optimal growth and to maintain the viability of the embryo
at various stages of development [154]. The culture media from different clinics varies
in composition but can be broadly classified into simple and complex media [155].
Simple culture medium includes Tryode’s, Earle’s T6, M16 and CZB, which contain
balanced salt solutions and energy sources such as pyruvate, lactate and glucose.
These are generally supplemented with serum from the patient or fetal cord serum
because the media are known to lack of components that are essential for the growth
and development of the embryo [156].
Efforts have been made to design media to match the dynamic in vivo
environment and have led to the development of human tubal fluid (HTF)
media [157]. HTF mimics the physiological environment of the human Fallopian
tube and is based on the chemical composition of human tubal fluid [153,157].
The complex tissue culture medium contains amino acids, vitamins, nucleic acid
precursors and metal ions and was originally designed to support somatic cells in
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culture, e.g., Ham’s F-10, MEM and TCM-199 [155]. In recent years, media were
designed with particular focus on each of the developmental stages of the embryo,
broadly divided into pre-compaction and post-compaction stages or the cleavage
and blastocyst stages [156].
The inclusion of human serum, which acts as a pH buffer and chelator for
embryonic toxins such as “transitional and heavy metals” in addition to providing
growth factors and nutrients such as amino acids and vitamins in the media, has been
long debated [158–160]. The use of human serum in different culture media during
the first 2 days of embryonic development in sheep leads to retarded growth but its
inclusion during later stages leads to more blastocysts formations [161]. However,
there are also reports of altered ultrastructure of the mitochondria and energy
metabolism, epigenetic disorders including errors in imprinting, abnormal growth
and gross abnormalities in several organ systems as a result of the addition of serum
in the media during the early stages of embryonic development [162–165]. Recently,
serum free culture media have been developed and proven to yield better results
with increased blastocyst formation, higher implantation rates and reduced risk of
contamination of the media by unknown components present in the serum [166,167].
We have described the complex maturation and developmental events of the
oocyte and embryo that occur in the periconceptional period. These events must
occur appropriately to allow gastrulation and the appropriate allocation of cells
to each of the developing organ systems. We have also described the nutritional
manipulations that the gametes and zygote are exposed to during the processes of
ARTs (Table 2). Together, this information leads to questions about whether there is
evidence that the periconceptional environment influences cardiovascular health as
a fetus and into adulthood.
5. What Is the Evidence that the Periconceptional Environment Influences
Cardiovascular Health in Fetal Life and Adulthood?
Cardiovascular disease is the leading cause of death worldwide causing an
estimated 17.5 million deaths worldwide in 2012 and it is estimated to reach
23.3 million by 2030 [168,169]. Cardiovascular disease in adults is generally attributed
to an unhealthy lifestyle during adulthood with most focus on poor diet, a sedentary
lifestyle and smoking [170,171]. However, a growing body of evidence suggests that
cardiovascular and metabolic disorders in adulthood may derive their origins from
insults during prenatal life, including the periconceptional period [20,172]. Barker
and colleagues coined the Fetal Origins of Health and Disease hypothesis, which
stated that changes in the development of a permanent somatic structure or the
“setting” of a physiological system by an early stimulus or insult during a critical
period of development during which any manipulation of either environmental
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or nutritional factors can have long-lasting consequences on the physiology of the
embryo and fetus [173,174].
Studies have shown that normal development of the mammalian cardiovascular
system during the embryonic period as well as the transition from proliferative to
hypertrophic cardiomyocytes growth during late gestation is dependent on the timely
and accurate activation of many genes and signalling pathways [59,175]. Some of
these signalling pathways are under epigenetic regulation such as DNA methylation
and histone modifications [176,177]. Any abnormalities in the epigenetic control
of these processes may result in cardiovascular malformation and susceptibility to
disease in adult life [178,179].
The heart is comprised of cardiomyocytes and non-myocytes including fibroblasts,
endothelial cells, mast cells, vascular smooth muscle cells and the surrounding
extracellular matrix [180,181]. During the first two thirds of gestation, heart growth
is predominantly due to proliferation of mononucleated cardiomyocytes [182].
In humans and sheep, cardiomyocyte maturation, characterised by quiescence
(absence of cardiomyocyte cytokinesis), occurs in the last third of gestation and
subsequently heart growth in late gestation and postnatal life is primarily through
cardiomyocyte hypertrophy [183,184]. In sheep, cardiomyocyte quiescence is easily
identified due to almost all mononucleated cardiomyocytes becoming binucleated
and subsequently terminally differentiated by birth [175,185–187]. In humans,
the majority of cardiomyocytes remain mononucleated, however, it is widely
accepted that only a tiny proportion of mononucleated cardiomyocytes undergo
cytokinesis/proliferation after birth [188,189]. Recent studies have also provided
evidence that cardiomyocytes continue to proliferate until almost 20 years of
age [190]. In rodents, all cardiomyocytes are mononucleated at birth and retain
the ability to proliferate and regenerate cardiac tissue after damage within the first
week of life [191,192]. Like sheep, rodent cardiomyocytes become binucleated and
terminally differentiated, however, unlike sheep and humans, this occurs rapidly
between 4 and 12 days after birth [192–194]. Due to the limited potential for
cardiomyocyte proliferation in postnatal life, the heart has a limited capacity to
replace cardiomyocytes that are lost due to disease and aging. Subsequently, the
number and the epigenetic profile of cardiomyocytes an individual is born with will
have lifelong implications for cardiac health.
Periconceptional Manipulations and Cardiovascular Disorders: Insights from Human and
Animal Studies
A series of epidemiological, clinical and experimental studies have shown that
nutritional manipulations during the periconceptional period, may have adverse
effects on cardiovascular health (Table 3) [59]. The most profound evidence was
from the Dutch Winter Famine of 1944/45, which demonstrated that offspring
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exposed to malnutrition as an embryo or fetus during early gestation had elevated
blood pressure in response to physiological stressors and 8.8% of those exposed
during early gestation also had an increased risk of coronary heart disease compared
to 0.9% and 2.5% of offspring whom were exposed to the famine in mid or late
gestation respectively [195,196]. In another cohort periconceptional maternal tobacco
smoking was associated with increased risk of congenital heart defects such as septal
defects [197,198]. Likewise, alcohol consumption during the periconceptional period
elevated conotruncal heart defects in offspring and that risk was associated with
the frequency and the number of drinks consumed [199]. In a study examining
the effects of the interaction of genetic factors and periconceptional nutritional
manipulations on congenital heart defects, it was found that a low maternal dietary
nicotinamide intake and usage of medicines such as antibiotics, anticonvulsants,
anti-inflammatory, hormones and antimycotics during the periconceptional period
independently increased the risk of congenital heart defects in the offspring by
2 fold [200].
Animal models have been useful in identifying the underlying mechanisms
that are responsible for the association between nutritional manipulation in
the periconceptional period and cardiovascular health in adult life (Table 3).
Maternal protein restriction during the preimplantation period in rats resulted
in a reduced number of cells in the blastocyst stage, a reduction in birth weight,
accelerated postnatal growth and elevated systolic blood pressure (SPB) in postnatal
life [201]. Maternal protein restriction, specifically during oocyte maturation, led
to hypertension in the adult offspring [202]. Similarly maternal protein restriction
from 0 to 3.25 days after mating reduced heart weight and increased SPB in offspring
in postnatal life [203]. In addition, the heart to body weight ratio in females was






























































































































































































































































































































































































































































































































































































































































In sheep, maternal undernutrition during the periconceptional period extending
from 60 days prior to conception until 7 days after fertilization resulted in an increase
in arterial blood pressure and rate pressure product in twins, but not singleton fetuses
in late gestation (term, 150 days) [204]. There was altered baroreflex sensitivity in
response to angiotensin II infusion at 1 year of age as a result of global energy
restriction from the day of conception until 30 days of gestation [205]. Maternal
undernutrition extending from 0 to 95 days gestation resulted in an increase in
prefeeding basal blood pressure and blunted baroreflex in response to norepinephrine
infusion at 3 years of age [206]. In another study undernutrition during the
30 days before conception resulted in diminished endothelium-dependent and
independent vasodilatation in third order femoral arteries [17]. An undernutrition
regime from 15 days prior to until 15 days after conception resulted in greater
vasoconstrictor responses in both left anterior descending coronary and left
internal thoracic arteries [17]. There was attenuated endothelium-dependent and
independent vasodilatation in third order femoral arteries as well as reduced
endothelium-independent vasodilation in both the left anterior descending coronary
and renal arteries [17]. There was an increase in blood pressure in response to
frusemide, a loop diuretic used to activate renin angiotensin system, in 1.5 year
old lambs of ewes that were undernourished between 1 and 31 days of gestation.
At 2.5 years, these lambs had increased interventricular septal wall thickness,
mean left ventricular wall thickness and increased constriction to acetylcholine
in isolated coronary arteries [207]. Furthermore, offspring born to ewes that were
undernourished from −61 days before until 30 days after conception had increased
fetal heart weight relative to body weight in late gestation [11]. In contrast, relative
heart weight was reduced in the offspring of ewes that were undernourished from
60 days prior to conception, 60 days before and 30 days after conception and 2 days
before and after conception [208].
The above studies provide evidence that nutritional manipulation in the
periconceptional period has adverse effects on the cardiovascular system, which
might predispose an individual to an increased risk of cardiovascular disease.
6. What Is the Evidence that ARTs Influence Cardiovascular Health Before
and After Birth?
Studies have demonstrated that not only insults during the periconceptional
period in vivo (Table 3), but also those that occur in vitro during this critical period of
development can have detrimental effects on cardiovascular development [13,59,204,
209,210]. This highlights the importance of understanding the long-term effects of
ARTs on cardiovascular development. There are reports of altered fetal and postnatal
growth and development as a result of in vitro nutritional manipulations during
the periconceptional period in humans, rodents, cows and sheep [211–213]. These
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reports have raised serious questions about the safety of ARTs for both the immediate
and long-term health of individuals conceived through ARTs. Among the long-term
health outcomes, cardiovascular health remains the most important concerns due to
the sensitivity of heart development to perturbations during the periconceptional
period [20,59,214,215].
A recent study reported the incidence of cardiac malformations using different
search terms related to cardiac malformations and/or ARTs in the Medline database
for the years 1999 to 2012. The search returned data on 32,000 births (21,000 naturally
conceived; 11,000 conceived through ART) [216]. Cardiac malformations occurred
in 1.8% (198 cases) of births conceived through ART compared to 0.4% (88 cases) of
births in the general population [216]. Comparing the incidence of specific forms
of cardiovascular disorders from a total of 11,000 pregnancies in ART children and
21,000 pregnancies in naturally conceived (NC) children respectively, there were
58 cases (0.53%) of atrial septal defect in ART vs. 26 cases (0.12%) in NC, 37 cases
(0.34%) of changes in the interventricular septum in ART vs. 18 cases (0.09%) in NC,
20 cases (0.18%) of coarctation of the aorta vs. 13 cases (0.06%) in NC, 18 cases (0.16%)
of aortic stenosis in ART vs. 11 cases (0.05%) in NC, 11 cases (0.10%) of tetralogy of
Fallot in ART vs. 5 cases (0.02%) in NC, 6 cases (0.05%) of stenosis of the pulmonary
trunk in ART vs. 5 cases (0.02%) in NC and 48 cases (0.44%) of other non-specified
cardiac defects in ART and vs 10 cases (0.05%) in NC. [216]. These data suggest
that compared to natural conception, there is an increased risk of cardiovascular
malformations in children conceived through ART.
6.1. Congenital Heart Defects in Human Population
Many studies have reported the incidence of congenital heart defects in children
conceived through ARTs (Table 4). In the first report of a relationship between
ART and congenital heart defects, Lancaster et al. found that there were 4 cases
of transposition of the great arteries in the offspring conceived through IVF [217].
Several studies have also confirmed these findings. For example, a significant increase
in overall congenital heart defects in children conceived through IVF compared to
children with unassisted conception was reported in different population based
studies [218–221]. The increase in cardiovascular defects also remained significant
when the analysis was performed in only singletons [218,219]. Another population
based study in Finland compared the risk of congenital defects in IVF and other
ART categories with the control population based on infant sex and multi-fetal
pregnancies and found an increase in congenital heart defects in the female offspring
of singleton pregnancies in other ART categories group [222].
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A case-control study using the California Linked Birth Cohort Dataset found an
increased risk of major cardiac malformations in 4.8% of births from ART (IVF with
or without ICSI, GIFT) compared to 3.0% in the matched control population [50].
After adjusting for maternal and infant factors such as maternal age, parity, race,
multiple births, infant sex and year of birth, the rate of congenital heart defects
was significantly higher in the infants born after ARTs [50]. When the heart
defects in singleton and multi-fetal ART pregnancies were compared, the multi-fetal
pregnancies had an increased risk of congenital cardiac defects than the singleton
pregnancies [50]. An increased rate of congenital malformations in infants conceived
by ART was also reported in a retrospective cohort study in Ottawa [223]. In a
cross-sectional descriptive study in Iran, 8 cases of IVF pregnancies with congenital
heart defects were reported in a population of 400 ART children [224].
In addition to evidence that ARTs increase the risk of cardiac defects, studies
have identified specific congenital cardiac defects associated with ARTs (Table 4).
The prevalence of congenital heart malformations such as atrial septal defects
and ventricular septal defects was four-fold higher in children born after IVF
than the matched controls in a Finnish population based cohort study [225] In a
cross-sectional study in Iran, children conceived through ARTs had increased risk
of ventricular and septal defects [226]. A population based study analysed specific
cardiovascular defects in the Danish population study and reported a significant
increase in the prevalence of a single umbilical artery in IVF children when compared
to controls [221]. In another population based, multicenter case controlled study
of birth defects in the United States, the singleton births resulting from IVF and
ICSI were at increased risk of septal heart defects, including ventricular septal
defect, atrial septal defect and other non-specified defects compared to unassisted
conception [227]. Using data from a Swedish database for the period 1982–2001,
it was found that in addition to an overall risk of congenital heart diseases, the
association between ARTs and congenital heart defects became more marked when
the analysis was restricted to major cardiac defects such as common arterial trunk,
double outlet right or left ventricle, D- and L-transposition of great vessels, double
inlet left ventricle, endocardial cushion defect, tetralogy of Fallot, tricuspid atresia
or stenosis, Ebstein’s anomaly, hypoplastic left heart syndrome, aortic valve atresia,
specified anomalies of the great veins or to septal defects [228]. In another study,
which used the Swedish database for the period 2001–2007 found an increased risk of
cardiovascular malformations, which was similar to the data from the same database
for the period (1982–2001) [229]. The study also reported an increased risk of septal
and ventricular defects but the risk was lower during the period 2001–2007 compared
to the previous time period [229].
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Based on a case-control study using data from Paris Registry of Congenital
Malformations, it was found that cases of congenital heart diseases were more
likely to be born as a result of ARTs when compared to controls [230]. The study
investigated three major categories of congenital heart defects (all congenital heart
diseases combined, congenital heart diseases without chromosomal abnormalities
and congenital heart diseases without chromosomal abnormalities (excluding
isolated ventricular septal defects)) and it was found that there was also a 40%
increase in the overall risk of congenital heart disease without chromosomal
abnormalities in infants conceived through ARTs after adjusting for maternal age,
socioeconomic factors and year of birth [230]. Specific congenital malformations such
as malformations of the outflow tracts and ventriculoarterial connections, cardiac
neural crest defects and double outlet right ventricle were significantly associated
with ARTs [230]. The study also reported that IVF and ICSI were associated with an
increased risk of congenital heart disease, but not ovulation induction alone [230].
Another case–control study using data from the population-based Paris Registry of
Congenital Malformations, and a prospective cohort study of congenital heart disease
in children (EPICARD) investigated the association between ARTs and four specific
forms of congenital heart diseases (hypoplastic left heart syndrome, transposition of
great arteries, tetralogy of Fallot, and coarctation of the aorta) [231]. The study found
that ARTs (IVF, ICSI and ovulation induction alone) were associated with a 2.4-fold
increased risk of tetralogy of Fallot, after adjusting for maternal age, occupation,
geographic origin, paternal age and year of birth [231]. There was no significant
association between ART and the other 3 congenital malformations [231].
6.2. Evidence of Risk Factors for Long-Term Cardiovascular Outcomes in Humans
The increased risk of cardiovascular defects at birth provides a strong
justification for follow-up studies to investigate the effect of the procedures involved
in ARTs on the long-term consequence on cardiovascular health outcomes. What
is not known is whether ARTs are associated with an increased risk for clinical
cardiovascular endpoints due to the young age of the ART population in humans.
However, emerging studies have provided evidence for an association of ARTs with
increased risk factors for cardiovascular disease (Table 5).
Fetuses from ART pregnancies had altered cardiac morphometry and impaired
systolic and diastolic function compared to controls [232]. When they were assessed
during neonatal life, an increased diastolic blood pressure percentile, aortic and
carotid intermedia thickness was reported in ART children compared to controls [232].
During infancy, children from ART pregnancies had increased right atrial size,
right ventricular wall thickness, aortic wall thickness, SBP and heart rate as well
as decreased shortening fraction, right sphericity index and systolic and diastolic
function [232]. This evidence suggests that cardiovascular remodelling was present
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in fetal life and persisted into infancy in ART children and this may suggest an
increased risk of cardiovascular disease in later life.
A study has also shown that the children conceived through IVF had increased
SBP and DBP at a mean age of 12.3 years [233]. Furthermore, there was an association
between early childhood weight gain and SBP during follow-up [234], which is
an important risk factor for cardiovascular disease in later life [235,236]. Similarly,
in a cross-sectional study in Athens, a higher SBP and DBP deviation score was
reported in ARTs children compared to naturally conceived children in the age group
4–14 year [237].
Vascular functions were studied in ART conceived children at around 12 years
of age and a ~25% reduction in flow-mediated dilation of the brachial artery
evoked by reactive hyperemia was reported but no difference was observed with
endothelium-independent vasodilation evoked by nitroglycerine [238]. This finding
is suggestive of endothelial dysfunction in ART offspring, which is an important and
early marker for the development of atherosclerosis in later life and has previously
been shown to be present in healthy children whom were at increased risk of
cardiovascular diseases [239–242]. The study also found a significant faster carotid
femoral pulse wave velocity, which is widely used as a gold standard for measuring
arterial stiffness as well as an increased carotid intima-media thickness, both of
which are markers for development of atherosclerosis and independent risk factors
for cardiovascular disease [238,243–245]. In addition, ART children had 30% higher
pulmonary pressure at higher altitude [238]. The findings from this study provide
evidence for both systemic and pulmonary vascular dysfunction in ART children,
which could lead to adverse cardiovascular outcomes in later life [238]. Most
importantly, it was reported that the vascular dysfunctions were not related to









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.3. Evidence of Cardiovascular Defects from Animal Models of ARTs
Animal models of ARTs have been instrumental in providing evidence for
further links between ARTs and an increased risk of cardiovascular defects (Table 6).
Table 6. Cardiovascular risk factors from animal models of ARTs.




Increased allometric growth coefficients of
heart at 61 and 125 days of gestation. [163]
125 day gestation
Increased absolute (25.8 ± 8.9 vs. 19.0 ± 4.1, p = 0.004) and relative
heart weight (6.5 ± 1.05 vs. 5.7 ± 0.76, p = 0.022) in in vitro embryo




Inverse relation between heart weight and IGFR2 gene expression
(r = −0.675, p < 0.001) and loss of methylation of IGF2R in embryo
culture group when compared to control group.
[58]
125 day gestation
A strong inverse relation between heart weight and IGFR2 gene
expression in the in vitro embryo culture





Increased heart girth (56.5 ± 1.2 vs. 52.4 ± 0.9, p = 0.01) and heart
weight (139.7 ± 8.3 vs. 116.2 ± 5.8, p = 0.02) in embryo transfer
and culture groups compared to controls.
[248]
At birth
Increased intra-ventricular septum in in vitro produced groups
compared to embryo transfer group (SOF: 11.8 ± 0.3, Co-culture:
12.0 ± 0.3, embryo transfer 10 ± 0.3, p < 0.05) Thicker left
ventricular wall during diastole in
in vitro produced group (co-culture) when compared to embryo
transfer group (14.5 ± 0.5 vs. 11.8 ± 0.6, p < 0.05).
[249]
1 year Increased relative heart weight in embryo culture group(4.01 ± 0.08 vs. 3.56 ± 0.12, p < 0.02). [250]
Rodents
21 days after birth Raised SBP in males. [62]
12–14 weeks
after birth
- Higher mean blood pressure during short-term (p = 0.017)
and during chronic measurements (p = 0.036) in ART mice
than in control mice.
- Impaired acetylcholine-induced vasodilation in the
mesenteric arteries in ART mice compared with control mice
(p < 0.0001).
- Increased vascular stiffness in ART mice compared to controls
measured by relationship between inner (p = 0.017) and outer
diameter (p = 0.033) and carotid pressure in vitro.
- Impaired acetylcholine-induced vasodilation in vitro
(p < 0.0001) and increased mean arterial blood pressure
in vivo (p < 0.001) was observed in the progeny of offspring
of ART mate and control female.
[63,251]
2 years after birth Increased heart weight in embryo culture with serum compared towithout serum group (0.29 ± 0.02 vs. 0.20 ± 0.01, p < 0.05). [54]
SBP, systolic blood pressure.
6.3.1. Evidence from Ruminants
Large Offspring Syndrome (LOS) is a serious side effect in culturing of sheep
and cow embryos in the presence of serum [252,253] and is associated with an
increase in birth weight that persists into postnatal life as well as alterations in the
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relative growth of organs [252,254]. Culturing sheep zygotes in vitro for 5 days in the
presence of bovine granulosa cell layers and serum supplementation increased the
allometric growth coefficients of key organs, including the heart, from as early as
61 days gestation and this change persisted to 125 days gestation [163]. Interestingly,
the allometric growth coefficient of the heart was significantly increased in the fetuses
that were cultured in synthetic oviductal fluid media that was supplemented with
serum, despite no change in body weight at 61 days gestation. However, by 125 days
gestation, the fetuses were significantly heavier with a higher allometric coefficient
of the heart [163].
Sheep embryos cultured in synthetic oviductal fluid resulted in fetuses
with increased heart weight compared to embryo transfer controls at 125 days
gestation [246]. Furthermore, adding serum to synthetic oviductal fluid media
during the first 48 h of embryonic development increased relative heart weight at
125 days gestation, which suggests that inclusion of serum during the precompaction
period is more detrimental to the development of the embryo and key organs than
the later stages of embryo development [246]. Young et al. found that a loss of
methylation of insulin-like growth factor 2 receptor (IGF2R) was associated with
the increased heart weight in the embryo culture groups compared to controls [58].
Interestingly, the expression of IGF2R was inversely correlated with heart weight and
a stronger inverse relationship existed when the analysis was restricted to the embryo
culture groups only, suggesting that IGF2R plays the role of a clearance receptor for
IGF2, and thus decreased IGF2R signalling may be responsible for the increase in
heart weight because less IGF2 is available to activate the IGF1R signalling pathway
leading to cardiac growth [247,255,256].
Similarly, another study also reported an increased heart girth and weight
in an embryo transfer and culture group at 222 days of gestation in cows
(term, ~ 280 days) [248]. Another study in cows reported an increased intra-ventricular
septum in in vitro produced groups (co-culture or synthetic oviductal fluid
supplementation) and an increased left ventricular wall during diastole at birth in
only the in vitro produced group (co-culture) when compared to the embryo transfer
group (term, ~280 days) [249]. Few studies have investigated the impact of embryo
culture and transfer on the growth and development of the heart in both fetal and
postnatal life. However, one study demonstrated that despite normalisation of body
weight by 1 year of age, the increase in heart weight persisted in the groups where
embryos were cultured in a nutritional media for 5 days after fertilization [250].
6.3.2. Evidence from Rodents
In vitro embryo culture during the preimplantation period resulted in increased
SBP in both male and female offspring at 21 days after birth [62]. The gene expression
of serum angiotensin converting enzyme, which is known to have vasoconstrictive
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effects through the renin-angiotensin system, was upregulated but only in female
offspring [62]. Interestingly, there were no changes in the male offspring, suggesting
that an alternative mechanism may be responsible for the increase in SBP [62].
Endothelial dysfunction, higher blood pressure and increased arterial stiffness were
found in a mouse model of ART at 12–15 weeks after birth [63,251]. The study also
found intergenerational effects of ARTs where the progeny of ART males and control
female had endothelial dysfunction and higher mean blood pressure [63,251]. There
was also an increase in heart weight in 20 month old mice when the embryos were
cultured in media containing fetal calf serum [54].
7. What Are the Most Likely Mechanisms Linking ART and Risk of
Cardiovascular Disease in Fetal and Adult Life?
7.1. Epigenetic Dysregulation
Many cardiovascular diseases are known to have an epigenetic origin [179,257].
It has been shown that individuals who were exposed to periconceptional
undernutrition such as during the Dutch winter famine 6 decades ago had an
altered methylation profile of imprinted and non-imprinted genes and those
individuals were also found to have an increased risk of cardiovascular diseases in
adulthood [258–260]. In animal studies, epigenetic modifications as well as increased
prevalence of many cardiovascular risk factors such as increased blood pressure,
adiposity and insulin resistance were found in the offspring exposed to nutritional
manipulations during the periconceptional period [59,261]. These findings suggest
that epigenetic dysregulation could be a plausible mechanism that links ARTs with
increased risk factors for cardiovascular diseases [262].
A series of studies have identified an association between ARTs and epigenetic
disorders [95,263]. Children with Beckwith-Wiedemann syndrome, which is
caused by an imprinting disorder, are 3–14 times more likely to be conceived by
ARTs [264–267]. Molecular analysis in these studies showed hypomethylation of
maternal copy of KCNQ1 overlapping transcript 1 (KCNQ1OTI), an antisense RNA
normally expressed from the paternal allele and located at one of the differentially
methylated regions (DMRs) of chromosome 11p15 [264–269]. Studies have also found
hypermethylation of HI9, which is located at another DMR of chromosome 11p15, as
well as hypomethylation of mesoderm-specific transcript homolog protein (MEST),
small nuclear ribonucleoprotein N (SNPRN), pleiomorphic adenoma gene-like 1
(PLAGL1) in ART children with Beckwith-Wiedemann syndrome [264,268,269].
There are also reports of other imprinting defects such as Angelman syndrome,
Retinoblastoma, Prader–Willi syndrome and Russell–Silver syndrome in children
conceived through ARTs [270,271]. At the blastocyst stage, IVF resulted in aberrant
H19 methylation in humans and mice [226,272]. Large offspring syndrome LOS is a
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frequent occurrence in livestock conceived through ARTs and is also caused by loss
of methylation in the maternal DMR of IGF2R, which is an imprinted gene [58].
A study investigating the DNA methylation levels of more than 700 genes
(1536 CpG sites) in the placenta and cord blood reported lower mean methylation at
CpG sites in the placenta and higher mean methylation at CpG sites in cord blood
from 10 children conceived in vitro compared to 13 children conceived naturally.
Upon examining the gene expression levels of a subset of genes that had altered
methylation levels, CCAAT/enhancer-binding protein alpha (CEBPA) in cord blood
and CEBPA, MEST, neuronatin (NNAT) and serpin peptidase inhibitor, clade F
(alpha-2 antiplasmin, pigment epithelium derived factor), member 1(SERPINF1) in
placenta had significant difference in mean transcript levels [273]. Interestingly these
genes are known to be associated with adipocyte development and differentiation,
insulin signalling and/or obesity [274–277].
Increased methylation of the imprinted genes H19, glucosyltransferase 2 (GTL2)
and decreased methylation of paternally-expressed gene 3 (PEG3) were found in
the aorta, but not in the liver of the mice conceived through ART [251]. This
alteration of the methylation levels was transmitted to the next generation with
levels comparable to the methylation of the parent generation [251]. Interestingly,
the altered methylation levels were restored in ART mice and in its progeny with
the administration of butyrate (a histone deacetylase inhibitor) [251]. As previously
mentioned, the study also found vascular dysfunction and arterial hypertension in
ARTs mice and its offspring. Consistent with this finding, the study reported an
increased DNA methylation of the promoter of the eNOS gene in the aorta of the
ARTs mice, which is an important regulator for systemic vascular function [251].
This increased methylation level resulted in decreased eNOS mRNA expression in
the vasculature and lower levels of nitric oxide in the plasma of ARTs mice [251].
In addition, butyrate administration to ARTs mice also normalized DNA methylation
of the promoter of the eNOS gene, eNOS mRNA expression and plasma nitric oxide
concentration [251].
These altered methylation levels provide strong evidence for epigenetic
dysregulation as a result of ARTs, which could possibly affect the expression levels
of genes involved in cardiovascular regulation as well as other major regulatory
pathways increasing the risk of long-term diseases in adult life [63]. These alterations
in epigenetic mechanisms may stem from several steps involved in ARTs such as
ovarian stimulations and in vitro embryo culture (Figure 3). Studies have investigated




Superovulation occurs during meiosis of oocyte development/maturation
when the oocytes are still acquiring imprinting marks and may lead to imprinting
defects. In humans, studies have reported hypomethylation of the KCNQ1OT1 DMR
(KvDMR1) in the germinal vesicle and metaphase I stage as well as hypomethylation
of KCNQ1OT1 in the metaphase II stage of the superovulated oocytes, which suggests
that ovarian hyperstimulation may result in the release of immature or young oocytes
that have not undergone complete methylation, including the establishment of
appropriate imprinting [85,280]. Imprinting errors have been found in H19 and
MEST in metaphase II oocytes after ovarian stimulation, however, it could not be
determined whether alterations in the methylation patterns of these genes were
associated with the superovulation process itself or the age and infertility status of
the patients [281]. There is evidence that superovulation can affect the quality of
the embryo as well as the uterine milieu, and these factors can indirectly affect the
epigenetic status of the oocyte [48].
In animal studies where infertility is not a confounding factor, an abnormal
methylation pattern at the 2 cell stage was found in the embryos from superovulated
mice using immunofluorescent staining [282]. Downregulation of candidate
reprogramming genes which are involved in base excision repair proteins such
as APEX nuclease (multifunctional DNA repair enzyme) 1 (APEX1), polymerase
(DNA directed), beta (POLB) and the 5-methyl-CpG were found at the morula
stage of the mouse embryo after superovulation and suggests that superovulation
may also hamper the maintenance of imprinting [278]. In line with this finding,
lower protein expression levels of APEXI were observed in both early and late
morula stages and the level of protein expression correlated the mRNA expression
levels [278]. Loss of methylation of SNRPN, KCNQ1OT1 and PEG3 in the blastocyst
stage was also observed in a dose-dependent manner with higher doses of hormones
resulting in greater imprinting disturbances [283]. Superovulation in mice decreased
the methylation levels of H19 and significantly increased the methylation levels
of PEG1 and SNRPN imprinted genes in the sperm of the offspring in both the
first and second generation [53]. Together these data suggest that changes in
global methylation may account for spontaneous embryo loss and developmental
failure, while locus-specific epigenetic errors may result in defined phenotypes
associated with genomic imprinting disorders; thereby suggesting that oocytes
from superovulated animals may have a reduced ability to complete the global
reprogramming necessary for proper development [282,284].
7.1.2. In Vitro Embryo Culture
In vitro embryo culture occurs during the sensitive period of maternal and
paternal demethylation and remethylation and thus may affect the maintenance
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of genomic imprinting during this process [285]. There is evidence of abnormal
methylation, mainly due to embryo culture, as a result of the IVF procedure in
mice [286]. For example, embryo culture of preimplantation mouse embryos using
Whitten medium resulted in biallelic expression and loss of methylation of the H19
gene [287]. Similarly a greater loss of methylation was observed in H19 after embryo
culture in M16 medium than in G1/G2 medium [287]. There were also differences in
the gene expression of 114 genes in the preimplantation embryos of the mice cultured
in Whitten culture medium and 29 genes when cultured in KSOM + AA [61]. Biallelic
expression of the imprinted gene H19 was found in the placenta which persisted
till mid gestation when the embryos were cultured in whitten or KSOM + AA
medium [288]. There is also evidence of perturbed gene expression after embryo
culture [163]. Increased expression of the imprinted genes, IGF2 and H19 and growth
factor receptor binding protein 10 (GRB10), along with increased methylation of
H19 and decreased methylation of growth factor receptor binding protein 7 (GRB7)
were observed in fetuses that had undergone preimplantation embryo culture in
M16 medium with fetal calf serum supplementation [61]. In vitro culture with
serum supplementation also resulted in hypomethylation of IGF2R associated with
LOS in ruminants [58]. It has been speculated that culture media procedures may
induce abnormal methylation at imprinted loci by facilitation the removal of methyl
groups from cytosine bases or interfering in normal gamete development which
may lead to incomplete imprint erasure and/or reestablishment of methylation
pattern [95,285]. The methionine content of the media may also affect DNA
methylation and imprinting [102,289].
These findings provide substantial evidence that in vitro embryo culture can
impair epigenetic mechanisms. Studies investigating epigenetic dysregulation
associated with both ovarian stimulation and embryo culture found that defects
in imprinting were neither observed in all the embryos nor at every imprinting
locus. Some loci were affected more than others. Hence, more studies are required to
understand the stochastic nature of these imprinting defects.
7.2. Impaired Gastrulation
Early interaction between the embryo and the endometrium is critical for proper
development and implantation of the embryo [290,291]. This in turn determines
proper gastrulation and organogenesis. Embryo cultured in media in vitro lacks these
early interactions and the exchange of factors between embryo and endometrium.
This can alter the timing of expression of Hox genes, which control the body plan of
an embryo along the anterior-posterior (head-tail) axis [292,293]. In addition, studies
have shown that culture of the embryo in vitro affects the proper differentiation of
the inner cell mass, which are precursors of ectoderm and endoderm (germ layers
formed during gastrulation) [294,295]. These two, individually or in combination,
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can alter gastrulation and subsequently organogenesis. It is reasonable to speculate
that organogenesis of the heart, which is the first organ to form, may be affected by
procedures involved in ARTs and abnormalities in heart development are known to
cause congenital defects and other cardiovascular disorders (Figure 3) [296].
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8. Conclusions
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of the long-t rm effects of ARTs in childhood and a ulthood. Some follow-up
studi s have confirmed thes findings in children of ART in the fe al and neonat l
periods. Given the young ag of the ART population, it is necessary to perf rm
life course studies that will provide valuable evide ce not only to ensure better
medical diagnostics and care for these children but also to call for more tudies
to pinpoint th mechanistic alt rations that are respo si le for RTs induced
cardiovascular risk factors. Understanding the import nt events that occur during
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the developmental periods when ARTs procedures are applied have identified
mechanisms underlying the link between ART and an increased risk of cardiovascular
defects in the embryonic period and cardiovascular disease in postnatal life.
Epigenetic alterations have emerged as a key mechanistic alteration that can
predispose an increased risk of cardiovascular disorders in the ART population.
A major challenge is to isolate the effects of infertility of the parents that sought
ARTs procedures and may render epigenetic alterations in the offspring. In this
regard, many animal models of ARTs have been a major source of evidence
suggesting the effects of ARTs procedures on cardiovascular dysfunctions and
epigenetic alterations. This warrants further studies to pinpoint specific epigenetic
alterations that directly link to the development of cardiovascular disease in later life.
Consequently, a genome-wide epigenetic profiling of children conceived through
ARTs during the embryonic stages can be used as a tool to identify embryos that
carry epigenetic alterations linked to the development of cardiovascular disease in
adult life. Furthermore, epigenetic profiling can also be conducted in both neonatal
and adult life, to identify individuals with a higher risk of developing cardiovascular
disease in later life.
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Impacts of Maternal Nutrition on
Vascularity of Nutrient Transferring Tissues
during Gestation and Lactation
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Abstract: As the demand for food increases with exponential growth in the world
population, it is imperative that we understand how to make livestock production as
efficient as possible in the face of decreasing available natural resources. Moreover,
it is important that livestock are able to meet their metabolic demands and supply
adequate nutrition to developing offspring both during pregnancy and lactation.
Specific nutrient supplementation programs that are designed to offset deficiencies,
enhance efficiency, and improve nutrient supply during pregnancy can alter tissue
vascular responses, fetal growth, and postnatal offspring outcomes. This review
outlines how vascularity in nutrient transferring tissues, namely the maternal
gastrointestinal tract, the utero-placental tissue, and the mammary gland, respond to
differing nutritional planes and other specific nutrient supplementation regimes.
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Meyer, A.M. Impacts of Maternal Nutrition on Vascularity of Nutrient Transferring
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1. Introduction
The world’s population reached 7 billion in 2012, and is projected to be greater
than 9 billion by 2050 [1]. Continued economic and population growth in developing
countries is expected to increase world-wide demand for meat, milk, and eggs [2].
Increased demand will require rapid development of new technologies to improve
food animal production systems in the face of limited land and water, competition
with bioenergy, and increasing environmental and animal welfare regulations. With
this in mind, it is imperative that we enhance livestock production efficiency by
optimizing the function of nutrient transferring tissues, namely the gastrointestinal
tract, placenta, and mammary gland. Large animal research ensures food safety
and improves the quality and affordability of meat and milk, as well as serve
as biomedical models. Understanding nutrient transferring tissue efficiency is
critical, not only for the growth and development of the dam, but also for the
offspring. Animal models are particularly important to human health in the area
of developmental programming. Maternal delivery of nutrients to the fetus can be
reduced by decreased placental function, just as poor neonatal nutrient delivery is
impaired by poor mammary gland development. Both the placenta and mammary
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gland are dependent upon the maternal gastrointestinal tract to adequately extract
and deliver dietary nutrients. While it is well known that the gastrointestinal tract,
placenta, and mammary gland adapt to different nutritional stimuli, how these
tissues adapt to different nutritional stressors (i.e., inappropriate nutrient supply,
conditional increases in nutrient demand, specific nutrient imbalances, etc.) may be
keys for enhancement of nutrient transfer efficiency.
The area of developmental programming and the study of nutrient exchange
in tissues is of interest to both agriculture and human health. Obviously, research
done in agriculturally relevant species such as the cow, sheep, and pig will directly
relate to those species. However, these large domesticated animals are also a primary
model for human research. The advantages of domesticated animal models are
important for moving concepts from the laboratory to human health applications
(http://adsbm.msu.edu/) [3]. In particular, sheep have been used as a relevant
model for biomedical research for humans because there is a large body of data
on reproductive function, including pregnancy, available [4–12]. A variety of
animal species, from laboratory rodents to domestic ruminants and non-human
primates, have been used to study pregnancy. This review will highlight how
nutrient transferring tissues are affected in several domesticated animals, with more
data presented from sheep. While no animal model truly recapitulates processes
happening in the human, the sheep model has some resemblances with human
reproduction which include: (1) a relatively long gestation length (i.e., ~150 days);
(2) generally carries singleton or twin fetuses; and (3) the villous tree of the sheep
cotyledon is structurally similar to the human placenta. Furthermore, the ewe
is a robust model allowing for surgical manipulations for repeated maternal and
fetal sampling/data collection to determine how both maternal and fetal tissues
respond to physiological stimuli (such as nutritional manipulations). Moreover,
there is a wealth of information in the sheep as it has been used extensively over the
past 40 years as a model of human pregnancy [9]. Additional appreciable features
of the sheep model which are relatively comparable to human fetal development
include: neonatal thermoregulation, metabolic regulation, specific organ growth rate,
fetal protein turnover, maturity of hypothalamic-pituitary-thyroid-adrenal axis and
others, as summarized by Symonds et al. [6]. Furthermore, a sheep model allows for
performing controlled studies using a greater number of animals, and for obtaining
a large amount of tissues from the relevant physiological states.
How Pregnancy Alters Physiology and Metabolism
During pregnancy, maternal physiologic state is associated with significant
but reversible modulations to meet metabolic demand as well as alterations to the
endocrine and cardiovascular systems. Endocrine secretions from the conceptus
allows for communication between the maternal endometrium and fetal membranes
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of the placenta during mid- to late-gestation, helping to ensure proper nutrient and
waste exchange during exponential growth of the fetus. Moreover, it is evident
that pregnancy alters vascularity of the small intestine [13] allowing for greater
uptake of nutrients. Maternal cardiovascular capacity also changes dramatically
during pregnancy, with decreases in systemic arterial blood pressure and vascular
resistance and increases in cardiac output, heart rate, heart stroke volume, and
blood volume [14]. Mean arterial pressure decreases in early pregnancy and persists
throughout gestation in several mammalian species. The decrease in arterial pressure
(~5%–10% decrease) is minor compared to the approximate 20%–30% decrease in total
peripheral vascular resistance. Maternal cardiac output has been shown to increase
as much as 30%–40% in pregnant vs. non-pregnant ruminants [14]. Therefore, the
increase in cardiac output is associated with a fall in systemic vascular resistance,
allowing researchers to characterize pregnancy as a state of systemic vasodilation
resulting in profound increases in total systemic flows to all vascular beds. In
addition to the changes in the maternal cardiovascular system during pregnancy,
it is also noteworthy to point out that the majority of mammals will return to the
non-pregnant levels of cardiovascular function 2–5 weeks postpartum indicating that
vascularity is important during involution and repair of the uterus.
Two important contributors to the alterations in the cardiovascular system
include vascular endothelial growth factor (VEGF) and nitric oxide (NO). Vascular
endothelial growth factor and its receptors are distributed widely throughout adult
and fetal tissues [15–19]. While many angiogenic factors are associated with fetal
development, VEGF is one of the most potent factors associated with fetal and
placental vascular growth in many species including sheep [17,18,20–22], cow [23,24],
and pig [25,26]. While changes in VEGF in the maternal circulation do not appear
to change in cattle or sheep (Table 1), there is an increase in fetal circulation in
swine [26]. Moreover, VEGF mRNA increases in the pig placenta, but is not altered
in ruminants as gestation advances. In addition to VEGF stimulating angiogenesis,
VEGF upregulates nitric oxide (NO) production by endothelial cells [27–30]. While
NO metabolites increase as gestation advances in the ewe [22] and cow ([31]; Table 1),
similar information has not been reported for pigs. Moreover, while endothelial nitric
oxide synthase (eNOS) mRNA expression does not appear to significantly change
as gestation advances, it is known that several NO mediated vascular events are
occurring in the placenta [32–35] and the mesenteric arteries [36,37].
While there are many reviews that focus on how different maternal nutritional
levels impact the growth and development of the offspring, this review will focus on
how differing maternal nutritional levels impact nutrient transferring tissues. We
hypothesize that in order to develop potential therapeutics that could spare negative
influences on the offspring, functions of the small intestine, placenta and/or the
mammary gland must become more efficient at nutrient delivery. Core mechanisms
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that regulate vascularization and blood flow within key nutrient transferring tissues
are beginning to be understood, and likely are a major determinant of animal growth
and nutrient utilization.
Table 1. Changes in VEGF protein and placental mRNA as well as nitric oxide
metabolite (NOx) and eNOS mRNA from mid- to late-gestation in cattle, sheep,
and swine.




Cow Maternal: No change [23] 8% increase [38],* 43% decrease [38],*
Sheep Maternal: No change [22] 36% increase [21],* 14% decrease [21],*
Pig Fetal: 83% increase [26] 50% increase [26] 18% increase [26]
Nitric Oxide NOx eNOS eNOS
Cow 210% increase [31] 29% increase [38],* 49% increase [38],*
Sheep 260% increase [22] 37% increase [21],* 42% increase [21],*
Pig ** ** **
*Not significant at p ≤ 0.05; ** Unknown.
2. Maternal Gastrointestinal Tract during Pregnancy
The maternal gastrointestinal tract is critical for nutrient acquisition but is
also a major nutrient sink during pregnancy. In ruminants, the liver and gut
consume approximately 40% of maintenance energy demands [39,40]. Within
the gastrointestinal tract, which consumes approximately 20% of maintenance
energy [41,42], a majority of these nutrient resources are consumed by ion transport,
protein turnover, enzyme secretion, and active transport [43,44]. The dam needs to
maintain functional capacity of the gastrointestinal tract, even though a decrease in
nutrient use by this tissue may be necessary, especially in cases of gestational nutrient
restriction. Pregnancy [13,45], stage of gestation [46–48], and nutrient intake (Table 2)
affect intestinal tissue mass and growth indices. Alternatively, some studies revealed
minimal or no differences in small intestinal mass in response to pregnancy [46],
stage of gestation [49], or nutrient intake (Table 3), leading us to hypothesize that
changes are influenced by species, age/parity, previous nutritional plane, diet type,
and other potential metabolic mechanisms.
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Table 2. Histological measurements to assess vascularity of nutrient transferring tissues.
Measure Calculation Used to Assess
Capillary Area Density (CAD) total capillary area ÷ tissue area blood flow
Capillary Surface Density (CSD) total vascular surface ÷ tissue area nutrient exchange
Capillary Number Density (CND) total number of vessels ÷ tissue area vascular branching
Area Per Capillary (APC) total capillary area ÷ number of vessels capillary size
Total Vascularity CAD × tissue mass total vascular bed of tissue
The small intestine, which has a high degree of plasticity, is a focus of research
during pregnancy because of its role in nutrient acquisition, nutrient utilization, and
immunocompetence. Interestingly, the similarities in nutrient-transferring functions
associated with the small intestine and the placenta have allowed many research
techniques to be adapted and shared across tissues and within studies, including
vascular perfusion and histological measures of vascularity (Table 2). In the small
intestine, most measures have focused on the proximal jejunum, where both digestion
and absorption occur. As with the placenta, these measures of vascularity have
been responsive to pregnancy, stage of gestation, and nutritional status during
pregnancy. Capillary area density and total vascularity of the jejunum increased
in pregnant multiparous ewes, and total vascularity increased from mid- to late
gestation [49]. In another study, jejunal capillary surface density and size increased
from mid- to late gestation, while capillary number density decreased from early
to late gestation in primiparous ewes [47]. Jejunal capillary area density and total
vascularity also decreased from early to mid-gestation, then increased from mid- to
late-gestation, possibly due to the maternal transition from the anabolic to catabolic
state of pregnancy [47]. Additionally, capillary area density of the jejunum also
increased from mid- to late-pregnancy in beef cattle [48]. These studies suggest that
vascularity of the small intestine may play more of a role as the nutrient demand of
fetal growth increases during late gestation. We hypothesize that we are observing
increases in vasodilation, which would decrease resistance to blood flow, and allow
for increased nutrient acquisition.
Overall, small intestinal size and function, including vascularity, are an
active component of maternal physiological adaptations during pregnancy. These
adaptations occur in response to increasing metabolic demands of advancing
gestation, altered nutritional plane, and inappropriate levels of specific nutrients
(Table 2). This should come as no surprise given that the small intestine is responsive
to changes in intake and metabolic demand [50].
Vascularization of the Maternal Small Intestine in Response to Different
Nutritional Treatments
Effects of nutrient intake in the face of pregnancy demands in ruminants
(especially sheep) have been studied extensively by our group, and vascular
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changes due to nutrient intake, including nutrient restriction, overnutrition, and
supranutritional selenium diets, are summarized in Table 2. Jejunal vascularity is not
affected by gestational nutrition in beef cows [48], but it has been variable in sheep.
Vascularity measures have increased, decreased, or not been affected by nutrient
restriction during pregnancy in sheep, even though the mass of the small intestine
is generally decreased by nutrient restriction (Table 2). Interestingly, mature ewes
undergoing nutrient restriction have increased jejunal capillary area density as the
mass of their small intestine decreases, allowing for similar total vascularity of the
small intestine in restricted compared with adequately nourished ewes [49]. This
phenomenon is not observed in ewe lambs (~8.5 month age at breeding) which
demonstrated both decreased capillary area density and small intestinal mass,
resulting in a decrease of total vascularity [51]. Because young females are still
growing, pregnancy may slow intestinal growth and affect development, resulting
in decreased mass and angiogenesis during times of combined physiological and
nutritional stress. More studies need to be conducted in order to determine how age,
parity, and stage of pregnancy contribute to vascular changes in the small intestine.
Overfeeding ewes during gestation affects vascularity of the small intestine
less often than nutrient restriction, despite an increase in mass of the small intestine
(Table 2). The increased mass associated with increased feed intake may allow for
enough of an increase in overall vascularity [52] that increased vascularity per unit
of tissue is not necessary in these instances to meet increased nutrient demand
associated with pregnancy.
Factors affecting regulatory mechanisms of vascularity of the small intestine are
not well understood. Nutrient intake appears to be a major factor, as growing steers
with greater feed intake have increased capillary area, number, and surface densities
as well as total vascularity [53]. This suggests that vascularity of the small intestine
may follow nutrient intake to allow for greater nutrient absorption, which seems
logical. In general, our studies with sheep support this notion, although fetal and
placental signals likely complicate this relationship during pregnancy. The VEGF and
NO systems play a role in modulating changes in vascularity and they are affected
by nutritional plane during gestation (Table 4). In general, expression of VEGF
and its receptors within intestinal tissues are altered more than eNOS or soluble
guanylate cyclase (GUCY1B3). Additionally, expression of VEGF receptors are down
regulated by supranutritional levels of selenium during pregnancy [52,54], whereas
even within supranutritional selenium, VEGF is increased with dietary selenium
(15 ppm > 3 ppm; 50). In vitro systems have demonstrated that VEGF delivery to
the small intestine increases vascularity [55]. In our studies, vascularity of the small
intestine and expression of genes for angiogenic factors change coordinately [52].
or, at times, in opposite directions [51,52,54]. Additionally, gene expression is not
always altered at the same time as a change in vascularity, and vice versa (Tables 3
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and 4). This could be due to the time of sampling of tissues, or differences in mRNA
and protein expression.
The small intestine exhibits a high degree of plasticity and responds to
nutrient presence in the lumen, immunomodulatory factors, hormones, growth
factors, local cell communication, and microbial and host interactions [56–59]. Thus,
changes in the vascularity and size of the small intestine in pregnant animals
could be due to increased intake (which is typical when food is consumed ad
libitum in most species), increased nutrient demand and resulting hormone and
growth factor signals, and signals coming directly from the placenta or fetus. For
example, estradiol-17β implants alter jejunal capillary number density and crypt cell
proliferation and interact with dietary linseed meal (contains diphenolic compounds
with estrogenic-like activity) and results in changes in impact mRNA expression of
VEGF receptors and GUCY1B3 in ovariectomized ewes [60]. Additionally, blood
flow to the small intestine increases with estradiol-17β infusion [14]. Thus, estradiol
during pregnancy may be one of the contributing factors in adaptation of the intestine
to pregnancy.
Proper and efficient function of the small intestine is necessary for the dam
to acquire and deliver nutrients to the fetus during pregnancy. In all of our sheep
studies, nutrient restriction in mid- and late-gestation reduces fetal growth (Table 3).
The overall decrease in the nutrient transferring capacity of the small intestine due
to changes in mass, vascularity, or other factors likely plays a role in decreased fetal
growth. Although the maternal small intestine appears to increase vascularity during
nutrient restriction in some studies [49], this has not occurred in all experiments. It is
possible that successful maternal adaptation of the gut during nutrient restriction
is able to prevent a decrease in nutrient delivery to the fetus in some animals, but
more research is necessary. While the maternal gastrointestinal tract has the first
opportunity to utilize nutrients after consumption, most data from stable isotope
studies indicate [61]. that the gut is a highly competitive tissue, deriving the majority
of its amino acids from arterial compared with luminal supplies. Maternal nutrient
sourcing (arterial or luminal) has not been well studied during advancing pregnancy.
If additional nutrients are used by the small intestine due to poor adaptation to
nutrient restriction or pregnancy, decreased nutrients would be available for delivery
to the fetus. Additionally, if the gastrointestinal tract is increasing in mass due





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4. Expression of VEGF and NO system mRNAs in the small intestine of ewes.
Treatment Stage Gene Expression 2
Sheep—Gestation
Control (CON) vs. Restricted (RES)
Day 64 to 135 gestation [51,54] Late gestation (Day 135)
VEGF, FLT1, KDR: RES >
CON
Control (CON) vs. Restricted (RES)
Day 40 gestation to parturition [52,63] Within 24 h post-partum FLT1: RES > CON
Control (CON) vs. Overnourished (HIGH)
Day 40 gestation to parturition [52,63] Within 24 h post-partum
VEGF, FLT1, and NOS3:
HIGH > CON
Adequate Se (ASe; 0.3 ppm) vs. High
Se (HSe; 3 ppm)
Day 0 to 135 gestation [51,54]
Late gestation (Day 135) NS 3
Adequate Se (ASe; 0.3 ppm) vs. High
Se (HSe; 3 ppm)
Day 0 gestation to parturition [52,63]
Within 24 h post-partum FLT1: ASe > HSe
Adequate Se (ASe; 0.14 ppm) vs. High
Se (HSe; 3 or 15 ppm)
Day 50 to 134 gestation [54,64]
Late gestation (Day 134) 4 KDR: ASe > HSe
High-Se wheat vs. Sodium selenate (3 ppm)
Day 50 to 134 gestation [54,64] Late gestation (Day 134)
4 NS
3 ppm vs. 15 ppm of Se (both
sodium selenate)
Day 50 to 134 gestation [54,64]
Late gestation (Day 134) 4 VEGF: 15 ppm > 3 ppm
Sheep—Lactation
Control (CON) vs. Restricted (RES)
Day 40 gestation to parturition [52,64,65] Early lactation (21 day) NS
Control (CON) vs. Overnourished (HIGH)
Day 40 gestation to parturition [52,64,65] Early lactation (21 day) NS
Adequate Se (ASe; 0.3 ppm) vs. High Se
(HSe; 3 ppm)
Day 0 gestation to parturition 1
Early lactation (21 day) NS
1 Fed to meet NRC requirements for lactation with adequate Se post-partum;
2 FLT1 = fms-related tyrosine kinase 1 (VEGF receptor 1), KDR = kinase insert domain
receptor (VEGF receptor 2), GUCY1B3 = soluble guanylate cyclase (NO receptor);
3 NS = not significant; 4 NOS3 and GUCY1B3 were not measured.
3. Placenta
Unlike most eutherians, livestock have non-invasive placentas. Gross
morphology of the ruminant placenta is termed cotyledonary, and pigs and
horses have a diffuse type of placentation. Microscopically, livestock species
have epitheliochorial placentation, with six cellular layers separating maternal
and fetal blood. Some argue that ruminant placentas are better classified as
syndesmochorial due to their formation of giant trophoblast cells by chorionic
and uterine epithelia [66–68]. In swine, the diffuse placenta has chorionic villi
attachment distributed over the entire surface of the chorion. The presence of primary
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and secondary rugae increases the relative surface area of attachment between
the endometrium and the fetal membranes [69]. Within the large white breeds
of domestic pigs, placental area of attachment continues to increase as gestation
advances [70,71] and vascular development of the placenta, as measured by the
density of larger blood vessels (i.e., arterioles), increases ~200% in the fetal portion
of the placenta [71] with maternal vascular density remaining similar [26,71] from
mid- to late-gestation. In ruminants, the fetal placenta attaches to discrete sites on
the uterine wall called caruncles, which are aglandular sites appearing as knobs
along the uterine luminal surface of non-pregnant animals [72]. The placental
membranes attach at these sites via chorionic villi in areas termed cotyledons. The
caruncular-cotyledonary unit is called a placentome and is the primary functional
area of physiological exchanges between mother and fetus. In the ewe, the growth
of the cotyledonary mass is exponential during the first 70–80 days of pregnancy,
thereafter slowing markedly until term [73]. In contrast, the placental growth
in the cow progressively increases throughout gestation [24,74]. Perhaps, these
alterations in growth patterns in the sheep and cow placenta help explain the change
of capillary area density (i.e., a blood flow related measure; [21]) that exist from
mid- to late-gestation [75]. While sheep placentas remain relatively similar in
weight from mid- to late-gestation, there caruncular and cotyledonary capillary
area density increase ~200 and 400%, respectively [21,75]. Bovine placentas exhibit
relatively modest changes in capillary area density (compared to sheep) from mid-
to late-gestation with capillary area density in caruncular tissue decreasing ~30%
and cotyledonary tissue increasing ~190%, with caruncular and cotyledonary tissue
weights increasing ~530% and ~650%, respectively [24].
3.1. Vascularity of the Placenta and Utero-Placental Blood Flow in Response to Different
Nutritional Treatments
Several authors have established that many of the models of placental
insufficiency are, in part, due to reduced placental vascularity and uterine or
umbilical blood flows (reviewed in [77–79]). When placental growth is restricted in
ewes, umbilical and uterine blood flows are reduced, limiting fetal growth [79].
Recently, in our laboratories, we have investigated if placental vascularity and
uterine/umbilical blood flows are impacted by different maternal dietary treatments.
In sheep, while we have observed reductions in umbilical blood flow [80] and
increases in arterial indices of resistance [81], we have not observed alterations in
placental capillary densities [82,83]. After 30 days whereby a 40% reduction in intake
was applied (i.e., on Day 50), umbilical blood flow of singleton fetuses was reduced
compared to adequately fed control ewes [80]. This reduction remains through late
gestation (Day 130). In beef cattle, we initially hypothesized that, similar to sheep,
reductions in intake would lead to reductions in uterine blood flow. In contrast,
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we observed that during a 110 day nutrient restriction (i.e., 40% of the control diet),
uterine blood flows were similar [84]. Interestingly, upon realimentation, blood
flow to the ipsilateral horn increases [84]. While our work has been done with
global nutrient restriction and realimentation, Perry et al. [85] reported that protein
restriction during the first trimester of pregnancy followed by increased protein
concentration during the second trimester enhances placental development and
fetal growth. Increased dry matter intake has been linked to enhanced maternal
insulin-like growth factor-1 during late pregnancy [86]. If exogenous insulin-like
growth factor-1 is administered to the dam, there is increased glucose and amino
acid uptake by both fetal and maternal tissues [87]. Uteroplacental blood flow
is undoubtedly associated with fetal growth and development; however, specific
nutrient transport across the feto-placental unit rely not only on adequate blood flow
but also on adequate nutrient transporter densities.
For our beef cattle studies, color Doppler ultrasonography was utilized. Prior
to our studies, others have used this non-invasive technique which has been used
to measure uterine blood flow and arterial indices of resistance in cattle [88–90].
Foundational uterine blood flow work in beef cattle has been conducted utilizing
more invasive techniques such as electromagnetic blood flow transducers [91] or
infusion of deuterium water [92]. By using color Doppler ultrasonography to assess
uterine blood flow and vascular resistance throughout gestation in pregnant beef
cows, we were able to examine the same animal continuously throughout gestation
with no surgical preparation and with minimal interference to dam. Similarly,
Bollwein et al. [88] measured uterine blood flow in cows during the estrous cycle.
They suggested that Doppler ultrasonography was a reliable method to determine
uterine blood flow and did not require use of blood flow probes and/or chronically
catheterized animals. Moreover, findings from this study and others suggest that
the use of Doppler ultrasonography as the technique to investigate uterine blood
flow during pregnancy may also constitute a reliable method. In several breeds of
cattle, when Doppler ultrasonography assessed uterine hemodynamics throughout
gestation (i.e., Day 30–270) resistance index decreased and uterine blood flow
increased exponentially with increased blood flow in ipsilateral vs. contralateral
horns [89,93]. Moreover, resistance index was negatively correlated to uterine
blood flow [93].
The hypothesis that during nutrient restriction total uterine blood flow would
be reduced was rejected. Moreover, while total uterine blood flow was similar
after realimentation, ipsilateral uterine blood flow was enhanced in cows that were
previously restricted. In many sheep models investigated to date [76,80], nutrient
restriction results in reduced uterine and/or umbilical blood flow. This could be
innate species differences, or also due to parity or age of the dam. Regardless,
until more beef cattle work is performed to confirm our results, caution should be
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used when comparing data acquired in sheep as it may not be directly applicable
to beef cattle. Inanition in swine during mid-pregnancy (Day 50–90; gestation
length = 114 days) resulted in no change to uterine blood flow, similar to our findings
in the beef cow, and resulted in no change in weight of the total uterine mass [94].
Despite this lack of change in uterine blood flow, Hard and Anderson [94] further
demonstrated that blood volume was reduced during inanition, but increased by
24% within 20 days of realimentation. Unfortunately, how realimentation influenced
uterine blood flow was not measured in the Hard and Anderson study. In women
experiencing hyperemesis gravidarum, uterine blood flow per 100 g of fetus is
increased compared to control women [95], but the authors were unable to locate
information on how normal intakes may have impacted uterine blood flow in those
pregnancies. While there is a paucity of information on how restriction and/or
realimentation impacts uterine blood flow, it appears most pregnant females alter
their body reserves to allow continuation of adequate blood flow for the developing
conceptus. However, to our knowledge, uterine blood flow in models of nutrient
restriction has not been measured upon realimentation in any species.
3.2. Utero-Placental Amino Acids
Uteroplacental and fetal uptake of amino acids can be primarily divided
into two areas of interest focusing on either metabolic pathways or transport
systems [77,96,97]. From a metabolic standpoint, research has shown consistent
uterine and fetal uptakes of essential amino acids [98]. However, there is evidence
that amino acid derivatives, such as creatine, which is actively transported across
the placenta, may provide beneficial impacts to the fetus [99]. Focusing on essential
amino acids, previous research has shown net uteroplacental consumption of
isoleucine, leucine, and valine, while methionine was the only essential Amino
Acid (AA) showing a net uteroplacental release [98]. The uteroplacental consumption
of branched-chain amino acids to their respective keto acids contributes extensively
to placental glutamate production via α-ketoglutarate. This relationship allows for
the establishment of a feto-placental glutamate–glutamine shuttle, whereby the fetus
is dependent on this exogenous supply of glutamine from the placenta [100–102],
which could be altered by placental insufficiency [103,104]). The ovine placenta
expresses glutamine synthetase, which catalyzes the condensation of glutamate and
ammonia into glutamine [98].
Branched-chain amino acids regulate mammalian target of rapamycin (mTOR),
which has been implicated as a nutritional sensor, that regulates cell growth
and protein synthesis via increased rates of mRNA translation through the
phosphorylation of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1)
and the ribosomal protein S6 kinase 1 [105–107]. Moreover, supplementation of
branched-chain amino acids to dams on a protein deficient diet can restore fetal
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growth and minimize the decreases in fetal organ mass and carcass fat, which is
associated with increased mTOR signaling in the fetus [108]. Recent evidence in
human placental cell cultures as well as choriocarcinoma cell lines indicate that
amino acid transporter expression and/or activity may be regulated by mTOR
signaling pathways [109]. Specifically, treatment of the BJAB cell line with rapamycin
(an inhibitor of mTOR complex 1) decreases mRNA expression of multiple amino
acid transporters [110]. In human primary trophoblast cell cultures, inhibition of
mTOR by rapamycin reduces the activity of system A, system L, and taurine amino
acid transporters; however, mTOR inhibition does not change amino acid protein
expression. Therefore, amino acid transporter activation is independent of increased
protein synthesis.
Multiple animal models of intrauterine growth restriction have been used
to examine amino acid concentrations and flux across the uteroplacenta. Table 5
summarizes maternal and offspring measurements of branched-chain amino acids
following nutrient or protein restriction in various animal models. Using a mid-
to late-gestation ovine model of intrauterine growth restriction, we examined
branched-chain amino acid exchange via the uteroplacenta [111]. For this experiment,
singleton pregnant ewes were provided 100% (control) or 60% (restricted) of nutrient
recommendations from Day 50–130 of gestation. On Day 130 of gestation, ewes
were anesthetized and concurrent blood samples were collected from a catheterized
maternal saphenous artery and the gravid uterine vein. Immediately following this
collection, the gravid uterine horn was dissected and concurrent blood samples
were collected from the umbilical vein and umbilical artery. This concurrent blood
sampling procedure was used to calculate gravid uterine flux of nutrients, which is
equal to uterine blood flow multiplied by the maternal arterial-venous concentration
difference (maternal saphenous artery–gravid uterine vein) of any given substance.
Fetal flux of nutrients was calculated by taking umbilical blood flow multiplied by
the fetal venous-arterial concentration difference (umbilical vein-umbilical artery)
of any given substance [111]. In this experimental model, we observed a decrease
in both umbilical artery and uterine artery blood flow (Table 5). Uterine and fetal
uptakes of isoleucine were decreased by nutrient restriction. Interestingly, similar
uterine uptakes of leucine and valine were observed between dietary treatments;
however, fetal uptake of both leucine and valine were decreased in nutrient restricted
vs. control fed ewes.
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Table 5. Maternal and offspring measurements of branched-chain amino acid (BCAA).
Dietary Treatment Dependent Variable Response
Ovine model of nutrient
restriction from Day 50 to
130 [80,111]
Fetal weight (Day 130) Decreased 15% to 20%
Placental weight (Day 130) Similar
Umbilical blood flow (Day 50–110) Decreased 20%
Uterine blood flow (Day 130) Decreased 20%
Uteroplacental nutrient flux (Day 130)
Uterine uptake of isoleucine Decreased 42%
Fetal uptake of isoleucine Decreased 37%
Uterine uptake of leucine Similar
Fetal uptake of leucine Decreased 60%
Uterine uptake of valine Similar
Fetal uptake of valine Decreased 69%
Ovine model of nutrient
restriction from Day 28 to
135 [112]
Fetal weight (Day 135) Decreased 15%
Maternal and fetal plasma BCAA
Maternal concentration of isoleucine Decreased 19%
Fetal concentration of isoleucine Decreased 28%
Maternal concentration of leucine Decreased 41%
Fetal concentration of leucine Decreased 38%
Maternal concentration of valine Decreased 43%
Fetal concentration of valine Decreased 35%
Ovine model of
metabolizable protein
restriction from Day 100 to
130 [113]
Fetal weight (Day 130) Decreased 20% to 45%
Placental weight (Day 130) Similar
Umbilical blood flow (Day 50–110) Similar
Uterine blood flow (Day 130) Increased 50% to 80% *NS
Maternal and Fetal BCAA (Day 130)
Maternal concentration of leucine Similar
Fetal concentration of leucine Decreased 40% to 50%
Maternal concentration of valine Similar
Fetal concentration of valine Decreased 30% to 50%
Porcine model of protein
restriction from mating to
Day 60 [114]
Maternal artery and umbilical vein BCAA
Maternal artery concentration of isoleucine Similar
Umbilical concentration of isoleucine Decreased 19%
Maternal artery concentration of leucine Similar
Umbilical concentration of leucine Decreased 29%
Maternal artery concentration of valine Similar
Umbilical concentration of valine Decreased 20%
Porcine model of
isocaloric diets with high
or low protein compared
to standard diet [115]
Litter weights; litter sizes Similar
Maternal and umbilical/fetal BCAA
Maternal venous concentration of isoleucine Decreased 32%
Umbilical/fetal concentrations of isoleucine Similar
Maternal venous concentration of valine Decreased 73%
Umbilical/fetal concentrations of valine Similar
Maternal venous concentration of leucine Decreased 21%
Umbilical/fetal concentrations of leucine Similar
6 Rodent model of protein
restriction from Day 1 to
term [108]
Newborn pup weights Decreased 9% to 18%
Maternal and newborn BCAA
Maternal concentration of isoleucine Decreased 36%
Newborn concentration of isoleucine Decreased 59%
Maternal concentration of leucine Decreased 43%
Newborn concentration of leucine Decreased 60%
Maternal concentration of valine Decreased 52%
Newborn concentration of valine Decreased 68%
* NS = not statistically different at p < 0.05.
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Other ovine models of nutrient or protein restriction have shown comparable
decreases in fetal weight and branched-chain amino acid profiles (Table 5). For
example, Kwon et al. [112] observed similar decreases in maternal and fetal
concentrations of isoleucine, leucine, and valine following maternal nutrient
restriction from Day 28–135 of pregnancy. Using an ovine metabolizable
protein restriction model where samples were simultaneously collected, Lekatz
and Vonnahme [113] showed a decrease in fetal concentrations of leucine and
valine; however, maternal concentrations of leucine and valine were not different
between dietary treatments. Similar to the ovine metabolizable protein restriction
model, Wu et al. [114] observed decreased fetal concentrations of branched-chain
amino acids with no difference in maternal concentrations of branched-chain
amino acids following protein restriction from early to mid-pregnancy in pigs.
Metzler-Zebeli et al. [115] observed maternal venous changes, but no differences in
umbilical or fetal blood of branch-chained amino acids (Table 5). Pregnant rats which
were protein restricted from Day 1 to term had a decrease (36%–68%) in both maternal
and newborn concentrations of branched-chain amino acids [108]. In addition
to these observations, this study also identified a critical role for branched-chain
amino acid supplementation in partially rescuing fetal growth restriction induced by
maternal dietary protein restriction.
In conclusion, we have made interesting observations of branched chain amino
acids in several sheep models of nutrient intake; however, more research is needed to
determine how the placenta adapts to other maternal stressors that impact nutrient
delivery, including amino acids, fatty acids, and sugars.
4. How Pregnancy Prepares the Dam for Lactation
The growth and development of the mammary gland from fetal life through
involution in livestock has been reviewed recently and sets the stage for the
discussion below [116]. As mentioned above, dramatic changes occur within
the maternal cardiovascular system during pregnancy [14] and maternal energy
consumption and metabolism also are altered [117] to nourish the growing conceptus
and to prepare the mammary gland for lactation. Although, lactating high producing
non-pregnant dairy cattle will show a substantial increase in cardiac output compared
to their non-pregnant non-lactating counterparts [118,119], this redistribution of
blood flow during the transition period from the uteroplacental vasculature towards
the mammary gland is still a phenomenal physiological feat to allow for peak
lactation shortly after parturition.
Mammary gland growth, milk yield, and mammary tissue DNA content
was influenced by energy and protein intake in sows during lactation [120].
Moreover, increased dietary lipids in peripubertal ewe lambs results in increased
mammogenesis [121]. While we have observed no effects of nutrition on mammary
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gland growth in our beef cow models [122], we do observe differences in ewes.
Development of the mammary gland is unique to ewes and unlike other livestock,
sheep do not exhibit post-parturient growth of the mammary gland [123]. Our
laboratory has recently reported that maternal selenium supplementation as well as
differing levels of maternal nutrition during mid- to late-gestation alters colostrum
yield and mammary gland microanatomy [65,124–126]. Mammary gland alveolar
epithelium has an increased proliferation index in overnourished ewes compared
with restricted and adequately fed ewes indicating that the increased level of
nutrients stimulated alveolar growth [124]. This increase in alveolar proliferation
may be indicative of an earlier differentiation of the gland, due to overnourished ewes
exhibiting decreased estradiol-17β and progesterone concentrations in circulation
compared to restricted and adequately fed ewes [86,127]. Decreases in estradiol-17β
reduce glucocorticoid-binding protein, allowing free cortisol to further complete
cellular differentiation in preparation for lactogenesis [128]. Overnourished ewes
have elevated levels of cortisol [86,127], potentially allowing for this increase in
mammary gland differentiation. Progesterone is also needed for lobular alveolar
growth in the mammary gland [128]. While colostrum yield is reduced in both
restricted and overnourished ewes [65,124], when ewes are fed similarly throughout
lactation, overfed ewes, but not restricted ewes, rebound in their milking ability to
yield similar milk weights as CON ewes [65].
Not only does maternal diet impact the milking ability of the ewe, but the
milking ability of her offspring and reproductive capacity of her grand-offspring [129].
This postnatal response may be linked to the anatomical differences observed in
mammary gland development during fetal life. Fetuses from maintenance fed ewes
had larger mammary gland weights at 100 days of fetal life compared to ad libitum
fed ewes, without impacting mammary duct area or number or fetal weights [130].
Perhaps, this enhanced milk production is due to decreased fat pad hyperplasia
and increased abundance of Mitogen-activated protein kinases (MAPK) and mTOR
pathway signaling proteins within the fat pad [131].
4.1. Vascularity of the Mammary Gland
The mammary gland is a very dynamic organ that is influenced by gestational
nutrition as evidenced by the alveolar proliferation and other cellular activity that
may occur. However, it does not appear that maternal nutritional plane during
gestation impacts the capillary vascularity of the mammary gland in sheep (Table 6) or
beef cattle [122]. Interestingly, our laboratory has demonstrated that supranutritional
levels of selenium fed during pregnancy increases mammary gland vascularity at
birth, as well as by the end of a 20 day lactation (Table 6). Moreover, enhanced
milk yields from ewes supplemented with supranutritional levels of selenium
compared to adequately levels of selenium in the diet of ewes have been reported [65].
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Investigations are on-going to determine what role enhanced vascularity may be
contributing to increased milk yield. While selenium has been reported as an
effective breast cancer reducing supplement [132], we hypothesize that the enhanced
vascularity of ewe mammary glands resulting from supranutritional selenium
supplementation may be advantageous from a milk production and offspring
standpoint. While most breast cancers are associated with higher estrogen levels in
women [133], we have not observed that supranutritional selenium supplementation
alters estradiol-17β concentrations in circulation [86,127]. It is unknown, however,
what concentrations of estradiol-17β are within the mammary gland itself.
Table 6. Impacts of maternal diet during pregnancy on vascularity and production
of the mammary gland in ewes.
Treatment Stage Impact on VascularityCompared to Control
Colostrum/Milk Production
Compared to Control
Nutritional plane At birth
Control vs. nutrient
restricted NS *
, [125,126] Decreased 53%–70% [65,124].
Control vs.
overnourished NS *




, [126] Decreased 28% [65]
Control vs.
overnourished NS *
, [126] NS [65]
Level of Selenium (Se) Supplementation
Control (0.3ppm) vs.
Supra (3.0 ppm) Se birth Increased 20%–25%
[125] NS *, [124]
Control (0.3ppm) vs.
Supra (3.0 ppm) Se birth NS *
, [126] Increased 37% [65]
Control (0.3ppm) vs.
Supra (3.0 ppm) Se Lactation Day 20 Increased 22%
[126] Increased 10% [65]
* NS = not significant at p > 0.05.
4.2. Maternal Small Intestine during Lactation
The shift from pregnancy to lactation typically includes an increase in voluntary
feed intake in addition to the other metabolic and hormonal changes; therefore,
the small intestine generally increases in mass during early lactation [52,134–136].
Increased intestinal mass during lactation could result from both increasing metabolic
demand and intake. Research with murine models demonstrate the influence of
metabolic demand of lactation on the small intestine. In lactating mice that had
undergone intestinal resection, small intestinal mass increases 200%–300% to enhance
nutrient acquisition, compared with a 60% increase in mass of controls [137]. Little
is known about changes in vascularity of the small intestine during early lactation.
In ewes, capillary area density decreased by 10% from Day 0–20 post-partum [52].
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Because mass of the small intestine also increased by 40% during the first 20 day of
lactation, this allowed for similar total vascularity between the two time periods. The
decrease in capillary area density may result from a dilution of vascular area caused
by the rapid increase in the mass of the small intestine. Furthermore, it appears
that the metabolic pressure of lactation may rely less on the vascularity of the small
intestine per unit area, and more on the increase in size of the small intestine to
increase nutrient absorption capacity.
Few data demonstrate the influence of pre-partum nutrition on small intestinal
measures during lactation. It is unknown if any of the changes that gestational
nutrition causes on the maternal small intestine program its function long-term. Due
to the plastic nature of the tissue, it appears that the small intestine changes rapidly
during early lactation, especially in the face of adequate nutrition post-partum.
In first parity ewes, we demonstrated that even when vascularity of the small
intestine was affected by nutritional plane or supranutritional levels of selenium at
parturition, the same measures were similar after being on common diets for 20 day
of lactation [52]. In fact, when ewes were fed to meet their nutrient requirements for
early lactation post-partum (i.e., all treatments experienced an increase in nutrient
intake), mass of the small intestine was similar for all ewes at Day 20 of lactation.
Mass of the small intestine rebounds faster than ewe body weight, resulting in ewes
that had previously been on a lower plane of nutrition having greater proportional
small intestinal mass (g kg−1 body weight) than control ewes. This results from a
greater increase in crypt cell proliferation in ewes that had been nutrient restricted
compared with those that had been adequately fed during gestation [52].
To our knowledge, vascularity of the small intestine during lactation in response
to previous plane of nutrition during gestation has only been reported in one
study ([52]; Table 3). In this study, ewes that had been nutrient restricted during
gestation have increased capillary surface density of the jejunum compared with
control ewes at 20 days of lactation. Additionally, ewes previously overnourished
during gestation had greater total vascularity compared with control ewes at 20 days
of lactation. In both cases, these changes due to nutrition during pregnancy were
consistent with those observed at parturition, suggesting that vascularity of the small
intestine does not change as quickly as proliferation and mass. Despite this, previous
intake of supranutritional selenium during gestation resulted in ewes having greater
capillary size in the jejunum at 20 days of lactation when compared with control,
even though these treatments had similar capillary size immediately post-partum.
This supports the hypothesis that selenium suppresses vascular beds, as capillary
size increased after return to an adequate selenium diet, although ewes had not
likely yet returned to the selenium status of control. The role of VEGF and NO
systems in altering vascular changes of the small intestine during early lactation
is not clear. In this study, any differences of divergent treatments from control
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immediately post-partum subsided by Day 20 of lactation, including gene expression
of angiogenic factors ([52]; Table 4).
Nutrient release by the portal-drained viscera (including small intestine)
increases with milk production in ewes, suggesting that nutrient absorption by
the small intestine increases with milk yield [138,139]. In our previous study,
milk production for the first 20 days of lactation did move in a similar direction
as vascularity of the small intestine for ewes that were nutrient restricted or fed
supranutritional selenium during gestation [52,65]. (Table 3). We hypothesized that
the small intestine impacts milk yield differences (decreased milk yield in ewes from
lower planes of nutrition during gestation) by altering nutrient acquisition or by
diverting nutrients from milk production to the rebuilding of body tissues including
the gastrointestinal tract. Perhaps, during these times of high physiological demands,
the intestine modulates its ability to secure more nutrients from luminal compared
with arterial supplies. Data addressing this question are not available in the literature
but would increase our understanding and potentially provide better positioning
for management during physiological stress. Additionally, it is not known if small
intestinal adaptation pre-partum is partially in preparation for lactation. Because the
gastrointestinal tract responds rapidly to changes in nutrient intake, inappropriate
nutrient intake pre-partum can alter the magnitude of its adaptation to lactation.
Moreover, periparturient changes in the small intestine are necessary for adequate
nutrient digestion and absorption to provide for milk yield, so this likely impacts
lactation and nutrient availability for offspring during postnatal life.
5. Conclusions
The vascularity of the gastrointestinal tract, placenta, and mammary gland may
be able to adapt to different nutritional stimuli, and in some cases, we know that
nutrient exchange can be altered. It is imperative that we continue to investigate
how the pregnant animal can not only survive under stressful nutritional paradigms
(i.e., inappropriate nutrient supply, conditional increased nutrient demand, specific
nutrient imbalances, etc.), but also how those adaptations may be impacting her
ability to deliver nutrients to the developing offspring. Continued effects to
understand how vascularity and other factors associated with nutrient extraction
may be key for enhancement of nutrient transfer efficiency.
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Abstract: The placenta is the primary interface between the fetus and mother
and plays an important role in maintaining fetal development and growth by
facilitating the transfer of substrates and participating in modulating the maternal
immune response to prevent immunological rejection of the conceptus. The major
substrates required for fetal growth include oxygen, glucose, amino acids and
fatty acids, and their transport processes depend on morphological characteristics
of the placenta, such as placental size, morphology, blood flow and vascularity.
Other factors including insulin-like growth factors, apoptosis, autophagy and
glucocorticoid exposure also affect placental growth and substrate transport capacity.
Intrauterine growth restriction (IUGR) is often a consequence of insufficiency, and
is associated with a high incidence of perinatal morbidity and mortality, as well as
increased risk of cardiovascular and metabolic diseases in later life. Several different
experimental methods have been used to induce placental insufficiency and IUGR in
animal models and a range of factors that regulate placental growth and substrate
transport capacity have been demonstrated. While no model system completely
recapitulates human IUGR, these animal models allow us to carefully dissect cellular
and molecular mechanisms to improve our understanding and facilitate development
of therapeutic interventions.
Reprinted from Nutrients. Cite as: Zhang, S.; Regnault, T.R.H.; Barker, P.L.;
Botting, K.J.; McMillen, I.C.; McMillan, C.M.; Roberts, C.T.; Morrison, J.L. Placental
Adaptations in Growth Restriction. Nutrients 2015, 7, 360–389.
1. Introduction
In eutherian mammals, the placenta is the primary interface between the fetus
and mother. One of the main functions of the placenta is to deliver nutrients and
oxygen to the fetus. Failure of the placenta to deliver an adequate supply of nutrients
to the fetus is termed placental insufficiency and results in intrauterine growth
restriction (IUGR), affecting up to 5%–10% of pregnancies in developed countries [1–3].
IUGR is also associated with a high incidence of perinatal morbidity and mortality
and an increased risk of cardiovascular disease and type II diabetes in later life [4–7].
In this review, we will focus on placental structure and function, factors affecting
placental nutrient transport capacity, animal models of IUGR and regulation of
placental growth and substrate transport in the IUGR pregnancy.
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2. Placental Structure and Function
In mammals, the placenta is the primary interface between the fetus and
mother and plays an important role in maintaining fetal growth by performing
several physiological functions, which, following birth, are controlled by the kidney,
gastrointestinal tract, lungs and endocrine glands. The main functions of the placenta
include modulation of the mother’s immune response to prevent immunological
rejection termed tolerance, facilitating the exchange of respiratory gases, water, ions,
nutrients and wastes between the maternal and fetal circulations, and producing and
secreting hormones, cytokines and other signalling molecules required to maintain
pregnancy and to ensure placental and fetal development and growth [8].
Maternal blood supply to the placenta is established at the end of the first
trimester of human pregnancy, with maternal blood entering the intervillous space
of the placenta from the transformed spiral arterioles for substrate transport to
the fetus [9–11]. The barrier between the maternal and the fetal circulations in
the human hemochorial placenta consists of three fetal cellular layers: (i) the
syncytiotrophoblast, a multinucleated epithelial layer formed following the fusion of
the mononucleated villous cytotrophoblasts; (ii) villous stromal tissue and (iii) the
fetal capillary endothelium (Table 1) [12]. The syncytiotrophoblast has two polarized
plasma membranes: the maternal-facing microvillous plasma membrane (MVM) and
the basal membrane (BM). The syncytiotrophoblast is the main regulator of substrate
exchange and nutrient transporters are expressed on both plasma membranes [13].
Table 1. An across species comparison of placental shape and structure [14–16].
Species Placental Shape Placental Structure
Humans Discoid Hemochorial
Ruminants (Sheep, cattle, goats) Cotyledonary Epitheliochorial
Rodents (rats, mice) Discoid Hemochorial
Pigs Diffuse Epitheliochorial
Horses Diffuse Epitheliochorial
Carnivores (cats, dogs) Zonary Epitheliochorial
Primates Discoid Hemochorial
It is important to understand the role of placental function in the IUGR fetus
from a clinical and scientific point of view. However, in vivo studies of the human
placenta are difficult as the methodology presents risks to both the mother and fetus.
Therefore, the majority of the body of knowledge about the placenta and its function
is a result of ultrasound studies across gestation or those performed in placentas
collected at delivery or in animal models. In terms of morphological similarities,
the placenta of higher primates is the most comparable to that of the human, with
a discoid hemomonochorial structure, where fetal trophoblast cells are in direct
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contact with the maternal blood supply [15]. However, primates that are suitable
for experimental studies are small, have small fetuses, and often abort or deliver
prematurely following intrauterine surgery, limiting their use in placental studies [17].
Therefore placental nutrient transport and exchange has been extensively studied
in the rabbit, guinea pig, rat, mice and human [18–20]. However, one of the most
widely used animal models for studies of fetal development and placental function
is the sheep [21–23].
One of the advantages of working with sheep compared to other animal
models of pregnancy is that the functional responses of the sheep fetus to short
or long periods of placental insufficiency can be studied in utero [24–28]. Like the
human, organogenesis in the sheep occurs during early gestation with the functional
maturation of the renal and cardiovascular systems by late gestation [23]. In addition,
pregnant ewes are comparable to humans in size with equally large fetuses that
tolerate intrauterine surgery well and most organ systems develop before birth [29].
Therefore, vascular catheters can be surgically implanted in the fetus, exteriorized
through the ewes’ flank and maintained for several weeks, allowing for repetitive
blood sampling from unanaesthetised pregnant ewes and their fetuses to measure
blood gases, hormones and cardiovascular parameters in response to placental
insufficiency during late gestation [23,30].
In sheep, implantation begins at ~14–16 days gestation (term = 150 ± 3 days
gestation) and is complete by ~22 days gestation, marking the initiation of
placentation [31], which is the process of placental growth and development,
resulting in the maturation of functional units called placentomes. Sheep have
a non-invasive, cotyledonary type of placentation in which specialized areas of the
endometrium termed caruncles are attachment sites for trophoblasts of the chorion
forming 50–90 placentomes during a normal singleton pregnancy (Table 1) [14,16].
Placentomes are divided into the maternal (caruncle) and fetal (cotyledon) portions
and consist of interdigitated maternal crypts and fetal villi that develop through
synchronised growth between the trophoblast and caruncular endometrium [16,32].
Morphologically, the maternal portion of the placentome is composed of maternal
connective tissue, maternal capillaries and maternal epithelial cells; while the fetal
portion of the placentome is composed of fetal trophoblasts, connective tissue and
fetal capillaries. The placentomes grow rapidly following implantation and reach
maximum weight at ~75–80 days gestation, from which point weight declines until
term [33]. However, placentomes undergo progressive structural remodelling, with
attenuation of all cell layers in both fetal and maternal tissues, bringing fetal and
maternal capillaries in close proximity to allow increased capacity for substrate
transfer during the second half of gestation when fetal demand for nutrients
is high [16].
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Placentomes are classified into four types (A–D) based on their gross
morphology [34]. The fetal side of the placentome is defined as a thin hemophagous
zone where maternal blood extravasates between the maternal crypts and fetal villi.
Type A placentomes are rounder in shape and the hemophagous zone is inverted
inside of the bulk of the placentome in which only a small area of the zone is visible
externally. Type D placentomes are flatter in shape and the hemophagous zone
is everted and covers the entire fetal surface of the placentome. Type B and C
placentomes are intermediate in the degree of hemophagous zone eversion that is
present. Throughout gestation, type A and B placentomes dominate, accounting
for ~ 60% of the total number in a normal pregnancy. Type C and D placentomes
are less common, occurring with greater frequency in multiple pregnancies and
during late gestation. They are larger, heavier and more everted compared to type
A placentomes. Although, the placentome types have different structures, it is not
known if they have differential functions [32]. Previous studies have suggested
that placentome eversion is an adaptation that occurs to increase the efficiency of
placental nutrient transfer to the fetus [35]. In sheep, gross placentome morphology
changes progressively throughout gestation with an increase in the number of everted
placentomes, type C and D, in late gestation at 125–135 days [35,36]. Interestingly,
it has been reported that early exposure to high plasma cortisol concentrations
decreases the proportion of type C and D placentomes, which indicates that
developmental shifts in placentome classification are not restricted to eversion [16].
3. Factors Affecting Placental Substrate Transport Capacity
Birth weight depends not only on maternal nutrition but also on the placenta’s
ability to transport substrates from the maternal to the fetal circulation [10]. Placental
efficiency or fetal-placental weight ratio, defined as grams of fetus per gram of
placenta, can vary between species and pregnancies [37]. At any gestational
age, placental efficiency measurements provide an indication of the conditions
experienced in utero and the extent to which placental adaptations during intrauterine
development have occurred in order to meet fetal growth demands. These
morphological and/or functional adaptations determine placental substrate transport
capacity and efficiency to the fetus. The major substrates required for fetal growth
include oxygen, glucose, amino acids and fatty acids [9,12,13].
While the placenta regulates the transport of nutrients to the fetus according
to the mother’s ability to deliver them, fetal demands as well as hormones and
growth factors secreted by the placenta, the weight, size and shape of the placenta
also affect its ability to transfer nutrients [38–40]. The transfer of highly permeable
molecules, such as gases, oxygen and carbon dioxide, is influenced by blood flow
and occurs via simple diffusion, whereas less permeable substrates are transferred
through passive and active transport processes. Glucose is transported across
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the placenta via facilitated diffusion and is orchestrated by hormones secreted
by the placenta [11]. Therefore, net glucose transfer is highly dependent on the
maternal-fetal concentration gradient. Nutrients such as amino acids are transported
via active transport using the charge provided by sodium ions and those that are
transported via exchange for another amino acid [13]. Furthermore, these processes
also depend on morphological characteristics of the placenta, such as placental size,
surface area for exchange, vascularity as well as blood flow [15].
3.1. Fetal Oxygenation
Simple molecules such as oxygen and carbon dioxide are transported by
diffusion and bulk flow. Oxygen (O2) plays a critical role in the development and
function of the placenta and fetal hypoxaemia is a common condition of complicated
pregnancy. Oxygen diffuses from the maternal to the fetal circulation across a
placental epithelial layer that consumes O2. This O2 consumption generates a
transepithelial oxygen partial pressure (PO2) difference whose magnitude depends
upon the rate of umbilical and uterine blood flow, fetal and maternal blood oxygen
carrying capacity, haemoglobin oxygen binding affinity, placental surface area and
placental permeability [41]. Placental gas exchange occurs across cellular layers
between the uterine and fetal circulations, once vascular beds have matured to allow
adequate supply across the two circulations [14]. As a result, placental oxygen
levels are low in the first trimester, increasing significantly by the second trimester.
Therefore the fetus develops in a hypoxic environment during early pregnancy until
the utero-placental vasculature can provide efficient gas exchange. Currently, much
of the understanding of fetal and placental respiration is from the study of sheep in
late gestation [42]. As the placenta is a highly metabolically active organ, it consumes
a large quantity of the oxygen taken up from maternal circulation; some 80% in
mid-gestation [42] and 40%–60% in late gestation [43]. Moreover, despite decreases
in maternal oxygenation and uterine blood flow, the PO2 gradient across the placenta
remains constant in order to sustain fetal oxygen delivery at a normal rate [44].
3.2. Placental Size and Morphology
Placental size has a direct effect on the capacity for nutrient transfer via
changes in surface area for transport. Placental weight is positively correlated
with birth weight at term in many animal models [15]. In humans, placental weight
progressively increases throughout pregnancy, while in rodents and sheep, placental
weight increases before plateauing in mid to late gestation and then declines until
term [45]. The small placenta increases nutrient transport capacity via morphological
adaptations such as increased relative surface area for nutrient exchange, vascularity
and decreased barrier thickness. These adaptations affect placental transport capacity
and alter fetal to placental weight ratio.
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3.3. Blood Flow and Vascularity
Blood flow is a major determinant of placental function and fetal growth.
Vascularity of the sheep placenta increases in mid gestation, due to increases in
the number and surface density of the placental capillaries, particularly those
in the fetal side of the placentomes [46]. Vasculogenesis, formation of new
blood vessels, and angiogenesis, formation of new branches from pre-existing
vessels [47], are critical to form a vascular system needed for effective transport
of nutrients, oxygen, and waste products. Several factors have been identified
as important regulators of these processes, including the vascular endothelial
growth factor (VEGF) family, basic fibroblast growth factor (bFGF), epidermal
growth factor (EGF), platelet-derived growth factor (PDGF) and angiopoietin-1
and -2 [48]. The VEGF proteins and receptors VEGFR1 (FLT-1) and VEGFR2 (FLK-1)
are the most studied family of growth factors known to regulate the processes of
vasculogenesis and angiogenesis. In pregnancy, VEGF is expressed by human villous
and extravillous trophoblasts and also participates in the proliferation, migration,
and metabolic activity of trophoblasts [49]; bFGF acts as a modulator of tissue
differentiation and placental angiogenesis [48]. Angiopoietin-1 and its antagonist
angiopoietin-2 act on the angiopoietin receptor (TIE-2) to regulate vascular integrity
and remodeling [50]. Angiopoietin-1 and -2 have both been detected in decidual and
placental tissues [51]. Vascular growth is necessary to increase placental-fetal blood
flow across gestation [52–54]. Therefore fetal growth is linked to the capacity of the
placenta to supply oxygen and nutrients for transfer to the fetus [55].
3.4. Insulin-Like Growth Factors
Insulin-like growth factors (IGFs), IGF-1 and IGF-2, are single chained
polypeptides that promote fetal and neonatal growth, acting in response to fetal,
maternal and placental signals such as nutrients, oxygen and hormones via the IGF
receptors, IGF-1R and IGF-2R, and the insulin receptor (InsR). IGF-2 is the most
abundant of the fetal IGFs, however, deletion of either Igf gene results in reduced
birth weight [55]. IGF-1 regulates fetal growth in response to nutrient availability
while IGF-2 stimulates placental growth and differentiation [56]. Furthermore IGFs
regulate substrate transport and hormone secretion and influence fetal growth
indirectly by influencing maternal substrate availability or directly by influencing
placental nutrient uptake and transport [56]. In human trophoblasts, IGF-1 and IGF-2
stimulate glucose and amino acid uptake [57]. Elevated maternal plasma IGF-1 has
been shown to increase fetal glucose and amino acid uptake in the guinea pig in
early pregnancy [27,28]. In sheep, elevated plasma IGF-1 concentrations in early
pregnancy are associated with increased maternal plasma glucose concentrations
and enhanced fetal growth [56]. Furthermore in late pregnancy, acute treatment with
IGF-1 alters placental metabolic function and increases glucose delivery to the sheep
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fetus [58]. IGF-1 stimulates system A amino acid uptake in cultured trophoblast cells
and can act by both the IGF-1R and InsR [57]. Interestingly, in a knockout mouse
model, deletion of the gene transcript for placenta specific expression of Igf2 results
in the reduction of placental growth while fetal growth is maintained in association
with an up-regulation of glucose transporter (GLUT3) and amino acid transporter
(SNAT2) during mid gestation, however IUGR still develops near term [59–61].
3.5. Placental Apoptosis, Autophagy and Glucocorticoid Actions
The role of the apoptosis cascade has been characterized in human villous
trophoblast turnover and syncytium formation [62]. Apoptosis occurs in placentas
of normal human pregnancies, and is regulated by the effector caspase pathway and
the apoptosis inhibitor B-cell lymphoma 2 (BCL-2) in the trophoblast [62].
Autophagy is a highly regulated and dynamic process involving invagination
and degradation of cytoplasmic components that maintain cellular homeostasis and
promote cell survival in response to environmental stresses such as starvation and
hypoxia [63]. Autophagy-related proteins such as beclin-1, light chain 3 isoform B
(LC3B), and damage-regulated autophagy modulator (DRAM) are present in the
trophoblast of human placenta during early, mid and late gestation [64,65]. Beclin-1 is
part of an early complex that promotes synthesis and growth of pre-autophagosomal
membranes [66]. LC3B is synthesized as proLC3B and converted to LC3B-I by
autophagy-related proteases, which is further processed into LC3B-II and integrated
into membranes of autophagosomes upon induction of autophagy [66]. DRAM is a
lysosomal protein that regulates autophagy in a p53-dependent manner [67].
In utero, the placenta and embryo/fetus are each exposed to physiological
glucocorticoids arising from either the maternal or fetal adrenal glands. Glucocorticoid
actions are moderated by the glucocorticoid receptor and two isoforms of intracellular
11β-hydroxysteroid dehydrogenases (11βHSDs) [68]. 11βHSD1, which is a reduced
nicotinamide adenine dinucleotide phosphate-dependent isoform, acts to convert
biologically inert cortisone to the active cortisol, whereas 11βHSD2, which is a
unidirectional nicotinamide adenine dinucleotide-dependent enzyme, catalyzes the
conversion of the biologically active cortisol to the inert cortisone. In placenta,
11βHSD1 protein is expressed specifically in the placental villous endothelial cells,
amnion, chorionic and extravillous trophoblasts, while 11βHSD2 protein is localized
exclusively in the syncytiotrophoblast and invasive extravillous trophoblasts with no
expression in the chorion or amnion [69]. 11βHSD1 expression increases throughout
pregnancy in response to progesterone in human placenta [70]. In human pregnancy,
placental 11βHSD2 activity increases markedly in the third trimester of pregnancy at
a time when maternal circulating levels of glucocorticoid are rising [71]. In contrast,
the placental inactivation of cortisol via placental 11βHSD2 activity decreases in the
latter stages of gestation in sheep and is not present in term ovine placenta [72]. The
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fetus is normally protected from the high levels of maternal cortisol by placental
11βHSD2 [69].
3.6. Placental Transporter Abundance
The placenta’s ability to transport substrates for fetal growth is also influenced
by the abundance, activity and localization of transporters in the placental
membranes [73]. Furthermore, transport of nutrients such as glucose and amino acids
is also determined by the placental barrier and specifically the expression and activity
of particular nutrient transport systems in the placental syncytiotrophoblast plasma
membranes, MVM and BM [9]. Glucose and amino acid uptake into fetal circulation
is dependent on three steps: (1) uptake from maternal circulation by transporters on
the microvillous membrane of the syncytiotrophoblast; (2) transport across cytoplasm
of the syncytiotrophoblast; and (3) transport across the fetal-facing basal membrane
of the syncytiotrophoblast into fetal circulation [14]. Enhanced expression of nutrient
transporters per unit of surface area is another key compensatory mechanism used to
increase efficiency of the small placenta. Activity of placental glucose and amino acid
transport systems is influenced by a wide range of environmental factors including
heat stress, hypoxia, under- and overnutrition as well as exposure to placental
hormones [55]. Placental glucose, amino acid and fatty acid transport systems are
discussed in detail below.
3.6.1. Placental Glucose Transport Systems
Glucose is the primary nutrient required for the fetus and placenta [13,74]. However,
the fetus and placenta have a limited ability for producing glucose, therefore glucose
availability is dependent on supply from the maternal circulation [13,75–77]. Placental
glucose uptake and transport to the fetus occurs down the concentration gradient
from maternal to fetal circulation where it crosses the placental barrier via facilitated
transport [14,78]. This is mediated by a family of sodium-independent transporter
proteins, encoded by 14 different genes of the SCL2A family, called glucose
transporters (GLUTs) [78]. GLUTs are present on both plasma membranes of the
syncytiotrophoblast [13]. As glucose is transported down the concentration gradient,
higher maternal glucose concentrations compared to fetal glucose concentrations
drive net glucose transport toward the fetus. A high density of GLUTs in the
MVM, together with a large surface area, allows for rapid glucose uptake into
the syncytiotrophoblast. This provides adequate glucose supply for placental
consumption while also maintaining a gradient between the syncytiotrophoblast
and fetal circulation, ensuring fetal supply [13]. GLUT expression on the BM is
much lower than the MVM and is associated with a smaller placental surface
area, which suggests transport across the BM is the rate-limiting step of placental
glucose metabolism [9,13]. The sheep and human placenta have two primary glucose
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transporters including GLUT1 (SLC2A1) and GLUT3 (SLC2A3) and less abundant
glucose transporters including GLUT4 (SLC2A4) and GLUT8 (SLC2A8).
GLUT1 is insulin independent and ubiquitously expressed in a variety of
human tissues including muscle, adipose, brain and endothelial cells [74]. GLUT1
is the main glucose transporter in the placenta and is highly expressed on both the
microvillous and basal membranes of the syncytiotrophoblast [13,79]. In humans,
GLUT1 expression is higher in the MVM compared to the BM, allowing for increased
glucose uptake from maternal circulation [9,80]. In sheep, GLUT1 is localised to
the base of the syncytial layer of the placenta, which is derived from the maternal
epithelial cells and chorionic binucleated cells, and the baso-lateral surface of the
trophoblast layer [81]. However, GLUT1 has not been found on the interdigitated
microvilli of the trophoblast and syncytial layer [14]. In sheep, placental GLUT1
mRNA expression increases throughout gestation, peaking at 120 days in singleton
pregnancies and 140 days in twins [79].
GLUT3 is insulin independent and its expression is cell-specific, depending
on the stage of pregnancy [78]. In both humans and sheep, GLUT3 is expressed
throughout gestation but decreases toward term, and therefore plays a greater role in
the transport of glucose during early fetal development [74,78]. Furthermore, GLUT3
expression in the placenta has been detected in the cytotrophoblast but not the
syncytiotrophoblast in the first trimester of human pregnancy [78]. However, in the
third trimester placental GLUT3 expression is localised to the vascular endothelial
cells of the fetal blood vessels and stromal cells [14,78,80]. In sheep, GLUT3 has
been found on the microvillous junction between the syncytium and trophoblast
layer [81]. Interestingly, GLUT3 is only expressed in one other tissue aside from the
placenta, the brain [74,80]. The brain, like the fetus, depends on a constant supply of
glucose in order to sustain energy production. Therefore, expression of GLUT3 in
the placenta may maintain glucose supply to the fetus, even when maternal plasma
glucose concentrations are low [14]. Furthermore, GLUT3 has a higher affinity for
glucose than GLUT1 and is therefore more efficient in transporting glucose at low
concentrations [81]. The high affinity of GLUT3 for glucose means that in conditions
where maternal glucose concentrations are lower than normal, GLUT3 may be the
key transporter in tissues where glucose is the primary metabolic substrate [74].
GLUT4 is insulin dependent and its immunostaining was detected in fibroblasts
from amnion and chorion [82]. A strong GLUT4 signal was also observed in
intravillous stromal cells, appearing to co-localize with InsR [83]. GLUT8 was
localized to the chorionic epithelial layer and uterine epithelial cell from mid to
late gestation and its expression in placenta increased during late gestation [84,85].
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3.6.2. Placental Amino Acid Transport Systems
The human placenta expresses more than 20 different amino acid transporters [13].
Fetal amino acid concentrations are generally higher than maternal amino acid
concentrations, reflecting an active transport mechanism across the placenta [13,86].
However, the placenta not only transports amino acids from mother to fetus but also
produces and utilizes amino acids to meet its own metabolic need, and therefore
plays a key role in determining the flux of amino acids into the fetal circulation [9].
Many types of placental amino acid transporters have been identified and are
characterized into distinct systems [13,86]. There are several major classes of amino
acid transporters present in the placenta, including neutral amino acid transporters,
cationic amino acid transporters and anionic amino acid transporters [87,88].
System A amino acid transporters are an example of neutral amino acid
transporters that facilitate the uptake of small non-essential neutral amino acids such
as alanine, glycine and serine. Uptake occurs against their concentration gradient
simultaneously with the transport of extracellular sodium into the cell. While system
A transporters are present on both placental membranes, expression is greater on
the MVM. System A activity contributes to the high intracellular concentration of
amino acids such as glycine, which is exchanged for extracellular essential amino
acids by system L transporters [9]. Therefore, system A transporters are important
for the placental transport of both non-essential and essential amino acids [13].
System A consists of three sodium-coupled neutral amino acid transporter (SNAT)
proteins, each encoded by independently regulated genes: SNAT1 (SLC38A1), SNAT2
(SLC38A2) and SNAT4 (SLC38A4) [59,89]. SNAT2 is ubiquitously expressed in
mammalian tissues, while SNAT1 is predominately expressed in the brain, heart
and placenta and SNAT4 expressed in the liver and placenta [89]. Throughout
gestation, the activity of system A transporter increases, although the individual
contributions of the three SNATs to total system A activity varies [13]. SNAT1 and
4 are found on both the MVM and the BM of the placenta [90]. SNAT1 has been
shown to play a significant role in the human term placenta [91]. SNAT4, which has
a lower substrate affinity for neutral amino acids, has a higher contribution in the
first trimester placenta than the term placenta [89].
System L transporters are sodium independent exchangers of neutral amino
acids. Non-essential amino acids are exchanged for essential amino acids with
aromatic or branched side chains such as leucine or phenylalanine to allow for
transport against their concentration gradient [92]. System L transporters consist of a
heterodimer formed from a light chain protein, large neutral amino acid transporter
(LAT)1 (SLC7A5) or LAT2 (SLC7A8), and a heavy chain transmembrane protein:
4F2hc/CD98 (SLC3A2) [92,93]. 4F2hc and LAT1 expression is higher in term than mid
gestation placentas [93]. Localization of the LAT isoforms are polarized, with LAT1
predominately found on the MVM and LAT2 on the BM [94], although LAT2 has also
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been shown to have functional activity in the MVM [95]. However, localization of
LAT2 on the BM allows for the exchange of amino acids between non-essential amino
acids in the fetal circulation and essential amino acids in the syncytiotrophoblast
cytoplasm [96]. Two additional system L light chains, LAT3 and LAT4 have recently
been reported in placental tissues [97,98]. They are localized to the BM and may play
an important role in the net efflux of amino acids to the fetus [99]. While transporting
a restricted group of system L substrates (leucine, isoleucine and phenylalanine),
LAT3 and LAT4 also appear to differ from the traditional system L transport in that
they do not require the co-expression of 4F2hc and function as facilitative diffusion
transporters [99,100].
It is well established that the cationic amino acid transporter (CAT) is the main
transporter for cationic amino acids in MVM [101]. Kamath et al. also found that
CAT1 (SLC7A1), CAT2 (SLC7A2), and CAT4 (SLC7A4) are expressed in cultured
trophoblast cells and in BeWo choriocarcinoma cells [102], supporting the possibility
that multiple members of the CAT family are present in BM of the placenta. CAT is
a sodium independent electrogenic transporter, which interacts only weakly with
neutral amino acids and therefore is specific for cationic amino acids.
Anionic or system XAG amino acid transporters are capable of sodium
dependent and D-aspartate-inhibitable glutamate/aspartate transport activity.
A family of five anionic amino acid transporters (excitatory amino acid transporters
EAAT1-5) have been cloned and, of these, EAAT1-4 are expressed in the human
and rat placenta [103–105]. EAAT1-4 are present in both plasma membranes of the
syncytiotrophoblast and increase over the last trimester [105,106].
3.6.3. Placental Fatty Acid Transporter Systems
Fatty acids are important precursors of bioactive molecules, which are structural
components of cells and provide a major source of energy [13]. Two sources of
fatty acids are taken up by the placenta from the maternal circulation, the esterified
fatty acids that are present in triglycerides (TG) and the nonesterified fatty acids
(NEFA) [13]. The primary source of fatty acids taken up by the placenta is maternal
TG because their uptake increases in the last trimester compared with NEFAs [107].
Fatty acid transfer from the mother to the fetus can be accomplished via simple
diffusion, as with NEFAs [107]. However, in late gestation the rate of simple diffusion
may not be adequate to supply the fetus [13,108]. Kazantzis and Stahl stated that the
cellular membrane fatty acid transport proteins (FATPs) are important for the cellular
uptake of long chain fatty acids [108]. There are five transport proteins in humans,
including FATP1-4 and FATP6 [109]. FATP1 is present on both the MVM and the
BM, but the exact cellular location of the others remains unknown [110]. Fatty acid
translocase (CD36) is the membrane-associated protein expressed in placenta with
the ability to transport fatty acids [110]. Upon entering the syncytiotrophoblast the
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hydrophobic fatty acids are transported across the cytosol to the BM or to other sites
within the cell where they undergo esterification or beta oxidation. To accomplish
this they bind with fatty acid binding proteins (FABPs) [13]. There are four forms
of the fatty acid binding proteins in the human placenta, including FABP1 and
FABP3-5 [111].
We have summarized the major placental changes in morphology and substrate
transport capacity that regulate placental efficiency and fetal growth in normal
pregnancies. As we know, placental insufficiency results in a failure of the placenta to
deliver an adequate supply of substrates to the fetus and IUGR develops. Therefore,
several different experimental methods used to produce placental insufficiency and
induce IUGR in animal models and a range of factors that regulate placental growth
and substrate transport capacity have been discussed in human and animal IUGR
studies below.
4. The Placenta and Development of Intrauterine Growth Restriction
Intrauterine growth restriction is clinically defined as a birth weight below
the tenth centile for gestational age where the fetus does not meet its growth
potential [23,112]. IUGR affects 6% of Australian pregnancies [1] and is associated
with a high incidence of perinatal morbidity and mortality [7]. IUGR neonates have
a greater risk of hypoxic-ischaemic encephalopathy, intraventicular haemorrhage
and necrotizing enterocolitis with longer hospital stays and higher health care
costs [23]. Furthermore, epidemiological, clinical and experimental studies from
around the world highlight an association between a poor intrauterine environment
and poor health outcomes in adulthood [7,113–115]. In particular, these studies
have demonstrated a significant relationship between small size at birth and the
risk of developing coronary heart disease, hypertension and type 2 diabetes in
adulthood [4–6]. Causes of IUGR can be of maternal, fetal or placental origin,
including maternal smoking, alcohol and drug abuse, genetic defects, chromosomal
abnormalities or placental pathologies [116]. In the developing world, IUGR is likely
to be a consequence of poor maternal nutritional status prior to or during pregnancy
whereas, in the developed world IUGR is commonly a consequence of placental
insufficiency [117].
Several different experimental methods have been used to produce placental
insufficiency and induce IUGR in both small and large animal models, and previously
discussed in detail [23]. For example, methodologies include reduction of uterine
blood flow by vascular occlusion or ligation in rats, guinea pigs and sheep,
hyperthermia, placental infarction by repetitive embolization in pregnant ewes or
uterine carunclectomy of non-pregnant ewes [23]. As sheep are used in all of these
methodologies to induce IUGR, the sheep models of placental insufficiency are
summarized below (Table 2).
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Table 2. Summary of experimental models of placental insufficiency and their
impact on the placenta and the fetus.
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5. Animal Models of Placental Insufficiency
5.1. Single Umbilical Artery Ligation (SUAL)
Single umbilical artery ligation (SUAL) involves the isolation and ligation of one
umbilical artery close to the fetal abdomen [118]. SUAL causes a partial infarction
of the placenta, which reduces umbilical blood flow and causes a reduction in
the capacity of the placenta to transfer substrates and induces IUGR in the sheep
fetus [118,119]. Furthermore, SUAL fetuses are significantly smaller than control
fetuses from 117 days gestation and are chronically hypoxaemic (PO2 < 17 mmHg),
but not acidotic in late gestation [121].
5.2. Maternal Hyperthermia
The hyperthermia-induced model of placental insufficiency induces fetal growth
restriction by exposing pregnant ewes to an environment with an increased ambient
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temperature with a diurnal cycle of 40 ◦C for 12 h and 35 ◦C for 12 h, from ~38 days
gestation until ewes are sacrificed at post mortem [2,122]. Ewes can be exposed to
this treatment for ~17 days (early gestation), ~52 days (mid gestation) or ~96± 5 days
(late gestation). This hyperthermia treatment results in an increase in maternal core
body temperature from ~39 ◦C to 40 ◦C in hyperthermia pregnant ewes [53,123].
It also results in a redistribution of blood flow toward the peripheral vascular system,
leading to a reduction in uterine and umbilical artery blood flow and a decrease in
placental weight and IUGR [2,30].
5.3. Placental Embolism
Placental embolism of the placental vasculature aims to mimic the onset of
IUGR in late gestation. This procedure involves repeated injection of microspheres
(15 µm) into the placenta via the umbilical artery through a catheter implanted in
the descending aorta or fetal umbilical vein [124–126]. The microspheres block the
placental capillaries resulting in reduced surface area for the transfer of substrates
from mother to fetus [120]. Placental embolism in late gestation causes acute
decreases in placental substrate supply after each daily injection over a period of
10–20 days, which leads to chronic fetal hypoxemia, hypoglycemia and IUGR.
5.4. Endometrial Carunclectomy
Uterine carunclectomy limits the number of placentomes after surgical removal
of the majority of the endometrial caruncles from the uterus of nonpregnant ewes
prior to conception. This restricts the number of placentomes that form during
pregnancy, consequently limiting placental and fetal growth [116]. Experimental
restriction of placental growth results in fetuses that are chronically hypoxaemic and
hypoglycemic [127]. Furthermore, the changes to nutrient supply and fetal blood
gases in placentally restricted (PR) sheep fetuses are similar to those measured in
cordocentesis studies of human infants who are born small for gestational age [116,121].
PR fetuses also have reduced placental and fetal weights at term [128].
6. Regulation of Placental Growth and Substrate Transport in IUGR Pregnancy
Fetal growth is dependent on substrate supply, which is dependent on substrate
transport and its regulation. These processes also depend on morphological
characteristics of the placenta, such as placental size, morphology, blood flow and
vascularity. Therefore placental nutrient transfer capacity is specifically regulated
by signals of fetal, maternal and placental origin in an effort to control fetal
growth. However, in late gestation, when fetal nutrient demand is at its greatest,
the compensatory upregulation is no longer sufficient to meet fetal demand
and thus IUGR develops [129,130]. Here, we focus on the morphological and
functional changes in the regulation of placental growth and substrate transport
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capacity in human pregnancy complicated with IUGR and animals models of
placental insufficiency.
6.1. Placental Size and Morphology
In human pregnancies, Chen and coworkers have found a significant decrease
in villi vascular density and cell proliferation in both trophoblast and stromal cell
compartments within the IUGR placentas compared with control placentas at 25 to
41 weeks of gestation [131]. Other reports have shown a decrease in surface area,
volume, and number of terminal villi, a reduced number of capillaries as well as
an increased thickness of the exchange barrier in the stroma of IUGR placentas as
compared with placentas from normal pregnancies [132,133]. Undernutrition in
guinea pigs during pregnancy increases barrier thickness and reduces placental
weight and placental area involved in nutrient exchange during late gestation [134].
In contrast, hypoxia during pregnancy cause a reduction in the barrier thickness
between maternal and fetal circulation in the human and guinea pig placenta that has
a direct effect on diffusional exchange [135,136]. In pregnant sheep, the total surface
of the cotyledons and surface occupied by vasculature were greater at high altitude,
whereas the number of cotyledons was smaller at high altitude [137]. These placental
morphological changes may improve maternal and fetal exchange and display an
efficient mechanism of adaptation to hypobaric hypoxia.
Experimental restriction of placental size by surgical removal of implantation
sites prior to conception, multiple pregnancy or adverse conditions in early gestation
restricts fetal growth, but increases fetal to placental weight ratio and placental
efficiency in late pregnancy [15,53]. Conversely, an increased fetal to placental
weight ratio may suggest fetal adaptations in response to the small placenta,
which maximizes transplacental concentration gradients and/or partitioning of
placentally derived nutrients to support and maintain fetal growth during suboptimal
intrauterine conditions [55]. Adverse conditions, such as maternal undernutrition
and hypoxemia resulted in increased eversion of placentomes and an increased
proportion of type C and D placentomes in late gestation sheep fetuses [138,139].
In contrast, adverse intrauterine conditions induced by umbilical cord compression
is associated with an increased proportion of type A and B, and fewer type C- and D
placentomes during late gestation in sheep [140]. Therefore, adverse conditions in
the intrauterine environment determine placental morphology during late gestation
depending on the type and duration of the insult.
6.2. Oxygen Supply/Uptake, Blood Flow and Vascularity
In situations of placental insufficiency and IUGR, there appears to be an
underdevelopment of the placental epithelial sites, with low hindrance to transplacental
O2 diffusion reducing the surface area of exchange between the uterine and umbilical
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circulations, and resulting in decreased fetal umbilical oxygen supply [30,132]. Under
hypoxic conditions, hypoxia inducible factor (HIF)-1, which consists of two subunits
HIF-1α and HIF-1β, acts on the cell nucleus and regulates the expression of genes
with hypoxia response element (HRE). HIFs recruit mechanisms to increase oxygen
supply (erythropoiesis, angiogenesis, and vasodilation), decrease oxygen demand
(increased glycolysis coupled with decreased oxidative metabolism), and regulate the
cell cycle, apoptosis, and autophagy [141]. In vitro studies have demonstrated that
hypoxia can affect the proliferation, differentiation, and invasion of cytotrophoblast
cells [142]. Following a three day exposure to low oxygen, there was decreased
HIF-1α and unchanged HIF-2α mRNA expression in cultured murine ectoplacental
cones [143]. Hypoxia resulted in an increase in the transcription and translation of
VEGF in cultured placental fibroblasts [144]. Low oxygen levels also resulted in a
shift of the angiopoietin-1: angiopoietin-2 ratio in favor of angiopoietin-2, leading to
vessel instability, angiogenesis and vessel remodeling [145].
Morphological studies show that physiological remodelling of the maternal
uterine vasculature into spiral arteries is deficient in IUGR pregnancies due to
inadequate trophoblast invasion [146,147]. This results in maternal blood entering the
placenta at an abnormally high rate, which causes damage to the placental villi and
may harm endocrine and transport functions of the placenta. The intensity of VEGF-A
immunostaining in syncytiotrophoblast was significantly reduced in placental villous
tissue from pregnancies complicated by IUGR and preeclampsia compared with the
control group [148]. However, it has been shown that the expression of VEGF-A and
bFGF was significantly higher in cytotrophoblasts, syncytiotrophoblasts, extravillous
trophoblasts, vascular smooth muscle cells, chorionic villous stromal cells and villous
vascular endothelial cells of the IUGR placenta when compared with those collected
from normal-term pregnancies using semi-quantitative immunohistochemistry [149].
This suggests that these factors play a role in promoting increased endothelial
cell proliferation, migration and pathological angiogenesis. Similarly in sheep,
hyperthermia-induced placental restriction resulted in increased uterine blood flow
and increased VEGF, angiopoietin-1, angiopoietin-2 and TIE-2 expression in the fetal
portion (cotyledon) of the placentome in early gestation as well as reduced expression
in FLT-1 and FLK-1 in the cotyledonary tissue in mid gestation, suggesting a
disorganized fetal capillarisation and angiogenesis as well as compensatory transport
capacity for the fetal circulation to uptake nutrients from the maternal circulation,
which fails to maintain placental and fetal growth [53,54,123]. These alterations
in angiogenic growth factors could impair normal placental vascular development




In knockout mice with a deletion of the placental-specific transcript (P0) of the
Igf2 gene, placental surface area is reduced and placental thickness increased, leading
to reduced placental growth and fetal growth restriction [60,61]. Placental IGF-I
mRNA expression was lower in the growth-restricted groups compared with normal
pregnancies [150]. Similarly, the mRNA expression of IGF1, IGFBP1 and human
placental growth hormone was significantly lower in placentas from human IUGR
pregnancies compared with that in placentas of fetuses with normal growth [151].
However in sheep, caruncle IGF1 mRNA expression was increased at 90 days
gestation in the placentas of hyperthermia-induced IUGR compared with the control
group [152]. Cotyledon IGF2 and caruncle IGFBP4 mRNA expression were also
elevated at 55 days gestation in these placentas [152]. In contrast, maternal hypoxia in
mice from mid to late gestation resulted in a decrease in placental mRNA expression
of IGF2, IGF1R and IGF2R [153].
6.4. Apoptosis, Autophagy and Glucocorticoid Action
Placentas from women with IUGR pregnancies show enhanced apoptosis when
compared with those from normal pregnancy [154,155]. Cultured trophoblasts
exposed to hypoxia alone show an upregulation of p53 activity and BCL-2-like
protein 4 (BAX) expression and decreased expression of the anti-apoptotic BCL-2,
all of which promote apoptosis [156]. Hypoxia/re-oxygenation results in even
more marked apoptosis regulated by increased expression of the pro-apoptotic
BAX and BCL-2 homologous antagonist (BAK) mRNA and protein and reduced
expression of BCL-2 mRNA in human placental villous tissues [157]. Expression of
p53 and the active form of caspase-3 is upregulated in villi from IUGR compared to
control pregnancies, and the increase is predominantly in the villous trophoblast in
humans [158,159]. The association between altered trophoblast cell turnover in IUGR
and increased p53 expression was also shown to be reminiscent of that following
exposure to hypoxia [160].
Compared with normal pregnant women, women with IUGR had increased
placental levels of autophagy-related proteins including LC3B-II, beclin-1, DRAM,
and p53 [161]. Furthermore, hypoxia induces apoptotic and autophagic changes in
primary human cytotrophoblasts [162].
Placental 11βHSD2 activity was significantly reduced in deliveries complicated
by IUGR compared with the term deliveries and with appropriately grown preterm
deliveries, suggesting that glucocorticoids may, in part, contribute to impaired
fetal growth closely controlled through placental 11βHSD2 expression [71]. There
is evidence that exposure of the pregnant sheep to maternal undernutrition for a
period extending beyond the preimplantation period, from 60 days before and the
first 30 days after conception or from early to mid gestation (between 28 and 78 days
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gestation), results in a decrease in placental 11βHSD2 expression or activity [72,163].
In mice, maternal hypoxia during mid to late gestation resulted in a decrease
in placental glucocorticoid receptor (GR) mRNA expression as well as placental
11βHSD2 mRNA and protein expression [153]. A previous study by Mericq et al
found a lower expression and activity of 11βHSD1 in both chorionic and basal plates
of the placentas from full term small for gestation age newborns compared with
those in the placentas from appropriate for gestational age newborns, suggesting a
possible compensatory mechanism to diminish the higher cortisol concentrations in
fetuses with IUGR [164].
6.5. Glucose Transport Systems
Alterations in placental glucose transport have been implicated in adverse
perinatal conditions such as IUGR and fetal hypoxia [165]. As glucose transport is
dependent on the glucose concentration gradient from mother to fetus, the IUGR
pregnancy has increased the transplacental glucose gradient and glucose uptake
across the placenta [10] and this represents an example of how the IUGR fetus
adapts to restricted placental size. In carunclectomized ewes with smaller placentas
and a larger proportions of type D placentomes, the rate of glucose transfer to the
fetus per gram of placenta is greater than that in controls [166,167]. Exposure to
hypoxic conditions resulted in an upregulation in GLUT1 protein abundance and
trans-epithelial glucose transport in BeWo choriocarcinoma cells [168]. GLUT3
mRNA expression and protein abundance in the trophoblast on the maternal
aspect of the placenta was increased in the full-term IUGR placenta compared with
normal placenta [169]. Increased placental GLUT3 expression was associated with
increased activation of placental HIF-1α, suggesting that hypoxia may play a role
in the upregulation of GLUT3. However, placental GLUT1 mRNA expression was
decreased in the maternal aspect of the IUGR placenta and GLUT4 mRNA expression
was increased in the fetal aspect of the IUGR placenta when compared with the
control pregnancies, although there was no difference in placental GLUT1 or GLUT4
protein abundance between the treatment groups [169] (Table 3). Similarly, placental
GLUT1, but not GLUT3 immunostaining in the terminal villi of severe preeclampsia
cases (both with and without IUGR) was significantly lower compared with the
control group [170]. Chronic hypoxia in vivo with high altitude pregnancies also
resulted in a decrease in GLUT1 expression in the BM but not MVM of the placenta,
leading to reduced nutrient supply and fetal growth [171]. In mice, maternal hypoxia
during mid to late gestation resulted in a decrease in placental GLUT1 mRNA and
protein expression in female fetuses, but no change in placental GLUT3 mRNA
expression in both female and male fetuses [153]. Another study demonstrated that
GLUT1 protein abundance is not altered in IUGR babies when compared to those that
are appropriate for gestational age (AGA) [172]. Placental GLUT8 mRNA expression
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and protein abundance was decreased in late gestation in a sheep model of IUGR
caused by placental insufficiency, which may contribute in part to the placental
glucose transport deficit that occurs in this model [84]. Taken together, these data
along with amino acid and fatty acid transport systems mentioned below suggest
that the regulation of nutrient transport in the IUGR pregnancies may depend on the
timing and type of the insult, and be species-specific and different from in vivo and
in vitro studies.
Table 3. Summary of human and sheep models of IUGR and their impact on oxygen
transfer, placental glucose, amino acid and fatty acid transporters.
Models of IUGR Impact on GlucoseTransporters
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GLUT4 mRNA,↔ GLUT1
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mRNA & protein [169] ↓











Artery Ligation (SUAL) NS NS NS
Maternal Hyperthermia ↓ GLUT8 mRNA & protein ↑ LAT-1 & LAT-2mRNA [19] NS
Placental Embolism NS NS NS
Uterine Carunclectomy NS NS NS
NS, not studied.
6.6. Amino Acid Transport Systems
In the IUGR placenta the different amino acid transport systems are affected.
Tracer studies of placental amino acid transport have demonstrated that there is a
significant reduction in the transplacental flux/fetal turnover ratios of essential
amino acids [176–178]. For example, reduced uptake of leucine and lysine
was found in vesicles from human IUGR placenta compared with the controls,
suggesting decreased activity of placental transporters for cationic and neutral
amino acids [176]. Similarly, there was a reduction of maternal leucine flux into
the placenta and fetus in the hyperthermia sheep model of IUGR [178]. However,
studies of fetal plasma amino acid concentrations have produced inconclusive
results. Although earlier reports showed decreased fetal plasma amino acid
concentrations [178], subsequent human and animal studies showed maintained or
increased amino acid concentrations [22,177,179]. In severely growth restricted sheep
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fetuses, where placental and fetal weights are reduced by 40%–60%, umbilical uptake
of oxygen, glucose and essential amino acids is significantly reduced, whereas the
fetal/maternal ratio of the amino acids that are transported from the placenta to fetus
showed normal or elevated fetal concentrations compared to control fetuses [22,30].
A previous study has shown that transplacental and total placental clearance of
a branched-chain amino acid analogue, the non-metabolisable neutral amino acid
aminocyclopentane-l-carboxylic acid per 100 g placenta, were significantly reduced
in a sheep model of hyperthermia-induced IUGR, suggesting impaired placental
non-essential amino acid transport in the IUGR placenta [180].
In normal pregnancy, system A transporter activity was shown to be the
highest in the smallest babies per milligram of microvillous protein [181]. In
contrast, placental system A transporter activity was not only reduced in IUGR
compared with normal pregnancies but also related to the severity of IUGR [173,174].
Placental SNAT2 mRNA expression and syncytiotrophoblast immunostaining were
significantly decreased in IUGR placentas with reduced umbilical blood flows
compared with those in control placentas [175]. Hypoxia also decreases placental
system A transport and activity in full-term human trophoblasts [182]. In mice,
maternal hypoxia during mid to late gestation resulted in an increase in placental
GLUT1 mRNA expression in female fetuses, but no change in placental SNAT4
mRNA expression. There was also a decrease in placental SNAT2 mRNA expression
in both female and male fetuses [153]. Interestingly, placental LAT-1 and LAT-2
mRNA expression was elevated in the moderately growth restricted sheep fetuses
where placental and fetal weight was reduced by 25% compared with the control
placenta [19].
6.7. Fatty Acid Transport Systems
Hypoxia enhances the expression of FABP1, -3, and -4 in term human trophoblasts,
suggesting that FABPs play a role in fat accumulation in the hypoxic placenta [111].
Similarly, hypoxia also resulted in increased FATP2 expression and reduced FATP4
expression in cultured primary term human trophoblasts [183]. However, placental
CD36 mRNA expression was unaltered in human pregnancy complicated with
IUGR [184].
7. Conclusions
The placenta is the main interface between the fetus and mother. Placental
insufficiency results in a failure of the placenta to deliver an adequate supply of
substrates to the fetus and IUGR develops. A range of human and animal studies in
IUGR pregnancies have suggested that placental restriction and insufficiency may
result in a series of placental changes such as altered placental growth and placental
substrate transport capacity, increased apoptosis and autophagy and increased
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glucocorticoid action (Figure 1). Such placental morphological and functional
changes may consequently lead to decreased fetal growth and IUGR, which is
modified by compensatory changes in placental efficiency. We have also noted
that there are different patterns of placental changes associated with the human
IUGR pregnancy and animal models of placental insufficiency induced IUGR. These
differences may be dependent on the nature of the causes of IUGR, the time, duration
and severity of insult exposure, species and in vivo or in vitro studies. While no
model system completely encapsulates complete human IUGR, these model systems
do allow us to carefully dissect aspects of the issue so as to further expand our
understanding of the cellular and molecular mechanisms involved, and promote the
development of therapeutic interventions.
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The Placental Microbiome Varies in
Association with Low Birth Weight in
Full-Term Neonates
Jia Zheng, Xinhua Xiao, Qian Zhang, Lili Mao, Miao Yu and Jianping Xu
Abstract: Substantial evidence indicated that low birth weight was an independent
risk factor for obesity, impaired glucose regulation, and diabetes later in life.
However, investigations into the association between low birth weight and placental
microbiome in full-term neonates are limited. Placentas were collected from low
birth weight (LBW) and normal birth weight (NBW) full-term neonates (gestational
age 37 w0d–41 w6d) consecutively born at Peking Union Medical College Hospital.
The anthropometric measurements were measured and 16S ribosomal DNAamplicon
high-throughput sequencing were utilized to define bacteria within placenta tissues.
It showed that birth weight, ponderal index, head circumference, and placenta weight
were significantly lower in LBW than NBW neonates (p < 0.05). The operational
taxonomic units (OTUs) (p < 0.05) and the estimators of community richness (Chao)
indexes (p < 0.05) showed a significantly lower diversity in LBW than NBW neonates.
There were significant variations in the composition of placenta microbiota between
the LBW and NBW neonates at the phylum and genus level. Furthermore, it indicated
that Lactobacillus percentage was positively associated with birth weight (r = 0.541,
p = 0.025). In conclusion, our present study for the first time detected the relationship
between birth weight and placental microbiome profile in full-term neonates. It is
novel in showing that the placental microbiome varies in association with low birth
weight in full-term neonates.
Reprinted from Nutrients. Cite as: Zheng, J.; Xiao, X.; Zhang, Q.; Mao, L.; Yu, M.;
Xu, J. The Placental Microbiome Varies in Association with Low Birth Weight in
Full-Term Neonates. Nutrients 2015, 7, 6924–6937.
1. Introduction
Nowadays, the prevalence of diabetes is increasing extremely rapidly worldwide.
However, the pathogenesis of diabetes has not been clearly understood yet.
Traditionally it has been widely acknowledged that genes together with adult lifestyle
factors including diet and exercise habits determine the risk of developing some
chronic non-communicable diseases such as obesity, insulin resistance, and diabetes
mellitus in later life. Recently, attention has been paid to distal risk factors in early
life. There is substantial evidence that intrauterine environment plays a critical role
in determining our susceptibility to these diseases in adulthood, which is known as
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“fetal programming hypothesis” [1]. The pioneering study by Hales et al. was the
first to show that people with low birth weight could increase the susceptibility to
type 2 diabetes later in life [2]. Numerous studies demonstrated that there was an
inverse relationship between birth weight (as a marker of fetal growth) and impaired
glucose tolerance, insulin resistance, and diabetes in adult life [3]. In our previous
study, it further indicated that low birth weight was an independent risk factor for
later impaired glucose tolerance, diabetes, and an increased presentation of metabolic
syndrome components [4,5].
The human microbiome is an enormous community of microorganisms
occupying the habitats of the human body. Different microbial communities are
found in each of the varied environments of human anatomy. The aggregate microbial
gene totally surpasses that of the human genome by orders of magnitude [6]. In 2007,
the National Institutes of Health (NIH) initiated the Human Microbiome Project
(HMP) which was focused on developing research resources to enable the study of
the microbial communities that live in and on our bodies and the roles they play
in human health and disease. Recently published works by the HMP Consortium
have provided the first reliable estimates of the breadth of structure, function, and
diversity of the healthy human microbiome across multiple body sites [7]. Most
organs including external (stool, skin) or internal (mouth, gut, stomach, urogenital
tract, lungs) appear to be associated with human health and disease [8]. Previous
studies have indicated that gut microbiota comprises a total genome of approximately
150 times as big as the human genome [9] and it is important in regulating metabolic
pathways in healthy people and in patients with obesity, diabetes, and cardiovascular
diseases [10]. However, little information is known about the placental microbiome.
The placenta is a vital organ that connects the developing fetus to the uterine
wall to allow nutrient uptake and gas exchange (via the mother’s blood supply), fight
against internal infection, and produce hormones to support pregnancy [11]. For a
long time, it was thought that the fetus developed in a sterile environment. However,
contrary to the prevailing idea of a “sterile” intrauterine environment [12], a recent
study demonstrated that the placenta harbors a unique microbiome, composed of
nonpathogenic commensal microbiota. It also revealed associations of the placental
microbiome with a remote history of antenatal infection, such as urinary tract
infection and preterm birth [13]. Recent advances in 16S ribosomal DNA (rDNA)
amplicon high-throughput sequencing could facilitate us to extensively define
bacteria within placenta tissue. Another study indicated that term and preterm
labor were associated with distinct microbial community structures in placental
membranes which were independent of mode of delivery [14]. A recent study
suggested that the preterm placental microbiome varies in association with excess
maternal gestational weight gain [15]. However, investigations into the association
between placental microbiome and birth weight are limited. Considering that
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birth weight is a marker of fetal growth and an important factor determining
the susceptibility to metabolic diseases in adult life, our aim in this study was
to investigate whether the placental microbiome varies in association with low birth
weight in full-term neonates
2. Experimental Section
2.1. Ethics Statement
Informed written consent was obtained from all participants, and the study
protocol was approved by the Institutional Review Board and Ethics Committee of
Peking Union Medical College Hospital (S-002).
2.2. Participants
The study population consisted of 24 (12 low birth weight and 12 normal birth
weight) full-term neonates (gestational age 37 w0d–41 w6d) consecutively born at
Peking Union Medical College Hospital Birth weight was used to identify cases
and controls: low birth weight (LBW) is <3000 g and normal birth weight (NBW)
is ≥3000 g and <4000 g. The birth weight of <3000 g but not <2500 g was determined
as the cut-off due to the fact that birth weight <2500 g neonates only took a very
small proportion in our full-term subjects. The more important reason is that low
birth weight (<3000 g) is also an independent risk factor for later impaired glucose
tolerance and diabetes in previous studies [5,16]. All the neonates were spontaneous
birth by vaginal delivery in order to prevent confounding factors related to the mode
of delivery. Selected low birth weight cases and controls were matched for gestational
age, race/ethnicity, body mass index (BMI) and age. Infants whose mothers had
multifetation, chronic hypertension, pregnancy-induced hypertension, gestational
diabetes mellitus, endocrine disorders, and other severe maternal illnesses, and
infants with a gestational age <37 or >42 weeks, asphyxia at birth, congenital
anomalies, and the presence of antepartum infections and antibiotic use (i.e., sexually
transmitted infection, urinary tract infection, skin abscesses, appendicitis, periodontal
disease, or bacterial meningitis) were excluded from the study.The risk factors for low
birth weight, such as smoking, drug use, poor maternal weight gain, prior low birth
weight baby, little education, and low income were also excluded from the study.
2.3. Placental Samples
All samples were collected by trained pathology personnel according to the
method previously described [13]. Briefly, following standard obstetrical practice,
the placenta was delivered and immediately passed off to trained personnel in a
sterile clean container. Then, four to six 1 cm × 1 cm × 1 cm cuboidal sections were
circumferentially excised from separate areas of the placenta, each located 4 cm from
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the cord insertion site. The excision was performed by trained pathology personnel
donning facial masks and sterile gloves and using a sterile scalpel and instruments.
The placental surfaces including the maternal decidua and fetal chorion-amnion were
thereafter excised and discarded to avoid potential contamination from maternal,
fetal, or environmental surface exposure during delivery or at the time of specimen
transport. Then, the placenta tissues were snap frozen in liquid nitrogen, and stored
at −80 ◦C for further analysis.
2.4. Anthropometric Measurement
Data were collected at delivery according to our previous publication [17].
Three trained research nurses and assistants collected data on maternal, pregnancy,
and birth characteristics using structured study questionnaires through face-to-face
interviews and medical chart reviews. Demographic data included maternal medical
history, maternal age, and BMI before pregnancy. The variables of the neonates
included gestational age, birth weight, body length, ponderal index (PI), head
circumference, and placenta weight. PI was calculated as body weight (kg)/body
length (m)3. The body weight of each neonate and placenta weight were determined
to the nearest 1 g using an electronic scale. Body length was determined to the
nearest 0.1 cm in the supine position with a length board. Head circumference was
determined with a plastic tape to the nearest 0.1 cm.
2.5. Microbial Diversity Analysis
2.5.1. DNA Extraction and Polymerase Chain Reaction (PCR) Amplification
Microbial DNA was extracted from placental tissue (about 100–150 mg) using
the E.Z.N.A.® DNA Kit (Omega Bio-tek, Norcross, GA, USA). The V3-V4 region of
the bacteria 16S ribosomal RNA gene were amplified by PCR using primers 338F
5′-ACTCCTACGGGAGGCAGCA-3′ and 806R 5′-GGACTACHVGGGTWTCTAAT-3′,
where barcode is an N-base sequence (N represent a unique 6 to 8-nt barcode) unique
to each sample. PCR reactions were performed in 20 µL mixture containing 4 µL of
5 ×FastPfu Buffer, 2 µL of 2.5 mM dNTPs, 0.8 µL of each primer (5 µM), 0.4 µL of
FastPfu Polymerase, and 10 ng of template DNA. Because of the concern for bias
in low-abundance samples, all specimens were thrice extracted and thrice run to
enable triplicate extraction and sequencing. Sequences from all three extractions
were combined for analysis, according to the method previously described [15].
2.5.2. IlluminaMiSeq Sequencing and Bioinformatic Analysis
Amplicons were extracted from 2% agarose gels and purified using the AxyPrep
DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, USA). Purified
amplicons were pooled in equimolar and paired-end sequenced (2 × 300) on an
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IlluminaMiSeq platform according to the standard protocols. Raw fastq files were
demultiplexed, quality-filtered using QIIME (version 1.17) with the following three
criteria: (1) The 300 bp reads were truncated at any site receiving an average quality
score <20 over a 10 bp sliding window, discarding the truncated reads that were
shorter than 50 bp; (2) exact barcode matching, two nucleotide mismatch in primer
matching, reads containing ambiguous characters were removed; (3) only sequences
that overlap longer than 10 bp were assembled according to their overlap sequence.
Reads which could not be assembled were discarded. Operational Units (OTUs) were
clustered with 97% similarity cut-off using UPARSE (version 7.1) [18] and chimeric
sequences were identified and removed using UCHIME. The phylogenetic affiliation
of each 16S rRNA gene sequence was analyzed by RDP Classifier [19] against the
silva (SSU115) 16S rRNA database using confidence threshold of 70% [20].
2.6. Statistical Analysis
The data were expressed as the mean ± standard deviation (S.D.). Statistical
analyses of anthropometric measurement were performed with Student’s t-test.
Unweighted UniFrac distance metrics analysis was performed using OTUs for each
sample and PCoA plots based on unweighted Unifrac metrics. Metastats was used to
compare the relative abundance of each taxon at different taxonomic levels between
LBW and NBW neonates [21]. Correlation analyses between relative abundance of
sequences belonging to different bacterial class and birth weight were performed by
using Spearman’s correlation analyses. p value < 0.05 were considered to indicate
statistical significance. All statistical analysis was calculated with SPSS 21.0 (SPSS,
Inc., Chicago, IL, USA).
3. Results
3.1. Clinical Characteristics and Anthropometric Measurements
The clinical characteristics and anthropometric measurements were shown in
Table 1. It indicated that birth weight (2623 ± 207 vs. 3452 ± 96, p < 0.01), ponderal
index (23.2 ± 5.2 vs. 26.2 ± 1.4, p = 0.02), head circumference (32.9 ± 1.6 vs. 34.6 ± 0.8,
p = 0.013) and placenta weight (492.8 ± 38.5 vs. 701.2 ± 106.7, p < 0.01) were
significantly lower in LBW than NBW subjects. The birth weight of normal birth
weight subjects in our present study is similar to the birth weight for the babies
delivered at Peking Union Medical College Hospital in one previous study [17].
However, no significant differences were detected in maternal age, maternal BMI


















































































































































































































































































































































3.2. Characteristics of Sequencing Results
A total of 403,965 high-quality sequences were produced in this study, with
an average of 16,831 sequences per sample (Table 2). The Good’s coverage of each
group was over 97%, indicating that the 16 S rDNA sequences identified in the
groups represent the majority of bacteria present in the samples of this study. The
operational taxonomic unit (OTU), the estimators of community richness (Chao) and
diversity (Shannon) are also shown in Table 2. There were statistically significant
differences of OUT (49 ± 4.18 vs. 48.44 ± 7.89, p = 0.026) and Chaoindexes (57 ± 7.19
vs. 54.44 ± 13.33, p = 0.044) between NBW and LBW groups, demonstrating the
significantly lower richness found in LBW neonates compared to NBW neonates.
Table 2. Sequencing data summary.
NBW LBW p Value
Sequences 17,600 ± 3693 16,150 ± 3768 0.49
OTUs 49 ± 4.18 48.44 ± 7.89 0.026 *
Chao 57 ± 7.19 54.44 ± 13.33 0.044 *
Shannon 0.96 ± 0.12 1.06 ± 0.36 0.083
Data represents as mean± S.D. (n = 12, in each group). Statistical analyses were performed
with Student’s t-test between the two groups. The number of OTUs, richness estimator
Chao, and diversity estimator Shannon were calculated at 3% distance. * p < 0.05 LBW vs.
the NBW group. Abbreviations: LBW, Low birth weight; NBW, Normal birth weight.
3.3. Principal Coordinates Analysis (PCA) between LBW and NBW Groups
Closer analysis of bacterial differences induced by birth weight were determined
by sequencing the 16S rRNA encoding genes present in the placenta. PCA
of IlluminaMiSeq amplicon data demonstrated significantly separate clustering
of the placenta communities between LBW and NBW groups with principal
component (PC1) percent variation explained = 96.89% and PC2 percent variation
explained = 0.7%. It indicated that there was a statistically significant clustering by
virtue of body weight (Figure 1).
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3.4. Microbial Structures of the Placenta in LBW and NBW Groups
Figure 2 shows relative abundance (%) of placenta microbiota in each sample at the genus level. The
overall microbiota structure for each group at the phylum and genus level is shown in Figure 3. At
the phylum level, the dominant phylum of the two groups was Firmicutes. The relative abundance (%)
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3.4. Microbial Structures of the Placenta in LBW and NBW Groups
Figure 2 shows relative abundance (%) of placenta microbiota in each sample at
the genus level. The overall microbiota structure for each group at the phylum and
genus level is shown in Figure 3. At the phylum level, the dominant phylum of the
two groups was Firmicutes. The rel ive abundance (%) of Firmicut s was decreased
in LBW group, while Proteobacteria and Actinobacteria were increased in LBW group,
compared with NBW group. At the genus level, the dominant phylum of the two
groups was Enterococcus. The relative abundance (%) of Enterococcus was decreased in
LBW group, while Lactococcus and Bacillus were increased in LBW group, compared
with NBW group. The relative abundance of microbiota sequences revealed that
microbial structures of the placenta differed significantly between LBW and NBW
groups. The heatmap according to bacterial genus level also demonstrated the same
phenomenon (Figure 4).
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of Firmicutes was decreased in LBW group, while Proteobacteria and Actinobacteria were increased
in LBW group, compared with NBW group. At the genus level, the dominant phylum of the two
groups was Enterococcus. The relative abundance (%) of Enterococcus was decreased in LBW group,
while Lactococcus and Bacillus were increased in LBW group, compared with NBW group. The
relative abundance of microbiota sequences revealed that microbial structures of the placenta differed
significantly between LBW and NBW groups. The heatmap according to bacterial genus level also
demonstrated the same phenomenon (Figure 4).
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group. The y axis is a neighbor-joining phylog n tic t ee, each row is a different
phylotype. The abundance plot shows the proportion of 16S rRNA gene sequences
in each group. Abbreviations: LBW, Low birth weight; NBW, Normal birth weight.
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3.5. Phylotypes Significantly Different between LBW and NBW Groups
To investigate whether the placental microbiome varies in association with
low birth weight in full-term neonates, we compared the phylum- and genus-level
relative abundance by body weight. As shown in Table 3, at the phylum level,
Fusobacteria was significantly increased and Cyanobacteria was significantly decreased
in LBW group, compared with NBW group (p < 0.05). The microbial composition
was also significantly different at the genus level, with 13 significantly different
genera between LBW and NBW groups (p < 0.05). It is indicated that the relative
abundance (%) of Lactobacillus, Clostridium_sensu_stricto_1, Cyanobacteria_unclassified,
Ruminococcus, Lawsonia and Cyanobacteria_norank were significantly lower in
LBW group at the genus level. Conversely, the relative abundance (%) of
Megasphaera, Faecalibacterium, DSSF69_norank, Jeotgalicoccus, Pediococcus, Sneathia,
and Sphingobacterium were significantly higher in LBW group, compared with NBW
group (Table 3).
Table 3. Phylotypes significantly different between LBW and NBW groups.
Taxonomic Rank NBW (%) LBW (%) * p Value
phylum Fusobacteria 0.000 0.011 0.001
phylum Cyanobacteria 0.020 0.003 0.008
genus Cyanobacteria_unclassified 0.007 0.000 0.001
genus DSSF69_norank 0.000 0.013 0.001
genus Jeotgalicoccus 0.000 0.005 0.001
genus Pediococcus 0.000 0.017 0.001
genus Sneathia 0.000 0.011 0.001
genus Clostridium_sensu_stricto_1 0.253 0.026 0.002
genus Lactobacillus 0.531 0.115 0.005
genus Ruminococcus 0.004 0.000 0.007
genus Megasphaera 0.003 0.016 0.008
genus Faecalibacterium 0.002 0.038 0.014
genus Lawsonia 0.004 0.000 0.014
genus Sphingobacterium 0.000 0.007 0.016
genus Cyanobacteria_norank 0.014 0.003 0.047
n = 12, in each group. Statistical analysis was performed by Metastats. Data of NBW and
LBW groups were relative abundance (%) of all sequences in each group. * p < 0.05 LBW
vs. NBW group. p value had no statistically significant difference (≥0.05) were not shown.
Abbreviations: LBW, Low birth weight; NBW, Normal birth weight.
3.6. Variation in the Placental Microbiome Associated with Birth Weight
Correlation analyses between relative abundance (%) of sequences belonging
to a specific bacterial genus and birth weight were performed by using Spearman’s
correlation analyses. It is indicated that Lactobacillus percentage were positively
associated with birth weight (r = 0.541, p = 0.025) (Figure 5).
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the predisposition to the development of some metabolic diseases such as obesity and
diabetes in adult life. Recently, numerous studies demonstrated that the microbiota
could be considered as one major player in the development of obesity and diabetes
mellitus [22,23]. Therefore, we investigated whether low birth weight was associated
with significant variation in the placental microbiome profile. Consistent with
previou studies, our s udy indicat d that the placenta harbors a low-abundance
microbiome. The placental microbiome was largely composed of nonpathogenic
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Fusobacteria phyla in all the LBW and NBW neonates [13,15].
Our present study indicated that the placenta of LBW neonates had significantly
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clinical study also demonstrated that individuals with a low bacterial richness
are characterized by more marked overall adiposity, insulin resistance, and
dyslipidaemia, which indicated that a low bacterial richness may be associated with
abnormal glu ose metabolism [24]. Similar to our study focused on placenta, one
study previously demonstrated that decreased richness in the placenta is associated
with spontaneous preterm birth [13]. Another study aimed to investigate whether
the preterm placental microbiome varies by virtue of obesity or alternately by excess
gestational weight gain and it indicated that preterm subjects with excess gestational
weight gain also had d creased species richnes . Thus, our s udy suggests that th
decreased richness in placenta may be associated with birth weight in neonates.
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Furthermore, 16S-based OTU analyses in our study revealed the relative
abundance of Lactobacillus was negatively associated with birth weight. Most
Lactobacillus in humans are considered un-harmful. Some strains of Lactobacillus
may possess potential therapeutic properties including anti-inflammatory activities,
as well as other features of interest. Several studies also showed that probiotic
products could regulate blood glucose levels in diabetic human and Lactobacilli are
often used as probiotic agents [25]. Naito et al. reported that oral administration
of Lactobacillus casei strain Shirota had the potential to prevent obesity-associated
metabolic abnormalities by improving insulin resistance in diet-induced obesity
mice [26]. One study showed that DNA of Lactobacillus rhamnosus was detected
in placenta samples independent of the mode of delivery. It also indicated that
DNA from intestinal bacteria was found in most placenta samples and the horizontal
transfer of bacterial DNA from mother to fetus may occur via placenta [27]. Therefore,
it can be speculated that Lactobacillus may be the potential probiotic to modulate
the placenta microbiota. However, more evidence and further investigation will
be needed.
To our knowledge, our present study for the first time demonstrated the
relationship between birth weight and placental microbiome profile in neonates.
Strengths of this study also include that microbial sequences were isolated and
identified successfully from placenta tissue which harbors a low-abundance
microbiome. More important, the sterile sample collection and robust analysis
were rigorously conducted. However, there are some limitations to our study. One
primary limitation was the small sample size. Because low birth weight neonates
only took a very small proportion in our study subjects which consisted of full-term
and spontaneous birth by vaginal delivery neonates in order to minimize the effect
of some confounding factors such as gestational age (full-term or preterm) and the
mode of delivery (vaginal delivery or cesarean delivery). Our ongoing work is aimed
to enlarge the sample size for further research. A second limitation was that our study
just focused on comparative 16S rDNA analysis but not metagenomic studies which
can provide additional insight into the function of complex microbial communities
and their role in host health. Therefore, our further research will be focused on
the function of microbial communities in placenta and their role in neonates and
mothers. A third limitation was that due to the small sample size (n = 12), it has
not been possible to perform a multivariate analysis, whose results are more reliable
than those from univariate one. The fourth limitation was that the used definition
of low birth weight (<3000 g) is not that universally accepted. This was due to the
fact that birth weight <2500 g neonates only took a very small proportion in our
full-term subjects. The more important reason is that low birth weight (<3000 g) is
also an independent risk factor for later impaired glucose tolerance and diabetes
in previous studies. However, our present study is also very meaningful which
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established an important theoretical foundation of metagenomic studies in placenta
of different birth weight neonates. Another potential limitation to our study was
the overall low abundance of microbiota in the placenta. However, we were able to
overcome the limitations of low-abundance microbiome by multiple biological and
technical replicates.
5. Conclusions
In conclusion, our present study is novel in showing that the placental
microbiome varies in association with low birth weight in full-term neonates.
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Abstract: Over recent years, studies have demonstrated links between risk of
cardiovascular disease in adulthood and adverse events that occurred very early
in life during fetal development. The concept that there are embryonic and fetal
adaptive responses to a sub-optimal intrauterine environment often brought about by
poor maternal diet that result in permanent adverse consequences to life-long health
is consistent with the definition of “programming”. The purpose of this review is to
provide an overview of the current knowledge of the effects of intrauterine growth
restriction (IUGR) on long-term cardiac structure and function, with particular
emphasis on the effects of maternal protein restriction. Much of our recent knowledge
has been derived from animal models. We review the current literature of one of the
most commonly used models of IUGR (maternal protein restriction in rats), in relation
to birth weight and postnatal growth, blood pressure and cardiac structure and
function. In doing so, we highlight the complexity of developmental programming,
with regards to timing, degree of severity of the insult, genotype and the subsequent
postnatal phenotype.
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1. Introduction
The importance of maternal nutrition to growth of the foetus has long been
recognised with inadequate maternal nutrition, as a result of undernutrition and/or
malnutrition, linked to induction of intrauterine growth restriction (IUGR) and
potential adverse impacts on lifelong health of the offspring. Importantly, over
recent decades both epidemiological and experimental studies have shown an
association between IUGR and an increased risk of cardiovascular disease later
in life [1–6]. This association has been linked to “developmental programming”
whereby sub-optimal growth during pregnancy results in fetal adaptations, including
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altered organogenesis, which can then render the offspring vulnerable to disease
processes later in life [7]. The purpose of this review is to provide an overview
of the current knowledge relating to IUGR and the long-term effects of IUGR on
the heart. There is particular emphasis on maternal protein restriction which is a
popular animal model used to induce IUGR and the subsequent effects on long-term
cardiac health.
2. Low Birth Weight is Linked to Long-Term Cardiovascular Disease
It is now well established that events occurring during early life can also impact
on long term levels of blood pressure and cardiovascular health [8–11], with impaired
growth in early life leading to long term vulnerability to cardiovascular disease. Over
recent decades many epidemiological studies have linked low birth weight with
long term heart disease [12–17] and with other disease processes that are directly
associated with an increased propensity for cardiovascular disease, such as metabolic
disease [18,19], insulin resistance [20,21], non-insulin dependent diabetes [22,23],
renal disease [24] and hypertension [25,26].
In 1977, Forsdahl was the first to report a close correlation between increased
rates of death from ischaemic heart disease and poverty in childhood and adolescent
years in Norway [27]. Similar relationships were reported in early studies from
England and Wales [28]. In the 1980s Barker and colleagues reported in a cohort
of 10,141 men from Hertfordshire, England, born between 1911 and 1930 that the
incidence of death from ischaemic heart disease was highest in the men with lowest
birth weights and weights at one year of age, compared to individuals of normal birth
weight; this was independent of lifestyle factors [29]. This is when the importance
of maternal diet during pregnancy to the long-term health of her offspring was
first recognised.
Since then, there have been many epidemiological studies in many populations
worldwide that have confirmed these observations [3,11,15,30–35]. Of particular
interest are the findings of the Nurses’ Health Study in which the health of 121,700
women in the USA was retrospectively followed up from 1976 and interestingly, the
strong associations between low birth weight and coronary heart disease remained
after adjustments were made for adult smoking, physical activity, dietary habits and
socio-economic status [3]. This association is strongest when there is accelerated body
growth after birth [4,15,36–40] and collectively, these studies suggest that it is the
accelerated postnatal growth that characteristically occurs in small-for-gestational
age infants, rather than low birth weight per se, that leads to the increased risk of
cardiovascular disease later in life.
Negative correlations between birth weight and levels of blood pressure in adult
life are also now well established [41–44]. The first studies indicating that high blood
pressure might have its origins in utero were population-based studies in the UK
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and other parts of Europe [8,9,31,45–47]. These studies have pointed out that an
increase in birth weight was associated with a fall in blood pressure in adulthood.
These correlations are reported to remain regardless of common risk factors such
as alcohol consumption and body mass index in adulthood [48–50]. The results
from a longitudinal study by Uiterwaal and colleagues following up 252 males and
231 females for 14 years demonstrated a strong and consistent inverse association
between birth weight and systolic blood pressure after adjustment for body weight
and height. This association persisted from adolescence into adulthood [49]. The
links between IUGR and increased risk of disease in adulthood appear to be strongest
when there is an accelerated postnatal catch up in growth [51,52].
3. Catch-Up Growth
The “catch-up” growth or “postnatal accelerated growth” hypothesis was
proposed approximately fifteen years ago by Alan Lucas and Atul Singhal [53,54].
This hypothesis proposes deleterious consequences to offspring when postnatal
growth rate exceeds otherwise normal linear growth, predisposing subjects to
increased risk of developing metabolic and cardiovascular disease.
It is well established that postnatal weight gain is an important indicator for the
programming of adult disease [55]. Accelerated weight gain in childhood is itself a risk
factor for elevated blood pressure later in life [56,57] and this is likely to be compounded
by low birth weight. Findings from a number of clinical studies have revealed that
postnatal catch-up in growth in low birth weight subjects can lead to adverse effects on
cognitive function [58], blood pressure [37], cardiac function [59–61], insulin sensitivity
and secretion [62], development of type 2 diabetes [63] and obesity [64] both in
childhood and in early adulthood. For example, in a study from Helsinki, low
birth weight children who had not only caught-up in body weight with their age
matched counterparts, but were heavier by the seventh year of life were shown to
develop hypertension in adulthood [65] and coronary heart disease [15]. In another
study metabolic syndrome has also been reported in men at 58 years of age [66]
who were born of low birth weight and experienced accelerated catch-up growth
in early adulthood, up to 18 years of age. In a prospective Australian study, where
a longitudinal pregnancy cohort was followed up from birth until 13 years of age,
it was reported that growth trajectory in childhood predicted cardiovascular risk;
cardiovascular risk was high in adolescents with restricted prenatal growth followed
by accelerated postnatal growth [38]. In addition, a prospective US study where data
were collected from a large biracial cohort of pregnant women and their offspring
concluded that increasing growth percentiles during any period of early childhood
increases the risk for high blood pressure [37].
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4. Low Birth Weight and IUGR
Low birth weight is defined as birth weight below 2.5 kg [67], irrespective of
gestational age and is universal to all ethnic groups/populations (according to the
World Health Organisation) and can result from inappropriate growth in utero [68],
preterm birth [69] or a combination of both. This review focuses on the effect of IUGR
rather than preterm birth.
In clinical practice IUGR is generally assigned to small for gestational age infants
with a birth weight and/or birth length below the 10th percentile for gestational
age [70]. It occurs as an abnormal restriction of foetal growth due to adverse genetic
or environmental influences [71].
In general, growth restriction commencing from early pregnancy leads to
proportional or symmetrical growth restriction, whereas in infants where there
is mid-trimester or third trimester growth restriction there is disproportionate or
asymmetrical growth restriction [72]. When there is symmetrical growth restriction
the growth of the head, femur and abdomen is equally affected [71], whereas
in asymmetric growth restriction there is disproportional growth of the foetus,
with preferential blood flow to the brain, termed brain sparing, resulting in a
baby with a relatively normal head size but a below normal body size [73]. This
asymmetric type of growth restriction develops when oxygen or substrate supply to
the foetus is reduced during the last trimester of pregnancy, often due to a reduced
functional capacity of the placenta [74]. There are a number of studies suggesting
that asymmetrical growth restriction in foetuses results in a worse outcome later in
life than symmetrical growth restriction [75].
IUGR is not a specific disease per se but a manifestation of many maternal
and foetal factors leading to poor foetal growth. There are many causes of IUGR
including environmental and genetic factors. In general, IUGR usually results from
nutrient and/or oxygen deprivation to the foetus, often due to both maternal and
foetal factors [76]. Experimental evidence indicates that the primary environmental
factor that regulates foetal growth in animals and humans is nutrient delivery to the
foetus [70,77]. Nutrient delivery is dependent on maternal nutritional intake and
adequate maternal blood flow, which is essential for normal placental function [78].
In developed countries placental insufficiency is the leading cause of IUGR [76],
whereas in developing countries maternal malnutrition is the major cause of IUGR
resulting from long-term nutrient deprivation to the growing foetus [79]. As a
result of the early observations of the link between IUGR and long term disease the
developmental programming hypothesis evolved.
5. Early Life Programming for Long-Term Disease
The concept that there are embryonic and foetal adaptive responses to a
suboptimal intrauterine environment that result in permanent adverse consequences
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is consistent with the definition of “programming” [80,81]. “Programming” refers
to the idea that an insult or stimulus applied during a critical or sensitive period of
development can have long lasting or persistent effects on the structure or function
of an organism [53]; the “programming” can be either beneficial or detrimental to
long term health. Both prenatal life and early postnatal life are “critical periods” that
are characterised by a high degree of plasticity [82–84] and a high cell proliferation
rate in the developing tissues [85,86]. Therefore, exposure to an adverse stimulus
during these “critical periods” can lead to detrimental consequences in the growth
of tissues and organs [55,87], which in turn, can cause persistent alterations in
body function. In addition, adaptive programming of the foetus to IUGR can lead
to modifications of biochemical and hormonal pathways within the foetus, again
rendering the individual susceptible to disease later in life [88].
Potential programming effects on tissue structure and on the number of
functional units formed in vital organs.
Adverse environmental factors acting during the developmental period have
the potential to disturb the processes of cell proliferation and differentiation [89].
The vulnerability of particular organs and organ systems to exposure to insults
during gestation usually coincides with the periods in development when the
organs are first forming and/or during “critical periods” of cellular proliferation and
differentiation [85,90]. Indeed, a reduction in cell number, or a change in the balance
of cell types within tissues, has been observed in a number of animal models in
response to an altered intrauterine environment [91,92]. Such changes may account
for subsequent alterations in gene expression and physiological function. Certainly,
a reduction in the complement of the functional units within vital organs has the
potential to adversely impact on the functional capacity and adaptive capabilities in
adulthood. This is especially important given that the proliferative capacity of the
functional units in many vital organs usually ceases prior to birth, or soon after birth,
hence reduced foetal growth can lead to a lifelong deficit in the functional capacity
of vital organs (Figure 1).
For example, a reduction in:
(1) Nephron number has been observed in offspring in response to a maternal
prenatal low-protein diet in the rat [93,94], mouse [95], and following uterine
artery ligation in the guinea pig [96] and rabbit [97] and following placental
embolization in sheep [98].
(2) Total cardiomyocyte number in the offspring of rats exposed to maternal
protein restriction or placental insufficiency during pregnancy [99] and in lambs
exposed to placental insufficiency the total complement of cardiomyocytes has
been shown to be directly related to heart size [100].
(3) The numbers of secondary muscle fibres has been reported in the young
offspring of a variety of species, including rats [101], pigs [102] and sheep [103]
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following maternal undernutrition during the critical proliferative period for
muscle fibre development.
(4) Total pancreatic weight, islet cell mass and the relative proportion of β-cells
within the islets [104] has been reported to be lower in IUGR rat offspring.
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Figure 1. Diagram showing how impaired maternal nutrition and/or abnormal
placental function leads to intrauterine growth restriction (IUGR) and subsequent
changes to organs that play a key role in cardiovascular function. These changes
have the potential to program for long-term cardiovascular disease.
Furthermore, it has been shown that the vasculature undergoes permanent
changes in reactivity as a result of maternal nutrient restriction [105]. In addition,
there are reports of persistent alterations of the hypothalamic-pituitary-adrenal
(HPA) axis of IUGR rat offspring [106,107] and this is postulated to play a critical
role in the observed association between foetal growth restriction and subsequent
cardiovascular and metabolic diseases.
Figure 1 collectively shows the sequence of events that can potentially lead to
the programming for increased risk of cardiovascular disease in IUGR offspring.
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6. Animal Model of IUGR—Maternal Protein Restriction in Rats
Much of our knowledge relating to the short term and long-term effects of
IUGR has been derived from animal studies. A number of animal models of
poor maternal nutrition and/or placental insufficiency have been developed over
recent years to investigate the causes and consequences of IUGR. A variety of
species have been studied, including: rodents, sheep and primates; and both,
maternal dietary manipulations or surgical interventional techniques have been
employed [108–114]. One of the most extensively studied and well-characterised
animal models is maternal protein restriction in rats. Regardless of how severe the
protein restriction is (mild- 9% diet or severe- 5% diet) the end result is reduction in
body weight of the offspring [115–119].
In our laboratory over the past decade we have comprehensively examined
the cardiovascular phenotype of rat offspring following maternal protein restriction.
However, as our studies have progressed, it has become clearly apparent, that the
cardiovascular and metabolic phenotype of the offspring using this model differs
between different laboratories, which likely relates to subtle differences in study
design. This in turn, makes comparison of the findings between studies difficult.
For example, there are differences in the strain of rats studied, levels of maternal
protein restriction in the diet, timing of administration of the diet to the dams and
postnatal differences in body growth and levels of blood pressure of the offspring.
These differences are highlighted in Table 1.
In our studies, Wistar-Kyoto (WKY) female breeder rats are fed a low protein
diet for two weeks prior to birth to get the dams accustomed to the diet, then during
pregnancy and for two weeks during lactation as the rodent organ systems are
still developing in the early postnatal period. To avoid a high mortality rate in the
offspring [120] we have chosen moderate protein restriction (8.7% casein in the diet)
for the dams [121–128], rather than a more severe protein deprivation (6% casein)
that is sometimes used by other investigators [129–131].
In the following sections we compare our findings with others; in doing so, we
highlight differences in the maternal protein restriction model, which may account


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7. Low Birth Weight and Postnatal Body Growth
In accordance with our findings, many laboratories worldwide have shown
that administration of a protein restricted diet to rat dams during pregnancy leads
to growth restriction in the offspring (Table 1). Given the relative consistency of
these findings, maternal protein restriction in rats has now become one of the most
commonly used animal models of IUGR (Table 1). To the contrary, however, the
long-term effects on body weight are not always the same; in some laboratories
the offspring undergo postnatal catch up in body growth, whereas in others the
body weight of the offspring remains attenuated throughout life (Table 1). It is
a consistent finding in our laboratory that the low protein diet (LPD) offspring
are born small and they then remain significantly smaller throughout life when
compared to normal protein diet (NPD) control offspring [99,117,143–145,147–149];
this is also reported in some other research groups [95,141]. In contrast, catch-up in
body growth in the IUGR rat offspring is often reported following maternal protein
restriction [51,137,140].
Why there are differences in postnatal growth in the offspring between studies is
unknown. It is conceivable that it may be the prolonged maternal protein restriction
after birth for two weeks during lactation in our studies that leads to the persistent
attenuation of body growth in the LPD offspring. In our studies, we have chosen
to feed the rat dams the specialized diets (LPD and NPD) for the first two weeks
of lactation as rats are an altricial species and are born at a time when their organs
are very immature. For instance, in the heart maturation of cardiomyocytes, which
occurs late in gestation in humans, occurs in the first two weeks after birth in the
rat [168]. Likewise, in the kidney nephrogenesis is complete by term birth in the
human but continues in the first two weeks after birth in the rat. Hence, in order to
more closely mimic the effect of IUGR on organ development, we have considered it
appropriate to continue the maternal protein restriction until two weeks after birth.
In addition, there is another important difference in relation to the dietary
feeding regime to the rat dams in our studies, compared to many other studies.
In our studies, the dams commence the diet 2 weeks prior to mating, in order to get
the dams accustomed to the specialised diets. In contrast, in the majority of studies
utilising the maternal protein restriction model, they have commenced feeding the
diet to the dams at the beginning of pregnancy. Hence, it may be the feeding of the
low protein diet to the dams during the periconceptional period that has led to the
long-term attenuation of postnatal growth and to some of the other differences in
findings, compared to other studies using the maternal protein restriction model.
Indeed, there have been a number of recent studies demonstrating long-term effects
on the offspring, as a result of insults; including impaired nutrition, experienced
by the mothers at around the time of conception [92,169–172], thus highlighting the
importance of the periconceptional period in long-term programming [129,173,174].
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Hence, in future studies, it would certainly be beneficial to explore the effects of
the timing of the low protein diet to the dams on the long-term outcomes in the
offspring, in order to differentiate the importance of the periconceptional, pregnancy
and lactation periods in mediating the long-term effects.
8. Elevated Blood Pressure in Adulthood is not a Direct Corollary of IUGR
Over recent decades there have been many epidemiological studies that describe
a direct link between being born small with an elevation of blood pressure in
adulthood [8,31,48,175–177]. Interestingly, however, our studies using the maternal
protein restriction model in rats do not support this concept. The blood pressure
measurements in our studies have been performed using various methods; (tail cuff
plethysmography, intra-arterial and high fidelity pressure sensor; and the outcome
is always the same. The IUGR LPD offspring remain normotensive through to
adulthood and their levels of blood pressure are not different to the non-IUGR NPD
offspring, thus demonstrating that an elevation in blood pressure is not a direct
corollary of IUGR.
The findings in relation to the effects of IUGR on blood pressure later in life
using animal models differs widely amongst studies; some studies report no effects
on blood pressure, whereas others report an elevation in blood pressure in adulthood
(Table 1). In our studies the absence of an elevation in blood pressure in the adult
IUGR offspring is in agreement with other previously reported studies [95,142,178]
yet contrary to others [93,116,132–134,139,151,155,156]. Collectively, the findings
clearly indicate that induction of hypertension in adulthood is not a direct corollary of
being born small. The question thus arises why do the IUGR offspring in some studies
develop high blood pressure in adulthood and in other studies blood pressure in
adult IUGR offspring is not affected? There are a number of potential explanations for
the discrepancies in findings. It may be that when body growth remains attenuated
throughout life that blood pressure is not affected. It is likely that the cardiovascular
system is programmed in utero and hence, cardiovascular function may only be
adversely affected when there is a mismatch in prenatal and postnatal growth.
Certainly, there are a number of experimental studies supporting this concept in the
programming of metabolic disease. Importantly in this regard, using our model of
maternal protein restriction in rats there is improved insulin sensitivity supporting
the concept that it is the “mismatch” in prenatal and postnatal growth that leads
to impaired glucose metabolism [179–183], the majority of studies shown in Table 1
support this concept in relation to the programming of hypertension [122,126,130,
135,156]. Hence, when the IUGR LPD offspring experience accelerated postnatal
growth, such that body weight is no longer different to the non-IUGR NPD offspring,
these offspring generally exhibit a significant elevation in blood pressure. However,
it is important to point out, that there are a few studies shown in Table 1, where body
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weights in the LPD offspring, at the time of examination, were still less than controls
but blood pressure was significantly elevated [93,131,133].
An alternative explanation for the differences observed in levels of adult blood
pressure may relate to whether the protocols used to measure blood pressure leads
to stress in the animals. Indeed, there have been a number of studies suggesting
that it is an elevated stress response in IUGR offspring that subsequently leads to
the elevation in blood pressure rather than a direct etiological effect [39,128,136,178,
184,185]. Hence, when rats are stressed during some procedures used to measure
blood pressure, there will be an elevated stress response in the IUGR offspring,
and hence, a concomitant elevated blood pressure response. This is similar to the
“white coat hypertension” often experienced by human subjects when their blood
pressure is measured in a clinical setting (and they have become stressed during
the procedure) [186–190]. Certainly measurements of tail-cuff blood pressure can
lead to stress in the animals, especially if they have not been well conditioned to the
procedure. In early studies in the field, “one off” measurements were performed
using tail-cuffs [155,156] and it is highly likely, that the rats were stressed during
these procedures. In such studies, blood pressure would have been elevated in both
IUGR and non-IUGR offspring during these procedures; however, if there was an
elevated stress response in IUGR offspring this would lead to a greater elevation of
blood pressure in these offspring. Van Abeelen and colleagues addressed this issue in
a recent systemic review where they included 101 experimental studies from sheep,
guinea pigs, rats and mice looking at the effects of maternal undernutrition (34 studies
of maternal general undernutrition and 67 studies of low protein undernutrition)
on the blood pressure in the offspring [185]. They pointed out that the values of
blood pressure reported from tail-cuff measurements overestimate the “true value”
of blood pressure when taken by a direct method using intra-arterial catheters.
Furthermore, they have indicated that a direct comparison between tail-cuff and
radiotelemetry would be beneficial when conducting studies [185]. In this regard,
Swali and colleagues have reported simultaneous measurements of blood pressure,
using tail-cuffs and telemetry, in IUGR and control offspring during baseline and
under various stress conditions [128]. They found a good correlation between tail-cuff
and radiotelemetry derived blood pressure data in control rats; however, in the IUGR
group the tail-cuff method revealed hypertension at eight weeks of age but the
telemetry method indicated significantly lower blood pressure at twelve weeks of
age compared to controls [128]. Hence, their interpretation of these findings was
that the increase in systolic blood pressure in LPD offspring reflects an increase in
peripheral vascular resistance as well as change in the degree of amplification of
blood pressure between central and peripheral regions.
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9. Cardiac Remodelling in the Adult IUGR Heart with Normal Basal Function
In our analyses of the adult hearts of the IUGR LPD offspring we have no
evidence of overt structural abnormalities in the myocardium of LPD offspring
compared to NPD offspring in early adulthood (18 weeks of age) as assessed
by echocardiography [150] and there is no significant difference in the amount
of interstitial collagen deposition within the myocardium between the LPD and
NPD groups [149]. Interestingly, however, when the biochemical composition of
the left ventricle was assessed using FTIR micro-spectroscopy [149] there were
marked differences detected in the biochemical spectra of the growth-restricted
myocardium. In particular, there was a significant increase in the intensity of lipids,
proteoglycans and carbohydrates as indicated by the increased absorbance of the
1455 and 1388 cm−1, 1228 cm−1, 1038 cm−1 bands, respectively. However, the protein,
lipid and proteoglycan spatial distribution was similar within the myocardium of
the left ventricular free wall and interventricular septum of the LPD and NPD
adult offspring [149]. Interestingly, the spatial distribution of carbohydrates was
different in the IUGR and non-IUGR hearts at 18 weeks of age with the most striking
difference between the NPD and LPD myocardium observed in the absorbance
band at 1228 cm−1, which is due to the presence of proteoglycans. Importantly,
in this regard it has been shown that an increase in proteoglycan deposition can
ultimately affect cardiac performance [191,192]. The increase in carbohydrate
content in the myocardium of IUGR offspring may be indicative of altered glucose
metabolism within the LPD offspring. Certainly, experimental studies link IUGR
with programming of altered glucose metabolism [193,194]. We have not directly
assessed glucose metabolism in the IUGR offspring in our model of maternal protein
restriction. However, in a previous study in our laboratory we have shown that
maternal protein restriction leads to the programming of improved postnatal whole
body insulin sensitivity when postnatal growth is similar to that in utero [145], which
does not support the concept that glucose metabolism is impaired. Future studies
are required to further investigate the cause of the increased carbohydrate content in
the LV myocardium and determine whether it relates to altered glucose metabolism.
It is conceivable that the biochemical changes that we have observed in the heart of
the adult IUGR LPD offspring may have developed during foetal life. In support
of our findings, Tappia and colleagues showed an altered phospholipid profile and
fatty acid content in IUGR offspring at birth [162].
Although no differences in myocardial collagen were observed between LPD
and NPD offspring at 18 weeks of age we have detected an increase in interstitial
fibrosis in LPD offspring at 24 weeks of age [143] and at 32 weeks of age [147];
hence, it is conceivable that there may be an exacerbated deposition of collagen
within the myocardium as the LPD offspring age. Interestingly, at 18 weeks
of age we found minimal evidence of overt cardiac dysfunction under basal
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conditions in the IUGR offspring as assessed using both echocardiography and
P-V catheterization techniques; fractional shortening a measure of myocardial
contractility was normal [150]. Likewise, in another study from our laboratory there
was preserved fractional shortening of the cardiac muscle in the IUGR offspring at
32 weeks of age [147]. Given our findings in relation to blood pressure and body
weight, it is not really surprising that basal cardiac function was normal in the
IUGR offspring; with normal blood pressure and attenuated postnatal body growth
of the IUGR offspring the hemodynamic demands on the cardiovascular system
are not likely to have increased in the IUGR offspring in adulthood. However, it
is important to note, that when the hearts were challenged with dobutamine that
the increase in both stroke volume and cardiac output were attenuated and the
arterial elastance remained significantly elevated in the IUGR offspring, indicative
of increased afterload on the heart [148]. In addition, echocardiographic analysis
demonstrated a significant increase in end systolic dimensions and a significant
reduction in aortic peak systolic velocity; which may indicate direct adverse effects
on aortic compliance or mild impairment of systolic function. Others have shown
in a rat model of maternal protein restriction that ejection fraction is significantly
depressed in IUGR offspring very early in life at two weeks of age but subsequently
normalised with no difference in ejection fraction between the IUGR and control
offspring at 40 weeks of age as assessed by echocardiography [118]. Contrary to our
findings, however, Menendez-Castro and colleagues have reported a significantly
reduced ejection fraction as evaluated by echocardiography early in life at 10 weeks
of age in IUGR offspring exposed to maternal protein restriction even though blood
pressure was normal [6].
10. Challenging the Adaptive Capabilities of the IUGR Heart
Over recent years we have tested the hypothesis that IUGR acts as a primary
insult to the heart, rendering the heart susceptible to secondary postnatal insults,
such as hypertension, high salt diet and hyperglycaemia. It is well known
that hypertension leads to left ventricular hypertrophy [195–199] and hence, it
was considered likely that when the adaptive capabilities of the IUGR heart are
challenged by hypertension, the pathological changes that ensue in the heart would
be exacerbated in the heart of offspring that were born IUGR. In our studies,
hypertension was induced by continuous infusion, at a pressor dose, of the potent
vasopressor hormone angiotensin II (Ang II) [200]. Importantly, given that the
IUGR LPD offspring in our studies do not normally develop high blood pressure in
adulthood, we were able to look at the secondary effects of induction of hypertension,
independent of an underlying primary hypertension.
Contrary to our initial hypothesis, when hypertension was induced as a
secondary cardiac insult, the response to hypertension was not exacerbated in the
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IUGR offspring. The cardiac hypertrophic growth response to Ang II infusion, as
assessed using echocardiography, was not different between the IUGR and non-IUGR
offspring; however, there were differences in cardiac tissue structure. Unexpectedly,
in the Ang II infused IUGR adult offspring the levels of interstitial collagen in the
left ventricle myocardium was markedly reduced when compared to the non-IUGR
offspring (unpublished observations from our laboratory). Hence, our findings
do not support the concept that the IUGR heart is necessarily more vulnerable
to hypertension in adulthood and importantly, our findings suggest that in some
circumstances the IUGR heart may be somewhat protected from adverse remodelling.
Further studies are required to elucidate the mechanisms for the reduced deposition
of collagen.
In other studies in our laboratory we have examined the effects of induction of
diabetes in adulthood, as a secondary postnatal insult, on the growth of the IUGR and
non-IUGR heart [147]. Similar to that seen with induction of hypertension, the overall
cardiac growth response to induction of diabetes, assessed by echocardiography, was
not different between the IUGR and non-IUGR hearts. Importantly, however, the
level of fibrosis was significantly greater in the IUGR diabetic hearts compared
to non-IUGR diabetic hearts [147]. Collectively, our findings suggest that the
IUGR heart may be better able to structurally adapt to a haemodynamic challenge,
but not to the challenge of hyperglycaemia. However, this may be a somewhat
simplistic interpretation of findings given that the mechanisms of the induction of
cardiac hypertrophy are complex and both secondary insults are likely to involve
haemodynamic and endocrine mechanisms.
There have been a number of studies that have examined the effect of a high
salt diet administered postnatally, as a secondary lifestyle insult, on blood pressure
in IUGR offspring [95,117,201–203]. Interestingly, several studies have shown that
the increase in blood pressure in response to a high salt diet is similar between IUGR
offspring and non-IUGR offspring [117,204], whereas some report salt-sensitive
hypertension [93] and others report a reduction in blood pressure [95]. In our
maternal protein restriction model it was previously shown that there was no
difference in the elevation of blood pressure response to a high salt diet between
LPD and NPD offspring [117]. Given that a high salt diet, is linked to induction of
cardiac fibrosis [205,206] it would be interesting in future studies to compare the
structural remodelling in the LPD IUGR offspring relative to NPD controls following
the feeding of a high salt diet in adolescence/adulthood.
11. Conclusions
In summary, the findings of this review highlight the importance of maternal
diet on the long-term cardiovascular outcomes of the offspring. Upon comparison
of the findings between different laboratories using rat models of maternal protein
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restriction we highlight the many differences in the cardiovascular phenotype of the
offspring between studies, which may relate to the rat strains studied, severity of the
dietary protein restriction and the timing of the diet administration. In addition, this
review emphasizes the complexity of the mechanisms relating to the developmental
programming of heart disease and highlights directions for future research that are
required to establish the importance of the periconceptional, pregnancy, lactational
and post-weaning windows in life-long developmental programming.
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Fetal Adrenal Demedullation Lowers
Circulating Norepinephrine and Attenuates
Growth Restriction but not Reduction of
Endocrine Cell Mass in an Ovine Model of
Intrauterine Growth Restriction
Melissa A. Davis, Antoni R. Macko, Leah V. Steyn, Miranda J. Anderson and
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Abstract: Placental insufficiency is associated with fetal hypoglycemia, hypoxemia,
and elevated plasma norepinephrine (NE) that become increasingly pronounced
throughout the third trimester and contribute to intrauterine growth restriction
(IUGR). This study evaluated the effect of fetal adrenal demedullation (AD) on
growth and pancreatic endocrine cell mass. Placental insufficiency-induced IUGR
was created by exposing pregnant ewes to elevated ambient temperatures during
mid-gestation. Treatment groups consisted of control and IUGR fetuses with either
surgical sham or AD at 98 days gestational age (dGA; term = 147 dGA), a time-point
that precedes IUGR. Samples were collected at 134 dGA. IUGR-sham fetuses
were hypoxemic, hypoglycemic, and hypoinsulinemic, and values were similar
in IUGR-AD fetuses. Plasma NE concentrations were ~5-fold greater in IUGR-sham
compared to control-sham, control-AD, and IUGR-AD fetuses. IUGR-sham and
IUGR-AD fetuses weighed less than controls. Compared to IUGR-sham fetuses,
IUGR-AD fetuses weighed more and asymmetrical organ growth was absent.
Pancreatic β-cell mass and α-cell mass were lower in both IUGR-sham and IUGR-AD
fetuses compared to controls, however, pancreatic endocrine cell mass relative to fetal
mass was lower in IUGR-AD fetuses. These findings indicate that NE, independently
of hypoxemia, hypoglycemia and hypoinsulinemia, influence growth and asymmetry
of growth but not pancreatic endocrine cell mass in IUGR fetuses.
Reprinted from Nutrients. Cite as: Davis, M.A.; Macko, A.R.; Steyn, L.V.;
Anderson, M.J.; Limesand, S.W. Fetal Adrenal Demedullation Lowers Circulating
Norepinephrine and Attenuates Growth Restriction but not Reduction of Endocrine
Cell Mass in an Ovine Model of Intrauterine Growth Restriction. Nutrients 2015, 7,
500–516.
1. Introduction
Intrauterine growth restriction (IUGR) is often caused by placental
insufficiency resulting in fetal hypoxemia and hypoglycemia, which elevate plasma
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catecholamines [1–10]. Elevated plasma norepinephrine (NE) concentrations
have been reported in human IUGR fetuses and in animal models of placental
insufficiency-induced IUGR [3,11–15]. In fetal sheep, NE is the major catecholamine
secreted from the adrenal medulla due to low expression of phenylethanolamine
N-methyltransferase (PNMT), an enzyme that converts NE to epinephrine [16].
Although sympathetic neurons, such as the splanchnic nerve, contribute to plasma
NE concentrations, the adrenal medulla has been shown to be primarily responsible
for hypoxia-stimulated increases of NE and epinephrine in fetal plasma [13,17–20].
High NE concentrations inhibit fetal insulin secretion via α2-adrenergic receptors
on pancreatic β-cells [3,12–15,17,19,21–29]. Expression of α2A-adrenergic receptor
mRNA was greater in islets isolated from the IUGR fetus, which potentially facilitate
the chronic inhibition of insulin, an anabolic hormone in the fetus [3–5,30,31].
Previous work has shown that continuous infusion of epinephrine or NE for >7 days
into normal sheep fetuses produced asymmetric fetal growth restriction and
chronically lowered plasma insulin concentrations [17,32]. In contrast to IUGR
islets, the α2A-adrenergic receptor mRNA concentrations were lower in NE-infused
islets [32]. Pancreatic endocrine cell mass was unaffected by NE-infusion, whereas
in IUGR fetuses β-cell mass was substantially lower because of slower β-cell
replication rates [4,32,33]. Exogenous replacement of insulin during the NE infusion
counteracted the growth restriction, which indicates that low insulin concentrations
were essential for decreased growth rates in fetuses with normal oxygen and glucose
concentrations [30,32]. Additionally, insulin-independent NE actions have been
associated with lower oxidative metabolism [20,30]. Together, these findings show
that chronically elevated plasma NE concentrations restrict fetal growth, promote
asymmetric growth, and suppress insulin concentrations in otherwise normal fetuses,
however NE actions have not been defined in IUGR fetuses with low blood glucose
and oxygen concentrations.
In IUGR fetuses, metabolic and endocrine modifications promote glucose and
oxygen sparing to preserve necessary fetal functions but also result in stunted and
asymmetrical fetal growth. However, the contribution of adrenal catecholamine
secretion to alter growth trajectory has not been evaluated [5,34,35]. Therefore,
the objective of this study was to determine the specific effects of chronically
elevated NE, independent of hypoxemia and hypoglycemia, on fetal growth and
pancreatic endocrine cell composition in the near-term, PI-IUGR sheep fetus. This
was accomplished by surgical ablation of the fetal adrenal medulla and therefore,
fetal NE responsiveness to hypoxemia and hypoglycemia. The bilateral adrenal
demedullation was performed at 98 days gestational age (dGA; term = 147 dGA), a
time point our group has previously determined to precede the onset of IUGR and
is predicted to preceded the elevation in fetal plasma NE in this model of placental
insufficiency-induced IUGR [30,33,36,37]. Fetal measurements were collected at
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Columbia-Rambouillet crossbred ewes (62 ± 3 kg) carrying singleton
pregnancies were purchased from Nebeker Ranch (Lanscaster, CA, USA). Ewes
were fed Standard-Bread Alfalfa Pellets (Sacate Pellet Mills) and provided water ad
libitum. Protocols were conducted with approval by the Institutional Animal Care
and Use Committee at The University of Arizona Agricultural Research Complex,
Tucson, AZ, USA.
2.2. IUGR and Control Fetuses
Singleton pregnancy was confirmed by ultrasound at approximately 35 days
gestation age. Ewes were randomly assigned to either a control (n = 15) or IUGR
(n = 11) treatment. Placental insufficiency-IUGR was created by exposing pregnant
ewes to elevated ambient temperatures (40 ◦C for 12 h; 35 ◦C for 12 h; dew point 22 ◦C)
from 39 ± 1 dGA until 94 ± 1 dGA (0.27–0.63 gestation) as described previously [4].
Control fetuses were from healthy pregnant ewes that were maintained at 25 ◦C and
pair-fed to the average daily feed intake of IUGR ewes. Feed was withheld 24 h prior
to surgery.
2.3. Surgical Preparation for Adrenal Demedullation and Cannulation
At 98 ± 1 dGA control and IUGR fetuses were randomly assigned to undergo
either a bilateral adrenal demedullation (AD) or sham (placebo) surgical procedure.
Fetal adrenal glands were isolated via retroperitoneal incisions and a straight
electrode was used to cauterize the inner medullary tissue while leaving the cortex
intact as previously described [20]. At 121 ± 1 dGA, each fetus underwent a second
surgical procedure to place indwelling, polyvinyl arterial and venous catheters for
blood sampling and infusion as described previously [5,38]. Animals were allowed to
recover for at least one week prior to fetal blood collection experimental procedures.
The catheters were flushed daily with heparinized saline solution (100 U/mL heparin
in 0.9% NaCl solution, Vedco, Inc, St. Joseph, MO, USA). The final treatment
designations were control-sham (n = 8), control-AD (n = 7), IUGR-sham (n = 7),
and IUGR-AD (n = 4) fetuses.
2.4. Postmortem Examination
The ewe and fetus (134 ± 1 dGA) were euthanized with intravenous
concentrated pentobarbital sodium (86 mg/kg) and phenytoin sodium (11 mg/kg,
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Euthasol; Virbac Animal Health, Fort Worth, TX, USA). After a hysterectomy, the
fetus was removed, blotted dry, and weighed. Fetal organs were dissected and
weighed. The fetal pancreas was dissected free, weighed, and divided from the
common bile duct to the anatomic left side of the portal vein (pancreatic notch, when
visible). Pancreas masses were obtained from control-sham (n = 7), control-AD (n = 5),
IUGR-sham (n = 4), and IUGR-AD (n = 3) fetuses due to other procedures.
2.5. Biochemical Analysis
Arterial blood gases were measured with an ABL 720 (Radiometer, Copenhagen,
Denmark) and values were temperature-corrected to 39.1 ◦C, the average core body
temperature for sheep. Plasma glucose concentrations were quantified with the YSI
model 2700 SELECT Biochemistry Analyzer (Yellow Springs Instruments, Yellow
Springs, OH, USA). Plasma concentrations of insulin (ovine insulin ELISA; ALPCO
Diagnostics, Windham, NH; intra- and inter-assay coefficients of variation <6%;
sensitivity 0.14 ng/mL), norepinephrine (noradrenaline ELISA; Labor Diagnostika
Nord GmbH & Co., KG, Germany; intra- and inter-assay coefficients of variation
<14%; sensitivity 35 pg/mL), and cortisol (ALPCO Diagnostics; intra- and inter-assay
coefficients for variation <10%; sensitivity 2.44 ng/mL) were quantified.
2.6. Pancreas Morphology and Pancreatic Endocrine Cell Proliferation
The splenic portion of the fetal pancreas was collected at necropsy and fixed
in 4% paraformaldehyde and embedded in O.C.T Compound (Sakura Finetek USA,
Torrance, CA, USA) as previously described [4,39]. Pancreas sections were cut and
analyzed at 100 µm intervals. Immunofluorescent staining identified mature cell
types within the pancreas: β-cells with guinea pig anti-porcine insulin (1:500; Dako,
Carpinteria, CA, USA); α-cells with mouse anti-porcine glucagon (1:250; Sigma-Alrich,
St. Louis, MO, USA); δ-cells with rabbit anti-human somatostatin (1:500; Dako,
Carpinteria, CA, USA); F cells with rabbit anti-human pancreatic polypeptide (PP)
(1:500; Dako, Carpinteria, CA, USA). β-cells in mitosis were identified with rabbit
polyclonal phosphorylated-Histone H3 (pHH3; 7.5 µg/mL; Upstate, Lake Placid,
NY, USA), anti-insulin, and DAPI (4′,6-diamidino-2-phenylindole; 1 mg/mL; Vector
Laboratories, Burlingame, CA, USA). Secondary antiserum against the appropriate
species immunoglobulin conjugated to 7-amino-4-methylcoumarin-3-acetic acid
(AMCA; Jackson ImmunoResearch Laboratories, West Grove, PA, USA), AlexaFluor
488 (Molecular Probes, Eugene, OR, USA), or AlexaFluor 594 (Molecular Probes,
Eugene, OR, USA) were used for detection. The fluorescent images were visualized
on the Leica DM5500 microscope system and digitally captured with a Spot
Pursuit 4 Megapixel CCD camera (Diagnostic Instruments, Sterling Heights, MI,
USA). Morphometric analysis was performed with ImagePro 6.3 software (Media
Cybernetics, Silver Spring, MD, USA). Positive areas were determined for 25 fields
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of view on at least two pancreas sections per animal separated by ≥100-µm intervals.
Data are expressed as a percentage of total pancreas area. Phosphorylated-Histone
H3 positive cells were determined per 3000–4000 DAPI positive cells within β-cells
on at least two pancreas sections per animal separated by ≥100-µm intervals. Data
are expressed as a percentage of the total number of DAPI positive cells per insulin
positive cell. β-cell mass (mg per pancreas) was calculated by multiplying relative
insulin-positive area (the percentage of insulin positive area over total pancreas area)
by pancreas mass.
2.7. Statistical Analysis
Significant differences (p < 0.05) among treatments were determined with
an ANOVA and post hoc LSD test using general linear means procedures in the
Statistical Analysis System (SAS Institute, Cary, NC, USA, v9.2, 2008). Data are
presented as mean ± SEM.
3. Results
3.1. Fetal Biometry and Blood Measurements
Arterial blood oxygen tension was lower in IUGR-sham and IUGR-AD fetuses
compared to control-shams and control-AD fetuses (Figure 1A). IUGR-sham fetuses
had lower plasma insulin and glucose concentrations compared to control-shams
(Figure 1). Fetal plasma NE concentrations were five-fold higher in the IUGR-sham
fetuses compared to IUGR-AD fetuses, as well as control-sham and control-AD
fetuses (Figure 1D). Plasma NE concentrations were not different among IUGR-AD
fetuses and the control groups. There were no differences in plasma cortisol
concentrations among treatment groups. (Figure 1E).
There were no differences in overall mass or the masses of individual organs
between control-sham and control-AD fetuses (Table 1). Compared to the control
groups, the mean fetal mass was 51% lower in the IUGR-sham group and 26% lower
in the IUGR-AD group. Placenta mass was lower in the IUGR groups compared to
the control groups, but were not different among the IUGR and control treatments.
Placental efficiency, calculated as the ratio of fetal to placental mass, was greater in
IUGR-AD fetuses (15.4 ± 0.9 g) compared to IUGR-sham (11.8 ± 0.7 g), control-sham
(10.7 ± 0.9 g), and control-AD (11.4 ± 0.7 g) fetuses. Compared to other treatment
groups, neural tissue (cerebrum, cerebellum, and brain stem) mass was lower in
the IUGR-shams. Heart and kidney masses were lower in IUGR-shams as well
as IUGR-AD fetuses compared to both control groups. Liver mass was greater
in the control-sham group compared to both IUGR groups. Pancreatic mass for
control-sham (n = 7), control-AD (n = 5), IUGR-sham (n = 4), and IUGR-AD (n = 3) was
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3.43 ± 0.23 g, 2.92 ± 0.22 g, 2.38 ± 0.48 g, 2.73 ± 0.50 g, respectively. In IUGR-shams,
pancreatic mass was lower compared to both control groups and the IUGR-AD group.
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Figure 1. Fetal arterial oxygen tension and plasma glucose and hormone concentrations. 
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Figure 1. Fetal arterial oxygen tension and plasma glucose and hormone
concentrations. Means (±SEM) for arterial blood oxygen tension (PaO2; A);
insulin (B); glucose (C); norepinephrine (D); and cortisol (E) are graphed for
control-sham, control-adrenal demedullation (AD), intrauterine growth restriction
(IUGR)-sham, and IUGR-AD treatment groups (x-axis). Error bars represent the
SEM and different superscripts denote statistically significant differences among
treatment groups (p < 0.05).
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Fetus 3250 ± 149 a 3242 ± 177 a 1577 ± 250 b 2394 ± 414 c
Placenta 319 ± 27 a 272 ± 8.7 a 137 ± 26 b 160 ± 36 b
Brain 50.5 ± 1.4 a 50.0 ± 1.7 a 40.9 ± 2.1 b 48.8 ± 3.1 a
Heart 22.6 ± 1.2 a 22.3 ± 1.6 a 12.2 ± 1.8 b 16.6 ± 1.9 b
Kidneys 22.4 ± 1.1 a 23.3 ± 1.3 a 11.7 ± 2.0 b 17.3 ± 1.1 c
Liver 96.5 ± 8.5 a 88.3 ± 5.2 a,b 45.0 ± 7.8 c 63.5 ± 11 b,c
Treatments with different superscripts differ (p < 0.05).
The mass of fetal organs in proportion to fetal mass (g/kg) revealed sparing
of brain and heart in IUGR-sham fetuses compared to all other treatment groups
(Figure 2). In IUGR-AD fetuses, the relative brain and heart proportions were
not different from either control group. There were no differences in the relative
mass of liver (control-sham, 29.4 ± 1.8 g; control-AD, 27.4 ± 1.4 g; IUGR-sham,
31.5 ± 2.0 g; IUGR-AD, 26.6 ± 1.6 g) and kidneys (control-sham, 6.9 ± 0.2 g;
control-AD, 7.2 ± 0.4 g; IUGR-sham, 8.5 ± 1.3 g; IUGR-AD, 7.6 ± 0.7 g) between
treatment groups. Relative pancreatic mass for IUGR-sham (1.41 ± 0.07 g/kg; n = 4)
was greater than control-sham (1.03± 0.04 g/kg; n = 7), control-AD (0.97± 0.11 g/kg;
n = 5), and IUGR-AD (1.09 ± 0.10 g/kg; n = 3).
3.2. Fetal Pancreas Morphology
Mature pancreatic endocrine cells areas for control-sham, control-AD,
IUGR-sham, and IUGR-AD fetuses were determined with immunofluorescent
staining (Figure 3). In IUGR-AD fetuses, insulin (β-cell) and glucagon (α-cell)
positive areas were lower than other treatment groups, although IUGR-sham fetuses
were also lower compared to control-shams (Figure 4). The combined somatostatin
and PP (δ- and F-cells) positive area was lower in IUGR-sham and IUGR-AD fetuses
compared to control-sham fetuses (Figure 4C).
Endocrine cell masses were calculated as the product of percent area and
pancreatic mass (Table 2). β-cell mass was lower in IUGR-sham and IUGR-AD fetuses
compared to control-sham fetuses. β-cell mass in control-AD was not different from
other treatment groups. Compared to control-sham fetuses, α-cell mass was lower
in all other treatment groups. No differences in the combined somatostatin and PP
mass were identified among treatment groups. The sum of the endocrine cell mass
(total endocrine cell mass) was lower in IUGR-sham and IUGR-AD fetuses compared
to control-sham fetuses. The total pancreatic endocrine cell mass also was lower in
control-AD fetuses than control-sham fetuses.
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(β-cells; blue), glucagon (α-cell; green) and the combination of somatostatin and PP  
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β-cell Mass 75.2 ± 12 a 51.6 ± 8.4 a,b 30.9 ± 7.8 b 22.2 ± 12 b
α-cell Mass 18.8 ± 2.1 a 12.2 ± 1.6 b 8.6 ± 2.2 b 5.5 ± 1.4 c
δ- a F-cell Mass 15.7 ± 2.2 a 9.2 ± 1.1 a 7.0 ± 2.2 a 6.1 ± 2.7 a
Total E docrine
Cell Mass 109.7 ± 14
a 73.0 ± 8.7 b 46.5 ± 12 b 33.8 ± 16 b
Treatment differences (p < 0.05) are den ted with different superscripts.
Total endocrine cell mass relative to fetal mass (mg/kg) was lower in IUGR-AD
f tuse compar d to ll other reatment groups (Figure 5D). The relative β-cell
mass f r IUGR-AD fetus s was lower than control-sha s and tended to be less than
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control-AD (p < 0.07) and IUGR-sham (p < 0.06) fetuses (Figure 5A). IUGR-AD fetuses
had a lower relative α-cell mass and combined δ- and F-cell mass compared to all
other treatment groups. In control-AD fetuses, relative α-cell mass and combined δ-
and F-cell mass were lower compared to control-sham fetuses.Nutrients 2015, 7 507 
 
 
Figure 4. Pancreatic endocrine cell areas. Insulin positive area (A); glucagon positive area (B); 
and the combined somatostatin and PP positive area (C) were measured and the mean percent 
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represent the SEM and different superscripts denote statistically significant differences 
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Figure 5. Endocrine cell mass relative to fetal mass. Means are graphed for β-cell (A); α-cell 
(B) combined δ-cell and F-cell (C); and total endocrine cell (D) mass expressed as a proportion 
of fetal mass (mg/kg). The treatment groups are presented on the x-axis. Error bars represent 
the SEM and different superscripts denote statistically significant differences among 
treatment groups (p < 0.05). 
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Figure 5. Endocrine cell mass relative to fetal mass. Means are graphed for
β-cell (A); α-cell (B) combined δ-cell and F-cell (C); and total endocrine cell (D)
mass expressed as a proportion of fetal mass (mg/kg). The treatment groups are
presented on the x-axis. Error bars represent the SEM and different superscripts
denote statistically significant differences among treatment groups (p < 0.05).
185
The proportion of pHH3 labeled β-cells was lower in IUGR-sham and IUGR-AD
fetuses compared to control-shams (Figure 6E). No differences in pHH3 labeled
β-cells were identified between control-sham and control-AD fetuses or between
IUGR-sham and IUGR-AD fetuses.Nutrients 2015, 7 508 
 
 
Figure 6. β-cell Proliferation Rates. Pancreas tissues were immunostained for  
phosphorylated-Histone H3 (pHH3; green), insulin (β-cells; red), and nuclear DNA (DAPI; 
blue). Representative micrographs are presented for control-sham (A); control-AD (B);  
IUGR-sham (C); and IUGR-AD (D). The mean (±SEM) percentages of pHH3 positive β-cells 
are graphed for treatment groups labeled on the x-axis (E). Error bars represent the SEM and 
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4. Discussion
Results of the experiments reported here provide strong support for the
hypothesis that catecholamines secreted by the adrenal medulla, independently of
hypoglycemia and hypoxemia, suppress the rate of growth and facilitate asymmetric
organ growth in fetuses with placental insufficiency-induced IUGR. Previous studies
have shown similar effects on fetal growth when plasma epinephrine and NE are
increased chronically [17]. However, those experiments did not address the effects of
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catecholamines in the context of restricted fetal oxygen and nutrient supply imposed
by placental insufficiency [10,40–43]. In the current study, ablation of the fetal
adrenal medulla at the end of the second trimester of gestation prevented the rise
in plasma NE concentrations, despite hypoxemic and hypoglycemic conditions,
in near-term in fetuses with placental insufficiency-induced IUGR. Suppression of
elevated plasma NE concentration, an indicator for adrenal catecholamine secretion,
significantly improved the magnitude of fetal growth by ~50% in IUGR fetuses and
curtailed asymmetric growth of brain and heart [20]. In IUGR-AD fetuses, reduction
in pancreatic endocrine cell mass was unaffected by adrenal demedullation while
the amount of endocrine mass relative to fetal mass was lower. These findings
indicate that adrenal release of catecholamines in response to fetal hypoxemia and
hypoglycemia secretion elevated NE concentrations and acted to inhibit somatic
cell growth in IUGR fetuses; however, the mechanism appears to be independent
of insulin because insulin concentrations remained low and pancreatic islet mass
was unaffected.
Greater fetal growth restriction in intact IUGR fetuses indicates that the
adrenal medulla plays a major role in coordinating inhibition of fetal growth and
asymmetry of growth as glucose, oxygen, and insulin concentrations are similar
among IUGR groups. Proposed mechanisms for the greater severity of IUGR with
high catecholamines are redistribution of fetal blood flow, secondary actions on the
regulation of anabolic hormones, and adaptations in metabolic substrate uptake and
utilization in tissues. It has been shown that during acute hypoxia (<48 h), fetal
blood flow increases to neural tissues, heart, and adrenals to maintain arterial oxygen
delivery, whereas blood flow to kidneys, pancreas, and carcass remains constant
or tends to decline [44–48]. The compensatory increases in blood flow to the brain
and heart are not found in IUGR models with longer durations of hypoxemia but
reduced blood flow to the carcass remains [49–51]. This may suggest changes in
extraction efficiencies of tissues when catecholamines are chronically elevated, which
is expected in neural tissues because glucose transporter 1 isoform concentrations
are increased [5]. Furthermore, raising NE concentrations to values similar to
those observed during hypoxemia also increased coronary blood flow, but the
redistribution of blood flow was not identical to that observed in hypoxic fetuses [48].
Therefore, it has been postulated that altered endocrine regulation and substrate
utilization are also potential mechanisms underlying IUGR. For example, NE or
epinephrine infusions have been shown to increase insulin-like growth factor binding
protein-1, which was associated with lowering insulin-like growth factor (IGF)
bioavailability and DNA synthesis in select tissues [52–54]. Infusion of NE increases
oxygen consumption in the fetus even though transplacental uptake of two major
substrates for oxidative metabolism, lactate and amino acids, are reduced [55,56]. The
net result is insufficient exogenous substrates for oxidative metabolism. Although
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not experimentally tested, this could partly explain reduced amino acid uptake from
the placenta in IUGR fetuses with placental insufficiency [41,57]. Furthermore, fetal
amino acid supplementation increased rates of fetal protein accretion in IUGR fetus
rather than being utilized as oxidative substrates as observed in control fetuses [41].
Greater placental efficiency in IUGR-AD fetuses could be explained by the lack of
NE regulation of fetal metabolism and placental uptake of amino acids.
Elevated plasma NE has been shown to acutely and chronically suppress plasma
insulin concentrations, and adrenal demedullation impairs β-cell function [4–6,8,24,
25,32,33]. In a previous study conducted in normal, near-term fetal sheep, ablation
of adrenal medullae did not influence plasma glucose and insulin concentrations at
baseline but lowered glucose-stimulated insulin concentrations, indicating that an
intact adrenal medulla potentiates glucose-stimulated insulin concentrations [36].
Acute pharmacological antagonism of adrenergic receptors in IUGR fetuses improved
glucose-stimulated insulin secretion at 103 dGA and 134 dGA, even though fetal
hypoxemia was present [3,30,33]. Cessation of a 7-day NE infusion in normal sheep
fetuses resulted in greater basal and glucose-stimulated insulin concentrations, which
indicates chronically elevated NE enhanced post-treatment β-cell responsiveness [32].
In the present study, ablation of the fetal adrenal medullae at 98 dGA decreased the
NE responsiveness to hypoglycemia and hypoxemia at 134 dGA, but plasma insulin
concentrations remained low because the prior conditions of placental insufficiency
(Figure 1). These findings are similar to results from chronically hypoglycemic sheep
fetuses that have blunted insulin secretion responsiveness [38,58]. Therefore, NE
or other hormones from the adrenal medulla regulate β-cell function under normal
conditions but also enhance insulin secretion following chronic exposure to high
NE concentrations.
Despite a greater fetal mass in IUGR fetuses with low NE, β-cell mass was
similar to IUGR fetuses with high NE and in both IUGR groups β-cell mass was
lower than control-sham fetuses. This indicates that IUGR conditions, not high NE,
are responsible for reducing β-cell mass. This is consistent with the similar reduction
in β-cell proliferation rate (Figure 6) and also consistent with other models in which
fetal NE concentrations were elevated [32,59]. Several growth factors regulate β-cell
proliferation and pancreas endocrine cell development [11,60–62]. IGF-I, fibroblast
growth factor-7 (FGF), and FGF receptor 2IIIb mRNA concentrations are lower in
the pancreas of the IUGR fetus and are proposed to decrease pancreatic progenitor
epithelial cell expansion and subsequently reduces β-cell mass [33,63]. Insulin-like
growth factor binding protein-2 (IGFBP-2) mRNA and protein concentrations are
greater the fetal pancreas and islets of IUGR fetuses, which is postulated to antagonize
IGF actions in β-cells [63]. Hepatocyte growth factor is also mitogenic, anti-apoptotic,
and insulinotropic for β-cells, but islet endothelial cell production is reduced in
IUGR fetuses [64]. An effect that is proposed to be influenced by lower islet vascular
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endothelial growth factor A expression in IUGR islets [64]. In the IUGR fetal pancreas,
reduced expression of growth factors or greater expression of IGFBPs could explain
declines in endocrine cell mass and appear to be dependent on hypoglycemic or
hypoxemic conditions associated with placental insufficiency.
Interestingly, preservation of α-cell mass appears to be dependent on an intact
adrenal medulla in both IUGR and control fetuses, which has not been shown
previously. In intact IUGR fetuses plasma glucagon concentrations were elevated,
which has been demonstrated with an epinephrine infusion in near-term fetal
sheep [65,66]. It is postulated that α-cells, via glucagon, influence β-cell function
and islet formation, but the mechanisms are undefined [67,68]. In fetal mouse islets,
mutation of the glucagon receptor delayed β-cell differentiation and impacted the
proportion of β- to α-cells, which reduced α, β-, and δ-cell mass in adulthood [67].
Because glucagon signaling activates transcription and translation of a number of
genes, including those related to adrenergic signaling and cell proliferation, the
lack of adrenergic receptor stimulation may indirectly impair pancreatic endocrine
mass [68]. For example, glucagon receptor deficient mice have decreased IGF, which
associates glucagon signaling and the IGF axis [63,69,70]. Future work is required to
understand the interaction between adrenal function and α-cell development.
5. Conclusions
Currently, no effective intervention to ameliorate the detrimental effects of IUGR
exists. Recent reports have identified several potentially promising therapeutic strategies,
including preservation of endocrine cell mass and function in utero [71,72]. Given the
well-documented, profound effects of catecholamines on fetal development, we
postulate that targeted manipulation of the adrenergic regulation of fetal growth
will be a key component of a successful therapeutic approach. Endocrine cell
mass appears to be regulated by other elements governing IUGR and may require
supplementation of oxygen, nutrients, like amino acids, or growth factors. The results
of the current study elucidate the role of the fetal adrenal medulla and induction
of chronically elevated NE on fetal growth and endocrine cell composition in the
context of IUGR. Further work to elucidate the underlying mechanisms and identify
targets for intervention is ongoing.
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Understanding the Role of Maternal Diet on
Kidney Development; an Opportunity to
Improve Cardiovascular and Renal Health
for Future Generations
Ryan James Wood-Bradley, Sanna Barrand, Anais Giot and
James Andrew Armitage
Abstract: The leading causes of mortality and morbidity worldwide are cardiovascular
disease (high blood pressure, high cholesterol and renal disease), cancer and diabetes.
It is increasingly obvious that the development of these diseases encompasses
complex interactions between adult lifestyle and genetic predisposition. Maternal
malnutrition can influence the fetal and early life environment and pose a risk
factor for the future development of adult diseases, most likely due to impaired
organogenesis in the developing offspring. This then predisposes these offspring to
cardiovascular disease and renal dysfunction in adulthood. Studies in experimental
animals have further illustrated the significant impact maternal diet has on offspring
health. Many studies report changes in kidney structure (a reduction in the number
of nephrons in the kidney) in offspring of protein-deprived dams. Although the
early studies suggested that increased blood pressure was also present in offspring of
protein-restricted dams, this is not a universal finding and requires clarification.
Importantly, to date, the literature offers little to no understanding of when in
development these changes in kidney development occur, nor are the cellular
and molecular mechanisms that drive these changes well characterised. Moreover,
the mechanisms linking maternal nutrition and a suboptimal renal phenotype in
offspring are yet to be discerned—one potential mechanism involves epigenetics.
This review will focus on recent information on potential mechanisms by which
maternal nutrition (focusing on malnutrition due to protein restriction, micronutrient
restriction and excessive fat intake) influences kidney development and thereby
function in later life.
Reprinted from Nutrients. Cite as: Wood-Bradley, R.J.; Barrand, S.; Giot, A.;
Armitage, J.A. Understanding the Role of Maternal Diet on Kidney Development; an
Opportunity to Improve Cardiovascular and Renal Health for Future Generations.
Nutrients 2015, 7, 1881–1905.
1. Maternal Nutrition and the Kidney
A plethora of evidence exists for to support the crucial role that the environment
plays during development in determining the future health of the offspring.
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Developmental programming refers to the mechanism underlying this phenomenon and
is defined as “a permanent change in the structure or function of an organism due
to alterations in development that occur in response to an environmental stimulus
during critical periods of organ development” [1]. Particularly implicated is maternal
nutrition, which has been shown to have an effect on offspring health, with both
over- and under-nutrition having negative consequences on offspring health [2–5]. A
number of studies have provided evidence to support the hypothesis that maternal
nutritional status plays a critical role on the health and wellbeing of the fetus [6–8].
Changes to maternal nutritional status may change the ability of the mother to supply
the growing fetus with the required nutrients for optimal growth. Initial studies
during early and mid 20th Century documented the nutritional requirements during
pregnancy in humans [9,10] as well as animals [11–14], indicating the importance of a
diet containing sufficient amounts of essential nutrients (proteins, fats, carbohydrates)
and micronutrients (iron and calcium) and a sufficient caloric value. These studies
reported that protein or micronutrient restriction in the mother lead to poor offspring
growth in utero and in early postnatal life. It was much later that we began to
appreciate the biological consequences of these fetal trade-offs in response to a
sub-optimal maternal diet.
Perturbations to the maternal diet during pregnancy and/or lactation are
associated with increased risk of renal, cardiovascular and metabolic disease in
the offspring [15,16]. The developing kidney is particularly susceptible to the effects
of a suboptimal maternal diet; changes in expression of genes and proteins important
for kidney development, are likely to underlie the developmental programming of
kidney structure and physiology. This paper will review the literature to describe
the role of maternal macro- and micro-nutrient imbalance in influencing fetal and
neonatal kidney development, final nephron complement and the effect of these
structural abnormalities on adult function. The mechanisms underlying these
observations will also be discussed.
In order to understand developmental programming of renal structure and
function in humans, animal models using dietary interventions have been established.
This is primarily due to the difficulty in quantifying structure of the human kidney by
non-invasive methods. For example, the effects of maternal dietary zinc, vitamin A
and protein restriction or maternal dietary fat excess all have been shown to have a
negative impact on kidney development and later renal disease in the offspring [16–19].
Furthermore, a decrease in nephron number is hypothesized to lead to disrupted
fluid and electrolyte balance, which in turn, may lead to volume expansion and finally
glomerular hyperfiltration and systemic hypertension [20]. Importantly, restricted
maternal protein intake in pregnancy has been linked to reduced birth weight,
impaired nephron endowment, elevated blood pressure and reduced glomerular
filtration rate (GFR) [21–29].
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1.1. Maternal Protein Restriction Programs Reduced Nephron Number but the Physiological
Consequences are Unclear
Interestingly, despite there being a consistent observation from several research
groups that protein restriction during development results in a reduction in nephron
number, the follow-on effects on renal function (characterized by a measurement
of glomerular filtration rate; GFR) and blood pressure are far from clear due to
inconsistent techniques used. For example, early studies by Woods et al. [26] clearly
showed that male offspring from protein restricted dams had a 25% nephron deficit,
an 11% GFR reduction and a 10 mmHg increase in mean arterial blood pressure
compared with control rats. The calculated single nephron glomerular filtration
rate in these protein deprived offspring was 20% greater in protein-restricted than
in protein-replete controls [26]. Increases in individual nephron GFR can be an
indication of renal hyperfiltration, which can ultimately lead to further nephron loss,
perpetuating this cycle [20].
Later studies demonstrated that the phenotype induced by maternal protein-
deprivation is not invariant. Woods et al. [27] reported that maternal diet
affected offspring in a sex-specific manner; female offspring of protein restricted
Sprague-Dawley rats did not demonstrate hypertension or a nephron deficit.
This suggests that sex-dependent variations in developmental programming of
the kidney exist, are subtle and highly reliant on the concentration of dietary
protein or, potentially, timing of the intervention. Furthermore, reductions in
nephron endowment associated with intrauterine protein restriction, are not always
accompanied by hypertension. For example, Zimanyi et al. (2006) reported a
nephron deficit in Wistar-Kyoto (WKY) rats fed an 8.7% (low) protein diet (control
rats were fed a 20% protein diet) with no alteration in blood pressure or evidence
of renal hyperfiltration in the protein-restricted group [30]. Maternal low-protein
or caloric restricted diets induce low birth weight in the offspring [31,32] and this
reduction in body size may correlate with changes in cardiovascular function and
growth [33,34]. Catch-up growth may exacerbate the adverse consequences, such
as hypertension, of developmental programming [15,35,36]. Together, these data
suggest that maternal protein restriction during pregnancy most likely results in
altered kidney and morphology but the follow-on effects on physiology and function
are currently not well understood. The variability in phenotype may be resultant from
exposure to dietary insult at different points of kidney development. Knowledge of
the molecular processes involved in controlling kidney development and ultimately
adult morphology are essential for understanding the impact of maternal protein
restriction and will be discussed in further detail later in the review.
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1.2. Maternal Overnutrition Has Subtle Impacts upon Kidney Development and Function
in the Offspring
Although early programming studies focused on the role of maternal
undernutrition as models for the Dutch Hunger Winter studies [37–39], it is apparent
that overnutrition is now a major risk to human health and wellbeing. The concept
of maternal malnutrition must therefore be expanded to include excess caloric
or fatty acid intake [40–44]. Over nutrition and obesity during pregnancy is risk
factor for poor outcomes for offspring health, including the susceptibility to chronic
diseases [45,46] as well as mortality from these diseases [42,47]. Investigating
neonatal outcomes in obese mothers, Catalano et al. [48] report that maternal
obesity leads to fetuses with greater fat mass, and insulin resistance. Likewise,
Boney et al. [49] reported that children born large-for-gestational-age to obese
mothers were at a greater risk of developing metabolic syndrome. In a rabbit
model of maternal high-fat feeding (containing 13% fat), Prior et al. [50] report
greater mean arterial pressure (6 mmHg), heart rate (13 bpm) and renal sympathetic
nerve activity (1.3 nU) compared with controls. These animals were slightly heavier
throughout postnatal life and at 4 months of age had significantly heavier white
adipose tissue (64%) compared with controls. Similarly, Jackson and colleagues
report glomerular sclerosis and reduced kidney function (increased urine albumin
excretion) in offspring exposed to a maternal diet high in fructose and fat compared
to controls [51]. In a rat model of maternal high fat feeding, Armitage et al. (2005)
report no change in nephron endowment in offspring of fat fed dams compared with
controls, but these same high fat offspring had abnormal renal renin activity which
the authors hypothesized to underlie the increased mean arterial pressure [52].
The mechanism by which maternal over nutrition leads to poor health outcomes
is not fully understood. Obesity is linked to a chronic inflammatory state in both the
mother and fetus [53] and it is possible that this is mediating the changes in gene
expression and the development of the offspring.
1.3. Maternal Micronutrient Status and Its Impact on Offspring Kidney Health
In utero development is characterized by rapid cell synthesis and therefore
the developing fetus has a particularly high demand for nutritional substrate.
Micronutrients are critical co-factors in enzymatic pathways of cell synthesis in
the fetus and therefore there is a high dietary demand for these compounds during
pregnancy. Maternal deficiencies in micronutrients can have lasting detrimental
effects on the fetus and again there is evidence that the kidney is preferentially
affected. Lelievre-Pegorier et al. [54] report a 20% reduction in nephron number
in adult rats born to mothers that were fed a vitamin A deficient diet during
3 weeks prior to pregnancy, throughout pregnancy up until day 21 of gestation.
The mechanism underlying this abnormal kidney phenotype is most likely the fact
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the vitamin A is a key ligand for the cRET receptor, which controls the earliest
processes of kidney development (see Section 2 for full details).
Although the role of vitamin A is well established, other maternal micronutrient
deficiencies are associated with abnormal kidney structure or function in her
offspring; but with less clear mechanisms Lisle et al. [55] reported that diet-induced
maternal iron deficiency is associated with greater systolic blood pressure and
reduced glomerular number in adult offspring, when compared with controls.
Similarly in a model of maternal zinc restriction, Tomat and colleagues [17,56,57]
reported reduced nephron number and kidney function (determined by nitric oxide
synthase activity) as well as greater blood pressure (tail cuff plethysmography) when
compared with controls. The pathway by which different micronutrient deficiency
leads to similar morphological phenotypes remains unknown; zinc deficiency has
negative effects on branching morphogenesis; a process key to kidney development,
but can also impact upon the development of the placenta, thereby affecting the
growth potential of the entire embryo or fetus [58].
Given the great disparity in the forms of maternal dietary challenge it is
intriguing that a similar phenotype is observed in the offspring in response to
challenges as diverse as zinc or protein deficiency. This prompts the hypothesis
that fundamental processes in kidney development may be sensitive to an array of
abnormal signals from the environment, eliciting a common adaptive response and
resulting in a characteristic phenotype. In order to discuss these mechanisms, we
will first consider the factors that underpin the development of the kidney.
2. Kidney Development
2.1. Early Signaling: Specification of the Ureteric Bud and Metanephric Mesenchyme
The kidneys play a vital role in health and disease. In mammals, the kidney
develops through three successive stages (Figure 1):
The Pronephros, a rudimentary structure that develops from the lateral plate
and intermediate mesoderm and continues to develop into the mesonephros [59].
The Mesonephros, a transient organ, although the mesonephric (nephric) duct
is important for the development of the metanephros, the permanent mammalian
kidney [59].
The Metanephros which begins to develop at day 35 in human gestation,
embryonic day 11.5 (E11.5) in the mouse [60] and embryonic day E12–E13 in
rats [61,62].
Nephrogenesis is complete by 36 weeks gestation in humans, by about PN3
(postnatal) in mice [59,63] and PN7 in rats [64]. The metanephros begins to develop
when cells from the caudal end grow out from the Wolffian duct (or mesonephric
duct) forming the ureteric bud in response to growth factors (discussed in the
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following sections) secreted by the metanephric mesenchyme [59,64–66]. Under
the influence of these growth factors, the ureteric bud invades the metanephric
mesenchyme and branches forming the collecting duct system.
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Figure 1. i ney development. The ma malian kidney develops through three
stages (pronephros, mesonephros and metanephros). The pronephros develops
from the nephric duct, following which, mesonephric development occurs in
conjunction with the degeneration of the pronephros and the formation of the
mesonephric tubules. The metanephros develops from the induction of the
metanepheric mesenchyme by the ureteric bud from the nephric (Wolffian) duct.
As the ureteric bud branches into the metanephric mesenchyme, the mesenchyme
around the tips of this branching structure are induced to form renal vesicles. Renal
vesicles will progress through the comma-shaped body and S-shaped body stages
before connecting to the collecting system of the developing kidney to form a
dev loped nephron.
2.2. Genetic Control f Kidney Development
2.2.1. Control of Branching: Molecules Involved in Branching and Inhibiting
Lateral Branching
Branching morphogenesis is the dichotomous arborisation of ureteric epithelium
and is responsible for the development of the collecting duct system of the kidney.
The process of branching morphogenesis is tightly regulated by inhibitors (BMP4,
bone morphogenic protein 4), promoters (GDNF, glial derived neurotrophic factor
and c-RET, c-ret tyrosine kinase receptor) and growth factors (TGF, transforming
growth factor β superfamily). These genes are essential regulators of ureteric bud
branching and patterning [67] (Figure 2).
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Figure 2. Molecular control of early kidney development. Early development
of the metanephr s, the permanent mammalian kidney, is under tight molecular
control. Outgrowth and branching morphogenesis of the ureteric bud is controlled
by the expression of receptors Gfrα1 and C-ret to which Gdnf binds. Production
of Gdnf is under the influence of Pax2, Together these factors stimulate branching
morphogenesis of the kidney. Bmp4 inhibits lateral branching of the ureteric, which
ensures tight control of branching morphogenesis. Induction of th metanephric
mesenchyme to undergo epithelial to mesenchymal transition is influenced by Wnt4
and Hnf4α. The formation of renal vesicles (from the cap mesenchyme) is controlled
by the number of Six2 positive cells (denoting renal stem cells). Once committed to
forming a nephron, these cells begin to express Pax2, Wnt4 and Hnf4α.
Branching morphogen sis begins with the interaction between the metanephric
mesenchyme and the ureteric bud, whereby inductive signals from both embryonic
derivatives (GDNF is released from the metanephric mesenchyme and binds to its
receptors c-RET and GFRα1 at the tips of the ureteric bud) initiate the branching
process [68–72]. Tight regulation of branching morphogenesis is essential to both
kidney development and function.
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2.2.2. Control of Nephrogenesis: Epithelial-Mesenchymal Transition (EMT)
Nephrogenesis is intricately involved with branching morphogenesis. The
induction of nephron development occurs only at the tips of the developing ureteric
tree. Metanephric mesenchymal cells adjacent to the ureteric branch tips are
induced, leading to condensation, epithelialization and proliferation of the cap
mesenchyme. This induced mesenchyme expresses genes involved in extracellular
matrix formation and remodeling, cell-adhesion molecules, cell survival and
proliferation [73–75]. Under influence of the genes Pax2, Wnt4 and Hnf4α [76–79]
the induced mesenchyme undergoes epithelialisation and differentiates successively
into renal vesicles, comma-shaped bodies, S-shaped bodies before the glomerular
vascular tuft develops and attaches to the proximal tubule to finally form mature
nephrons, the functional units of the kidney.
3. Specification of Nephron Structures
The induced mesenchyme continues to develop through various morphological
steps including a comma-shaped body which is characterised by expression of
the primitive podocyte marker MNFB and genes involved with Bmp signalling
including Bmp2, 4, 7 [80–84]. Then, the comma-shaped body develops into an
S-shaped body through FGF8 and PAX2 signalling [77,85,86], linking up with the
ureteric epithelium. The S-shaped body contains the primitive cells of the glomerulus
with the invasion of angiogenic cells. With capillarisation and connecting to the
tubule (influenced by FGF2 and LIF expression) [87] the basic structure of the nephron
is complete. However, the nephron continues to undergo maturation in the form of
tubular elongation.
The metanephric mesenchyme is preserved through the maintenance of a
population of progenitor cells. This leads to sufficient support of the progression
and development of nephrogenesis. Extensive study, aimed at identifying the genes
involved in the maintenance of this cell population, has indicated the importance
of Six2, Fgf2 and Bmp7 [88,89]. Self et al. [90] reported that knockout of Six2 lead
to premature development of renal vesicles. This suggests that Six2 is required to
maintain a population of cells required for the development of progenitor cells that
form renal vesicles. The generation of Six2 positive cells is related to cortical stromal
cells expressing Foxd1, which suggests that there are complex interrelationships
between cell subsets that give rise to cells that can control the development of
structures within the kidney [91].
4. Arcade Formation
In humans nephrogenesis is complete by approximately 36 weeks of gestation,
while in rodents, nephrogenesis continues for a short time after birth [64,92]. Until
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approximately 14–15 weeks of pregnancy in humans, and the end of gestation in
rodents, each tip of the ureteric tip connects to a single nephron produced by the
surrounding mesenchyme. When arborisation of the ureteric tree is finished and
branching ceases, nephrogenesis continues by a process of nephron arcade formation
whereby multiple nephrons attached to the same tip.
A second nephron is induced by the same tip, attaches to this tip and the
connecting tubule of the older nephron shifts to the new nephron. Other nephrons
are then induced until four to seven nephrons form an arcade arrangement by being
attached to the stalk rather than just to the tips forming a common connecting
segment. Arcade formation enables deep and mid-cortical nephrons to connect
to collecting ducts located in the renal cortex [93]. After 20–22 weeks of gestation
in humans, and by the very end of kidney development in rodent, nephrons are
attached individually and directly along the entire length of the collecting duct
and are not incorporated in the arcade [63,65]. Arcade formation is thought to be
underpinned by the activity of a number of genes within the Notch pathway as they
are involved in the formation of intercellular connections (such as N-cadherin and
integrins), however further elucidation of the mechanism is required [94]. Arcade
formation is a period of rapid nephron formation and therefore disruption of kidney
development durign this critical window can have a profound impact.
5. Final Nephron Endowment
The processes controlling the time at which nephrogenesis ends are less well
described than those controlling active nephrogenesis. One hypothesis is that the
population of cells in the metanephric mesenchyme limits the magnitude of cells that
can aggregate and differentiate into nephrons. Indeed this has been proposed as
a factor underlying the large variability in nephron number in mammals [95–97].
In human, the peak period of nephrogenesis occurs during the last third of
pregnancy after the cessation of branching morphogenesis. The progenitor cells of the
metanephric mesenchyme provide the basis from which all the cells of the nephron
will differentiate. For this reason, as the population of metanephric mesenchyme
diminishes there is a natural cessation of nephrogenesis.
Nephron endowment is also dependent upon the branching capacity of the
ureteric bud, as nephrons only form adjacent to ureteric tips [54,64,98]. Retarded
branching of the ureteric epithelium can therefore manifest in a permanent reduction
of nephrons and impaired kidney growth.
In addition, factors involved in the ureteric branching and the epithelisation of
the metanephric mesenchyme including growth factors and their receptors, degrading
enzyme, proto-oncogenes, transcription factors, suppressor genes extracellular matrix,
teratogens and fetal/maternal environment are all involved in the regulation of
kidney development and can impinge on nephron endowment [61,99]. It is perhaps
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not surprising therefore that the number of nephrons in human kidneys varies widely,
from 300,000 to nearly 2 million [95,100–106].
Early Investigations Supporting Changes during Kidney Development (Genes and
Pathways, Cells and Timing)
Kidney development occurs across a number of periods of plasticity and is
therefore subject to a number of “critical periods” when external insults may produce
life-long structural and potentially functional changes in kidney. Importantly,
once kidney development is complete (at around gestational week 38 in humans
and postnatal day 8 in rat), no further nephrons are formed. Therefore, a
reduction in nephron number caused by interventions during kidney development
persists throughout life and may contribute to the burden of disease in later life.
Singh et al., 2007 showed in rats that glucocorticoid exposure during the early stages
of kidney development (embryonic day E14 to E15), permanently decreased nephron
number at PN30 [98]. This is in agreement with an earlier study by Woods et al.
(2004), which showed that maternal protein restriction during the second half of the
pregnancy, when nephrogenesis is active, is associated with a reduction in nephron
endowment [28].
Interestingly, the dietary insult need not occur during the period of active
nephrogenesis to promote a reduction in nephron number. Welham et al. 2005
demonstrate that exposure low protein maternal diet from start of the pregnancy until
day E13 in rats (prior to the onset of nephrogenesis) is sufficient to cause reduction
in glomerular numbers by approximately 20% [99]. Additionally, uteroplacental
insufficiency and reduction in litter number has similar effect during the late stage
kidney development [107,108]. Conversely, removing dietary insult during postnatal
life may improve glomerular numbers [107,109] owing to the fact that nephrogenesis
in rats proceeds until approximately PN7-8. These studies together suggest that
dietary insults during critical developmental window may cause changes, especially,
in kidney morphology, which may translate to physiological deficits.
The underlying nephron deficit observed in studies of maternal dietary
manipulation must be underpinned by changes in the expression of genes and
proteins. However, only few studies have analyzed the early gene expression
profiles of the kidney exposed to a suboptimal intrauterine environment and how
these changes lead to nephron deficit still remains unclear. Abdel-Hakkem and
colleagues (2008) induced global caloric restriction in Sprague-Dawley rats, and
analyzed 10 critical genes involved in branching morphogenesis and nephrogenesis
at E20 [110]. Genes involved in mesenchymal to epithelial transformation
(Wnt4, Wt1, Fgf2 and Bmp7) were found to be up-regulated, while genes
involved in branching morphogenesis (Pax2, Gdnf, Fgf7, Bmp4, and Wnt11) were
down-regulated [110]. Additionally, proteins of GDNF and MAPK-ERK pathway
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(e.g., Gfraα1, phosphorylated ERK1/2 and mitogen-activated protein kinase 1/2) are
altered already at E20 by maternal food restriction, indicating the importance of these
pathways for normal nephrogenesis [111]. In addition a recent study in rats, adult
offspring (16 weeks) of low-protein dams showed up-regulation of TGF-β1 and ZEB2
mRNA in kidneys displaying nephron deficit [112]. The authors further suggested
that TGF-β1 may induce ZEB2 expression further leading to down-regulation of
specific miRNAs within the glomeruli, leading to altered function [112]. These studies
suggest that aberrant gene expression of various pathways may underlie reduced
nephron endowment, however, the exact mechanism remain to be determined.
For some time, there have been suggestions that apoptosis of mesenchymal
cells in developing kidneys play a role in the reduction of nephron endowment [113].
Rats exposed to a maternal LP diet demonstrated a 20% reduction in adult nephron
number and up-regulation of apoptotic pathways (e.g., Bax and Bcl-2) [99]. Apoptotic
gene expression is also altered by maternal undernourishment [114] particularly
increased levels of proteins in late embryonic life (E20; Fas-receptor and Caspase-9)
and early postnatal life (PN1; Fas-receptor and caspase-3). These molecular changes
were accompanied with increased apoptosis in the nephrogenic zone (the area of
active nephrogenesis) of the kidney [115]. These findings demonstrated that maternal
programming might increase apoptosis in the developing kidney, which in turn may
contribute to nephron deficit.
Other mechanisms proposed to contribute to the nephron deficit, include
dysregulation of the Renin-angiotensin system (RAS). Angiotensin is essential in
forming blood vessels and tubules during nephrogenesis as well as the development
of smooth muscle in the ureter [116,117]. Thus, deficits in nephron number
may be preceded by suppression of RAS further contributing to disturbed fluid
and electrolyte balance (dysfunction of kidney) and adulthood hypertension.
Interestingly, a recent report suggests sex-specific alteration of RAS system is induced
by in utero exposure to a low-protein diet [19]. Cooke et al. 2014 showed that
expression of Angiotensin converting enzyme (ACE) was up-regulated in male, but
not in female offspring, as early as at E19 relative to control [19]. Additionally,
expression of the G-protein coupled receptor of RAS, AT1R, was observed in male
offspring at PN21 [19]. Thus, maternal low protein diet may alter nephron numbers
in the developing kidney through altered expression of the RAS system, especially in
the male offspring. Another study has highlighted the potential function of the Na
co-transporters and the RAS in the developmental programming of the kidney [109].
Na-K-Cl co-transporter and Na-Cl co-transporters display functional role in Na
reabsorption in kidney and altering levels of these co-transporter could ultimately
lead to development of adulthood hypertension.
The exact mechanism underpinning the programming of a nephron deficit
remains unknown, but most likely involve alterations in multiple pathways such
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as apoptotic-pathways, RAS and specific EMT related pathways. The mechanism
underlying these gene modulations is proposed to be heritable but not related to
mutations in the genome.
6. Maternal Diet and the Offspring Epigenome
Changed gene expression; not mutations within the genome, but changes in
the way that the genome is expressed, is controlled by epigenetic “marks” such
as gene methylation, histone modifications and the binding of DNA proteins.
These marks can act independently or in concert to modify expression of genes.
Epigenetics may play a role in developmental programming of adult disease as it
provides a mechanism that explains the change in gene expression, and therefore
the change in phenotype. These changes can be brought about through multiple
epigenetic pathways.
The maternal environment, before, during and after birth can have a significant
impact on the epigenome of the offspring [118–122]. Essentially, the epigenetic
profile of the organism is malleable during any stage of development—as during this
stage the genome is undergoing modifications and specification. Before the genome
becomes heritably stable, changes in the epigenetic profile can be incorporated into
the phenotypic profile and therefore be inherited over multiple cellular cycles and
alter the gene expression of that cell line or organ system. One of the most well
studied models of how the maternal environment affects the offspring genome
through epigenetic mechanisms, is that of the agouti mouse.
The agouti viable yellow (AvY) mouse strain has been used extensively to
demonstrate the effects of a methyl deficient diet and subsequent disease outcome.
The agouti gene is under the control of a methylation sensitive promoter and infers
a yellow coat colour and an increased preponderance to obesity, diabetes, cancer
and a shorter lifespan when expressed [123–125]. Pregnant AvY mice exposed to
methyl deficient diets give birth to pups displaying variable coat colours but the
majority of offspring present with the agouti phenotype. This phenotype occurs in
response to hypomethylation of the agouti locus and an increase in expression. The
phenotype is not reversible by later methyl donor supplementation. Where methyl
donors are freely available in the maternal diet, the agouti locus remains methylated
and the gene repressed, thus the majority of offspring have a brown coat and normal
physiology, metabolism and life expectancy.
Studies that have investigated the consequences of maternal dietary
manipulation on offspring phenotype, commonly report changes in gene expression
and major function in the offspring [126]. Epigenetic control of gene expression is
maintained and regulated by three major mechanisms: DNA methylation, histone
acetylation and non-protein coding RNA [126]. Few studies have investigated the role
of epigenetics in kidney development however there is strong evidence that relatively
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high level (i.e., changes to enzymes that have wide-reaching effects, rather than those
that control a particular process of kidney development) epigenetic changes may
drive later kidney disease. Pham et al. [127] used uteroplacental insufficiency as a
model of intrauterine growth restriction and report that CpG methylation of p53 was
altered leading to changes in expression of genes involved in apoptosis within the
kidney. While methylation is one form of epigenetic modification, there is also the
production and implication of microRNAs. The importance of Dicer; the enzyme
which cleaves non-coding microRNAs into active microRNAs during mammalian
kidney development has been shown by Nagalakshmi et al. [128]. These authors
used a transgenic mouse model (Six2Cre) where Dicer was conditionally ablated from
the progenitors of the nephron epithelium. The removal of Dicer lead to elevated
apoptosis and premature termination of nephrogenesis. Ablation of Dicer from
ureteric bud epithelium (using HoxB7Cre transgenic mice) resulted in disrupted
branching morphogenesis and the development of renal cysts [128]. Likewise in a
mouse model with the conditional knockout of Dicer1 from the developing urogenital
tract, Pastorelli et al. [129] report renal abnormalities including hydronephrosis and
cyst formation. Furthermore, offspring had increased renal apoptosis combined
with reduced glomerular number. These results illustrate the importance of miRNA
function during kidney development.
Offspring of rats whose mothers were fed protein restricted diets in pregnancy
and lactation demonstrate global changes to the methylation status of whole organs,
and important gene pathways that play a major role in kidney development and adult
function [130–132]. These studies have further investigated these effects to show
that important enzymes involved in setting the methylation profile of the genome
are altered (specifically DNMT1, which is involved in maintaining the methylation
status of the genome during replication), as well as receptors involved in protein
metabolism [133,134]. Given that methylation is highly dependent on dietary intake
of methyl donors, it has now been demonstrated that when either the maternal or
early postnatal diet are supplemented with methyl donors (such as glycine and
folic acid), the deleterious cardiovascular effects of maternal protein restriction
may be at least partially ameliorated or rescued. Song et al. 2010, suggest that a
number of genes underlying ureteric bud formation (including elements of the renin
angiotensin system) are controlled by histone acetylation; certainly HDAC inhibitors
have a negative impact on kidney development. Interestingly, despite the intense
interest in determining epigenetic changes in models of maternal or developmental
programming, there is still little direct evidence for an epigenetic modification in the
development of kidney disease or morphological abnormality [135]. This is likely
due to the complex interplay between histone acetylation, gene methylation and
miRNA post-translational modifications.
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7. The Impact of Nephron Endowment on Adult Cardiovascular
and Renal Health
As nephrons are the functional units of the kidney a reduction in number is
theoretically detrimental to kidney function. Low nephron number may result
in adult kidney dysfunction including hypervolaemia, electrolyte balance and
toxaemia [136] and is implicated in hypertension and renal disease [137].
The mechanism underlying this link between nephron number and
cardiovascular/renal function was first described and popularized by
Brenner et al. [20]. Brenner hypothesised that a reduction in renal filtration
surface area (due to either lower nephron number or lower filtration surface area
per glomerulus) would lead to limited sodium excretion, secondary hypervolaemia
which promotes an increase in glomerular capillary pressure. Over time this
excessive pressure results in glomerular sclerosis [20], further reductions filtration
surface area a further increase in systemic blood pressure.
There is strong evidence to support the hypothesis that there is an associate
between nephron number and blood pressure but due to fact that present methods
for estimating human nephron endowment can only be conducted post mortem it
is not possible to show causation. Keller et al. [105] reported an inverse association
between nephron endowment and hypertension in humans. However, it was
unclear whether the lower numbers of nephrons in subjects with a history of
hypertension were responsible for hypertension or a consequence of hypertension.
Keller et al. [105] analysed kidneys obtained at autopsy from Caucasian subjects
(normotensive and hypertensive patients) between the age of 35 and 59 years,
and found that 10 normotensive subjects had a median glomerular number of
1,429,200 while 10 hypertensive subjects had a median glomerular number of 702,379.
Although it was unclear whether the lower numbers of nephrons in subjects with
a history of hypertension were responsible for hypertension or a consequence of
hypertension. The hypertensive patients showed very few obsolescent glomeruli
which may suggest that the hypertension had not caused the deficit in nephron
number. Douglas-Denton et al. [100] also reported that hypertensive subjects
have significantly fewer nephrons (746,468 ± 133,240) than normotensive subjects
(1,402,360 ± 346,357).
Low birth weight (LBW) is often used as an indication of intra-uterine growth
restriction and has been correlated with the incidence of kidney disease [138,139].
For example, Lackland [138] provided evidence that kidney failure and end-stage
renal disease demonstrate a racial and geographic disparity. This concept is
supported by findings of Hoy et al. [101] that the kidneys of Australian Aboriginals
contain 30% fewer nephrons than those of non-indigenous Australians. This
phenomenon may explain in part why Australian Aborigines in remote areas
have a much greater incidence of renal disease (as well as hypertension and
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cardiovascular disease) than non-Aboriginal peoples in remote areas [140]. A study
by Lackland [141] focused on the incidence of hypertension, demonstrating that
adults born with LBW had a much higher systolic blood pressure and were more
likely to suffer from hypertensive-related end-stage renal disease than those of
normal birth weight. Investigating the developing kidney in the human fetus,
Lori et al. [142] report that IUGR was associated with reduced renal volume compared
to gestational-age adjusted controls. While renal volume can be indicative of nephron
number, no technique is available for in situ measurement of human fetal nephron
number. The investigation by Lori et al. does provide information on how the
human intrauterine environment impacts directly upon the kidney and the finding
is repeatable. A more recent investigation by Wang et al. [143] in human fetal
kidneys also reports that fetal growth restriction is associated with smaller kidneys
which appears to be caused by increased apoptosis and reduced expression of renin
and angiotensinogen.
Although the limited human data appear to be supportive of an association
between low birth weight and reduced kidney size this association is not always
observed in animal studies [144] where tighter control over experimental conditions
and potential bias are possible. In support of this hypothesis Langley-Evans et al. [145]
reported that a deficit of 13% in nephron number was associated with a 13 mmHg
elevation in arterial pressure of protein-restricted offspring (Wistar rats exposed to a
9% protein diet, while controls had a normal 18% protein diet). On the other hand,
no relationship between nephron number and blood pressure was found in female
offspring from protein restricted Sprague-Dawley dams (on a 8.5% protein diet, while
controls were on a 19% protein diet) by Woods et al. [27].
Investigations into the relationship between nephron number and cardiovascular
health do not support the Brenner Hypothesis unconditionally (see review by Kett
and Denton [146]. Nephron deficiency is not always associated with elevated arterial
pressure. For example, Zimanyi et al. (2006) reported a nephron deficit in offspring
of WKY rats fed an 8.7% (low) protein diet (while control rats were fed a 20% protein
diet) but blood pressure and renal filtration were normal [30]. The absence of change
in blood pressure between the dietary groups may also be a product of offspring
exposed to maternal protein restriction failing to demonstrate catch-up growth.
Moreover, reduced nephron endowment does not necessarily underlie systemic
high blood pressure, in a model of hypertension unrelated to maternal nutrition.
Investigating the Spontaneously Hypertensive Rat (SHR), Black and colleagues [147]
report no change in nephron number but a 29 mmHg increase in blood pressure
(measured via tail cuff plethysmography). This is in contrast to the findings of
Skov et al. [148] who reported reduced nephron number in the SHR compared to
normotensive WKY rats. While it is understood that the hypertension that develops
in the SHR is multifactorial, the relationship that nephron endowment may play is
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unclear. The results from these studies indicate that the relationship between nephron
number and blood pressure is not direct and may be influenced by other factors
including the renin-angiotensin-aldosterone systems and aberrant sympathetic nerve
activity. The other potential confounding factor is the blood pressure measurement
technique. Tail-cuff plethysmography is known to induce a stress response in animals
that may lead to increased blood pressure [149,150]. Further studies are required
using less stressful techniques, such as radiotelemetry [149,150], to further elucidate
the underlying mechanism of hypertension within the SHR.
Tonkiss and colleagues, using radiotelemetry devices, reported that malnourished
rat offspring (6% maternal LP diet) demonstrated a 4 mmHg increase in diastolic
blood pressure compared with controls, however offspring of protein-restricted rats
elicited a greater cardiovascular arousal response (increased systolic pressure) to
acute stress compared with controls [151]. This same study did not report nephron
number in malnourished offspring, but did find that malnourished offspring weighed
the same as controls at the time of blood pressure measurement. In a rat model of
maternal caloric restriction, Brennan and colleagues reported a nephron deficit and no
change in adult blood pressure (recorded using radiotelemetry) [152]. Lim et al. [153]
report that in rats exposed to maternal protein restriction that while there was no
change in mean arterial pressure (consciously measured with indwelling catheters)
there was greater filtration of the kidney. Therefore, the question still remains
about the relative contribution of postnatal growth and nephron number to adult
blood pressure.
Although multiple studies have reported low nephron number in offspring
of dams exposed to a protein-restricted diet, the renal physiological effects of this
reduction in nephron number have received less attention and findings have been
contradictory. Alwasel and Ashton [154] reported no change in GFR in male or
female rat offspring exposed to maternal LP diet (no nephron number reported),
while Nwagwu et al. [23] reported reduced GFR in rat offspring exposed to maternal
LP diet (no nephron number reported). Hoppe et al. [22] using a model of life
long protein restriction in rats reported no change in GFR with a 31% reduction in
nephron number.
Sidduque et al. (2014) show no association between hypertension and low
nephron number in the offspring of Sprague Dawley rats fed 6% protein from 12 days
of gestation [109]. Neonates of these dams were cross-fostered and studied. Offspring
exposed to a high protein diet (20% w/w) in utero and cross-fostered to a mother fed
a low-protein (6% protein) diet showed increased blood pressure and expression of
the co-transporters after birth relative to control animals (20% protein throughout
life) [109]. Surprisingly, these animal maintained similar nephron number and
blood pressure compared with controls [109]. On the other hand, animals that were
maintained on a protein restricted diet throughout the pregnancy and suckling
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recorded increased blood pressure, increased expression of renin and ANGII, had
reduced nephron number, but did not show alteration in the Na co-transporter
expression relative to controls [109]. This study indicates that dietary impact at
different time points indeed could affect kidney development through different
pathways. In summary, suboptimal maternal diet may alter gene and protein
expression in the developing kidney leading to permanent reduction of nephron
number but whether or not this results in hypertension is clearly dependent on other,
yet to be identified factors.
There is also evidence that pre- vs. post-natal nutritional planes have differing
effects on kidney development in altricial species such as rats and mice. Jennings
and colleagues used a cross-fostering method in rats to compare the contributions
of the fetal and postnatal environments on offspring growth [155]. Pups that were
exposed to protein restriction in utero then switched to a control dam post birth
underwent catch-up growth and had similar weight to control pups by PN21,
while pups that were maintained on a low protein diet postnatally did not. In
fact, pups that underwent catch-up growth had reduced longevity. Investigations
into catch-up growth also report changes in insulin sensitivity [156] and reduced
β-cell proliferation and islet size during fetal life [157]. Wlodek et al. [107] using an
uteroplacental insufficiency model in rats to induce fetal growth restriction report
that offspring that were growth restricted in utero and postnatally had higher
blood pressure as well as a nephron deficit, compared to controls. Meanwhile,
offspring that were restricted in utero and were then cross-fostered to control dams
did not have a reduced nephron endowment or increased blood pressure [107].
These studies indicate that postnatal nutrition of offspring is critical to the
development of disease. Many studies that have linked maternal low protein diet to
reduced nephron endowment and hypertension also observed accelerated growth
postnatally [26,158,159].
The difficulty in translating these rodent studies back to the human condition
is that rats and mice are born immature and nephrogenesis proceeds for up to a
week postnatal. In humans, this process of nephrogenesis occurs in utero until
38 weeks gestation, therefore the postnatal period has little impact upon term infants.
In the premature infant, however, the situation may be very different because these
children are born whilst nephrogenesis is ongoing. Moreover, in many cases, the
supply of breast milk is constrained in mothers of premature infants and formula
supplementation may be required.
Investigating the impact of preterm birth in humans on kidney development and
function, Gubhaju et al. 2014 report that renal function was affected by gestational
age and may be linked to renal maturity [160]. Assessing the maturity of preterm
kidneys, Sutherland et al. (2011) report that while there is a renal maturation
in infants born preterm (before the cessation of nephrogenesis) this accelerated
212
maturation is associated with morphologically small glomeruli [161]. These data
further illustrate that in both animals and humans there is great potential for the
kidney to be influenced by the environment, whether that be maternal or postnatal.
8. Conclusions
The dietary intake and nutritional status of pregnant and breastfeeding mothers
is a major public health concern given the robust evidence from human and animal
studies which indicates that a healthy pregnancy (normal birth weight and absence of
congenital defects) predicts a healthy start to life that will continue into the offspring’s
adult life. Indeed, maternal malnutrition is still a major health concern world-wide, in
both developing nations (malnutrition) and developed nations (over-nutrition). The
consequence of poor maternal diets can potentially affect future generations, leading
to them developing hypertension, diabetes, obesity or the metabolic syndrome.
Of particular interest is the susceptibility of the kidney to the in utero environment
because this organ develops slowly and across most of fetal life. The molecular
control of the kidney has been well-reported (www.gudmap.org), however the impact
of maternal diet on these molecular targets not been. It remains to be discovered
when the maternal diet influences kidney development, what molecular processes are
effected and if the phenotype can be rescued or halted. While the current generation’s
in utero experience cannot be altered, there are protective measures that can be
encouraged to minimise the potential for the in utero environment to be deleterious
to future health.
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Lower Protein-to-Carbohydrate Ratio in
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Age Four Years
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Abstract: The prenatal environment can influence development of offspring blood
pressure (BP), which tracks into adulthood. This prospective longitudinal study
investigated whether maternal pregnancy dietary intake is associated with the
development of child BP up to age four years. Data are from 129 mother-child
dyads enrolled in the Women and Their Children’s Health study. Maternal diet was
assessed using a validated 74-item food frequency questionnaire at 18 to 24 weeks
and 36 to 40 weeks, with a reference period of the previous three months. Child
systolic and diastolic BP were measured at 3, 6, 9, 12, 24, 36 and 48 months,
using an automated BP monitor. Using mixed-model regression analyses adjusted
for childhood growth indices, pregnancy intakes of percentage of energy (E%)
polyunsaturated fat (β coefficient 0.73; 95% CI 0.003, 1.45; p = 0.045), E% omega-6
fatty acids (β coefficient 0.89; 95% CI 0.09, 1.69; p = 0.03) and protein-to-carbohydrate
(P:C) ratio (β coefficient −14.14; 95% CI −27.68, −0.60; p = 0.04) were associated
with child systolic BP trajectory up to 4 years. Child systolic BP was greatest at
low proportions of dietary protein (<16% of energy) and high carbohydrate (>40%
of energy) intakes. There may be an ideal maternal macronutrient ratio associated
with optimal infant BP. Maternal diet, which is potentially modifiable, may play an
important role in influencing offspring risk of future hypertension.
Reprinted from Nutrients. Cite as: Blumfield, M.L.; Nowson, C.; Hure, A.J.;
Smith, R.; Simpson, S.J.; Raubenheimer, D.; MacDonald-Wicks, L.; Collins, C.E. Lower
Protein-to-Carbohydrate Ratio in Maternal Diet is Associated with Higher Childhood
Systolic Blood Pressure up to Age Four Years. Nutrients 2015, 7, 3078–3093.
1. Introduction
The worldwide burden of cardiovascular disease (CVD) has substantially
increased, to cause an estimated 17.3 million deaths in 2008 [1]. It is forecast that
by 2030, more than 23 million people will die annually from CVDs [2]. Elevated
blood pressure (BP) and childhood adiposity are independent predictors of adult
hypertension and CVD [3]. Both obesity and hypertension are increasingly prevalent
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in the pediatric population, with 42 million children under five estimated to be
overweight in 2013 and 2% to 5% of children considered hypertensive globally [2].
There is strong evidence across diverse populations for tracking of BP from childhood
into adulthood [4]. Even short periods of hypertension in childhood increases the
adult risk of hypertension [1]. Thus early prevention of elevated BP is an important
global public health goal.
Variations in maternal diet during pregnancy may lead to elevated offspring risk
in adulthood for hypertension and obesity. Both human and animal studies provide
compelling evidence suggesting a link between maternal nutritional status and
offspring cardiovascular function [5]. Animal studies provide indisputable evidence
that maternal protein restriction or a global reduction in dietary intake during
pregnancy can influence offspring cardiovascular function [5–8]. Studies have mainly
focused on interventions in pregnant rodents, although several dietary intervention
studies in pregnant sheep suggest commonality among species [5]. Raised blood
pressure has frequently been reported in offspring of nutritionally deprived animals
and those fed a low protein-to-carbohydrate (P:C) ratio diet during pregnancy [5,9].
Prenatal exposure to protein restriction or dietary global restriction in animal models
has produced offspring with abnormalities in vascular function in isolated resistance
arteries [5]. However in recent cross-sectional studies of children born in developed
countries, associations between changes in diet during pregnancy with childhood BP
have been small, or negligible [10]. A recent Finnish study found systolic BP in four
year old children was positively associated with maternal pregnancy carbohydrate
and fat intakes [11]. The same group also reported a U-shaped relationship between
both maternal carbohydrate and monounsaturated fat intakes and infant BP at six
months [12].
The escalation in prevalence of maternal and child obesity increases the public
health significance of determining the extent to which maternal diet can predict
offspring BP [10]. In healthy weight pregnant women exposed to a variety of dietary
and/or supplement regimes there was minimal impact on offspring BP, compared to
women who experienced lifestyle and nutritional limitations similar to conditions
in World War II [12,13]. However, much stronger associations have been reported
on later BP when birthweight and/or accelerated postnatal growth were considered,
or adjustment for current body weight [13]. This highlights the inter-relationships
between childhood growth, current body weight and cardiovascular control.
Our previous work identified that across a wide range of species optimal ratios
of macronutrients exist and that protein intake is a critical determinant of total energy
intake [14,15]. Animal models confirm that the ratio of dietary P:C impacts on aging
and disease, with indirect evidence from human models suggesting the P:C ratio
is a primary determinant of health [16]. We have demonstrated a link between
maternal dietary ratio of protein to non-protein energy to variations in offspring
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body composition [15]. In human pregnancy, maternal macronutrient profile was
associated with fetal adiposity and fat distribution [14]. Here we have examined the
link between maternal macronutrient ratios and childhood blood pressure trajectory.
We hypothesized that after adjustment for potential confounders and growth indices,
child systolic BP up to age four years would be associated with maternal pregnancy
macronutrient intake and protein-to-carbohydrate (P:C) ratio.
2. Experimental Section
2.1. Sample
The sample is from the Women and Their Children’s Health (WATCH) study
(n = 179). WATCH is a prospective, longitudinal cohort investigating whether
maternal nutrition is an important predictor of offspring outcomes including growth,
body composition and childhood cognition [17]. The WATCH study was initiated
in July 2006 in Newcastle, Australia. Pregnant participants were recruited from
the antenatal clinic at the John Hunter Hospital from July 2006 to June 2008. A
consent rate of 61% was achieved for pregnant women who were approached [18].
No exclusion criteria were used during recruitment. Women attended study visits
during pregnancy at 19, 24, 30, and 36 weeks of gestation. Postnatal follow-up of
women and their children occurred at 3-month intervals during the first year after
birth and annually thereafter, until age 4 years.
The characteristics of the WATCH cohort have been reported previously [19,20].
The WATCH study contained a higher proportion of women with post-school
qualifications and socioeconomic advantage, but a similar proportion of overweight/
obese and of indigenous ethnicity as the Australian population [14,20]. Significant
differences were also previously found between women with available dietary data
(n = 156) and women without dietary data (n = 23). Women without dietary data
were less likely to be married or in a de facto relationship (p = 0.03) and more likely
to be of socio-economic disadvantage (p = 0.04) and to have had a preterm delivery
(p = 0.001) [14].
Dietary and BP data from 129 mother-child dyads were available for the current
analysis. All participants gave written informed consent and ethical approval for
the study was obtained from the Hunter New England Human Research Ethics
Committee (06/05/24/5.06). Recruitment, withdrawals and participant attendance
during pregnancy has previously been described [20].
2.2. Data Collection
Details of the data collection have been described elsewhere [20]. Demographic
and social data were collected during the first study visit using questions modeled on
those in the Women’s Health Australia, Australian Longitudinal Study on Women’s
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Health survey. Pre-pregnancy weight was self-reported at either the first antenatal
clinic visit at 14 weeks gestation or at the first study visit. Dietary data during
pregnancy were collected between 18 to 24 weeks and again at 36 to 40 weeks
gestation using a validated 74-item food frequency questionnaire (FFQ), the Dietary
Questionnaire for Epidemiological Studies. This tool was previously validated
against weighed-food records in young women [21]. The FFQ includes food and
beverage data but does not ask about vitamin or mineral supplement use. The dietary
intake reference period was the previous three months. Therefore, dietary data
collected between 18 to 24 weeks and 36 to 40 weeks gestation referred to a reference
period of 6 to 24 weeks gestation (early pregnancy) and 24 to 40 weeks gestation
(late pregnancy), respectively. Positive moderate to strong pairwise correlations have
been previously reported between all dietary variables in early and late pregnancy
(0.46 < r < 0.78; p < 0.001) [14]. Therefore, maternal dietary intakes during pregnancy
were expressed as the mean of intakes during early and late pregnancy.
Child systolic and diastolic BP were measured at each postnatal study visit using
an automated DINAMAP PRO 300V2 BP monitor (GE Healthcare, Helsinki, Finland)
under standardised conditions. Maternal and child anthropometric measurements
were taken at every study visit by a team of Accredited Practising Dietitians, each
with Level One Anthropometry certification from the International Society for the
Advancement of Kinanthropometry (ISAK). Weight and height were measured in
accordance with the ISAK protocol.
2.3. Statistical Analysis
The main outcome measures were child systolic and diastolic BP (mm/Hg).
Dietary predictors included maternal intake of energy yielding nutrients (energy,
protein, total fat, saturated fatty acids (SFA), monounsaturated fatty acids,
polyunsaturated fatty acids (PUFA), omega-3 (n-3) fatty acids, omega-6 (n-6) fatty
acids, total carbohydrate, sugars, starch and fibre) expressed as total intakes (grams),
percentage of total energy intake, and the ratio of P:C intake and n-6:n-3 intake.
Nutrient intakes were adjusted for energy using the residual method [22]. Childhood
growth indices included birthweight and BMI z-score. BMI was converted to z-scores
using the WHO Child Growth Standards reference data [23].
Normally distributed data were reported as mean ± SD and non-parametric
data as median, 25th and 75th percentiles. Comparisons were performed using
two-sample t-tests, the Kruskal-Wallis test or the chi-squared statistic. Linear
mixed-models used longitudinal data to determine whether maternal macronutrient
intakes during pregnancy were associated with the development of childhood BP up
to 4 years. Independent predictor variables were assessed for colinearity.
In preliminary univariate analyses, maternal age, pre-pregnancy weight,
education, parity, smoking status, weight gained during pregnancy, preterm delivery,
228
marital status, ethnicity and child gender were not significant predictors for
childhood systolic or diastolic BP (p < 0.2) and did not remain in multivariate models
(data not shown). Analyses were conducted using: (i) unadjusted data; (ii) data
adjusted for maternal energy intake and child birthweight; and (iii) data adjusted
for maternal energy intake, birthweight and child BMI z-score. All analyses were
repeated with and without women who reported diabetes or hypertension during
pregnancy. The main findings did not change with the exclusion of women who
reported diabetes (n = 8) or hypertension (n = 10) during pregnancy, thus analyses
were not adjusted for these conditions. To address potential dietary misreporting,
the pregnancy energy cut-off values recommended by Meltzer et al. (2008) [24]
were applied, by excluding those who reported daily energy intakes <4.5 or
>20.0 MJ/day [24].
Parametric response surfaces for mean systolic BP were fitted over
macronutrient intake arrays and then visualized by using nonparametric thin-plate
splines. This approach allowed the complex relationship between infant systolic
BP up to four years and the two major axes of percentage protein and percentage
carbohydrate in the maternal diet to be visualized.
All data manipulation and statistical analyses were performed using Intercooled
Stata 11.2 (Stata, College Station, Texas, USA). Graphics were performed using R
software. p-Values < 0.05 were considered statistically significant.
3. Results
The final sample included 129 mother and child dyads. Maternal characteristics
are presented in Table 1. There were no significant differences between individuals in
this sub-study (n = 129) and the total sample of women and children in the WATCH
cohort (n = 179).
The BP and growth characteristics of children are summarized in Table 2.
Compared with female children, male children became significantly heavier (p < 0.01)
and longer (p < 0.05) between birth and 24 months, and had a larger BMI between
3 and 12 months (p < 0.01). No significant differences were found between child
gender and BP measurements.
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Table 1. Maternal characteristics of the participants in the Women and Their
Children’s Health Study.
Characteristic Women (n = 129)
Age (year) 29.1 ± 5.4 1
Height (cm) 165.1 ± 6.5
Born in Australia [n (%)] 2 120 (93.0)
Aboriginal, not Torres Strait Islander [n (%)] 4 (3.1)
Married or in de facto relationship [n (%)] 114 (88.4)
Education [n (%)] 3 96 (74.4)
Socioeconomic status, IRSAD 4 decile <= 5 [n (%)] 5 37 (28.7)
Smoked during pregnancy [n (%)] 15 (11.6)
Prepregnancy weight (kg) 65.0 (58.0, 79.0) 6
Weight gain during pregnancy (kg) 12.0 (8.9, 17.0)
Nulliparous [n (%)] 59 (45.7)
Preterm delivery before 37 weeks of gestation [n (%)] 9 (7.0)
1 Mean ± SD (all such values); 2 Other countries include England (n = 3), Belgium (n = 1),
Canada (n = 1), Malaysia (n = 1), New Zealand (n = 1), Papua New Guinea (n = 1) and
the United States (n = 1); 3 Maternal education level ≥Australian year 12 high school
certificate; 4 IRSAD, index of relative socioeconomic advantage and disadvantage; 5
Relative disadvantage and lack of advantage based on postcode (IRSAD decile ≤ 5), ([25]);
6 Median; 25th and 75th percentiles in parentheses (all such values).
Table 2. Characteristics of children in the Women and Their Children’s Health Study.
Child Characteristics Males Females P 1
Birth
Gender [n (%)] 67 (51.9) 62 (48.1) 0.66
Gestational age (week) 39.5 ± 1.3 2 39.3 ± 2.1 0.45
Birthweight (g) 3618.7 ± 552.7 3318.2 ± 591.2 0.003
Length (cm) 51.9 ± 2.8 50.3 ± 4.0 0.01
3 months
n 64 60
Weight (kg) 6.5 ± 0.8 5.7 ± 0.7 <0.001
Length (cm) 63.0 ± 2.5 60.6 ± 2.8 <0.001
BMI 16.1 ± 1.5 15.2 ± 1.5 <0.001
BMI z-score −0.5 (−1.2, 0.2) −0.7 (−1.7, −0.1) 0.26
n 20 21
Systolic blood pressure (mmHg) 96.0 (82.5, 104.5) 3 96.0 (86.0, 103.0) 0.77
Diastolic blood pressure (mmHg) 60.0 (34.0, 66.5) 55.0 (47.0, 59.0) 0.68
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Table 2. Cont.
Child Characteristics Males Females P 1
6 months
n 61 53
Weight 8.2 ± 1.1 7.3 ± 1.0 <0.001
Length 69.3 ± 2.9 66.4 ± 3.0 <0.001
BMI 17.0 ± 1.4 16.5 ± 1.5 0.03
BMI z-score −0.2 (−0.9, 0.4) −0.3 (−0.9, 0.3) 0.72
n 36 36
Systolic blood pressure (mmHg) 101.0 (96.0, 108.0) 103.0 (95.5, 109.0) 0.78
Diastolic blood pressure (mmHg) 57.0 (51.0, 65.5) 52.5 (45.5, 62.0) 0.30
9 months
n 54 56
Weight 9.5 ± 1.4 8.5 ± 1.0 <0.001
Length 73.9 ± 2.9 71.3 ± 2.9 <0.001
BMI 17.1 ± 1.7 16.6 ± 1.2 0.03
BMI z-score −0.1 (−0.9, 0.8) −0.04 (−0.7, 0.5) 0.76
n 40 48
Systolic blood pressure (mmHg) 103.0 (98.0, 109.0) 101.5 (93.5, 110.0) 0.78
Diastolic blood pressure (mmHg) 55.5 (49.5, 62.0) 56.5 (46.0, 61.5) 0.54
12 months
n 57 55
Weight 10.5 ± 1.3 9.3 ± 1.0 <0.001
Length 78.0 ± 3.3 75.1 ± 2.9 <0.001
BMI 17.1 ± 1.4 16.4 ± 0.9 0.001
BMI z-score 0.1 (−0.5, 0.8) 0.1 (−0.5, 0.5) 0.24
n 37 38
Systolic blood pressure (mmHg) 98.0 (94.0, 106.0) 98.5 (94.0, 108.0) 0.81
Diastolic blood pressure (mmHg) 58.0 (50.0, 66.0) 56.0 (46.0, 62.0) 0.59
24 months
n 47 44
Weight 13.5 ± 1.6 12.6 ± 1.8 0.009
Length 89.1 ± 4.9 86.7 ± 4.2 0.02
BMI 17.0 ± 1.3 16.7 ± 1.3 0.37
BMI z-score 1.0 (−0.1, 1.4) 0.7 (0.06, 1.2) 0.97
n 35 32
Systolic blood pressure (mmHg) 100.0 (96.0, 105.5) 98.0 (92.0, 104.0) 0.13
Diastolic blood pressure (mmHg) 61.0 (56.0, 65.0) 61.0 (58.0, 64.5) 0.63
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Table 2. Cont.
Child Characteristics Males Females P 1
36 months
n 42 38
Weight 15.4 ± 1.8 14.4 ± 2.8 0.06
Length 97.4 ± 5.7 95.0 ± 7.3 0.11
BMI 16.1 ± 1.4 15.8 ± 1.5 0.34
BMI z-score 0.4 (−0.5, 1.3) 0.2 (−0.3, 0.7) 0.60
n 36 33
Systolic blood pressure (mmHg) 103.0 (98.5, 111.0) 104.0 (97.0, 113.0) 0.87
Diastolic blood pressure (mmHg) 63.0 (59.5, 66.0) 62.0 (58.0, 67.0) 0.90
48 months
n 40 45
Weight 17.7 ± 2.1 17.4 ± 3.0 0.61
Length 105.3 ± 7.4 103.6 ± 5.8 0.24
BMI 15.1 ± 1.3 16.1 ± 2.5 0.61
BMI z-score 0.4 (−0.2, 1.3) 0.3 (−1.2, 0.8) 0.69
n 26 28
Systolic blood pressure (mmHg) 101.0 (95.0, 114.0) 106.0 (94.0, 115.0) 0.72
Diastolic blood pressure (mmHg) 65.0 (59.0, 66.0) 65.0 (58.5, 67.5) 0.89
Systolic blood pressure up to 4
years (mmHg) 101.5 (97.0, 106.3) 101.6 (94.7, 106.3) 0.78
Diastolic blood pressure up to 4
years (mmHg) 60.3 (55.3, 63.5) 57.0 (50.3, 61.0) 0.01
1 p Values were derived by 2-sample t tests or the Kruskal-Wallis test; 2 Mean ± SD (all
such values); 3 Median; 25th and 75th percentiles in parentheses (all such values).
Maternal dietary composition during pregnancy is summarized in Table 3.
Results of the mixed-model regression analyses examining relationships between
pregnancy diet and child systolic BP up to age 4 years are summarized in Table 4.
The components of maternal diet associated with child systolic BP included: PUFA
(% of energy), specifically n-6 fatty acids (% of energy), and the P:C ratio (Table 4).
Median (25p, 75p) P:C ratio was 0.43 (0.38, 0.48). Therefore, for each 0.1 unit decrease
in the P:C ratio during pregnancy, child systolic BP increased by 1.41 mmHg (Table 4).
Similar findings were observed in the comparison of energy-adjusted values (Table 4).
In subgroup analyses, maternal smoking status did not have a significant effect
on childhood systolic BP (data not shown). There were no relationships between
maternal pregnancy diet and child diastolic BP up to 4 years.
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Table 3. Maternal dietary composition during pregnancy (n = 129) 1.
Absolute Values Grams % of Energy
Protein 81.4 (64.8, 105.6) 19.1 (17.4, 20.9)
Total fat 73.0 (57.7, 95.8) 37.6 (34.7, 40.0)
SFA 31.1 (23.2, 41.7) 15.9 (13.6, 18.4)
PUFA 11.2 (7.8, 13.7) 5.0 (4.0, 6.2)
n-3 Fatty acids 1.4 (1.0, 1.7) 0.7 (0.6, 0.8)
n-6 Fatty acids 9.2 (6.2, 11.9) 4.2 (3.3, 5.3)
MUFA 25.4 (19.5, 33.2) 13.0 (11.8, 13.9)
Total carbohydrate 185.3 (153.7, 244.0) 41.5 (39.3, 44.4)
Sugars 92.1 (72.2, 115.1) 19.5 (17.0, 22.1)
Starch 99.2 (79.3, 125.1) 21.2 (19.8, 23.5)
Fibre 19.2 (14.5, 24.9) 2.1 (1.7, 2.4)
Energy (kJ) 7298.4 (5890.1, 9234.2)
P:C ratio 0.43 (0.39, 0.48)
n-6:n-3 ratio 6.38 (5.22, 7.78)
Energy-adjusted values Grams
Protein 121.9 (89.3, 128.6)
Total fat 103.7 (97.4, 109.1)
SFA 44.3 (39.6, 49.2)
PUFA 13.5 (11.5, 16.2)
n-3 Fatty acids 1.9 (1.7, 2.1)
n-6 Fatty acids 11.1 (9.6, 13.9)
MUFA 36.3 (34.4, 38.2)
Total carbohydrate 250.0 (240.0, 264.3)
Sugars 117.9 (106.1, 129.7)
Starch 128.2 (116.4, 137.4)
Fibre 26.7 (23.4, 30.0)
P:C, protein-to-carbohydrate. n-6:n-3, omega-6-to-omega-3. 1 All values are medians; 25th
and 75th percentiles in parentheses.
The association between maternal P:C ratio during pregnancy and child mean
systolic BP up to 4 years is presented in Figure 1. The surface plot highlighted that
mean child systolic BP remained constant with changing proportions of dietary fat,
but was influenced by the P:C ratio of maternal diet during pregnancy. A maternal
diet with a P:C ratio of 0.29 corresponded with a child systolic BP of 104.5, compared
with a systolic BP of 97.5 for a P:C ratio of 0.9. Child systolic BP was greatest at low
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The association between maternal P:C ratio during pregnancy and child mean systolic BP up to  
4 years is presented in Figure 1. The surface plot highlighted that mean child systolic BP remained 
constant with changing proportions of dietary fat, but was influenced by the P:C ratio of maternal diet 
during pregnancy. A maternal diet with a P:C ratio of 0.29 corresponded with a child systolic BP of 
104.5, compared with a systolic BP of 97.5 for a P:C ratio of 0.9. Child systolic BP was greatest at low 
proportions of dietary protein (<16% of energy) and high carbohydrate (>40% of energy) intakes. 
 
Figure 1. Effects of maternal macronutrient intake during pregnancy on child mean systolic 
blood pressure up to four years. Plotted onto arrays of maternal dietary macronutrient 
composition points are fitted surfaces for the response variable (child mean systolic blood 
pressure). The isolines for the child mean systolic blood pressure rise in elevation from dark 
blue to dark red. A maternal diet with a P:C ratio of 0.29 corresponded with a child systolic 
BP of 104.5, compared with a systolic BP of 97.5 for a P:C ratio of 0.9. Child systolic BP 
was greatest at low proportions of dietary protein (<16% of energy) and high carbohydrate 
(>40% of energy) intakes. 
4. Discussion 
This is the first prospective study to longitudinally examine the relationship between maternal diet 
during pregnancy and the trajectories of child BP up to four years. Results indicate that lower P:C ratios 
in maternal diet are associated with increased child systolic BP up to four years of age. Childhood 
systolic BP was also positively associated with maternal intake of PUFA and n-6 fatty acids, despite 
remaining constant with changing total fat intake. 
 













































Figure 1. Effects of maternal macronutrient intake during pregnancy on child mean
systolic blood pressure up to four years. Plotted onto arrays of maternal dietary
macronutrient composition points are fitted surfaces for the response variable
(child mean systolic blood pressure). The isolines for the child mean systolic blood
pressure rise in elevation from dark blue to dark red. A maternal diet with a P:C
ratio of 0.29 corresponded with a child systolic BP of 104.5, compared with a systolic
BP of 97.5 for a P:C ratio of 0.9. Child systolic BP was greatest at low proportions of
dietary pr tein (<16% f energy) and high carbohydrate (>40% of energy) intakes.
4. Discussion
This is the first prospective study to longitudinally examine the relationship
between maternal diet during pregnancy and the trajectories of child BP up to four
years. Results indicate that lower P:C ratios in maternal diet are associated with
increased child systolic BP up to four years of age. Childhood systolic BP was also
positively associated with maternal intake of PUFA and n-6 fatty acids, despite
remaining constant with changing total fat intake.
Strong evidence supports the tracking of BP from childhood to adult life [4].
Women who gave birth during the Dutch famine in 1944–1945 illustrate that offspring
BP as young adults was inversely associated with the P:C ratio of the average ration
during the third trimester, but not associated with any absolute measure of intake [26].
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This suggests that long-term health may be linked more strongly to the macronutrient
ratio of maternal diet as opposed to absolute intakes. This study is the first to confirm
similar findings in children. Mean childhood BP measures were within normal
ranges (i.e., below the 90th percentile) [27]. However, mean systolic BP and diastolic
BP measures within this study were significantly higher than those reported by other
contemporary birth cohorts [11,13]. The most likely explanation for these higher
values is that BP was only measured on one occasion at each time point rather than
an average of the two or three values used in other studies. The P:C ratio may
further influence non-energy providing micronutrients that may affect childhood
BP. Intervention studies have shown that a modest increase in dietary protein (5.3%
of energy) with a corresponding reduction in carbohydrate subsequently decreased
sodium intake (25mmol/day) in adults, in conjunction with a reduction in blood
pressure [28]. Macronutrient ratios may influence offspring health and disease [16].
Future research is required to include the P:C ratio when evaluating the influence of
maternal macronutrient composition during pregnancy on offspring health outcomes,
and consider its impact on micronutrient intakes.
While potential molecular mechanisms related to our findings are poorly
understood, animal models provide important mechanistic insights and suggest
that nutritional deprivation or excess during pregnancy may stimulate epigenetic
processes [5,13]. These events lead to both acute changes in offspring tissue structure
and organ development, and permanent alterations in gene expression through
DNA and histone methylation or histone acetylation [29,30], with subsequent
cardio-metabolic consequences [5]. Rodent and sheep models support findings
in the current study and provide strong evidence of a relationship between maternal
protein intake during pregnancy and offspring cardiovascular function [6,8,31].
Offspring of nutritionally deprived animals commonly display elevated BP, while
offspring exposed to protein or energy restriction during pregnancy show abnormal
vascular function in isolated resistance arteries [32]. Additional consequences
include increased sympathetic outflow [6], possibly due to altered interactions
between the aberrant central signaling pathways in the renin-angiotensin system
and sympathetic efferent activity [32]. While others have suggested mechanistic
changes in renal sodium transport, including altered mRNA expression of α1- and
β1- Na+/K+ ATPase and renal tubular bumetanide-sensitive and thiazidesensitive
sodium co-transporters [5]. However, evidence for associations between maternal
diet during pregnancy and offspring cardiovascular function in human cohorts,
while valuable, is indirect. Causality cannot be inferred from this study because of its
observational nature and the possibility of residual confounding cannot be excluded.
Therefore, the effect of variations in maternal macronutrient composition requires
further investigation using (i) animal model interventions; (ii) observational studies
using statistical approaches such as propensity score analysis, to address residual
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confounding; or (iii) opportunistic examination within interventions targeting
maternal nutrition to improve pregnancy dietary intake.
Compelling arguments have emerged from animal models of dietary balance
(specifically the ratio of dietary P:C) regarding nutritional targets for optimal health
and ageing [16]. The balance of macronutrients, rather than the absolute intake of a
single nutrient, is a key determinant of lifespan [16]. In insect and mouse models,
diets with decreased P:C were associated with increased lifespan and improved
cardio-metabolic outcomes in later life [16]. These data are supported indirectly by a
systematic review showing increased mortality in human studies associated with low
carbohydrate diets [16], and a recent study showing increased mortality and cancer
in humans on high protein diets [16]. Both high and low P:C diets have benefits and
risks [33], which highlights an important role for macronutrient balance in optimizing
the relationship between diet and disease risk. Recent evidence indicates that the
interaction of a dominant protein appetite with weaker carbohydrate and fat appetites
is a primary driver of total energy intake in mice and humans (termed “protein
leverage”) [15]. The findings suggest that pregnant women may be driven to achieve
a “target” percentage protein intake, as the median percentage of energy from protein
throughout pregnancy within our sample was stable at 19% [14]. This potentially
dominant appetite for protein during pregnancy may significantly influence the
development of offspring BP in early childhood and thus play an important role
in the development of pediatric and adult hypertension. Coupled with a severe
decrease in P:C ratio being related to a greater tendency to store excess body fat
and increased risk of decreased longevity associated with obesity [15], maternal
macronutrient ratio may further increase the risk of elevated blood pressure through
its influence on offspring adiposity [14]. Research investigating protein leverage
during pregnancy, including the role of macronutrient balance (maternal prenatal
and offspring postnatal diet) in the development of offspring blood pressure up
until adulthood, and secondary outcomes such as increased adiposity, are required
before pregnancy dietary recommendation to optimize childhood blood pressure can
be formulated.
The role of maternal pregnancy PUFA intakes with development and regulation
of child BP remains unclear. It is known that dietary PUFA intakes play a role in BP
regulation and have usually been associated with beneficial effects [34]. However,
emerging evidence suggests that PUFA classes (n-3 and n-6) have differential health
effects, with n-6 PUFAs and PUFA ratios generating scientific debate regarding
their role in human physiological processes [34]. Both classes of fatty acids have
been shown to reduce BP in adult rats and hypertensive subjects [35,36]. However,
significant reductions in BP in normotensive subjects have not been shown, nor
have beneficial effects of PUFA on CVD risk markers been reported universally [36].
Arguments for reduced n-6 intakes surround the notion that inflammation plays a
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key role in CVD mechanisms [36]. Recent evidence from the Sydney Diet Heart Study
reported that in men aged 30 to 59 years, substituting dietary n-6 linoleic acid (LA) in
place of SFA showed no cardiovascular benefit and actually increased the risk of death
from all causes, coronary heart disease and CVD [37]. The proposed mechanistic
model linking n-6 PUFAs to cardiovascular pathogenesis is based on a diet-induced
increase in the production of bioactive oxidized LA metabolites [37]. Oxidized LA
metabolites are the most abundant oxidized fatty acids in oxidized low-density
lipoprotein molecules. Ramsden and colleagues hypothesize that oxidative stress
combined with diets high in n-6 LA facilitate this oxidation, leading to oxidized
LA metabolite mediated atherosclerotic progression and increased cardiovascular
mortality [37]. Increased circulating oxidized low-density lipoprotein has been
reported in hypertensive men [38] and women with pre-eclampsia [39]. Limited
research has been conducted in pregnancy. There is a lack of population-based
research examining the relationship between maternal pregnancy PUFA intake and
offspring BP. Results in the current study support a positive relationship between
trajectory of childhood systolic BP up to age four years and maternal PUFA and n-6
fatty acids intakes during pregnancy, despite BP remaining constant with changing
maternal total fat intake and being altered with P:C ratio. The influence of maternal
diet on child BP may also be secondary to its influence on maternal BP during
pregnancy. A higher maternal BP during pregnancy could reflect the mother’s own
fetal experience, which consequently influences the intrauterine environment she
provides for her children. Further research to elucidate the role of n-6 fatty acids in
cardiovascular disease mechanisms, particularly maternal and child blood pressure,
is warranted.
Limitations of the current study include the use of self-reported FFQ data to
measure dietary intake. Dietary data is strengthened by the similarities between the
daily mean energy intake reported in our study (8070 kJ/day) and that reported in
a representative sample of pregnant women in the Australian Longitudinal Study
on Women’s Health (7795 kJ/day) in 2003 [40]. Macronutrient distributions were
also similar to the population nation data in pregnancy [40]. Physical activity
data for children were unable to be obtained for our sample. BP measurements
should be interpreted with caution. Automated BP monitors overestimate systolic
BP and underestimate diastolic BP [41], and thus are not recommended for use
in children in clinical settings where the accuracy of the absolute measurement is
required [41]. In epidemiological studies where differences in BP between groups are
more important than absolute levels, automated BP monitors such as the Dinamap
are appropriate to reduce observer bias and digit preference [41]. Lastly, the WATCH
study contained a higher proportion of women with post-school qualifications,
socio-economic advantage and in a married or de facto relationship, but had a
similar proportion of overweight/obesity and indigenous ethnicity compared to the
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Australian population [14]. Therefore, care should be taken in extrapolating results
at the population level.
5. Conclusions
This study provides some evidence for an optimal maternal macronutrient
profile associated with a healthy child BP. The development of systolic BP up to four
years was positively associated with higher maternal PUFA intakes and a lower P:C
ratio. Future focus on the maternal protein-to-carbohydrate ratio during pregnancy
will be an important research area and may offer strategy to optimize offspring
cardiovascular health. Further research has the potential to elucidate the role of
maternal diet in childhood BP and in refining dietary recommendations provided to
pregnant women in order to optimize offspring health long-term.
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Association between Dietary Patterns
during Pregnancy and Birth Size Measures
in a Diverse Population in Southern US
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Abstract: Despite increased interest in promoting nutrition during pregnancy,
the association between maternal dietary patterns and birth outcomes has been
equivocal. We examined maternal dietary patterns during pregnancy as a
determinant of offspring’s birth weight-for-length (WLZ), weight-for-age (WAZ),
length-for-age (LAZ), and head circumference (HCZ) Z-scores in Southern United
States (n = 1151). Maternal diet during pregnancy was assessed by seven dietary
patterns. Multivariable linear regression models described the association of WLZ,
WAZ, LAZ, and HCZ with diet patterns controlling for other maternal and child
characteristics. In bivariate analyses, WAZ and HCZ were significantly lower for
processed and processed-Southern compared to healthy dietary patterns, whereas
LAZ was significantly higher for these patterns. In the multivariate models,
mothers who consumed a healthy-processed dietary pattern had children with
significantly higher HCZ compared to the ones who consumed a healthy dietary
pattern (HCZ β: 0.36; p = 0.019). No other dietary pattern was significantly associated
with any of the birth outcomes. Instead, the major outcome determinants were:
African American race, pre-pregnancy BMI, and gestational weight gain. These
findings justify further investigation about socio-environmental and genetic factors
related to race and birth outcomes in this population.
Reprinted from Nutrients. Cite as: Colón-Ramos, U.; Racette, S.B.; Ganiban, J.;
Nguyen, T.G.; Kocak, M.; Carroll, K.N.; Völgyi, E.; Tylavsky, F.A. Association between
Dietary Patterns during Pregnancy and Birth Size Measures in a Diverse Population
in Southern US. Nutrients 2015, 7, 1318–1332.
1. Introduction
Pregnancy is a critical period for the offspring’s metabolic development [1].
Inadequate maternal nutrient or energy intake during pregnancy is thought to lead
to low birth size [2–4], a risk factor for infant and child mortality and morbidity, and
potential risk factor for predisposition to cardiometabolic diseases later in life [5–8].
In the context of an increasingly energy-dense, nutrient-poor food environment in the
US [9–11], there is increased interest in the promotion of nutrient-rich diets during
pregnancy, with emphasis on iron-rich foods, folic acid, calcium-rich foods, and
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plenty of fruits and vegetables [12,13]. Dietary patterns are a way to capture the
quality of the entire diet consumed by study populations.
Dietary patterns integrate dietary behaviors of a population through food
and nutrient-group analyses. They are therefore more intuitive to public health
nutrition recommendations than analyses that focus on single nutrients. Dietary
patterns consider beneficial or harmful interactions among nutrients in different foods
consumed together, as well as different food sources of the same nutrient [14]. The
two most common approaches to study dietary patterns are a priori and a posteriori
approaches [15]. The first one establishes a priori scores of foods and nutrients
based on a hypothesis (e.g., adherence to the Mediterranean Diet Score [16], the
Healthy Eating Index [17,18] or a score for junk food intake [19]). The second
approach is exploratory, usually employing principal component analysis or factor
analysis to generate patterns that maximally explain the variance in food intake in a
population, where the results are data-driven and context-specific. Both approaches
have been shown to be biologically meaningful [20,21]. For example, patterns
characterized by a high intake of nutrient-poor, highly refined foods containing
added sugar or unhealthy fats have been associated with biomarkers of inflammation
and increased risk factors for cardiovascular disease, type 2 diabetes, and obesity
compared to patterns characterized by high intake of lean proteins, vegetables, fruits
and whole-grain cereals [15,22–29].
Few studies have examined the association between pregnancy or preconception
dietary patterns and birth outcomes; most used principal component analysis
or factor analysis [21,30–35] and approaches such as a priori scores [16–19,36–38].
In general, these studies suggest that energy-dense, nutrient-poor dietary patterns
characterized by foods high in saturated and trans fats, refined sugar, or sodium
are negatively associated with birth size outcomes [30,31,34,35,39], and that patterns
characterized with nutrient-rich foods such as fruits, vegetables, and whole grains,
were positively associated with birth size outcomes [30,31,33–35,39]. However, there
are some inconsistencies in findings, probably due to the variation in birth size
outcome measures, context of the population and resulting dietary patterns [31,32,39].
The majority of these studies have been conducted among white European or
European American populations and, to date, no study has examined the association
between maternal dietary patterns and birth size outcomes in a population with a
high burden of low birth weight.
Due to the important differences in eating patterns by geography, culture and
other context-specific characteristics of the population, we sought to determine the
influence of specific dietary patterns on birth size outcomes in a diverse, largely
black African-American and low-income population residing in the South of the
US. The objective of this study was to examine the extent to which maternal dietary
patterns are associated with offspring size at birth (birth weight, length, and head
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circumference). Dietary patterns were used to describe patterns that emerge from the
data and display the unique features of that population which may not be captured
by any predefined score. We hypothesized that dietary patterns characterized by
energy-dense, nutrient-poor processed foods that are high in saturated and trans fats,
sodium, and refined sugars would be associated with lower birth weight, length, and
head circumference compared to healthy dietary patterns during pregnancy.
2. Materials and Methods
This analysis was conducted in a pregnancy cohort of 1151 women who were
followed from the second trimester of pregnancy until delivery.
2.1. Setting
The Conditions Affecting Neurocognitive Development and Learning in Early
Childhood (CANDLE) study is a longitudinal cohort study set in Shelby County,
the southwestern corner of the state of Tennessee. Shelby County is largely
African-American with mid-level education, and low income status (<200% poverty
level). The CANDLE study aims to investigate the effects of different exposures such
as mother’s prenatal habits and characteristics, home environment and childhood
experiences, genetics, and exposure to potentially harmful substances on the
neurocognitive development of children from birth to age three years. The study
was conducted in accordance with the Helsinki Declaration and was approved and
reviewed by the Institutional Review Board of the University of Tennessee Health
Science Center on 17 June 2014 (approval code: 06-08495-FB).
2.2. Participants
Women were eligible to enroll in the CANDLE study if they were between
16–28 weeks pregnant, were a resident of Shelby County, had a low medical risk
pregnancy, were between the ages of 16–40 years, spoke and understood English,
had a single pregnancy and were willing to give consent. The CANDLE study
recruited a total of 1503 pregnant women; 1474 mother-child dyads were available
for follow up after excluding post-consent ineligibilities, pre-delivery withdrawals,
and fetal demises. Of the 1474 participants, 1151 had diet data at the visit between
16–26 weeks, when their diet was assessed.
2.3. Variables
Outcomes were Z-scores for weight-for-length (WLZ), weight-for-age (WAZ),
length-for-age (LAZ), and head circumference (HCZ). Exposure of interest was the
maternal dietary patterns that have been previously assessed via factor analysis [40].
Independent variables were socio-demographic, behavioral, and medical history
245
characteristics that would be considered as confounding variables in the association
between pregnancy outcomes and diet.
2.4. Data Sources
Data used for this study were collected during the second trimester and at
birth. During the second trimester, participants completed questionnaires asking
about demographics, health status, diet, and medical history. At birth, research
assistants conducted medical chart abstractions for birth outcomes (weight, length,
head circumference).
Diet Instrument: Diet was assessed at enrollment (16–26 weeks of pregnancy)
using the Block 2005 food frequency questionnaire (FFQ) that asks consumption of
111 food and drink items during the previous three months [41–43]. The Block FFQ
has been shown to be a valid and reliable instrument to rank individuals according
to dietary and nutrient intake [44]. Interviewers were trained by registered dietitians
and re-certified by a registered dietitian based on a taped interview every six months
to estimate the frequency and quantity of intake. Nutrient values were obtained from
NutritionQuest (Berkeley, CA, USA). Over and under-reporters of total caloric intake
(>5000 kcal per day or <1000 kcal per day) were excluded (n = 152).
Dietary patterns: Seven dietary patterns were identified previously using
exploratory factor analysis with principal component extraction and varimax rotation
method to determine the frequency of 111 food and beverage groups that made
up distinct dietary patterns. Volgyi et al. [40] describe these patterns as: healthy
(characterized by high factor loadings of vegetables, fruits, non-fried fish and chicken,
and water); processed (i.e., processed meat, fast food items, snacks, sweets, and
soft drinks); Southern (i.e., cooked cereals, peaches, corn, fried fish, beans, greens,
pig’s feet, neck bones oxtails, tongue, pork); healthy-processed; healthy-Southern;
Southern-processed, and mixed. The “mixed” pattern reflects foods from all of the
other patterns together. In brief, to create the patterns, Volgyi and colleagues [40]
estimated a factor score for each participant as a sum of daily frequency of intake
of each food group, multiplied by the loading score for the food group. A large
segment of the population belonged to mixed patterns rather than to single pure
patterns (such as healthy, processed or Southern), so they then created combined food
patterns based on the individual’s rank order in each single factor. Dietary patterns
were assigned based on the individuals’ scoring in the quintiles for each food factor.
These dietary patterns are distinct from each other in their content of energy-adjusted
nutrients and explain more than 80% of the variance in macronutrient intake for this
study population [40].
The demographic survey: Administered during enrollment asked respondents
about formal education, medical insurance, annual household income, age, race
and ethnicity.
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Maternal baseline data form: At the time of enrollment, researchers collected the
participant’s self-reported pre-pregnancy length and weight, tobacco use, alcohol
use, and total number of pregnancies (including abortions, miscarriages, stillbirths
and current pregnancy). Pre-pregnancy body mass index (BMI) was calculated using
the self-reported heights and weights.
Labor and delivery forms and neonatal summary forms: At the time of labor and
delivery, the following information was abstracted from the medical charts: maternal
weight and newborn birth weight, length, and head circumference.
2.5. Data Analyses
For full term infants (≥37 weeks), WHO Child Growth Standards were used
to calculate Z-scores for each outcome WLZ, WAZ, LAZ and HCZ [45]. Normal
distribution of scores was assessed via Q-Q plots of residuals for each birth
outcome. Descriptive statistics (i.e., mean, standard deviation, frequencies and
percent frequencies) were reported for all socio-demographic, behavior, and health
characteristics. These variables were cross-tabulated by race, dietary patterns, and
birth outcomes, and significant differences were assessed. Pearson correlations were
conducted to assess linear relationship between birth outcomes and dietary patterns.
Bivariate associations (least square means comparisons) were conducted between
outcomes of interest (WLZ, WAZ, LAZ, HCZ) and maternal socio-demographic (age,
length, race, education, health insurance) and health characteristics (BMI, tobacco
use, gestational age, gravidity, total pregnancy weight gain, alcohol use, dietary
patterns, use of multivitamin) and sex of the newborn.
Multivariable models for each outcome variable were constructed to describe
their association with the exposure of interest (e.g., dietary patterns). These models
were adjusted for any maternal socio-demographic or health characteristic that was
independently and significantly associated with the outcomes of interest and with
the exposure of interest in bivariate models. An alpha level of 0.05 was used for all
statistical tests and p-values reported were not adjusted for multiplicity; therefore,
the results must be considered in a hypothesis generating context. All analyses were
performed using SAS version 9.3.
3. Results
3.1. Dietary Patterns and Nutrient Content
Table 1 describes each dietary pattern by its nutrient content and MyPyramid
equivalents [46]. All of the dietary patterns were distinct in their macro and
micronutrient contents. Below is a description of the most notable differences
between patterns. The processed-Southern dietary pattern had the highest content
in energy, total fat (% energy and total grams, including saturated, omega 3 fatty
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acids, monounsaturated, and polyunsaturated fats), total sugar, iron, zinc, sodium,
and meats, and had the lowest content in whole grains. The processed dietary
pattern was the highest in trans fats, total grains and potato servings. In contrast, the
healthy-Southern dietary pattern had the highest content of fiber, folate, egg-meat
equivalents, oils, vegetables (including dark green and orange vegetables, and
tomatoes, excluding legumes and potatoes) and fruits (including fruit juice). The
healthy-processed was characterized by high intake of nuts, seeds, whole grains,
and dairy, as well as highly refined foods that are higher in simple sugars and
fat. The healthy dietary pattern had the lowest energy, fat, total sugar, sodium,
egg-meat equivalents and meats, and highest content of protein, carbohydrate, and
soy legumes.
3.2. CANDLE Study Population Characteristics
Table 2 shows the socioeconomic characteristics of the CANDLE population
sample for this study by race. There were significant differences in socio-demographic
and behavioral characteristics of the racial groups. The African American mothers
tended to be younger, have a higher body mass index (mean 28.8 kg/m2), be less
likely to smoke, less likely to have completed higher education, and more likely to
have Medicaid/Medicare insurance compared to the European Americans. Dietary
patterns were significantly different by racial group, with European Americans and
other race more likely to report a healthy dietary pattern. Mean birth weight for
age, length for age, and head circumferences were significantly lower for African
American offspring. European Americans were less likely to have more than
one pregnancy.
3.3. Modeling
In bivariate analyses, eating processed and processed-Southern dietary patterns
compared to healthy dietary pattern were negatively associated (p < 0.05) with
weight-for-age Z-Score (WAZ), and head circumference Z-Score (HCZ), and
positively associated with length-for-age Z-score (LAZ).
Variables that were associated with the various outcomes of interest in the
bivariate analyses and also with the exposure of interest were included in the final
multivariable model using race as a control variable. We also constructed each
model for each race sub-group independently, controlling for potential confounders
identified in the bivariate analyses. Since results by race groups were similar, we
show the multivariable model that includes race as a control variable (Table 3),
which is more powerful than the race-based analysis. For the outcome of HCZ, the
healthy-processed dietary pattern was a positive significant predictor (HCZ β: 0.36;
p = 0.019 compared to the healthy dietary pattern). None of the other dietary patterns


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2. Population characteristics of mothers and newborns of the CANDLE study
(n = 1151). Values are number (%) or means (standard deviation).
Characteristics African American(n = 718)
European
American (n = 401)
Other Race
(n = 32) p-value
Maternal characteristics
Length, m 1.64 (0.07) 1.65 (0.07) 1.64 (0.06) 0.002
Age, years 25.13 (5.32) 28.65 (4.78) 30.00 (4.59) <0.0001
Total weight gain, kg 14.78 (7.67) 14.83 (6.48) 13.41 (5.34) 0.80
Multivitamin, (% yes) 656 (91.4) 391 (97.5) 31 (96.9) 0.015
Body Mass Index, kg/m2 28.75 (8.07) 25.69 (6.02) 25.75 (5.58) <0.0001
Tobacco, (% yes) 49 (6.8) 49 (12.2) 5 (15.6) 0.004
>1 pregnancy, (% yes) 512 (71.3) 254 (63.3) 23 (71.9) 0.021
Education, n (%) <0.0001
<High school 489 (69.4) 123(30.7) 12 (37.5)
>High school 219 (30.5) 278 (69.3) 20 (62.5)
Insurance, n (%) <0.0001
No insurance 15 (2.1) 4 (1.0) 2 (6.3)
Medicaid/Medicare 511 (71.2) 86 (21.4) 9 (28.1)
Private 192 (26.7) 311 (77.6) 21 (65.6)
Alcohol use (% yes) 43 (6.0) 59 (14.7) 3 (9.4) <0.0001
Premature delivery (% yes) * 68 (9.5) 26 (6.5) 2 (6.3) 0.18
Diet Pattern, n (%) <0.0001
Healthy 7 (1.0) 121 (30.2) 7 (21.9)
Healthy-Southern 74 (10.3) 13 (3.2) 11 (34.4)
Southern 109 (15.2) 5 (1.2) 2 (6.3)
Mixed 286 (39.8) 143 (35.7) 9 (28.1)
Healthy-processed 30 (4.2) 98 (24.4) 2(6.3)
Processed-Southern 131 (18.2) 3 (0.7) 1 (3.1)
Processed 81 (11.3) 18 (4.5) 0 (0)
Newborn characteristics, mean (SD)
Weight-for-Length Z-score −0.60 (1.23) −0.57 (1.19) −0.63 (0.98) 0.92
Weight-for-Age Z-score −0.12 (0.91) 0.35 (0.92) 0.32 (0.91) <0.0001
Length-for-Age Z-score 0.35 (1.18) 0.91 (1.23) 0.87 (1.27) <0.0001
Head Circumference Z-score −0.27 (1.22) 0.33 (1.23) 0.36 (1.22) <0.0001
Significant differences across groups were tested using Chi-square or Kruskal Wallis. *
Premature delivery defined as gestational age <37 weeks.
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Table 3. Crude least square means (standard errors) and adjusted βeta estimates
(standard errors) from generalized linear models of dietary patterns of mothers and
































































This model was adjusted for age, race, pre-pregnancy BMI, education, alcohol and total
weight gain. * p ≤ 0.05.
4. Discussion
This study examined the potential association between maternal dietary patterns
during pregnancy and birth outcomes in a diverse population with historical high
burden of low birth weight and other adverse birth outcomes [47–49]. The dietary
patterns examined emerged from the foods that this population eats, and captured
cultural food items related to traditional Southern cuisine, including fried fish, pig’s
feet, tongue, pork, and dark green vegetables [40]. However, after controlling for
confounders, our results do not offer strong evidence for the association between
dietary patterns and birth outcomes in this population. Our findings indicate that
only one dietary pattern (healthy-processed) characterized by intake of nuts, seeds,
whole grains, and dairy, as well as highly refined foods that are higher in simple
sugars and fat, is uniquely associated with higher HCZ compared to a healthy dietary
patterns characterized by water, fruits and vegetables.
Our findings are somewhat comparable to those from previous publications
in which dietary patterns characterized with nutrient-rich foods such as fruits
and vegetables, whole grains, and water were associated with larger birth size
outcomes[30,31,33–35,39]. The healthy-processed pattern was rich in whole grains,
although one of the lowest in terms of dark green or orange vegetables. Our
findings do not offer any evidence that either the “healthy” dietary pattern or the
251
“processed” dietary pattern in this population was uniquely associated with birth
weight or any other outcome, which is in contrast to what has been observed in other
populations [30,31,34,35,39].
A potential explanation for this discrepancy is the antagonistic interaction
among nutrients and food sources in the combined dietary patterns consumed
by this population. For example, the healthy dietary pattern in the current
study includes vegetables, fruits, non-fried fish and chicken, and water, similar to
other studies, with the caveat that other studies have also included oils in their
healthy pattern [16,17,33,34,50], contrary to the current study. In addition, the
“healthy-Southern” pattern, but not the healthy pattern, is characterized by the
highest intake of fruits, dark green and orange vegetables, fiber and folate. This
division between healthy and “healthy-Southern” perhaps diluted the potential
beneficial effects that a healthy diet may have had on birth outcomes. Similarly, the
“healthy-processed” pattern, was characterized by high intake of nuts, seeds, dairy,
whole grains, but also included processed and red meats, relatively high levels of
saturated and trans fats, and refined sugars, which may have diluted some of the
beneficial effects of the healthy foods on the other birth outcomes. Nuts, seeds and
whole grains have high concentrations of unsaturated fats, protein, fiber, a variety of
micronutrients and phytonutrients [51], and have been identified as part of a healthy
diet pattern that was associated with favorable birth outcomes in other population
studies [30,33,52]. The healthy-processed pattern was also characterized by dairy;
dairy intake from milk and cheese can potentially provide optimum amounts of
calcium and vitamin D. A few studies suggest that low calcium intake could have
effects on the skeletal growth of the fetus, affecting birth, length and weight [53].
Optimum intake of calcium and vitamin D and low levels of parathyroid hormone
are associated with decreased risk of SGA birth and a significantly higher birth
weight, birth length, and head circumference [54]. These potentially antagonistic
relationships could be assessed in a future study by nutrient-based patterns.
Although each dietary pattern has a variety of foods containing nutrients that
have been shown to be antagonistic in their health effects, these dietary patterns
were distinct in their nutrient profile and explained a large variance in food intake.
Other potential explanations for our findings may have to do with socioeconomic
or racial characteristics of the study population. Volgyi and colleagues [40] showed
that women who were older and had higher level of education were more likely
to eat a healthy dietary pattern than processed, Southern or mixed. Only seven
African-American mothers consumed a healthy dietary pattern, whereas most
European Americans consumed healthy or mixed patterns. Twenty-four percent of
European American compared to only 4% of African American mothers consumed a
healthy processed diet. Although our analyses statistically controlled for race, there
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may be contextual factors that affect birth weight and that are covariant with race,
but are not completely captured by race.
The results of this study are limited by their reliance on self-reported dietary
intake, the inherent limitations of quantifying dietary intake with a food frequency
questionnaire, and the inevitable overlap between different dietary patterns.
However, we took measures to overcome some of these limitations by excluding
from the analyses all potential over and under-reporters of total caloric intake. In
addition, the dietary patterns did show distinct factor loadings, suggesting that this
population does eat diet patterns that combine “healthy” and “unhealthy” food items
in an overlapping manner (i.e., the mixed diet patterns).
5. Conclusions
In sum, our findings do not provide sufficient evidence that either the healthy or
the processed dietary pattern in this population is uniquely associated with positive
or negative birth outcomes. The mixed dietary patterns consumed by this study
population may provide antagonistic relationships between foods and nutrients that
result in null associations with birth outcomes. To further investigate this hypothesis,
it would be necessary to discriminate the population by nutrient or micronutrient
status, perhaps using biomarkers to potentially disentangle any antagonistic effects in
foods or preparations. Our results also imply that there are other socio-environmental
and maybe genetic aspects related to race in the Southern US that require careful
further investigation in their association with birth outcomes.
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Abstract: Diet is a modifiable factor that can contribute to the health of pregnant
women. In a sample of 577 HIV-positive pregnant women who completed
baseline interviews for the Breastfeeding, Antiretrovirals, and Nutrition Study in
Lilongwe, Malawi, cluster analysis was used to derive dietary patterns. Multiple
regression analysis was used to identify associations between the dietary patterns
and mid-upper arm circumference (MUAC), arm muscle area (AMA), arm fat area
(AFA), and hemoglobin at baseline. Three key dietary patterns were identified:
animal-based, plant-based, and grain-based. Women with relatively greater wealth
were more likely to consume the animal-based diet, which had the highest intake of
energy, protein, and fat and was associated with higher hemoglobin levels compared
to the other diets. Women with the lowest wealth were more likely to consume the
grain-based diet with the lowest intake of energy, protein, fat, and iron and were
more likely to have lower AFA than women on the animal-based and plant-based
diets, but higher AMA compared to women on the animal-based diet. Pregnant,
HIV-infected women in Malawi could benefit from nutritional support to ensure
greater nutrient diversity during pregnancy, when women face increased nutrient
demands to support fetal growth and development.
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1. Introduction
Infection with human immunodeficiency virus (HIV) increases resting energy
expenditure and may limit dietary intake and reduce nutrient absorption [1].
In addition, nutritional status can influence the progression of HIV disease. Women
are disproportionately affected by HIV compared to men. Across all age groups there
is a higher rate of HIV prevalence among women than among men. Approximately
60% of adults living with HIV in Malawi are female [2]. HIV-infected pregnant
women are particularly at risk since they have additional nutrient demands to
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support fetal growth and development [3]. Diet during pregnancy is a potentially
modifiable factor that can contribute to the health of pregnant women and improve
birth outcomes [4].
Women account for an estimated 60% of HIV infections in sub-Saharan Africa,
where food availability, malnutrition, and infectious disease morbidity can vary
substantially by season due to cycles of rainfall and agricultural production [5,6]. In
Malawi, the annual famine season extends from August to March. The typical
Malawian diet includes a staple food, such as Nsima, a thick maize porridge
molded into patties, served with beans, vegetables, or relish for flavor. Most
animal-source foods, rich in protein and micronutrients, are expensive and scarce.
The current study used cluster analysis to identify three dietary patterns among 577
HIV-positive pregnant women in Lilongwe, Malawi, and compare sociodemographic
and anthropometric characteristics of the women across diet patterns.
2. Experimental Section
Dietary recalls were collected from women who enrolled in the Breastfeeding,
Antiretrovirals, and Nutrition (BAN) Study from April 2004 to March 2006. The BAN
Study recruited women from four antenatal clinics with outreach to all pregnant
women in Lilongwe [7]. At the first antenatal visit, consenting women were screened
for pre-delivery study inclusion criteria: (1) ≤30 weeks gestation based on last
menstrual period or fundal height; (2) ≥14 years of age; (3) confirmed HIV infection;
(4) hemoglobin ≥ 7 g/dL; (5) CD4 count ≥ 200 cells/µL; (6) no prior antiretroviral
medication use; (7) normal liver function tests (<2.5 times the upper limit of normal);
(8) no serious complications of pregnancy; and (9) not previously enrolled in the
BAN Study. At the second antenatal visit (referred to as the baseline visit), women
completed a standardized interview, physical exam, and specimen collection. All
women received prenatal iron folate tablets (200 mg ferrous sulfate and 0.25 mg
folic acid) per Malawi standard of care and all women diagnosed with malaria were
treated. The BAN Study included up to 5 antenatal visits, a labor and delivery
visit, and 14 postpartum visits, with randomization occurring within 1 week of
delivery to a 2-arm nutritional intervention to prevent maternal depletion and a 3-arm
antiretroviral intervention to prevent HIV transmission during breastfeeding [8,9].
The BAN Study protocol was approved by the Malawi National Health Sciences
Research Committee and the institutional review boards at the University of North
Carolina at Chapel Hill and the U.S. Centers for Disease Control and Prevention
(ClinicalTrials.gov identifier NCT00164762).
From April 2004 to March 2006, 738 women completed baseline interviews
and delivered live singletons. Trained BAN Study staff collected 24-h dietary
recalls at the baseline visit. Recipes and ingredients of mixed dishes were recorded.
Women were asked if the diet recall indicated “typical intake” and were prompted
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for an explanation if it did not. Food models and utensils were used to help
respondents recall portion sizes and proportion of mixed dishes consumed. A Malawi
nutrient food composition table (FCT) [10] was used to estimate nutrient intakes.
Supplemental nutrient information was obtained from Malawi’s Ministry of Health’s
FCT, a Tanzanian FCT [11], and the USDA nutrient database [12]. The resulting
database had nutrient content of individual food items as well as mixed dishes based
on standard recipes. Dietary recalls were reviewed for plausible portion sizes and
nutrient intakes; 577 recalls were deemed reliable for this analysis. Independent
sample t-tests were used to evaluate potential selection bias.
Weight, height, mid-upper arm circumference (MUAC), and triceps skinfold
thickness were measured by trained BAN Study staff. Weight was measured to the
nearest 100 g at each visit with an electronic scale checked regularly with a standard
5 Kg weight. Height was measured with a wall-mounted stadiometer. At each
visit, MUAC was measured at the midpoint between the olecranon and acromion
process, to the nearest 0.1 cm using an insertion tape, while the arm hung freely at
the side. Triceps skinfold thickness was measured in triplicate at each visit using
Lange Calipers. The mean of the three measurements was used with MUAC to
derive arm muscle area (AMA = [MUAC − (triceps skinfold × π)]2/4π) and arm
fat area (AFA = MUAC2/4π − AMA) [29]. Only the initial baseline measure, which
was typically in the second trimester, was used in this analysis. Infant weights were
measured at delivery or at the first visit post-delivery for home deliveries.
Anemia was defined as mild (<12 g/dL) or moderate (<10 g/dL) in accordance
with the 2004 Malawi Demographic Health Survey (MDHS) definitions [13].
Statistical Analysis
To identify dietary patterns, we categorized food items into 12 groups: (1) grains;
(2) legumes, groundnuts, seeds and soy; (3) tubers; (4) fruit; (5) leafy green vegetables;
(6) fish; (7) meat poultry, and eggs; (8) dairy; (9) fats and oils; (10) sugars, candy, soft
drinks; (11) hot beverages; and (12) miscellaneous. Nutrient densities (grams/total
calories) of each food group were calculated and daily intake was used in the
cluster analysis. Standardization by energy contribution helps to remove dietary
variations due to differences in age, body size, and physical activity and to retain
the proportional differences in food intake patterns [14,15]. Prior to cluster analysis,
values were transformed into sample-specific Z-scores so that food intake differences
between clusters could be illustrated and compared. Dietary patterns were generated
by K-means cluster analysis [16] based on nutrient densities of each food group. We
examined solutions with 2 to 5 clusters to evaluate which set of clusters was more
meaningful to define dietary patterns.
The STATA [16] kmeans cluster method was used to group women
according to nutrient densities of intake derived from each of the 12 food groups.
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The three-cluster solution was determined most appropriate based on power
requirements and sufficient representation of typical dietary patterns of Malawian
women with nutritionally meaningful variation between clusters. Sociodemographic
characteristics, anthropometrics, and macro-nutrient intakes were compared across
the three clusters using chi-square tests for categorical variables and a one-factor
analysis of variance (ANOVA) for continuous variables. If the global p-value was
significant (<0.05), pairwise comparisons were made using a Bonferroni correction for
multiple comparisons (p-value considered significant if <0.017). Multivariable linear
regression was used to examine associations between dietary patterns and maternal
nutritional indicators: MUAC, AMA, AFA, and hemoglobin. The multivariable
models included a variable indicating whether or not the 24-h dietary recall reflected
the participant’s typical diet. Exposure to the famine season, defined by the number of
days during the previous month that were spent in the famine season (August-May),
was also included as a covariate. A wealth index of five quintiles was derived using
principal component analysis of household characteristics: house construction (type
of walls, floors, and roof), number of rooms and residents, electricity, refrigeration,
sanitation, water source and cooking fuel source [17]. Other covariates included
in the regression models were total energy intake, age, parity, education, maternal
employment status, height and CD4 count. Multivariable models were assessed
for statistically significant interactions (p < 0.20) between the dietary patterns and
exposure to the famine season and between dietary patterns and wealth status [18].
3. Results
There were no significant differences (p < 0.05) in anthropometric, clinical, or
seasonal indicators between the 577 women included (Table 1) and those excluded
from this study, suggesting no selection bias. The mean daily energy intake was
low (1378 kcal, interquartile range: 778, 1813), and over half of the women had mild
(32.1%) or moderate (23.7%) anemia. No significant interactions were detected
between dietary patterns and exposure to famine season and between dietary
patterns and wealth status.
The three diet pattern clusters were labeled: (1) animal-based; (2) grain-based;
and (3) plant-based. By definition, Cluster 1 had the highest intake of fish, meat,
poultry, fat/oil, eggs and dairy, providing diets rich in energy and micronutrients
(Figure 1). A typical meal in this cluster was a meat stew or soup with added oil or
dried fish. Cluster 2 represents a grain-based diet of maize, rice, and millet, providing
low levels of energy and micronutrients. A typical meal in this cluster was a plate
of nsima only. Cluster 3 represents a mostly plant-based diet of leafy vegetables,
beans, legumes, tubers, nuts, and fruits providing high levels of protein-rich or
micronutrient-rich carbohydrates. A typical meal in this cluster was nsima with
mustard greens and groundnut flour.
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Table 1. Baseline demographics, nutritional status, caloric intake, and clinical
characteristics among 577 pregnant women participating in the BAN Study.
Characteristic N = 577
Age (year) [mean ± SD] 1 25.9 ± 4.9
Education
No school (%) 11.3
Primary (%) 52.8








Parity (live births) [mean ± SD] 1.7 ± 1.3
Gestational age (weeks) [mean ± SD] 25.2 ± 5.4
CD4 count (cells/uL) [range (IQR) 2] 442 (325–601)
Hemoglobin (g/dL) [mean ± SD] 10.8 ± 1.2
Daily energy total intake (kcal) [mean ± SD] 1378 ± 821
Mid-upper arm circumference (cm) [mean ± SD] 26.4 ± 2.6
Arm muscle area (cm2) [mean ± SD] 36.6 ± 6.4
Arm fat area (cm2) [mean ± SD] 19.5 ± 7.8
1 SD: standard deviation; 2 IQR: interquartile range.
Comparisons across the three clusters indicated that employment status and
median CD4 count did not differ significantly but mean age (p = 0.02) and education
(p = 0.05) did. However, in pairwise comparisons with Bonferroni correction, age
and education were not significant. The clusters differed by wealth and exposure
to the famine season. Significantly more women in the grain-based cluster were in
the lowest wealth index quintile compared to women in the animal-based cluster,
and more were exposed to the famine season compared to either the animal-based
or plant-based clusters (Table 2). Women in the grain-based cluster compared to the
animal-based cluster also had a history of more live births. Women in the grain-based
diet cluster consumed significantly fewer calories, protein, fat, and iron than women
in the animal-based or plant-based diets (Table 2). They also had significantly lower
carbohydrate intake than women in the plant-based cluster. In univariate analysis,
women in the grain-based cluster had significantly lower AFA compared to women
in the plant-based cluster (Table 2). However, in multivariable analysis, the predicted
mean difference in AFA was significant comparing the grain-based cluster to both the
plant-based (−2.47 cm2 lower) and animal-based (−2.09 cm2 lower) clusters (Table 3).
Compared to women in the animal-based cluster, women in the grain-based cluster
had significantly higher AMA and lower hemoglobin level in both univariate and
multivariable analysis. The predicted mean increase in AMA was 1.86 cm2 and
the predicted decrease in hemoglobin level was −0.27 g/dL. The animal-based diet
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cluster had the highest intake of energy, protein, and fat at levels significantly above
those of the plant-based cluster. In contrast, the plant-based diet had the highest
intake of carbohydrates at a level significantly above that of the animal-based diet.
While there were no differences between in maternal anthropometrics of women in
the animal-based and plant-based diet clusters in univariate analysis, in multivariable
analysis, the plant-based cluster had a significantly lower predicted mean difference in
hemoglobin level (0.32 g/dL) than the animal-based cluster (Table 3). These measures
did not have any clinical significance; however, it describes the association between
prenatal body composition and dietary profiles. There were no differences in mean
MUAC between the clusters in unadjusted (Table 2) or adjusted analysis. Furthermore,
there were no differences between the diet clusters in infant weight at delivery.
Table 2. Demographic, nutrient, and clinical indicators by the 3 diet clusters among
577 pregnant women participating in the BAN Study.
Indicators
Animal-Based
1 (n = 160)
Grain-based
2,3 (n = 254)
Plant-based 4
(n = 163)









Age (year) (mean ± SD) 25.0 ± 4.4 26.2 ± 5.1 26.2 ± 4.9 - - -
No school (n = 65) [n(%)] 11 (6.9) 37 (14.5) 17 (10.4) - - -
Lowest wealth index
(n = 108) [n(%)] 17 (15.7) 63 (58.3) 28 (25.9) 0.001 - -
Parity > 2 (n = 133) [n(%)] 23(14.3) 67 (26.4) 43 (26.3) 0.014 - -
Any famine
season exposure
(n = 348) [n(%)]
83 (51.9) 180 (70.9) 85 (51.2) <0.001 - <0.001
Nutrition status
Daily energy total
intake (kcal) 1776.8 ± 859.5 1083.5 ± 672.2 1445.4 ± 818.5 <0.001 <0.001 <0.001
Carbohydrates (g/day) 195.8 ± 116.3 201.1 ± 128.9 237.4 ± 135.3 - 0.010 0.014
Protein (g/day) 69.3 ± 57.1 32.6 ± 28.3 47.1 ± 35.9 <0.001 <0.001 0.001
Total fat (g/day) 82.9 ± 51.2 19.9 ± 18.5 41.2 ± 43.8 <0.001 <0.001 <0.001
Iron (g/day) 10.1 ± 9.9 6.9 ± 5.9 11.3 ± 8.4 <0.001 - <0.001
Hemoglobin (g/dL) 11.0 ± 1.1 10.7 ± 1.2 10.7 ± 1.1 0.017 - -
MUAC (cm) 26.3 ± 2.7 26.3 ± 2.6 26.8 ± 2.6 - - -
AMA (cm2) 35.3 ± 6.2 37.3 ± 6.5 37.0 ± 6.3 0.007 - -
AFA (cm2) 20.2 ± 8.0 18.7 ± 7.0 20.7 ± 8.5 - - 0.003
Infant weight at delivery (g) 3058.6 ± 431.4 2976.9 ± 434.4 3053.9 ± 395.2 - - -
1 Food pattern of high fish, meat and oil; 2 Food pattern of high grain and grain-derived
foods; 3 Food or food group contributed the relatively lowest mean intake across the 3
clusters; 4 Food pattern of high leafy vegetables, nuts, tubers, fruits; 5 Determined by t tests
or chi-square tests (values p < 0.017, Bonferroni adjustment for multiple comparisons);
6 CD4 and maternal work status are not included in the table because no significant
differences were found when comparing across three clusters (i.e., global p-value > 0.05).
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Figure 1. Cluster analysis of dietary patterns among HIV-infected M lawian
pregnant women.
Table 3. Predicted mean difference in arm muscle area (AMA), arm fat area (AFA),
and hemoglobin level (Hb) of women in the three clusters of dietary patterns.
Outcome Mean Difference 95% CI p value
AMA 1 (cm2)
Grain (compared to animal) 1.86 0.53 3.19 0.01
Plant (compared to animal) 1.23 −0.14 2.60 0.08
Plant (compared to grain) −0.63 −1.89 0.63 0.33
AFA 1 (cm2)
Grain (compared to animal) −2.09 −3.75 −0.44 0.01
Plant (compared to animal) 0.38 −1.33 2.08 0.67
Plant (compared to grain) 2.47 0.90 4.03 <0.01
Hb 1 (g/dL)
Grain (compared to animal) −0.27 −0.52 −0.01 0.04
Plant (compared to animal) −0.32 −0.59 −0.07 0.01
Plant (compared to grain) −0.06 −0.30 0.18 0.62
1 Adjusted for total energy intake, season, age, parity, education, wealth index, maternal
employment status, height and CD4 count.
4. Discussion
T our knowledge, this is the first study to use cluster analysis to examine
die ry pa terns among pr gnant, HIV-infected women in sub-Sahara Africa.
Thi sample represents a young group of HIV-positive Malawian wom n with
low levels of education, high une ployment, low parity and relatively high CD4
counts, indicative of good immune status. The women in our study had relatively
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healthy values of MUAC, AMA, and AFA that are representative of Malawian
women [19–21]. Despite the provision of prenatal iron tablets, women in the study
were mildly anemic. However, anemia is common among HIV-infected women in
resource-limited areas where nutritional deficiencies are compounded by parasitic
infections, compromised immunity, and the hematological consequences of chronic
and systemic inflammation [22,23].
Three key dietary patterns were identified and were associated with differences
in nutrient quality, sociodemographic characteristics, and nutritional outcomes for
the women. Women in the lowest wealth index were more likely to consume
grain-based diets with the lowest intake of energy, protein, fat, and iron. A higher
proportion of women on grain-based diets were exposed to the famine season,
which would be expected to negatively impact nutritional outcomes, and had
lower AFA compared to women on the plant-based and animal-based diets [24].
However, women on grain-based diet had a higher AMA compared to women
on animal-based diets. The higher lean muscle mass among women consuming
grain-based diets may reflect increased manual labor, such as farming. Women
on animal-based diets had the highest intake of energy, protein, and fat and had
significantly higher mean difference in hemoglobin level compared to women on the
plant-based and grain-based diets. In addition, high intake of phytate and low intake
of heme-iron results in lower bioavailability of iron, which would further compound
low iron intake.
While multiple 24-h recalls would be ideal for analyzing associations between
diet and maternal body composition [25], only one 24-h recall was collected in the
BAN Study. Although one study suggested that Malawian diets among low-income
women have little daily variation [10], another recent study among pregnant, rural
Malawian women found high within and between individual variance in energy
intakes [19]. As such, our use of only one dietary recall per participant may result
in some diet misclassification. Further misclassification may arise due to the use of
nutrient content based on the raw ingredients of each dish although several dishes
were consumed cooked.
With more than 500 dietary recalls from HIV-infected, pregnant Malawian
women, we derived dietary patterns typical of Malawians using cluster analysis
and showed that the patterns differed markedly in diet quality. The use of dietary
patterns rather than individual nutrients in assessing diet and health relationships
has emerged as a method of capturing the total diet [26–29]. This type of evaluation
allows for the examination of associations of multiple dietary components with the
outcome of interest [15]. Analyzing foods instead of nutrients makes it easier to
translate results into intervention messages. Furthermore, seasonal and cultural
factors influence diet patterns, which in turn affect nutrient intakes.
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Some limitations of the cluster analysis method include inherent subjectivity,
which occurs throughout the pattern analysis because investigators must decide
how to collapse the data into food groups and how to quantify the contribution of
each food group to the total diet [26,30,31]. Additionally, the label attributed to a
given diet pattern is a crude and sometimes subjective description, based either on
a quantitative measure of the predominant food group consumed or a qualitative
measure of health of the diet. To the best of our ability, we objectively used food
composition databases and substantial knowledge of Malawian diets to select food
groups and clusters most representative of diet patterns of Malawian women.
Although WHO and Malawi guidelines for ART initiation has changed
and many of the subjects in this study would be eligible for ART, pregnant,
HIV-infected women in Malawi could still benefit from nutritional counseling and
food supplementation to ensure greater nutrient diversity during the gestational
period, when they face additional nutrient demands to support fetal growth
and development.
5. Conclusions
In summary, we identified three patterns of diet among pregnant HIV-infected
women in Malawi, and these patterns were related to socioeconomic status as well as
nutritional outcomes. A primarily grain-based diet had the least nutrient quality, and
women consuming this diet appeared to be the most vulnerable to adverse nutritional
outcomes. This study describe typical diets of HIV-infected, pregnant women and
highlights poor quality of maternal diets that need to enhanced to meet demands of
this particular group of pregnant women, vulnerable to both HIV and malnutrition.
Therefore, nutrition interventions and food aid programs tailored to the needs of
HIV-infected pregnant women are of great importance, particularly those with low
socioeconomic status and those with limited food intake during rainy seasons when
food insecurity is at its peak. This analysis also presents a novel way to assess and
analyze dietary intake patterns among pregnant women in sub-Saharan Africa.
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High Dietary Fat Intake during Lactation
Promotes the Development of Social
Stress-Induced Obesity in the Offspring
of Mice
Tsuyoshi Tsuduki, Kazushi Yamamoto, Shuang E, Yu Hatakeyama and
Yu Sakamoto
Abstract: This study examined how a maternal high-fat diet (HD) during lactation
and exposure of offspring to isolation stress influence the susceptibility of offspring to
the development of obesity. C57BL/6J mice were fed a commercial diet (CD) during
pregnancy and a CD or HD during lactation. Male offspring were weaned at three
weeks of age, fed a CD until seven weeks of age, and fed a CD or HD until 11 weeks
of age. Offspring were housed alone (isolation stress) or at six per cage (ordinary
circumstances). Thus, offspring were assigned to one of eight groups: dams fed a CD
or HD during lactation and offspring fed a CD or HD and housed under ordinary
circumstances or isolation stress. Serum corticosterone level was significantly
elevated by isolation stress. High-fat feeding of offspring reduced their serum
corticosterone level, which was significantly elevated by a maternal HD. A maternal
HD and isolation stress had combined effects in elevating the serum corticosterone
level. These findings suggest that a maternal HD during lactation enhances the stress
sensitivity of offspring. White adipose tissue weights were significantly increased by
a maternal HD and isolation stress and by their combination. In addition, significant
adipocyte hypertrophy was induced by a maternal HD and isolation stress and
exacerbated by their combination. Thus, a maternal HD and isolation stress promote
visceral fat accumulation and adipocyte hypertrophy, accelerating the progression
of obesity through their combined effects. The mechanism may involve enhanced
fatty acid synthesis and lipid influx from blood into adipose tissue. These findings
demonstrate that a maternal HD during lactation may increase the susceptibility of
offspring to the development of stress-induced obesity.
Reprinted from Nutrients. Cite as: Tsuduki, T.; Yamamoto, K.; E, S.; Hatakeyama, Y.;
Sakamoto, Y. High Dietary Fat Intake during Lactation Promotes the Development of
Social Stress-Induced Obesity in the Offspring of Mice. Nutrients 2015, 7, 5916–5932.
1. Introduction
Obesity is characterized by an excess of adipose tissue and may induce the
development of metabolic syndrome. This syndrome is characterized in part by
hypertension, dyslipidemia, and type 2 diabetes mellitus [1,2], the progression of
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which leads to the development of highly lethal diseases such as atherosclerosis.
Therefore, it is critical to define the mechanisms underlying the pathogenesis of
obesity and to develop preventive strategies. Previous studies in humans have
shown that maternal undernutrition during pregnancy and lactation significantly
influences the susceptibility of offspring to metabolic syndrome [3,4]. Moreover, in
rats and mice, maternal overnutrition has been shown to increase the susceptibility
of offspring to the development of obesity, hypertension, and insulin resistance [5–7].
These findings have prompted researchers worldwide to study the effects of maternal
overnutrition on offspring [5–7]; in a recent study in mice, we demonstrated that a
maternal high-fat diet during lactation predisposes offspring to the development of
diet-induced obesity [8]. Unbalanced maternal nutrition is the first risk factor for the
development of metabolic syndrome to which offspring are exposed; therefore, it is
important to examine its association with other risk factors for obesity. Apart from
excessive energy intake or maternal malnutrition during pregnancy and lactation,
risk factors for obesity are ubiquitous in the daily life of humans [1,2]; of these
factors, stress has garnered particular attention recently. Stimuli that cause stress
in humans include illness, work, family problems, changes in environment, diet,
isolation, gender differences, and lack of sleep [9]. These types of stressors, referred
to as social stressors, can cause mental illnesses such as depression and can induce
bulimia and metabolic abnormalities, thereby increasing the risk of developing
metabolic syndrome, obesity, insulin resistance, cardiovascular disease, and fatty
liver in humans and mice [10–12]. Social stress is a significant risk factor for obesity
because it exists for everyone. Mice reared in isolation following weaning experience
isolation stress characterized by elevated plasma corticosterone levels, a known
stress parameter, compared with rats reared in groups [13]. Moreover, isolation stress
has been shown to increase susceptibility to metabolic syndrome in mice [11]. We
hypothesized that the interaction between two risk factors for obesity, maternal
over nutrition during lactation and isolation stress in offspring, would further
increase the susceptibility of offspring to the development of obesity. In the present
study, we tested this hypothesis in mice by examining how a maternal high-fat
diet during lactation and exposure of offspring to isolation stress influence the
susceptibility of offspring to the development of obesity, specifically via the lipid
and carbohydrate metabolic pathways. A maternal high-fat diet during lactation
was shown to increase the stress sensitivity of offspring, significantly accelerating
the progression of obesity. These findings demonstrate that a maternal high-fat diet
during lactation and isolation stress experienced by offspring may have combined
effects in increasing the susceptibility of offspring to the development of obesity.
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2. Experimental Section
2.1. Animals and Diets
All procedures were performed in accordance with the Animal Experiment
Guidelines of Tohoku University. The animal protocol was approved by the Animal
Use Committee at Tohoku University. C57BL/6J mice that were 14–16 days pregnant
were obtained from CLEA Japan (Tokyo, Japan). Dams were fed a commercial diet
(control diet, CD) (CE-2; CLEA Japan) during pregnancy. There were no significant
differences in sex distribution or litter size among the litters. After giving birth, dams
were fed a CD or a high-fat diet (HD) (Quick Fat; CLEA Japan) during lactation
(3 weeks) (Figure 1). The male offspring were weaned at 3 weeks of age. After
weaning, they were fed a CD for 4 weeks (until they were 7 weeks old) and then a CD
or an HD for 4 weeks (until they were 11 weeks old). Offspring in the isolation stress
treatment were housed at one mouse per cage immediately after weaning; mice were
considered to be housed under ordinary circumstances at six mice per cage [11]. Thus,
the offspring were assigned to one of eight groups: dams fed a CD during lactation
and offspring fed a CD and housed under ordinary circumstances (CC− group, n = 6)
or isolation stress (CC+ group, n = 6), dams fed an HD during lactation and offspring
fed a CD and housed under ordinary circumstances (HC− group, n = 6) or isolation
stress (HC+ group, n = 6), dams fed a CD during lactation and offspring fed an HD
and housed under ordinary circumstances (CH− group, n = 6) or isolation stress
(CH+ group, n = 6), and dams fed a HD during lactation and offspring fed an HD
and housed under ordinary circumstances (HH− group, n = 6) or isolation stress
(HH+ group, n = 6). Mice were housed with free access to food and distilled water
in a room at constant temperature and humidity with a 12 h light/12 h dark cycle.
The diet composition (CD or HD, g/kg diet) was as follows: nitrogen-free extract,
500 or 465; crude protein, 251 or 242; crude fat, 48 or 136; crude ash, 67 or 52; crude
fiber, 42 or 30; and moisture, 93 or 75. The energy content was 343.1 kcal/100 g diet
(CD) or 405.5 kcal/100 g diet (HD). The HD used to induce obesity was determined
with reference to a previous report [8]. At 11 weeks of age, mice were weighed and
then sacrificed by decapitation between 9:00 AM and 11:00 AM. Brain, heart, kidney,
liver, lung, spleen, epididymal white adipose tissue, mesenteric white adipose tissue,
perinephric white adipose tissue, and serum were collected and stored at −80 ◦C
until assays were performed.
2.2. Stress Parameters
Serum corticosterone levels, as a measure of stress, were determined using an
ELISA kit (Yanaihara, Fujinomiya, Japan) according to the manufacturer’s protocol.
At 11 weeks of age, mice were sacrificed by decapitation between 9:00 AM and 11:00
AM. Then, serum were collected and stored at −80 ◦C until assays were performed.
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For each sample, 10 µL of serum was used, and the absorbance was measured using
a microplate reader (Infinit F200; Tecan Japan, Kawasaki, Japan) at a wavelength
of 450 nm.
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2.3. Histological Analysis of White Adipose Tissue
Epididymal white adipose tissue was fixed in 10% formalin and embedded in
p raffin [14]. Vertical sections (5 µm) were cut, mounted on a glass slide, stained with
hematoxylin and eosin, and observed under a microscope (BZ-9000; Keyence, Osaka,
Japan). A i cyte ize was determ ed at 100×magnification using a microscope
(BZ-9000). To ensure the accuracy of measurements, we averaged 30 measurements
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for each animal (10 images of each animal analyzed by three different investigators).
Measurements were obtained from six animals per group. Data are presented as the
mean ± standard error (SE) for each group.
2.4. Biochemical Analyses of Serum
The lipid composition of serum was measured as described previously [14,15].
Triacylglycerol, total cholesterol, phospholipid, non-esterified fatty acid, and glucose
levels in serum were measured using commercial enzyme kits (Wako Pure Chemical
Industries, Osaka, Japan) according to the manufacturer’s protocol. The insulin level
in serum was determined using an ELISA kit (Shibayagi, Shibukawa, Japan).
2.5. mRNA Expression Analysis
For real-time quantitative reverse transcription PCR (qRT-PCR), total RNA
was isolated from 50 mg of white adipose tissue using an RNeasy Lipid Tissue
Mini Kit (Qiagen, Valencia, CA, USA) [14,16], eluted with 30 µL of RNase-free
water, and stored at −80 ◦C until use. The amount of total RNA was determined
spectrophotometrically at 260 nm and 280 nm. RNA integrity was confirmed by
visualizing intact 28S and 18S ribosomal RNA on a denaturing formaldehyde
agarose gel. Using a TP870 Thermal Cycler Dice Real Time System (Takara Bio,
Otsu, Japan), mRNA expression levels in white adipose tissue were determined
for the following genes: cluster of differentiation 36 (Cd36), fatty acid synthase
(Fas), glucose-6-phosphate dehydrogenase (G6pdx), glyceraldehyde-3-phosphate
dehydrogenase (Gapdh), hormone-sensitive lipase (Hsl), lipoprotein lipase (Lpl),
monocyte chemotactic protein 1 (Mcp1), malic enzyme (Me), and tumor necrosis
factor-α (Tnfa). This system allows real-time quantitative detection of PCR products
by measuring the increase in fluorescence caused by binding of SYBR Green to
double-stranded DNA. In brief, cDNA was prepared from total RNA from white
adipose tissue using a Ready-To-Go T-Primed First-Strand Kit (GE Healthcare,
Buckinghamshire, UK). The cDNA was subjected to PCR amplification using
a SYBR Premix Ex Taq (Perfect Real Time) kit (Takara Bio, Otsu, Japan) and
gene-specific primers for Cd36, Fas, G6pdx, Gapdh, Hsl, Lpl, Mcp1, Me, or Tnfa. The
primer sequences were as follows: Cd36 (NM_007643), 5′-ATGGGCTGTGATCGG
AACTG-3′ (forward) and 5′-GTCTTCCCAATAAGCATGTCTCC-3′ (reverse); Fas
(NM_007988), 5′-CCTGGATAGCATTCCGAACCTG-3′ (forward) and 5′-TTCACAG
CCTGGGGTCATCTTTGC-3′ (reverse); G6pdx (NM_008062), 5′-GAAAGCAGAGT
GAGCCCTTC-3′ (forward) and 5′-CATAGGAATTACGGGCAAAGA-3′ (reverse);
Gapdh (NM_008084), 5′-CATGTTCCAGTATGACTCCACTC-3′ (forward) and
5′-GGCCTCACCCCATTTG ATGT-3′ (reverse); Hsl (NM_001039507), 5′-TTCTCCAA
AGCACCTAGCCAA-3′ (forward) and 5′-TGTGGAAAACTAAGGGCTTGTTG-3′
(reverse); Lpl (NM_008509), 5′-GGGAGTTTGGCTCCAGAGTTT-3′ (forward)
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and 5′-TGTGTCTTCAGGGGTCCTTAG-3′ (reverse); Mcp1 (NM_011333),
5′-TGTCACCCTTGGAGCTCATG-3′ (forward) and 5′-TTTTTCGACTTTTATCCTC
TGTTG-3′ (reverse); Me (M29546), 5′-CCTCACCACTCGTGAGGTCAT-3′ (forward)
and 5′-CGAAACGCCTCGAATGGT-3′ (reverse); and Tnfa (NM_013693), 5′-GCTGT
CCCTGCGCTTCA-3′ (forward) and 5′-CTCGTCCCCAATGACATCCT-3′ (reverse).
For each gene, the PCR conditions were 95 ◦C for 10 s and then 40 cycles of 95 ◦C for
5 s and 60 ◦C for 31 s. Melting curve analysis was performed after each reaction
to confirm that a single reaction product was present. The threshold cycle is the
PCR cycle at which an increase in reporter fluorescence above a baseline signal was
first detected. The ratio of the Gapdh contents of standard and test samples was the
normalization factor.
2.6. Thiobarbituric Acid Active Substance Assay
To examine oxidative stress caused by aging, we measured the levels of
thiobarbituric acid active substances (TBARS) in white adipose tissue as described
previously [15].
2.7. Statistical Analysis
Results are expressed as mean ± SE. The significance of the effects of high
dietary fat intake in dams and isolation stress in offspring, and their interaction,
was tested using two-way ANOVAs. When a significant interaction (p < 0.05) or a
tendency to interaction (p < 0.10) was found, individual comparisons were made
using Tukey’s test. Differences were considered significant at p < 0.05.
3. Results
3.1. Stress Susceptibility
Serum corticosterone level, a known stress parameter, was determined in
offspring to examine the effects of a maternal high-fat diet during lactation on
stress sensitivity in offspring (Figure 2). Serum corticosterone level was significantly
elevated in mice housed one per cage, confirming that these mice were experiencing
isolation stress. High-fat feeding of offspring reduced their serum corticosterone level,
which was significantly elevated by a maternal high-fat diet. A maternal high-fat diet
and exposure of offspring to isolation stress were found to have combined effects in
elevating the serum corticosterone level (p = 0.097). These findings suggest that a
maternal high-fat diet during lactation increases the stress sensitivity of offspring.
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Figure 2. Effects of high dietary fat intake in dams during lactation and isolation
stress on serum corticosterone level as a stress parameter. Serum corticosterone
level was significantly increased by isolation stress (p < 0.01), and also increased
by high dietary fat intake in dams during lactation (p < 0.01). Moreover, serum
corticos erone level had a tendency to increase by a sig ificant interaction between
HD intake in dams during lactation and isolation stress of offspring (p = 0.097).
Values are means± SE, n = 6. Statistical analysis of data was performed by two-way
ANOVA followed by the Tukey-Kramer test to identify differences among groups.
Different superscript letters indicate significantly different ans at p < 0.05.
3.2. Growth Parameters
The effects of a maternal high-fat diet during lactation and exposure of offspring
to stress on the growth parameters of offspring were examined (Table 1). Offspring
body weight at weaning (three weeks old) was significantly increased by a maternal
high-fat diet. The increase in body weight caused by a maternal high-fat diet
was no longer observed at seven weeks, following four weeks of a standard diet;
however, increases in body weight due to isolation stress were observed. Body
weight at the end of the experiment (11 weeks) was significantly increased by
isolation stress, but there was no combined effect of a maternal high-fat diet and
isolation stress in offspring. Similarly, food intake was significantly increased by
isolation stress, but no combined effect of a maternal high-fat diet and isolation
stress was observed. In contrast, food intake corrected by weight was significantly
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increased by a maternal high-fat diet, but there was no combined effect of a maternal
high-fat diet and isolation stress. Calorie intake was significantly increased by a
maternal high-fat diet alone and in combination with isolation stress. The weights of
epididymal and perinephric white adipose tissues were significantly increased by
both a maternal high-fat diet and isolation stress as well as by their combination. The
weight of mesenteric white adipose tissue was significantly increased by a maternal
high-fat diet and isolation stress, but no difference was observed as a result of their
combination (p = 0.053). These results demonstrate that the weight of white adipose
tissue in offspring is increased by isolation stress, and the increase is exacerbated by
a maternal high-fat diet during lactation. However, no significant differences were
observed in the weight of brain, heart, kidney, liver, lung, or spleen as a result of the
combination of a maternal high-fat diet and isolation stress.
Table 1. Body weight, food intake and tissue weight in offspring.
CC HC CH HH Two-way ANOVA
Stress
− − − −
Mother Stress Interaction+ + + +
Body weight and food intake (g)
3-week
9.9 ± 1.0 10.9 ± 0.9 9.9 ± 0.9 11.0 ± 0.6
<0.05 ns ns
10.4 ± 0.2 11.8 ± 0.3 10.7 ± 0.2 11.7 ± 0.3
7-week
23.3 ± 0.9 24.0 ± 0.9 23.6 ± 0.6 23.5 ± 0.9 ns 0.096 ns
24.0 ± 0.6 24.4 ± 0.7 23.8 ± 0.3 24.7 ± 0.4
11-week
27.7 ± 1.1 27.6 ± 1.2 30.7 ± 0.6 30.5 ± 1.1 ns <0.01 ns




3.0 ± 0.2 3.2 ± 0.1 3.0 ± 0.1 3.0 ± 0.1 ns <0.05 ns
3.2 ± 0.2 3.3 ± 0.2 3.1 ± 0.1 3.3 ± 0.1
Food intake (g/100 g body weight/day)
Food
intake
0.11 ± 0.00 0.12 ± 0.01 0.11 ± 0.00 0.10 ± 0.00
<0.01 ns ns




10.3 ± 0.0 a 11.1 ± 0.0 a 13.5 ± 0.0 d 12.2 ± 0.0 b, c
<0.01 0.059 <0.01
11.0 ± 0.4 a 11.3 ± 0.3 a 12.9 ± 0.4 c, d 13.2 ± 0.3 c, d
Tissue weight (g/100 g body weight)
Brain
1.78 ± 0.05 1.81 ± 0.07 1.56 ± 0.03 1.62 ± 0.05 ns <0.05 ns
1.72 ± 0.03 1.75 ± 0.04 1.57 ± 0.05 1.43 ± 0.05
Heart
0.53 ± 0.04 0.53 ± 0.03 0.49 ± 0.02 0.47 ± 0.02 ns ns ns
0.52 ± 0.03 0.52 ± 0.03 0.44 ± 0.03 0.42 ± 0.02
Kidney 1.29 ± 0.05 1.17 ± 0.03 1.08 ± 0.02 1.06 ± 0.01 <0.05 0.067 ns
1.44 ± 0.16 1.23 ± 0.02 1.18 ± 0.04 1.09 ± 0.03
Liver
4.12 ± 0.11 4.15 ± 0.06 3.82 ± 0.01 3.75 ± 0.02 ns <0.01 ns
4.40 ± 0.08 4.25 ± 0.06 4.17 ± 0.06 4.08 ± 0.17
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Table 1. Cont.
CC HC CH HH Two-way ANOVA
Stress
− − − −
Mother Stress Interaction+ + + +
Lung 0.73 ± 0.05 0.77 ± 0.08 0.66 ± 0.03 0.72 ± 0.04 ns ns ns
0.69 ± 0.04 0.84 ± 0.06 0.67 ± 0.06 0.66 ± 0.04
Spleen 0.30 ± 0.02 0.30 ± 0.02 0.26 ± 0.01 0.27 ± 0.01 ns ns ns
0.29 ± 0.02 0.26 ± 0.01 0.27 ± 0.02 0.26 ± 0.03
White adipose tissue
Epididymal 0.31 ± 0.04
d 0.24 ± 0.07 d 0.86 ± 0.09 b, c 0.88 ± 0.09 b, c
<0.05 <0.01 <0.01
0.47 ± 0.06 d 0.53 ± 0.06 c, d 0.93 ± 0.16 b 1.50 ± 0.07 a
Mesenteric
0.11 ± 0.01 b 0.08 ± 0.02 e 0.33 ± 0.04 a, b, c 0.30 ± 0.03 b, c, d
<0.05 <0.01 0.053
0.19 ± 0.03 d, e 0.19 ± 0.03 c, d, e 0.37 ± 0.05 a, b 0.510.04 a
Perinephric 0.07 ± 0.01
e 0.11 ± 0.02 d, e 0.36 ± 0.04 b 0.36 ± 0.04 b
<0.01 <0.01 <0.05
0.17 ± 0.04 c, d, e 0.25 ± 0.04 b, c, d 0.37 ± 0.09 b, c 0.67 ± 0.06 a
Values are means ± SE, n = 6. a, b, c, d, e Different superscript letters indicate significantly
different means at p < 0.05. ns, no significant difference. CC- group, dams fed CD
during lactation and offspring fed CD and were under ordinary circumstance; CC+ group,
dams fed CD during lactation and offspring fed CD and were under isolation stress
circumstance; HC− group, dams fed HD during lactation and offspring fed CD and were
under ordinary circumstance; HC+ group, dams fed HD during lactation and offspring
fed CD and were under isolation stress circumstance; CH− group, dams fed CD during
lactation and offspring fed HD and were under ordinary circumstance; CH+ group,
dams fed CD during lactation and offspring fed HD and were under isolation stress
circumstance; HH−, dams fed HD during lactation and offspring fed HD and were under
ordinary circumstance; HH+, dams fed HD during lactation and offspring fed HD and
were under isolation stress circumstance.
3.3. White Adipose Tissue
Following the observation that the weight of white adipose tissue was
significantly increased by the combination of a maternal high-fat diet and isolation
stress in offspring, the size of white adipocytes, which are strongly involved in the
progression of obesity, was examined. White adipose tissue sections stained with
hematoxylin and eosin were examined under a microscope to determine adipocyte
size (Figure 3). Adipocyte hypertrophy was observed following a maternal high-fat
diet and isolation stress in offspring. The area of adipocytes was then calculated and
compared among treatment groups (Figure 4). Significant adipocyte hypertrophy
was induced by a maternal high-fat diet and isolation stress and exacerbated by
their combination. These observations demonstrate that a maternal high-fat diet
and isolation stress promote visceral fat accumulation and adipocyte hypertrophy,
accelerating the progression of obesity through their combined effects.
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Figure 3. Effects of high dietary fat intake in dams during lactation and isolation
stress on adipocytes of offspring. Hematoxylin-eosin staining of white adipose
tissue sections from representative mice of each group (scale bar = 100 µm).
Figure 4. Effects of high dietary fat intake in dams during lactation and isolation
stress on adipocyte size of offspring. Adipocyte size was significantly increased
by isolation stress (p < 0.01), and also increased by high dietary fat intake in dams
during lactation (p < 0.01). Moreover, adipocyte size was significantly increased
by a significant interaction between HD intake in dams during lactation and
isolation stress of offspring (p < 0.01). Values are means ± SE, n = 6. Statistical
analysis of data was performed by two-way ANOVA followed by the Tukey-Kramer
test to identify differences among groups. Different superscript letters indicate
significantly different means at p < 0.05.
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3.4. Expression of mRNA for Genes Related to Lipid Metabolism and Inflammation in White
Adipose Tissue
The expression of mRNA for genes involved in lipid metabolism and
inflammation in white adipose tissue was analyzed by qRT-PCR to examine the
mechanism by which the combination of a maternal high-fat diet and isolation stress
in offspring promotes visceral fat accumulation and adipocyte hypertrophy (Table 2).
Fas and Me are both involved in fatty acid biosynthesis. The expression of Fas mRNA
was significantly increased by isolation stress alone and in combination with a
maternal high-fat diet. The expression of Me mRNA was significantly increased
by a maternal high-fat diet, but no difference was observed as a result of the
combination of a maternal high-fat diet with isolation stress. The expression of
mRNA for three genes (Lpl, Hsl, and Cd36) involved in lipid influx from blood
into adipocytes was also determined. The expression of mRNA for Lpl, which is
involved in lipoprotein degradation, increased as a result of a maternal high-fat diet
(p = 0.064), and the increase was significantly greater in combination with isolation
stress. The expression of mRNA for Hsl, which is involved in fatty acid secretion from
adipocytes into blood, was significantly reduced by isolation stress, but no difference
was observed as a result of the combination of isolation stress with a maternal
high-fat diet. No significant difference was observed in the expression of mRNA for
Cd36, which is involved in fatty acid influx. These findings suggest that a maternal
high-fat diet and isolation stress in offspring have combined effects in promoting
fatty acid synthesis and lipid influx in white adipose tissue, thereby accelerating
adipocyte hypertrophy and the increase in white adipose tissue weight in offspring.
The expression of mRNA for two genes involved in inflammation, Mcp1 and Tnfa,
was also determined. The expression of Mcp1 mRNA was significantly increased by a
maternal high-fat diet and isolation stress, but no difference was observed as a result
of their combination. The expression of Tnfa mRNA was significantly increased by a
maternal high-fat diet, but no difference was observed as a result of the combination
of a maternal high-fat diet with isolation stress. These observations suggest that a
maternal high-fat diet significantly affects the expression of mRNA for genes related
to inflammation, although no combined effect with isolation stress was observed.
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Table 2. mRNA expression levels for lipid and carbohydrate metabolism and
inflammation-related genes in white adipose tissue of offspring.
CC HC CH HH Two-way ANOVA
Stress
− − − −
Mother Stress Interaction+ + + +
(Ratio)
Cd36
1.00 ± 0.28 0.94 ± 0.40 1.15 ± 0.43 1.89 ± 0.43 ns ns ns
1.37 ± 0.21 1.32 ± 0.71 0.24 ± 0.03 0.81 ± 0.23
Fas
1.00 ± 0.21 c, d 0.47 ± 0.13 d 3.47 ± 1.05 a, b, c 2.64 ± 0.36 b, c, d ns <0.05 <0.05
0.57 ± 0.13 c, d 1.28 ± 0.28 b, c, d 4.01 ± 1.19 a, b 5.77 ± 0.63 a
Hsl
1.00 ± 0.44 1.09 ± 0.38 0.24 ± 0.13 0.32 ± 0.12 ns < 0.05 ns0.59 ± 0.09 0.27 ± 0.16 0.11 ± 0.01 0.09 ± 0.02
Lpl 1.00 ± 0.14
a, b 0.38 ± 0.11 b 1.04 ± 0.13 a, b 1.39 ± 0.19 a, b
0.064 ns <0.05
0.51 ± 0.10 a, b 1.28 ± 0.49 a, b 0.81 ± 0.06 a, b 1.43 ± 0.11 a
Me
1.00 ± 0.23 0.63 ± 0.11 0.92 ± 0.07 2.92 ± 0.70
<0.05 ns ns1.51 ± 0.25 1.28 ± 0.47 0.78 ± 0.19 2.35 ± 0.25
MCP-1
1.00 ± 0.23 1.28 ± 0.40 1.97 ± 0.35 3.47 ± 0.83
<0.01 <0.05 ns1.16 ± 0.12 2.00 ± 0.61 4.22 ± 0.76 4.68 ± 1.09
TNF-α
1.00 ± 0.43 1.34 ± 0.30 4.09 ± 1.40 4.51 ± 1.77
<0.01 ns ns2.19 ± 0.57 2.33 ± 0.52 4.29 ± 0.80 6.40 ± 1.39
Values are means ± SE, n = 6. a, b, c, d Different superscript letters indicate significantly
different means at p < 0.05. ns, no significant difference. Cd36, cluster of differentiation 36;
Fas, fatty acid synthase; Hsl, hormone sensitive lipase; Lpl, lipoprotein lipase; Me, malic
enzyme. CC− group, dams fed CD during lactation and offspring fed CD and were under
ordinary circumstance; CC+ group, dams fed CD during lactation and offspring fed CD
and were under isolation stress circumstance; HC− group, dams fed HD during lactation
and offspring fed CD and were under ordinary circumstance; HC+ group, dams fed
HD during lactation and offspring fed CD and were under isolation stress circumstance;
CH− group, dams fed CD during lactation and offspring fed HD and were under ordinary
circumstance; CH+ group, dams fed CD during lactation and offspring fed HD and were
under isolation stress circumstance; HH−, dams fed HD during lactation and offspring
fed HD and were under ordinary circumstance; HH+, dams fed HD during lactation and
offspring fed HD and were under isolation stress circumstance.
3.5. Lipid and Carbohydrate Parameters in Serum
Parameters of lipid and carbohydrate metabolism in offspring were determined
(Table 3). Serum triacylglycerol levels were significantly reduced as a result of a
maternal high-fat diet and isolation stress, and serum free fatty acid levels were
significantly reduced as a result of isolation stress. However, there were no combined
effects of a maternal high-fat diet and isolation stress on either of these parameters.
No significant change was observed in serum total cholesterol levels. Serum
phospholipid levels were significantly elevated as a result of a maternal high-fat diet,
and they increased further as a result of the combination of a maternal high-fat diet
with isolation stress (p = 0.083). These results indicate that both a maternal high-fat
diet and isolation stress in offspring influence lipid parameters, but no combined
effects were observed. Isolation stress significantly elevated serum glucose levels,
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which appeared to cause an increase in serum insulin levels as well (p = 0.064).
These observations suggest that isolation stress in offspring significantly affects
carbohydrate parameters, although no combined effect with a maternal high-fat diet
was observed. Serum adiponectin levels were significantly elevated as a result of
isolation stress, and serum leptin levels were significantly elevated as a result of
a maternal high-fat diet and isolation stress. In addition, TBARS levels in white
adipose tissue were significantly elevated as a result of isolation stress. These
observations suggest that isolation stress in offspring significantly affects adiponectin,
leptin, and TBARS levels, although no combined effect with a maternal high-fat diet
was observed.
Table 3. Serum lipid and carbohydrate metabolism parameters and stress
parameter, and TBARS in white adipose tissue (WAT) of offspring.
CC HC CH HH Two-way ANOVA
Stress
− − − −
Mother Stress Interaction+ + + +
TG (mmol/L)
1.08 ± 0.02 0.94 ± 0.07 1.44 ± 0.08 1.22 ± 0.08
<0.05 <0.01 ns0.90 ± 0.07 0.73 ± 0.08 1.09 ± 0.05 1.20 ± 0.08
TC (mmol/L)
1.54 ± 0.09 1.70 ± 0.12 2.19 ± 0.07 2.24 ± 0.03 ns ns ns
1.66 ± 0.04 1.61 ± 0.08 2.43 ± 0.15 2.56 ± 0.17
PL (mmol/L)
2.27 ± 0.13 d 2.65 ± 0.07 b, c 2.69 ± 0.05 a, b, c 2.95 ± 0.03 a
<0.01 ns 0.083
2.19 ± 0.04 d 2.00 ± 0.08 c, d 2.98 ± 0.05 a, b, c 3.01 ± 0.10 a
NEFA (mEq/L) 0.91 ± 0.06 0.91 ± 0.08 0.85 ± 0.01 0.79 ± 0.02 <0.01 ns0.76 ± 0.06 0.67 ± 0.01 0.80 ± 0.03 0.77 ± 0.05
Glucose
(mmol/L)
8.4 ± 0.7 8.7 ± 0.4 9.9 ± 0.6 10.8 ± 0.4
0.100 <0.01 ns12.6 ± 0.9 12.8 ± 0.8 14.1 ± 0.8 16.4 ± 1.3
Insulin (ng/mL) 0.43 ± 0.16 1.54 ± 0.87 0.46 ± 0.11 1.56 ± 0.84 ns 0.064 ns1.88 ± 0.94 2.18 ± 1.00 2.82 ± 1.14 2.03 ± 1.32
Adiponectin
(µg/mL)
3.19 ± 0.62 3.89 ± 0.26 3.51 ± 0.38 3.88 ± 0.27 ns <0.05 ns2.56 ± 0.12 2.86 ± 0.45 2.43 ± 0.26 3.57 ± 0.59
Leptin (ng/mL) 0.29 ± 0.01 0.34 ± 0.01 0.74 ± 0.01 0.81 ± 0.04 <0.01 <0.01 ns0.37 ± 0.02 0.47 ± 0.02 0.92 ± 0.03 1.10 ± 0.13
WAT TBARS
(nmol/g WAT)
2.05 ± 0.19 2.82 ± 0.36 2.71 ± 0.21 2.91 ± 0.15 ns <0.05 ns3.01 ± 0.29 3.02 ± 0.28 3.12 ± 0.15 3.39 ± 0.41
Values are means ± SE, n = 6. a, b, c, d Different superscript letters indicate significantly
different means at P<0.05. ns, no significant difference. TG, triacylglycerol; TC, total
cholesterol; PL, phospholipid; NEFA, non-esterified fatty acid. CC− group, dams fed CD
during lactation and offspring fed CD and were under ordinary circumstance; CC+ group,
dams fed CD during lactation and offspring fed CD and were under isolation stress
circumstance; HC- group, dams fed HD during lactation and offspring fed CD and were
under ordinary circumstance; HC+ group, dams fed HD during lactation and offspring
fed CD and were under isolation stress circumstance; CH− group, dams fed CD during
lactation and offspring fed HD and were under ordinary circumstance; CH+ group,
dams fed CD during lactation and offspring fed HD and were under isolation stress
circumstance; HH−, dams fed HD during lactation and offspring fed HD and were under
ordinary circumstance; HH+, dams fed HD during lactation and offspring fed HD and
were under isolation stress circumstance.
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4. Discussion
We recently demonstrated that maternal overnutrition during lactation increases
the susceptibility of offspring to the development of diet-induced obesity [8]. It has
also been reported that social stress, such as isolation, can be a risk factor for the
development of obesity [10]. The present study, in mice, examined the combined
effects of a maternal high-fat diet during lactation and exposure of offspring to
isolation stress on the susceptibility of offspring to the development of obesity.
Serum corticosterone levels were determined to assess the effects of a maternal
high-fat diet during lactation on stress sensitivity in offspring. Serum corticosterone
levels were significantly elevated by isolation stress and a maternal high-fat diet,
and the two treatments appeared to have combined effects in elevating serum
corticosterone levels (Figure 2). Several studies have demonstrated that serum
corticosterone levels increase with exposure to chronic isolation stress or intense
stress; serum corticosterone is thus known to be an important stress parameter [17,18].
In addition, serum corticosterone has been shown to play a critical role in the
progression of obesity because it elevates blood glucose levels [19]. Thus, alteration
of serum corticosterone levels is a critical parameter of both stress exposure and the
development of obesity. We have recently demonstrated that a maternal high-fat diet
during lactation increases the lipid and calorie contents of dam’s milk [8]. Therefore,
we hypothesized that if offspring of a mother that consumed a high-fat diet were
fed a high-calorie diet during infancy, their steady-state blood glucose level would
be elevated, which is known to alleviate stress. Upon exposure to stress, blood
glucose levels in these offspring would increase more than those in offspring fed a
normal diet during infancy, leading to secretion of larger amounts of corticosterone.
In addition, serum corticosterone levels are known to be reduced by consumption
of a high-fat diet [20]. In the present study, high-fat feeding of offspring reduced
their corticosterone levels (Figure 2). However, corticosterone levels were found
to be high in the HH+ group, in which visceral fat accumulation was strongly
promoted, suggesting that individuals in the HH+ group experienced greater stress.
These findings suggest that a maternal high-fat diet during lactation increases the
stress sensitivity of offspring, thereby facilitating the development of stress-induced
obesity. Moreover, significant adipocyte hypertrophy was observed as a result of the
combined effects of a maternal high-fat diet and isolation stress (Figures 3 and 4).
This demonstrates that a maternal high-fat diet during lactation and isolation stress
have combined effects in facilitating the development of obesity in offspring.
The mechanisms underlying adipocyte hypertrophy were examined next. The
mRNA expression levels of Lpl, which facilitates lipid influx from blood [21], and
Fas, which facilitates fatty acid synthesis [22], were increased by the combined effects
of a maternal high-fat diet and isolation stress in offspring (Table 2). This suggests
that triacylglycerol accumulation in white adipose tissue was facilitated by increased
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fatty acid synthesis and lipid influx from blood. The expression of Fas and Lpl
mRNA in adipose tissue was increased by a maternal high-fat diet during lactation,
consistent with our previous report [8]. Social stress has also been reported to increase
expression of Fas [23]. The present study demonstrated that the expression of these
genes in adipose tissue is further increased by the combination of a maternal high-fat
diet during lactation and isolation stress. In addition, in this study, an increase in
calorie intake was observed as a result of the combination of a maternal high-fat
diet and isolation stress in offspring. Therefore, calorie intake may also be related to
adipocyte hypertrophy.
Offspring body weight at weaning was significantly increased by a maternal
high-fat diet, consistent with our previous report [8] (Table 1). The increase in
food intake observed as a result of isolation stress was also consistent with a
previous report [10] (Table 1), suggesting its involvement in the progression of obesity.
A maternal high-fat diet significantly reduced kidney weight, whereas isolation
stress significantly reduced brain weight and increased liver weight (Table 1). These
changes occurred as a result of the body weight increase associated with visceral fat
accumulation, and no significant changes were observed when the values were not
corrected for body weight.
Serum glucose level, which is known to increase in response to stress [9],
was significantly increased as a result of exposure of offspring to isolation stress
(Table 3). Serum insulin level appeared to increase as a result of isolation stress
(Table 3), which may be a response to the increased blood glucose level caused by
isolation stress. Moreover, insulin, as well as corticosterone, has been reported to
facilitate lipid synthesis in white adipose tissue [24]. This suggests that the observed
decrease in serum triacylglycerol and free fatty acid levels was a result of these
molecules being used for lipid synthesis (Table 3). Additionally, the significant
decrease in the mRNA expression level of Hsl, which functions in triacylglycerol
degradation, may also have played a role (Table 2). These findings demonstrate that
several parameters of serum lipid and carbohydrate metabolism are significantly
influenced by a maternal high-fat diet and isolation stress. In addition, it has been
reported that adipocyte hypertrophy causes an increase in serum leptin level and
a decrease in serum adiponectin level [14,15]. Similar observations were made in
this study. These findings demonstrate that serum leptin and adiponectin levels are
significantly influenced by a maternal high-fat diet and isolation stress. It has also
been shown that adipocyte hypertrophy causes an increase in mRNA expression
levels for inflammation-related genes such as Mcp1 and Tnfa [25]. Similar phenomena
were observed in this study. These findings demonstrate that mRNA expression
levels for inflammation-related genes are significantly influenced by a maternal
high-fat diet and isolation stress. Moreover, our study confirms previous reports that
the inflammatory condition increases oxidative stress [8,16], demonstrating that the
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level of oxidative stress is significantly influenced by a maternal high-fat diet and
isolation stress.
In this study, corticosterone level was the only stress parameter used. Although
other studies have used corticosterone level as the only stress parameter, it will be
necessary to confirm the degree of stress using several stress parameters in the future.
The weaning weight of the offspring (three weeks old) was increased by a
maternal high-fat diet during lactation. This difference disappeared after offspring
were fed a control diet from three to seven weeks of age. However, the risk of offspring
becoming obese at 11 weeks of age was changed by the diet of the dams. This suggests
that metabolic memory during infancy influences future metabolism in offspring.
Recent studies suggest that epigenetic mechanisms such as DNA methylation and
histone acetylation are involved in this phenomenon. For example, it is known that
DNA methylation influences the mRNA level of genes related to lipid metabolism
and that high dietary fat intake alters DNA methylation [26]. Furthermore, maternal
nutritional status during pregnancy and lactation can influence the methylation of
genes related to lipid metabolism in offspring [27,28]. Therefore, these epigenetic
mechanisms may underlie the results obtained in this study. Further studies are
needed to confirm this hypothesis. Fatty acid biosynthesis may also be involved in
the observed changes in white adipose tissue weights because the mRNA level of Fas,
which promotes fatty acid biosynthesis [22], was significantly increased by high-fat
feeding of offspring. This increase may account for the increased lipid accumulation
in adipocytes. Epigenetic mechanisms may also underlie this result, and further
studies are needed to examine this hypothesis as well.
In humans, maternal overnutrition has been shown to increase the susceptibility
of offspring to the development of obesity, hypertension, and insulin resistance [5–7].
In addition, social stressors (events in everyday life, including illness, work, family
problems, changes in environment, diet, isolation, gender differences, and lack of
sleep) have been shown to cause mental illnesses such as depression and to induce
bulimia and metabolic abnormalities, thereby increasing the risk of developing
metabolic syndrome, obesity, insulin resistance, cardiovascular disease, and fatty
liver [9–12]. Therefore, the possibility that a similar phenomenon occurs in humans
was suggested, though the present study was an examination of mice.
5. Conclusions
Maternal nutritional status is the first risk factor for the development of obesity
to which offspring are exposed; therefore, it is important to elucidate its association
with other risk factors for the development of obesity. The findings of the present
study demonstrate that a maternal high-fat diet during lactation and isolation stress
in offspring may interact to significantly facilitate the development of obesity.
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Altered Fetal Skeletal Muscle Nutrient
Metabolism Following an Adverse In Utero
Environment and the Modulation of Later
Life Insulin Sensitivity
Kristyn Dunlop, Megan Cedrone, James F. Staples and Timothy R.H. Regnault
Abstract: The importance of the in utero environment as a contributor to later
life metabolic disease has been demonstrated in both human and animal studies.
In this review, we consider how disruption of normal fetal growth may impact
skeletal muscle metabolic development, ultimately leading to insulin resistance
and decreased insulin sensitivity, a key precursor to later life metabolic disease. In
cases of intrauterine growth restriction (IUGR) associated with hypoxia, where the
fetus fails to reach its full growth potential, low birth weight (LBW) is often the
outcome, and early in postnatal life, LBW individuals display modifications in the
insulin-signaling pathway, a critical precursor to insulin resistance. In this review,
we will present literature detailing the classical development of insulin resistance
in IUGR, but also discuss how this impaired development, when challenged with
a postnatal Western diet, may potentially contribute to the development of later
life insulin resistance. Considering the important role of the skeletal muscle in
insulin resistance pathogenesis, understanding the in utero programmed origins
of skeletal muscle deficiencies in insulin sensitivity and how they may interact
with an adverse postnatal environment, is an important step in highlighting
potential therapeutic options for LBW offspring born of pregnancies characterized
by placental insufficiency.
Reprinted from Nutrients. Cite as: Dunlop, K.; Cedrone, M.; Staples, J.F.;
Regnault, T.R.H. Altered Fetal Skeletal Muscle Nutrient Metabolism Following an
Adverse In Utero Environment and the Modulation of Later Life Insulin Sensitivity.
Nutrients 2015, 7, 1202–1216.
1. Introduction
Recent clinical, epidemiological and animal studies have highlighted an
association between an altered, adverse in utero environment and growth, and the
subsequent propensity of these offspring to develop hallmarks of the metabolic
syndrome [1–3]. The metabolic syndrome is a cluster of factors indicative of
altered metabolism, including hypertension, visceral obesity, glucose intolerance and
dyslipidemia, that predispose the patient to the development of comorbidities such
as cardiovascular disease, non-alcoholic fatty liver disease and type 2 diabetes [4].
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Decreased insulin sensitivity, or insulin resistance, is a critical precursor of the
metabolic syndrome, as it is typically evident before other overt symptoms are
apparent; and therefore it may represent an early, key step in the pathophysiological
progression towards the metabolic syndrome [4].
It has been postulated that the origins of the metabolic syndrome, and insulin
resistance specifically, originate during fetal development and early postnatal life [5].
As such, an adverse in utero environment has the potential to influence the relative
risk of the offspring to the development of aberrant nutrient metabolism in later life,
independently of postnatal diet. An adverse in utero environment, often characterized
by suboptimal nutrient transfer to the fetus, culminates in intrauterine growth
restriction (IUGR). IUGR is the endpoint of a continuum of conditions that result in
the failure of the fetus to attain its inherent growth potential, which can be diagnosed
using ultrasonography during pregnancy [6]. Clinically, IUGR often results in a baby
born with a weight or length below the 10th percentile for gestational age [6,7].
The etiology of IUGR is multifactorial, with adverse environmental or genetic
and epigenetic factors likely playing a role in the abnormal growth and development
of the fetus. One of the most important environmental factors regulating fetal growth,
is nutrient delivery to the fetus via placental diffusion and transport [7]. A reduced
functional capacity of the placenta, or placental insufficiency, is typically associated
with poor placental vascular development, which prevents adequate nutrition and
oxygen from reaching the developing fetus, resulting in a hypoxic, nutrient deprived
in utero environment. Interestingly, it should be noted that, independent of reductions
in nutrient supply, hypoxia alone has been shown to have a significant impact on
fetal growth, emphasizing hypoxia as a key contributor to impaired fetal growth and
potentially IUGR [8].
With exposure to a hypoxic in utero environment, the fetus undergoes some
key adaptations to ensure survival. A key component of this adaptation in the
acute setting has been considered a redistribution of fetal cardiac output towards
essential organs such as the brain, heart and adrenal glands, at the expense of other
organ systems, including the lungs, kidney, liver and skeletal muscle [9–11]. With
prolonged hypoxia, animal and human studies have highlighted a redistribution
of blood flow toward the brain, as well as increased blood flow towards adrenal
glands [12–15], and it is inferred from this redistribution that the brain continues to
receive sufficient perfusion and nutrient supply to maintain relative growth. This
brain sparing effect is visible at birth, with the size of the fetal head being larger than
that of the abdomen, giving rise to an observable asymmetrical growth restriction.
Concurrent with the overall reduction in body weight and brain sparing effect,
fetuses exposed to hypoxic in utero environments also display a reduced muscle
mass compared with normal birth weight offspring [16,17], and are predisposed
to altered insulin sensitivity [1,3,5,18]. Furthermore, rodent models of low birth
293
weight have also demonstrated a decrease in skeletal muscle mass [19], similar to
the altered muscle to fat ratio observed in older men who were born low birth
weight [20]. With this altered development there are metabolic changes to the
offspring, resulting in what has been proposed as a “thrifty phenotype” [1,18]. The
“thrifty phenotype” encompasses a collection of metabolic adaptations initiated to
aid in fetal survival when challenged with nutrient deprivation in utero [21]. While
the “thrifty phenotype” represents the observable phenotype associated with IUGR,
theories of fetal programming postulate that altered oxygen and nutrient transfer
during critical windows of development, when the fetus is most sensitive to its
environment, are associated with permanent alterations in structure and metabolism,
and a fixed functional capacity of vital organs in postnatal life [1]. Since the plasticity
of the organs in utero is lost in postnatal life, adaptations to these metabolic organs
initiated in utero may persist into adulthood, increasing the propensity for these
offspring to develop metabolic disease with age [1,22].
Markers of altered fetal growth (including low weight at birth and asymmetric
growth) are most widely used as indicators of IUGR or a hypoxic in utero environment.
However, more subtle adaptations at the physiological level may be the drivers
underlying the observable later life phenotypes, such as changes in skeletal muscle
metabolic function and anabolic capacity, and overall oxygen consumption. Once
the organs have fully developed in utero, the IUGR fetus faced with a postnatal
environment characterized by nutrient excess, a highly prevalent and easily accessible
diet in modern society, may develop long-term adverse metabolic consequences [1,
5,18]. Unfortunately, the mechanisms underlying these alterations in the metabolic
capacity of the IUGR fetus and their propensity towards the development of later
life insulin resistance and the metabolic syndrome remain poorly defined.
2. Skeletal Muscle Insulin Signaling and IUGR
Skeletal muscle is the primary location for insulin-stimulated glucose uptake,
accounting for up to 70% of whole body glucose disposal [23], and is a key
regulator of whole body energy metabolism [24], with other metabolic organs,
including liver, adipose tissue and pancreas also involved in the insulin response and
pathogenesis of insulin resistance. The primary metabolic objective in the skeletal
muscle is production of ATP for contractile purposes; however, skeletal muscle is
also responsible for the production and storage of glycogen, an insulin dependent
process that provides the cells with glucose for ATP production when circulating
levels are low. β-oxidation, a process whereby free fatty acids are broken down to
provide muscle with carbon chain substrates, is also important for skeletal muscle
ATP production. Since the skeletal muscle is a critical producer of ATP and an
important location for glucose and fat metabolism, determining the propensity of
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skeletal muscle towards developing insulin resistance is a key determinant in the
pathophysiological progression towards metabolic syndrome.
Depressed insulin sensitivity, or insulin resistance, is a metabolic state in which
peripheral tissues, such as skeletal muscle, are no longer responsive to the anabolic
effects of insulin, thereby reducing insulin-stimulated glucose uptake and perpetuating
a state of hyperglycemia. Insulin resistance at the level of the skeletal muscle has been
associated with a modulation of the serine/threonine phosphorylation status of insulin
receptor substrates (IRS) [25–27]. A relative increase in the serine phosphorylation of
IRS-1, the predominant isoform in skeletal muscle [28], at Ser307 reduces its ability to
activate or complex with phosphatidylinositol 3-kinase (PI3-kinase). This activation
failure impairs downstream phosphorylation of protein kinase B (Akt) at Ser473, and
Akt Substrate of 160 kDa (AS160) at Thr642, ultimately leading to a reduction in
glucose uptake into skeletal muscle cells through glucose transporter 4 (GLUT4)
transporters [25,27,29].
A hypoxic in utero environment, commonly associated with IUGR, is known
to negatively influence the fetus during critical periods of development [1,5,18].
Interestingly, IUGR offspring in animal models display improved insulin sensitivity
in very early postnatal life, as assessed by intravenous glucose tolerance challenge;
however, a shift towards impaired glucose clearance and decreased insulin sensitivity
is evident as these offspring age [30–32]. The timing of this shift in insulin sensitivity
appears to be sex-specific, with insulin action being impaired earlier in males and
later in females [30]. These animal studies highlight that sexually dimorphic effects
occur with adverse in utero environments, and in the case of insulin resistance,
studies suggest males appear to be more susceptible to a programmed later life
insulin resistance [30,33].
Interestingly however, this sex-specific programming of insulin resistance may
not exist in humans. In a mixed cohort of offspring aged 25 who were growth
restricted in utero, a significantly lower insulin-stimulated glucose uptake was
observed compared to controls, as well as a higher plasma insulin concentration,
suggesting the development of insulin resistance. Of note, these observations were
in conjunction with a normal glucose tolerance challenge, thus representing an early
phase in the pathogenesis to insulin resistance and the metabolic syndrome [34].
However, by age 64, men who were born small exhibited a strong link with impaired
glucose tolerance and type 2 diabetes [35], while data concerning women born small
is not widely available. Therefore, understanding the early steps in the progression
towards insulin resistance in the low birth weight population, and any sex-specific
effects, is of critical importance for mitigating the risk of these offspring to the
development of later life type 2 diabetes.
Animal models of IUGR, as well as some human studies, have also been
used in order to identify the molecular changes occurring at the level of the
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insulin-signaling cascade that may be underlying the reduced insulin sensitivity
in this population [29,36]. In early postnatal life, expression of the insulin receptor
is increased in low birth weight sheep, as a compensatory mechanism for the low
insulin and glucose levels experienced in utero [37]. However, the expression of the
insulin receptor is no different to normal birth weight controls in skeletal muscle of
older low birth weight rodent offspring, highlighting that the later life alterations
in insulin sensitivity are likely due to a defect down-stream of the receptor that
affects the ability of GLUT4 to translocate to the membrane and take glucose into
the cell [36]. Analysis of key intermediates in the insulin signaling cascade has
demonstrated sex-specific alterations that may be responsible for altered GLUT4
expression and reduced glucose uptake that is associated with states of insulin
resistance [17,29,36,38].
In rodent models of placental insufficiency, young adolescent male offspring
show altered GLUT4 transport in conjunction with an increased phosphorylation
of IRS-1 [29], which is known to blunt the physiological response to insulin [27]
by reducing the coupling efficiency of the insulin receptor and IRS-1 [39]. IRS-1
is also known to complex with PI3-kinase, and in young male low birth weight
offspring, reduced expression of the p85 regulatory subunit and p110β catalytic
subunit of PI3K has also been observed in rodent, as well as larger animal (e.g.,
sheep) models of placental insufficiency [31,36,37]. Downstream of IRS-1, the total
Akt levels were not altered by insulin infusion in growth restricted males [29,36];
however, phosphorylation of this intermediate was increased by insulin, suggesting
a compensatory mechanism may be at play to maintain this physiological response to
exogenous insulin [29]. Although Akt’s involvement in the insulin cascade appears
to be unaffected, downstream AS160 shows reduced phosphorylation in response to
insulin [29], suggesting a functional impairment that impacts GLUT4 translocation
to the plasma membrane [40].
In young adolescent female rodent offspring, the phosphorylation status of Akt is
higher in the basal state, and insulin infusion is still able to increase the phosphorylation
further. Additionally, there are no changes in the phosphorylation of protein kinase C
isoforms and an increased phosphorylation of phosphoinositide-dependent kinase
(PDK), all of which point to programming of heightened insulin sensitivity [38]. This
heightened sensitivity is in accordance with the early improvement observed in
sheep models [30], and may represent a protective response initiated to maintain
whole body insulin sensitivity at this early age [38]. However, despite this enhanced
sensitivity during the growth phase, with age these offspring exhibited a decrease in
insulin sensitivity and progression towards an insulin resistant phenotype [41].
Human data has suggested similar molecular alterations are present in young
males born low birth weight, including reduced expression of the p85 and p110β
subunits of PI3-kinase and reduced skeletal muscle GLUT4 content [16,36]. These
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alterations occur in conjunction with a blunted phosphorylation of Akt in response to
insulin infusion, but with maintenance of glucose tolerance and whole body insulin
sensitivity [16,36]. Taken together, changes in the molecular expression of key insulin
signaling intermediates in skeletal muscle of low birth weight offspring may precede
development of whole body insulin resistance and glucose intolerance, representing
an early defect in metabolism that could be indicative of future metabolic disease [36].
However, the mechanisms by which the in utero environment may be modulating
these changes in insulin sensitivity remain ill defined.
3. Fiber Type, Oxygen Consumption and IUGR
Skeletal muscle has a high demand for energy in order to perform its contractile
function, with most of its energy requirement being met through oxidative
phosphorylation (OXPHOS). While OXPHOS produces greater amounts of adenine
triphosphate (ATP) than glycolysis, it is an aerobic process requiring oxygen,
conducted within the Krebs cycle and electron transport system of the mitochondria.
The density of mitochondria is the primary determinant of oxidative capacity, and
this is ultimately set by fiber type and fiber distribution within the skeletal muscle
bed. There are a number of different skeletal muscle fiber types distinguished
primarily by their oxidative capacity. Type Ia (slow oxidative) fibers are the
most mitochondria-rich fibers, and type IIb (fast glycolytic) fibers have the least
mitochondria and thus the lowest oxidative capacity. Types IIa and IIx (fast oxidative)
fibers have an intermediate number of mitochondria and oxidative capacity [42].
Maximal rates of OXPHOS is dictated by mitochondrial number and consequently
directly related to fiber type composition [43,44].
OXPHOS is adversely affected in skeletal muscle of growth-restricted
animals [19,45,46], in conjunction with decreased mitochondrial number [19].
These factors, combined with a lowered ATP production are associated with the
development of insulin resistance [47,48]. The individual OXPHOS complexes,
including ATPase activity, have been studied using respirometry, a technique
measuring oxygen consumption using a number of substrates that are metabolized by
individual complexes within a closed cell chamber. The rate of oxygen consumption
is measured in “states”, where state 1 represents baseline respiration, state 2
follows the addition of malate and glutamate, malate and pyruvate (metabolized
as NADH at complex 1) or rotenone and succinate (rotenone inhibiting complex 1
and succinate metabolized at complex 2). State 3 respiration follows the addition
of ADP (measuring ATPase activity) and state 4 follows the addition of oligomycin
(inhibiting ATPase activity). The ratio of state 3/state 4 respiration rates, termed
the respiratory control ratio (RCR), is commonly used to measure mitochondrial
dysfunction. Generally, a low RCR is associated with mitochondrial dysfunction
as it measures how tightly respiration and phosphorylation are coupled. In rats,
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IUGR skeletal muscle state 3 was decreased irrespective of substrate used, compared
to controls.
In addition to impaired OXPHOS reported in IUGR rats, reduced fetal glucose
oxidation is observed in the heat stress ovine IUGR model [49]. These changes may
reflect in the in utero determination of skeletal muscle fiber type composition of low
birth weight offspring later in life [17,19,50]. In human studies, low birth weight is
associated with an increase in type II fibers and no change in type I fibers at 19 years
of age [17], and an increased proportion of glycolytic fibers are reported to precede
insulin resistance in the vastus lateralis of low birth weight males [17]. In rodent
studies, IUGR offspring exhibit a lower proportion of type Ia muscle fibers [19] and
a shift towards more glycolytic (type IIb) fibers [17], ultimately altering the oxidative
capacity and GLUT4 content of the muscle fibers. The results of these adverse in utero
associated changes however, is not always consistent. For instance, in IUGR piglet
studies, the proportion of type I fibers increase in the hind-limb muscles, but the
proportion of type IIb were not reported due to methodological difficulties [51,52].
These conflicting conclusions may lie, in part, to species differences, age of fiber
collection, but also may be due to the different muscle groups studied.
It is interesting to note that the alterations in skeletal muscle fiber composition
and function early in life in low birth weight, IUGR offspring as reported above, appear
similar to those observed in later life obese and type 2 diabetic individuals [53,54]. This
similarity potentially highlights possible similar mechanisms at play in low birth
weight offspring as those at work in patients with a propensity to develop insulin
resistance and subsequent type 2 diabetes with age, independent of birth weight and
an adverse in utero environment. Understanding these similarities will help define
the mechanisms underlying altered fiber type distribution and oxygen utilization
changes in these various disease states.
4. The Impact of IUGR and Later Life Impaired Skeletal Muscle Fat Metabolism
upon the Progression of Insulin Resistance
A key traditional factor identified in the development of insulin resistance has
been poor diet. The increasing prevalence of a “Western”, or energy-dense, high-fat
diet has been implicated as a key-contributing factor in the pathogenesis of insulin
resistance, promoting accumulation of fat within the skeletal muscle and impacting
mitochondrial function [55–57], leading to a diminished mitochondrial fatty acid
oxidation capacity [58]. Consumption of this diet generates a surplus of free fatty
acids, ultimately leading to ectopic lipid accumulation in non-adipose tissues such
as skeletal muscle [59]. Once in the skeletal muscle, excess fatty acids are activated
to form their acyl-CoA derivatives, which can be esterified into diacylglycerol
(DAG), metabolized into ceramide, or conjugated to acylcarnitine for entry into the
mitochondria to undergo β-oxidation [60]. Excess lipids may also be stored in lipid
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droplets as triacylglycerols, generating a pool of substrates termed intramyocellular
triglycerides (IMTG) [56]. IMTG content is known to increase with percentage
body fat, and to be elevated in obese or type 2 diabetic individuals. IMTGs are
broken down by lipases to undergo oxidation, however disturbances in the rate
of breakdown or oxidation may lead to accumulation of toxic lipid intermediates
and subsequent insulin resistance [56,61]. The type of triglyceride (saturated vs.
unsaturated) that make up the skeletal muscle lipid pool is also important, since
unsaturated triglycerides may be destined to accumulate as IMTG, whereas saturated
triglycerides may be broken down into DAGs [62]. Additionally, a higher proportion
of saturated fatty acids within this lipid pool has recently been associated with
insulin resistance [62]. Skeletal muscle relies heavily on fatty acid β-oxidation
to generate energy, using this method to provide up to 90% of its total energy
demand [58]. Therefore, any alterations in fatty acid oxidation may impair skeletal
muscle metabolic capacity. Certainly in rodent IUGR studies, muscle oxidative
ability is adversely affected in growth-restricted animals [19,45], and as such could
set the stage for impaired mitochondrial function when challenged with a postnatal
Western diet.
In rodent lipid infusion studies, insulin resistance develops, and increased
concentrations of long-chain acyl CoAs have been associated with insulin resistant
skeletal muscle [25]. This increased lipid availability has been associated with
reduced levels of skeletal muscle β-oxidation [63,64], leading to accumulation of
toxic lipid metabolites including DAG [25] and ceramide [65]. While specific changes
in long-chain acyl CoA levels have not been reported in IUGR/low birth weight
offspring, reductions in enzymes involved in β-oxidation have [66], suggesting
that accumulation of long-chain acyl CoAs secondary to a reduction in oxidative
capacity may be involved in the pathogenesis of insulin resistance. Accumulation
of these lipid metabolites in the skeletal muscle has been associated with increases
in stress-induced kinases, such as protein kinase C (PKC)-θ or ε, isoforms known to
act upstream of c-Jun N-terminal kinase (JNK) and IκB (inhibitor of NFκB) kinase
(IKKβ). Notably, JNK and IKKβ are two central serine/threonine kinases mediating
phosphorylation of IRS-1 at Ser307, a subsequent reduction in Ser473 phosphorylation
of Akt, and reduced insulin-stimulated glucose uptake [25,60,65,67], similar to the
molecular alterations that have been observed in the insulin signaling pathway in
skeletal muscle of the low birth weight population [29,36]. PKC-θ activation itself
(translocation from the cytosol to the plasma membrane) has also been reported
to occur during a state of lipid overload in skeletal muscle, and may represent an
alternative pathway mediating alterations in the serine/threonine phosphorylation
status of key insulin signaling intermediates [25,61]. Direct evidence that these
changes may be happening in low birth weight IUGR offspring as they age is still
lacking, but if occurring, presents a potential pathway where in utero induced changes
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in fatty acid oxidation may play a contributing role to later life insulin resistance
when challenged with a postnatal high fat diet.
While the concept of reduced fatty acid oxidation has been held as a corner
stone of the development of insulin resistance, new studies now suggest excessive,
rather than diminished, fatty acid oxidation in skeletal muscle mitochondria may
be the root cause. Evidence for this new concept comes from rodent studies, where
animals were fed high-fat diets and subsequently display a metabolic phenotype
associated with mitochondrial overload, a situation in which an increase in fatty acid
uptake and β-oxidation rate is stimulated, but later steps of metabolism, including the
tricarboxylic acid (TCA) cycle or the electron transport chain, remain unaltered [26,58].
This mismatch between subsequent steps of oxidation allows accumulation of
acylcarnitine intermediates that are indicative of incomplete oxidation or partial
fatty acid degradation [26,58]. Incomplete oxidation occurs during mitochondrial
overload because the high rates of β-oxidation generates excessive intermediates that
overwhelm the TCA cycle, preventing further oxidation and allowing accumulation
of acylcarnitines [26,58]. The recent interest in metabolomics has allowed for
profiling of these acylcarnitine intermediates, highlighting a method that allows
for further investigation of the relationship between incomplete β-oxidation and
the pathogenesis of insulin resistance. High-fat feeding in rodents has been shown
to induce a lipid profile high in even-chain acylcarnitines. Accumulation of these
even-chain acylcarnitine species ranging in length from C6-C22 indicates that a
large proportion of the fatty acids entering the mitochondria are only partially
degraded for use as metabolic substrates [26,68]. Of interest, recent evidence has
suggested that one even-chain acylcarnitine in particular, L-C14 carnitine, which can
accumulate with incomplete β-oxidation, has the ability to activate pro-inflammatory
pathways, as well as an induction of JNK which may modulate the serine/threonine
phosphorylation status of insulin signaling intermediates, perpetuating a state of
insulin resistance [67,69]. Mitochondrial overload has also been observed in rodent
models of diabetes, including the Zucker Diabetic Fatty rat, further supporting
the idea that incomplete fatty acid oxidation and accumulation of acylcarnitine
intermediates may be implicated in the pathogenesis of insulin resistance [26,70].
The impact of high fat feeding in low birth weight IUGR offspring upon acylcarnitine
production and mitochondrial overload has not been reported. However, short-term
high fat feeding trials in human low birth weight offspring show that low birth
weight is associated with a reduced degree of plasticity [71], suggesting that changes
to β-oxidation and the TCA cycle, in conjunction with postnatal high fat ingestion,
may be different in low birth weight offspring and potentially exacerbated.
The regulation of mitochondrial fatty acid oxidation rate is also an important
determinant of the propensity for mitochondrial overload to occur when skeletal
muscle is faced with excess free fatty acids. Ingestion of a fatty diet appears to
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alter the activity of an important family of nuclear transcription factors regulating
mitochondrial oxidative capacity, known as the peroxisome proliferator-activated
receptors (PPARs). The PPARα isoform is mainly expressed in highly oxidative
tissues, including skeletal muscle, liver and heart, with activation of this transcription
factor promoting an increase in fatty acid uptake and β-oxidation [58,72].
Interestingly, overexpression of PPARα in skeletal muscle of transgenic mice has
been associated with increases of lipid-oxidative genes, yet with the development
of glucose intolerance [73], lending support to the notion that over-activation of
PPARα in skeletal muscle is detrimental to insulin sensitivity [58]. While it appears
that increasing fatty acid oxidation in skeletal muscle during periods of high-fat
feeding through activation of PPARα should promote fat clearance by increasing
fatty acid oxidation, evidence has suggested that only the genes related to fatty acid
oxidation and uptake have been increased, with no changes in the downstream
steps of oxidation [68,70]. In addition to detrimental changes in PPARα activity, a
chronic high fat diet has been associated with a decrease in skeletal muscle levels
of peroxisome proliferator-activated receptor-γ co-activator 1α (PGC1α). PGC1α
plays an important role in regulating mitochondrial biogenesis and is a critical
component of the PPARα-activated transcriptional machinery [68]. Decreases in
PGC1α lead to a reduction in the coupling efficiency between β-oxidation and TCA
cycle, preventing the mitochondria from completely oxidizing fatty acids in response
to high lipid availability [68]. This decrease in PGC1α levels with consumption
of a Western diet would contribute to the mismatch of β-oxidation and TCA cycle
activity observed in mitochondrial overload. Recent studies have also reported
reduced mRNA levels of PGC1α [74,75] and reduced PGC1α protein levels in the
soleus [75] and gastrocnemius [76] muscle of young adolescent low birth weight
offspring. Additionally, alterations in the methylation status of the PGC1α promoter
have been observed in both rodent [76] and human [77] models of IUGR, highlighting
a potential epigenetic link with altered fat storage and metabolism in postnatal life.
Therefore, reductions in PGC1α due to consumption of a Western diet, combined
with a low birth weight situation could promote further incomplete oxidation and
the potential for acylcarnitine intermediates to accumulate in the skeletal muscle and
potentiate alterations in the phosphorylation status of insulin signaling molecules
through the actions of stress-induced kinases. These emerging studies in the low
birth weight population highlight a new area of investigation that is working to better
characterize the epigenetic modifications to those genes involved in mitochondrial
function and β-oxidation, which is a new and expanding field in understanding the
development of insulin resistance in offspring of adverse intrauterine pregnancies.
Collectively, new studies suggest there are alterations in the storage and
metabolism of fat in the skeletal muscle of low birth weight offspring. However,
the nature of the specific alterations, their degree of plasticity, and their underlying
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contribution to insulin resistance, when challenged with an adverse postnatal diet as
these offspring age, remains to be fully elucidated.
5. Conclusions
Infants of an adverse in utero environment represent a unique population
who appear to be at a greater risk for the development of insulin resistance and
subsequent metabolic disease [1,5,18]. Adaptive programmed changes in skeletal
muscle metabolic development and function (i.e., changes in insulin signaling, fiber
type distribution, oxygen consumption, and oxidative capacity) due to an adverse
in utero environment, lead to structural and metabolic deficits later in life. Further,
and more concerning are recent studies suggesting that these low birth weight
offspring are unable lose weight as efficiently as normal birth weight offspring
when placed on a calorie restricted diet [19], and that PGC1α deficiencies associated
with IUGR appear resistant to exercise intervention [78]. These studies highlight
that these unique offspring, while being at a higher risk of developing aspects
of metabolic syndrome, may be resistant, or lack plasticity to respond, to current
intervention practices. When these infants with programmed alterations in skeletal
muscle development are faced with a postnatal environment of nutrient excess,
they appear to be at greater risk for aberrant skeletal muscle function. Definitive
studies examining the interactive linkages between in utero programmed insulin
resistance and postnatal environmental challenges, and those investigating the
distinct mechanisms underlying the developmental origins of insulin resistance,
and a lack of plasticity to later life challenges in low birth weight offspring are
needed. With these data, the therapeutic options for this unique population can be
better delineated.
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Reducing Postpartum Weight Retention and
Improving Breastfeeding Outcomes in
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Abstract: Overweight and obesity is prevalent among women of reproductive age
(42% BMI > 25 kg/m2) and parity is associated with risk of weight gain. Weight
gain greater than that recommended by the Institute of Medicine (IOM )is also
associated with lower rates of breastfeeding initiation and duration in women.
The aim of this pilot randomised controlled trial is to examine the feasibility of
recruiting and maintaining a cohort of pregnant women with the view of reducing
postpartum weight retention and improving breastfeeding outcomes. Women (BMI
of 25–35 kg/m2 (n = 36)) were recruited from the John Hunter Hospital antenatal
clinic in New South Wales, Australia. Participants were stratified by BMI and
randomised to one of three groups with follow-up to six months postpartum.
Women received a dietary intervention with or without breastfeeding support from
a lactation consultant, or were assigned to a wait-list control group where the dietary
intervention was issued at three months postpartum. Feasibility and acceptability
was assessed by participation rates and questionnaire. Analysis of variance and
covariance was conducted to determine any differences between groups. Sixty-nine
per cent of the participants were still enrolled at six months postpartum. This
pilot demonstrated some difficulties in recruiting women from antenatal clinics
and retaining them in the trial. Although underpowered; the results on weight;
biomarkers and breastfeeding outcomes indicated improved metabolic health.
Reprinted from Nutrients. Cite as: Martin, J.; MacDonald-Wicks, L.; Hure, A.;
Smith, R.; Collins, C.E. Reducing Postpartum Weight Retention and Improving
Breastfeeding Outcomes in Overweight Women: A Pilot Randomised Controlled Trial.
Nutrients 2015, 7, 1464–1479.
1. Introduction
Overweight and obesity is prevalent among women of reproductive age (25–34
years) with 42% having a BMI > 25 kg/m2 [1]. Having children is associated with
maternal weight gain, particularly in the long-term [2]. Fifty to eighty percent of
women retain 1.4–5 kg up to 12 months postpartum, with 20%–50% retaining 5 kg
or more [3–7]. Weight gain increases the risk of developing diabetes and heart
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disease [8,9]. The amount of weight retained after pregnancy can shift women
from the healthy weight category into the overweight or obese BMI categories.
Starting the next pregnancy at a higher weight increases the risk for poor pregnancy
outcomes [9,10], such as gestational diabetes (RR = 2.09 for BMI > 30 kg/m2) [11],
delivery intervention [10], macrosomia (OR = 1.57 for BMI >25–30 kg/m2 and 2.36 for
BMI > 30 kg/m2) [12,13] and lower rates of breastfeeding initiation and duration [14].
Women with a high BMI have been reported to have a 7% lower breastfeeding
initiation rate and breastfeed for six weeks less on average, compared to women with
a normal BMI (18.5 to 24.9 kg/m2) [15]. Concomitantly, evidence from a nationally
representative sample of Australian women indicate that women are not eating in a
manner compliant with national food group recommendations, and therefore, may
not be meeting their nutrient intake targets [16].
Childbearing presents an opportunity to facilitate behaviour change towards a
healthy lifestyle [17]. Recently, mothers who had a BMI of >25 kg/m2 were consulted
to determine barriers to postpartum weight loss [18]. The 10 face-to-face interviews
reported that the major barriers included a lack of time, maternal low energy
levels, the low priority of weight loss, overall low motivation and psychological
concerns [18]. Despite this, there is evidence to suggest that women can be motivated
to make healthy choices for themselves and their families, and frequently seek advice
and support from family, friends and health professionals during pregnancy and
after birth [19,20]. Women at this life-stage have frequent contact with clinicians,
which provide potential opportunities to implement lifestyle education.
There is growing evidence that overweight and obese women have reduced
rates of breastfeeding initiation and breastfeed for a shorter duration, likely due to
the physical size of the breast and diminished lactogenesis [21–24]. In a longitudinal
cohort (USA, n = 405), overweight and obese women were 1.8 and 2.2 times more
likely to have delayed lactogenesis compared to underweight and normal weight
women [22]. In a similar study (n > 37,000), overweight and obese Danish women
had a shorter breastfeeding duration compared to normal weight women (RR: 1.12,
95% CI: 1.09–1.16 for overweight and RR: 1.39, 95% CI: 1.19–1.63 for obese) [25].
Lactation adds to energy expenditure, and therefore could assist with weight loss in
the postpartum period [5]. In combination, this suggests that women with a higher
BMI may need to be targeted for additional breastfeeding support.
Two Cochrane systematic reviews assessed a range of antenatal and postnatal
educational methods used to enhance breastfeeding initiation [26] and duration [27].
These included formal and informal education, one-on-one and group education,
workshops, peer counseling, discussion groups, practical skills and were provided
individually and in combination. The antenatal interventions that improved
breastfeeding initiation included peer counseling and regular education from an
International Board Certified Lactation Consultant (IBCLC) [26,27]. The reviewers
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concluded that there was a lack of well-conducted Randomised Controlled Trials
(RCTs) in this area, and this research was needed to determine the best ways to
improve breastfeeding initiation and duration rates, in particular with a focus on
those at risk of suboptimal initiation and duration rates such as overweight and
obese women.
The aim of this study was to determine the feasibility of delivering an intervention
during pregnancy (at week 35), which aimed to reduce weight retention in women
up to 12 months postpartum, who were overweight and obese before pregnancy
and who were intending to breastfeed. While interventions for postpartum weight
loss or to optimise breastfeeding have been trialed as separate interventions, to the
best of the authors’ knowledge, there has not been a randomised controlled trial
combining both. In the current study a dietary intervention for weight loss, with and
without lactation support, was compared to a wait-list control group with patterns
of breastfeeding also compared between groups. The intent on including a lactation
consultant (IBCLC) was to increase the duration of breastfeeding in overweight and
obese women to positively impact on energy balance.
2. Experimental Section
A pilot, RCT was undertaken at a public tertiary obstetrics hospital in Newcastle,
Australia, from October 2010 to September 2011. The approved study protocol
prohibited direct recruitment by research staff, therefore flyers were distributed
in clinic which encouraged potential participants to seek further information.
Eligible participants were randomised to one of three groups: (i) antenatal dietary
intervention for postpartum weight loss; (ii) antenatal dietary intervention and
breastfeeding support for postpartum weight loss; or (iii) wait-listed control, where
dietary intervention for weight loss was offered at three months postpartum. The
baseline study visit was conducted at approximately 26 weeks gestation followed by
a study visit at 35 weeks gestation (study visit 2) and then three months postpartum
(study visit 3) as outlined in Figure 1.The fourth and final study visit was scheduled
for approximately six months after birth. Antenatal visits were conducted at the
John Hunter Hospital and postpartum visits were completed at the hospital or in the
participants’ home if they were unable to attend the hospital. Ethics approvals were
provided by the Hunter New England Health Human Research Ethics Committee
and the University of Newcastle Human Research Ethics Committee.
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Figure 1. Flow diagram of recruitment and randomisation for a pilot randomised controlled trial. 
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The research dietitian circulated the study flyer in the obstetrics clinic (n = 423
flyers were distributed in the clinic by clinic administrators) any pregnant women
who inquired were provided with written information about the study in the
antenatal clinic by midwives and the study dietitian (JM), from October 2010 to
September 2011. The inclusion criteria were: aged > 18 years, pre-pregnancy
BMI 25–35 kg/m2, intention to breastfeed, singleton pregnancy, English-speaking,
and <26 weeks gestation at the initial screening. Women also had to agree not to
participate in any other weight loss program in the postpartum period while enrolled
in the study. Self-reported pre-pregnancy weight and height was recorded during
the initial screening and used to calculate BMI to determine if the participants met
the inclusion criteria. Previous research has demonstrated self- report compared to
actual pre pregnancy weight results in the same BMI classification [28].
2.2. Study Design
2.2.1. Randomisation
Block randomisation (groups of three) using a computerised generated random
number sequence was used to randomise women who were also stratified by
pre-pregnancy weight status categories of overweight (BMI 25–29.99 kg/m2) and
obesity (BMI 30–35 kg/m2). Numbered cards allocating women to an intervention
group or the control group were placed in opaque, sequentially numbered envelopes.
The person responsible for participant allocation (LMW) did not have direct contact
with participants, therefore allocation concealment was maintained.
2.2.2. Blinding
The study dietitian (JM) was blinded to the participant’s group allocation for
women in the two dietary intervention groups. Blinding was maintained by ensuring
the study dietitian was not aware of the group allocation until post study, and by
asking the participants not to reveal their allocation. The researcher responsible for
allocation concealment (LMW) contacted the study’s lactation consultant directly
with the participant’s details for those allocated to the dietary intervention and
breastfeeding support arm of the trial. The lactation consultant then contacted the
participant directly to arrange follow up. By necessity the study dietitian was not
blinded to the control group.
2.2.3. Dietary Intervention
Both intervention groups received the antenatal dietary intervention for
postpartum weight loss, provided by an Accredited Practicing Dietitian (APD) at
35 weeks gestation (study visit 2). Specifically, women were educated to implement
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the self-directed weight management program “Total Eating Management System”
(TEMplate System™) post-partum. The TEMplate System™ is based on social
cognitive theory and includes goal setting, cognitive restructuring, and self-monitoring
of food, physical activity, and weight. Energy intake was targeted at 7000 kJ/day
(standard weight loss diet of 5000 kJ plus 2000 kJ per day lactation allowance), with
additional 500 kJ blocks allocated based on physical activity undertaken. Participants
were provided the TEMplate System™ which is based on based on healthy eating
principles and the five food groups, including the lunchbox and dinner disc for
maintaining meal portion control. Education was provided to ensure participants
could successfully implement the following four steps to the program:
The TEMplate System™ encourages self-efficacy and uses four steps:
1. Eat a healthy breakfast;
2. Pack a daily lunch and snack box ahead of time;
3. Use TEMplate™ dinner disc to guide portion size at main meals, including four
different coloured vegetables;
4. Adjust “extras” (1 extra = 500 kJ) to balance energy expenditure from physical
activity and lactation, for example women exclusively breastfeeding were
given advice on adding an additional 4 extras to their eating plan, partially
breastfeeding were allowed an additional 2 extra servings The APD provided
advice on appropriate nutrient dense “extras” that could be added to the diet.
The Wait-List Control Group Received Standard Antenatal Care and the Dietary
Intervention Was Offered at Three Months Postpartum (Study Visit 3).
2.2.4. Lactation Support
One arm of the dietary intervention groups also received breastfeeding
support provided by an accredited Lactation Consultant (IBCLC). “The lactation
consultant gave advice on lactation issues only. There was no further dietary advice
provided by the lactation consultant. During the antenatal period, participants
attended two 30 min face-to-face education sessions with the IBCLC to discuss the
fundamental elements of breastfeeding, previous breastfeeding experience, infant
feeding expectations, goals and building rapport. A home visit was conducted
up to two weeks post-delivery to ensure breastfeeding was established and for
the participant to discuss any concerns. Follow up phone calls were conducted as
required, to address the raised concerns of the individual participants.”
2.2.5. Outcome Measures
Data collection followed many of the same procedures as had been previously
employed in the Women and their children (WATCH) Study and further details are
published elsewhere [29].
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2.2.6. Weight and BMI
Weight was measured, to the nearest 50 grams, in indoor clothing without
shoes using AND™ FV-150 K electronic weighing scales (A & D Mercury Pty Ltd.,
Thebarton, South Australia), which were calibrated annually according to hospital
protocol. Height was measured without shoes, to the nearest millimeter, on a wall
mounted Seca stadiometer (Seca Deutschland, Hamburg, Germany).
2.2.7. Biomarkers
Blood collection and analyses were outsourced to the Hunter Area Pathology
Service, a National Association of Testing Authorities (NATA)-accredited laboratory.
Samples were obtained at 35 weeks gestation (visit 2), three months postpartum
(visit 3) and six months postpartum (visit 4). Fasting blood samples were analysed
for fasting glucose (mmol/L), fasting insulin (mIU/L), glycosylated haemoglobin
(HbA1c, %), lipids (total cholesterol, LDL, HDL, and triglycerides, in mmol/L),
and C-reactive protein (mg/L). Homeostatic model assessment (HOMA-IR) was
estimated: (glucose × insulin)/22.5.
2.2.8. Breastfeeding
Infant feeding data were obtained by the study dietitian at the three and six
month follow up. The Infant Feeding Recall questionnaire was used to collect
information on breastfeeding initiation, duration and exclusivity. The Current
Feeding Practices questionnaire was also used to record the infant’s breastfeeding
and formula intake and whether the child received any of the following within the
previous 24 h: vitamin or mineral supplements; medicine; plain water; sweetened or
flavoured water (for example, cordials and soft drinks); fruit juice; tea or infusion;
canned, powdered, or fresh milk; solid or semi-solid foods; oral rehydration salts;
and other foods or fluids.
2.2.9. Further Data Collection
A 13-item questionnaire was administered in study visit 1 to determine medical
history and intake of prescribed and/or non-prescribed medication including
supplements. Education level, socio economic advantage and disadvantage using
Socio-Economic Indexes for Areas (SEIFA) index, income and marital status
were assessed by asking another six questions, modelled on the Australian
Longitudinal Study of Women’s Health surveys (http://alswh.org.au/). The Index of
Relative Socioeconomic Advantage and Disadvantage (IRSAD) was used to provide
information on social and economic status of households based on area. The IRSAD
is scored one to ten with a low score indicating greater disadvantage and a higher
score indicating greater advantage.
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2.3. Statistical Analyses
Statistical analyses were performed using Intercooled Stata, version 11
(StataCorp LP, College Station, Texas, USA) with significance set at α = 0.05.
Normality tests were conducted to determine the distribution of data. One-way
ANOVA, Kruskal-Wallis, Chi2, and Fisher’s exact tests were used to determine
differences by intervention groups. Comparisons were also made between those
who withdrew and those who remained in the study. Intention to treat analysis was
not conducted as this was a pilot feasibility study with small numbers in each group.
3. Results
Figure 1 summarises participant recruitment, randomisation and follow-up.
Thirty-six women consented (22 overweight, 14 obese), and 12 were randomised
to each group, with two were lost to follow-up before the first visit. At six months
postpartum, 25 of participants completed the study. Women who were lost to
follow-up reported being too busy (n = 1), were not able to be contacted by the
research team (n = 4), had a preterm delivery and chose to discontinue participation
(n = 1), moved interstate (n = 1), or changed hospitals during antenatal care (n = 1).
Table 1 summarises the baseline characteristics and birth data for all participants
and by group allocation. The mean age for the study population was 31 years and
85% of participants were having their first birth. Just over half the babies were female
(58%) and the mean birth weight was 3.7 kg. There were no significant differences in
baseline socio-demographic variables between those who withdrew and those who
remained in the study, though the study was underpowered to detect any differences
(data not shown).
Table 1. Baseline characteristics and birth data for pilot randomised controlled
trial participants.
Participant Characteristic All (n = 34) Diet (n = 11) Diet + LactationSupport (n = 11) Control (n = 12) p-Value
Age (years) 30.9 ± 6.0 29.5 ± 7.8 31.6 ± 5.1 31.3 ± 5.6 0.27
Height (cm) 165.4 ± 6.2 165.1 ± 6.5 166.8 ± 5.7 164.4 ± 6.5 0.44
Born in Australia, n (%) 33/34 (97) 10/11 (91) 11/11 (100) 12/12 (100) 0.65
Married or de facto, n (%) 25/31 (81) 7/10 (70) 8/9 (89) 10/12 (83) 0.63
Education ≥ year 12, n (%) 26/31 (84) 9/10 (90) 8/9 (89) 9/12 (75) 0.79
IRSAD ≥ 5, n (%) 23/32 (72) 7/10 (70) 9/10 (90) 7/12 (58) 0.22
Smoking, n (%) 4/34 (12) 2/11 (18) 1/11 (9) 1/12 (8) 1.00
Multiparous, n (%) 5/34 (15) 1/11 (9) 2/11 (18) 2/12 (17) 0.39
Gestational diabetes, n (%) 3/34 (9) 2/11 (18) 1/11 (9) 0/12 (0) 0.76
Infant sex, male n (%) 14/33 (42) 3/11 (27) 6/10 (60) 5/12 (42) 0.23
Birth weight (kg) 3.7 (3.3, 4.0) 3.9 (3.7, 4.1) 3.5 (3.1, 3.7) 3.5 (3.2, 4.0) 0.19
Mean ± SD for normally distributed continuous data or median (25th–75th percentile)
for non-normally distributed data.
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Table 2 summarises the pregnancy and postpartum weight data for the
randomised controlled trial participants. Self-reported mean pre-pregnancy weight
was 80.5 kg and the median BMI was 28.8 kg/m2. By 35 weeks gestation the women
had gained on average 13.6 ± 6.6 kg (mean ± SD). This is considerably higher
than the Institute of Medicine’s recommendations of 5–11.5 kg for women with a
BMI of 25 or more [30], especially considering the final weight measurement was
at 35 rather than 40 weeks gestation. Mean gestational weight gain in the dietary
intervention group at 35 weeks gestation was on average 5–6 kg lower, however, this
was not significant (p = 0.06) and may have occurred by chance. At three months
postpartum weight retention was not significantly different between groups, however
those in the dietary intervention groups (with or without lactation support) retained
less weight compared to the control group. At three months postpartum, control
participants commenced the dietary intervention and there was less difference in
weight retention at six months postpartum. There was a trend for fewer women
in the dietary intervention group to retain 5 kg or more than their pre-pregnancy
weight at six months after birth, compared to the control group (p = 0.06).
Table 3 summarises the fasting biochemical data including glycaemic markers,
lipids and the inflammatory biomarker CRP. There were no significant differences by
group allocation.
All participants initiated breastfeeding which was to be expected on the basis
of the inclusion criteria. At three months postpartum, the majority of participants
had continued breastfeeding (74%). The dietary intervention with lactation support
group had the highest rates of breastfeeding compared to the dietary intervention






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fourteen of the participants who completed the study returned the evaluation
questionnaire for the TEMplate™ program. Of those who returned the questionnaire,
six agreed that the TEMplate™ program was easy to understand. On completion of
the TEMplate™ program, the majority of participants reported that they now weigh
themselves (n = 10), keep a record of what they eat (n = 5), try to be more active
(n = 14), and plan (n = 9) and cook healthier meals (n = 13). Two of the participants
found the TEMplate™ program too time consuming, and six found it difficult to use
the program whilst also caring for a new baby. Additional barriers that were reported
included time constraints (n = 7), and tiredness (n = 6). Two of the participants also
suggested they would prefer face-to-face contact with a dietitian (n = 2) during
the program.
4. Discussion
This pilot RCT examined the feasibility of a program that included dietary
intervention and breastfeeding support for overweight and obese pregnant women,
with the aim of reducing postpartum weight retention and enhancing rates of
breastfeeding. As a pilot study, it was not intended to be adequately powered
to show significant between group differences in outcomes of interest: weight,
biomarkers, and breastfeeding. However, the results indicate that the approach
is feasible and acceptable to pregnant women attending an antenatal clinic and that
the methodology, including the collection of blood for biomarker assessment, and
could be adapted based on qualitative feedback to a larger, adequately powered RCT.
The use of paid, dedicated research midwives to undertake the recruitment of
women in an antenatal clinic setting would be an improvement on the recruitment
strategy used in this pilot, given the known difficulties in recruitment in this
population. Retention was at 69%, which is not ideal. However, the issues identified
such as difficulty attending the primary measurement site will allow for better
retention in the subsequent RCT. Women were lost to follow up for a number of
reasons, in particular due to the burden of attending face to face visits. The use of a
flexible delivery model, such as a web-based intervention strategy, combined with
home visits for follow-up, should be considered to overcome this barrier.
Research shows the postpartum period to be associated with many adjustments
for a mother, including increased time constraints, a change in priorities and child
care concerns [31,32]. These adjustments can make it difficult for women to achieve a
healthy lifestyle [31,32] and have been reported to contribute to the lack of success in
postpartum weight loss interventions. High drop-out (up to 40%) and low attendance
rates [33–35], led researchers to conduct interviews on participants from the Active
Mothers Postpartum (AMP) study to further investigate lack of participation in this
cohort of women [32]. Results indicate numerous barriers to achieving a healthy
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lifestyle at this life-stage, including: lack of time in a busy schedule; health of the
family as first priority; lack of social support; lack of child care during the intervention
and/or education; and location distant from the study centre [32]. This pilot study
attempted to address a number of these reported issues. Women were provided
with a self-management program to complete in their own time, which increased
flexibility and eliminated the need for child care. Phone calls and home visits
were offered for women who were unable to visit the hospital due to geographical
location or who had child care issues. Additionally, in the current study the weight
management education was provided during an antenatal visit towards the end
of pregnancy to help prepare and organise the women for the postpartum period.
Despite anticipating the known barriers in the literature to a weight loss program,
there were substantial withdrawals from the program, however they predominantly
occurred during the antenatal period.
Results from the evaluation suggest the majority of participants reported
improved awareness of their eating and exercise behaviours as a result of the
intervention. The participants indicated that they were able to record intake, monitor
weight, and increase everyday exercise, plan meals and make healthier food choices
using the provided program materials. Still, half of the women indicated they found it
difficult to complete the program with a new baby, despite this being an intervention
which they could complete in their own home. From this feedback we can deduce that
any intervention in this life-stage must be goal-orientated, include self-monitoring,
and be home-based, while also being quick and easy. Using web-based or mobile
device technologies may be one way to enhance access within the home, to address
the time and travel barriers expressed in the evaluations.
All the participants in this pilot study initiated breastfeeding, but the duration
of breastfeeding was greatest in the group with additional lactation support, though
small numbers meant this was not statistically significant. The provision of IBCLC
support appeared to be both feasible and acceptable to overweight and obese mothers.
Suboptimal breastfeeding initiation and duration rates have been frequently cited
for women with a high BMI [15,25,36–39]. In a systematic review of 15 observational
studies the relationship between maternal overweight and obesity and breastfeeding
initiation and duration identified the rates for any breastfeeding at six months in
overweight women were 17% to 52% while rates for obese women were 17% to 37%
compared to normal weight women (29% to 57%) [40].
For pregnancy and postpartum metabolic markers the direction of the results
was in the intended direction, indicating a potential improvement in metabolic profile
due to the intervention, although not statistically significant. The pilot study was not
powered to show significance. Further research in this area is warranted.
Research to manage postpartum weight retention is of increasing interest. There
have been a number of lifestyle RCTs aimed at reducing postpartum weight retention
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or increasing weight loss [33–35,41–44]. Two of these studies had lower weight
retention for both intervention and control groups compared to the current study
although only one of these was significant (Control versus intervention: 1.0 and 1.8,
p = 0.42; 5.1 and 2.3, p < 0.001) [42,43]. However, none of these studies include
a breastfeeding support commencing in pregnancy; a novel component of our
trial. There are a number of important methodological differences between the
current study and RCTs conducted to date. The strength of the current study
is the recruitment of women in the antenatal period to prepare them to achieve
postpartum weight loss. Early recruitment of participants may have the added
advantage of preventing gestational weight gain, although our study participants
generally gained more than current recommendations [27]. Similarly, the current
study uses self-reported pre-pregnancy weight, combined with weight at initial visit
as objective markers of gestational weight gain and weight retention. The current
study primarily focused on dietary intervention. Finally focusing on overweight and
obese women targets those who may have difficulty initiating breastfeeding while
supporting longer breastfeeding duration.
Our pilot study participants in the dietary intervention only group retained less
weight at both three and six months postpartum compared to the two other RCTs
reporting weight retention as their primary outcome [42,43]. Kinnunen et al. (2007)
intervened during the postpartum period focusing on lifestyle change to reduce
weight retention [43]. Huang, Yeh and Tsai (2011) provided weight management
education during pregnancy, similar to our pilot study, however, the aim of their
intervention was to limit gestational weight gain, rather than prepare the participants
solely for weight loss in the postpartum period [42]. This makes it difficult to
determine the postpartum impact of this intervention because gestational weight
gain is a significant determinant of weight retention [45,46].
This pilot study had a number of limitations that need to be acknowledged. The
primary limitation is the small sample size, making it difficult to detect significant
differences in outcome variables and limiting the applicability of the study to the
general population. However, as this was a feasibility study, it is more important
to look at the recruitment and retention information and the evaluation data. In
addition to this, the retention rate was suboptimal suggesting the need for further
consideration with this population and their unique stage of life. To improve the
study sample size and retention rates, regular contact with a health professional
and incentives to complete the study could be considered. Additionally, providing
flexible study visits to suit mothers’ postpartum lifestyles may require home visits,
regular phone calls, and internet support.
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5. Conclusions
Overweight and obesity in women is an independent risk factor for lifestyle
disease such as diabetes and heart disease [47,48]. Pregnancy can further impact
this due to gestational weight gain, postpartum weight retention and lower rates of
successful breastfeeding initiation and duration. Lifestyle changes, such as healthy
eating and exercise, which are used in traditional weight loss programs, may be
problematic for women with infants because of time constraints and changes in
priorities. Despite postpartum weight retention being common and a relevant
concern for women, there are currently no programs or strategies routinely offered
to assist women to achieve a healthy weight after birth. The current study provides
evidence to support the feasibility and preliminary efficacy of providing overweight
and obese women with targeted dietary advice and breastfeeding support to improve
weight, metabolic, and breastfeeding outcomes. An adequately powered RCT is
now required to determine the true effect, if any, of these interventions and the costs
involved in implementing those that are effective on a larger scale.
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The Two-Component Model for Calculating
Total Body Fat from Body Density: An
Evaluation in Healthy Women before,
during and after Pregnancy
Elisabet Forsum, Pontus Henriksson and Marie Löf
Abstract: A possibility to assess body composition during pregnancy is often
important. Estimating body density (DB) and use the two-component model (2CM) to
calculate total body fat (TBF) represents an option. However, this approach has been
insufficiently evaluated during pregnancy. We evaluated the 2CM, and estimated
fat-free mass (FFM) density and variability in 17 healthy women before pregnancy,
in gestational weeks 14 and 32, and 2 weeks postpartum based on DB (underwater
weighing), total body water (deuterium dilution) and body weight, assessed on
these four occasions. TBF, calculated using the 2CM and published FFM density
(TBF2CM), was compared to reference estimates obtained using the three-component
model (TBF3CM). TBF2CM minus TBF3CM (mean ± 2SD) was −1.63 ± 5.67 (p = 0.031),
−1.39 ± 7.75 (p = 0.16), −0.38 ± 4.44 (p = 0.49) and −1.39 ± 5.22 (p = 0.043) % before
pregnancy, in gestational weeks 14 and 32 and 2 weeks postpartum, respectively. The
effect of pregnancy on the variability of FFM density was larger in gestational week
14 than in gestational week 32. The 2CM, based on DB and published FFM density,
assessed body composition as accurately in gestational week 32 as in non-pregnant
adults. Corresponding values in gestational week 14 were slightly less accurate than
those obtained before pregnancy.
Reprinted from Nutrients. Cite as: Forsum, E.; Henriksson, P.; Löf, M. The
Two-Component Model for Calculating Total Body Fat from Body Density: An
Evaluation in Healthy Women before, during and after Pregnancy. Nutrients 2014, 6,
5888–5899.
1. Introduction
Information regarding body composition during pregnancy is needed when
estimating the requirements for dietary energy during gestation and when
investigating relationships between maternal nutritional status and offspring
development. Generally used body composition methods may not be appropriate
during pregnancy when the body is undergoing dynamic changes to support fetal
development. Based on extensive reviews of the literature Hytten [1] described how
pregnancy changes the physiology of the human female including how the products
of conception contribute to the composition of the pregnant body. Based on this
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work, van Raaij et al. [2] estimated average changes in fat-free mass (FFM) density
and water content throughout the course of gestation. The Food and Agricultural
Organization [3] and the Institute of Medicine [4] have stated that body composition
methods based on these modifications [2] are satisfactory for use with pregnant
women. Hopkinson et al. [5] evaluated these modifications in gestational week 36 and
concluded that the FFM density suggested by van Raaij et al. [2] for women at this
stage of pregnancy produce reliable mean estimates of body fat. However, except for
this report [5], no validation studies have confirmed the statement quoted above [3,4].
Pregnancy is associated with retention of water, protein and mineral, i.e., the
components of FFM. This results in an increased water content of FFM while its
concentrations of protein and mineral decrease slightly [2]. The combined effect
of these changes is a decreased density of FFM [2]. This decrease is of interest
when calculating total body fat (TBF) from body density (DB) using the so-called
two-component model (2CM) [6], a common procedure for assessing human body
composition in vivo. In the past, DB was assessed using underwater weighing
whereas air-displacement plethysmography (ADP) [7] is now more common. Due to
its convenience and capacity to assess DB in subjects with varying body sizes [7,8],
ADP is increasingly used and, as pointed out by Hu [9], represents an excellent
alternative to underwater weighing in pregnant women. However, the use of ADP
during pregnancy has been limited [10], possibly because the capacity of the 2CM to
calculate TBF from DB has been insufficiently studied during gestation. Thus studies
of this capacity are needed.
As indicated above, average values for FFM hydration and FFM density are
available throughout the course of pregnancy [2]. However, information regarding
average FFM density is insufficient to conclude that the 2CM is satisfactory during
pregnancy. It is also important to determine the variability of FFM density at each
particular stage of pregnancy, since small differences in this value have a substantial
impact on TBF when calculated from DB using the 2CM [11]. Thus a high variability
in FFM density is associated with a lower accuracy in estimates of TBF of individual
women. In a previous study [12] conducted before, during and after pregnancy
we found that the variability of FFM hydration depends on the stage of gestation.
Thus the accuracy of the 2CM may well vary during the course of pregnancy. In the
present paper we use data obtained in the previous study [12] to evaluate TBF
results, calculated from DB using the 2CM and based on published average FFM
density values. For women in the prepregnant state we used an FFM density of 1.1
g/mL [6,13]. During pregnancy, we used the values published by van Raaij et al. [2]
and the FFM density value published by Hopkinson et al. [5] was used postpartum.
We have also calculated average FFM density and its variability.
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2. Experimental Section
2.1. Subjects, Design, Body Composition Methodology and Calculations
The study was conducted on 17 healthy women before pregnancy, in gestational
weeks 14 and 32, and 2 weeks postpartum. The ethics committee in Linköping
approved the study on 19 November 1995 (95237). At the measurement before
pregnancy women were 29 ± 4 years old with a body mass index (BMI) of
24.3 ± 5.3 kg/m2. Three women (18%) were overweight (BMI = 25.0–29.9 kg/m2)
and 2 (12%) were obese (BMI ≥ 30.0 kg/m2). This distribution of BMI values
is similar to the corresponding distribution assessed for contemporary Swedish
childbearing women [14]. All women delivered one healthy infant (birthweight
3770 ± 470 g) and none had generalized oedema. The subjects in this study, as well
as the methods and procedures used were described previously [12]. In brief, DB
was assessed using underwater weighing where weight under water was recorded
7 times, each time with a simultaneous recording of lung volume (Volugraph 2000,
Siemens-Elema, Stockholm, Sweden) [12]. Total body water (TBW) was assessed by
means of deuterium dilution. After collection of background urine samples subjects
received 0.05 g 2H2O per kg body weight per os. Five urine samples were collected
during the following 15 days. 2H-enrichments of dose and urine samples were
analyzed by using an isotope ratio mass spectrometer (Deltaplus XL, Thermoquest,
Bremen, Germany) as previously described [12]. 2H-space was calculated using
zero-time enrichment, obtained from the exponential isotope disappearance curve,
providing the rate constant for 2H elimination. 2H-space was divided by 1.04 to
obtain TBW [12]. DB and TBW were used together with body weight to obtain
reference estimates of TBF based on the three-component model (3CM) [13] where f
represents the fraction of fat in the body:
f = (2.118/DB) − (0.78 × TBW/body weight) − 1.354 (1)
TBF was also calculated from DB based on the 2CM: [6,13]
1/DB = f/0.9007 + (1 − f)/FFM density (2)
FFM density was calculated using Equation (2) and f assessed by means of
Equation (1).
2.2. Statistics
Values given are means and standard deviations (SD). Linear regression and
Student’s t test were used. The Bland and Altman [15] procedure was used to
evaluate results. Thus the mean and 2SD of the difference between TBF (%), obtained
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using the 3CM and TBF (%) obtained using the 2CM, were calculated. This difference
(y) was regressed on the average of the two estimates of TBF (%) (x). Calculation
of the methodological component of the total variability in FFM density was based
on propagation of error analysis [12,16]. In this calculation precision values were
1.05% [17] for TBW and 0.01 kg [18] for body weight. Precision for DB was assessed
on 4 occasions in one weight-stable, non-pregnant woman with a weight and volume
of 56.6 kg and 53.9 L, respectively, and was 0.0016 g/mL corresponding to 0.371 L
(0.7%) for body volume [12]. As described previously [12], the methodological error
was based on measurement errors expressed in two different ways, i.e., in % of an
appropriate mean value or in kg and L [12]. Biological variability was calculated from
total observed variability and the propagated methodological error [12]. Significance
was accepted when p < 0.05. Statistical calculations were conducted using SPSS
Statistics 21 (IBM, Armonk, NY, USA).
3. Results
3.1. Total Body Fat Calculated by Means of the 2CM versus the 3CM
Table 1 shows body weight (kg), TBW (kg), DB (g/mL) and TBF (%), assessed
by means of the 2CM and the 3CM, of the women before pregnancy, in gestational
weeks 14 and 32, and 2 weeks postpartum. As shown in the table, the FFM density
suggested for the particular stage of reproduction was used in the 2CM. The 2CM
provides lower estimates of TBF (%) than those obtained by means of the 3CM and
this difference was significant before pregnancy and 2 weeks postpartum.
Figure 1 shows TBF (%) of the women in the study, obtained by means
of the 2CM (x) and the 3CM (y), and plotted around the line of identity. The
regression equations were y = 0.84x + 6.8, r = 0.95, p < 0.001 (before pregnancy),
y = 0.72x + 10.3, r = 0.94, p < 0.001 (gestational week 14), y = 0.87x + 4.5, r = 0.97,
p < 0.001 (gestational week 32) and y = 0.78x + 8.9, r = 0.96, p < 0.001 (2 weeks
postpartum). Figure 1 demonstrates that the 2CM and the 3CM agree fairly well on all
measurement occasions.
Figure 2 shows a Bland and Altman evaluation of our data. 2SD corresponds to
7.75% and 4.44% TBF at gestational weeks 14 and 32, respectively. The corresponding
values before pregnancy and 2 weeks postpartum were 5.67% and 5.22% TBF,
respectively. At gestational week 14 and 2 weeks postpartum, significant relationships
were found between TBF (%), assessed by means of the 2CM minus TBF (%) assessed
by means of the 3CM, on the one hand, and the average of these two estimates, on
the other hand. The corresponding relationships before pregnancy and in gestational
week 32 were not significant.
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Table 1. Body weight, total body water, body density and total body fat assessed
by means of two- and three-component models in healthy women [12] before









Body weight (kg) 66.6 ± 12.8 68.4 ± 13.2 77.3 ± 13.0 71.5 ± 12.8
Total body water (kg) 31.5 ± 4.0 32.5 ± 4.3 38.1 ± 4.4 33.6 ± 4.2
Body density (g/mL) 1.029 ± 0.019 1.027 ± 0.021 1.021 ± 0.018 1.020 ± 0.017
Total body fat (%)
Two-component model 31.4 ± 9.0 2 31.8 ± 10.1 3 32.7 ± 8.8 4 33.8 ± 8.5 5,6
Three-component model 7 33.0 ± 7.9 33.2 ± 7.7 33.1 ± 7.9 35.2 ± 6.8
p for difference 8 0.031 0.16 0.49 0.043
1 Mean ± SD, n = 17; 2 Calculated using Equation (2) and fat-free mass density 1.1
g/mL [6,13]; 3 Calculated using Equation (2) and fat-free mass density 1.099 g/mL [2];
4 Calculated using Equation (2) and fat-free mass density 1.092 g/mL [2]; 5 Calculated
using Equation (2) and fat-free mass density 1.094 g/mL [5]; 6 The corresponding result
calculated using Equation (2) and fat-free mass density 1.1 g/mL [6,13] is 35.4% ± 8.3%
total body fat, which does not differ significantly from the corresponding value, assessed
by means of the three-component model; 7 Calculated using Equation (1); 8 Student’s
t test for paired observations.
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Figure 1. Total body fat, assessed using a three-component model (y) versus total body fat, 
assessed using a two-component model (x) in 17 healthy women [12] plotted around the line 
of identity. The fat-free mass density used in the two-component model is also given.  
(A) Before pregnancy, FFM density = 1.1 g/mL [6,13]; (B) Gestational week 14,  
FFM density = 1.099 g/mL [2]; (C) Gestational week 32, FFM density = 1.092 g/mL [2];  
(D) 2 weeks postpartum, FFM d nsity = 1.094 g/mL [5]. FFM, fat-free mass; TBF3CM, total 
body fat assessed using a thre -co pon nt model; TBF2CM, total body fat, assessed using a 
two-component model. 
 
Figure 2 shows a Bland and Altman evaluation of our data. 2SD corresponds to 7.75% and 4.44% 
TBF at gestational weeks 14 and 32, respectively. The corresponding values before pregnancy and  
2 weeks postpartum were 5.67% and 5.22% TBF, respectively. At gestational week 14 and 2 weeks 
postpartum, significant relationships were found between TBF (%), assessed by means of the  
2CM minus TBF (%) assessed by means of the 3CM, on the one hand, and the average of these  
two estimates, on the other hand. The corresponding relationships before pregnancy and in gestational 

































































Figure 1. Total body fat, assessed using a three-component model (y) versus total
body fat, assessed using a two-component model (x) in 17 healthy women [12] plotted
around the line of identity. The fat-free mass density used in the two-component model
is also given. (A) Before pregnancy, FFM density = 1.1 g/mL [6,13]; (B) Gestational
week 14, FFM density = 1.099 g/mL [2]; (C) Gestational week 32, FFM
density = 1.092 g/mL [2]; (D) 2 weeks postpartum, FFM density = 1.094 g/mL [5].
FFM, fat-free mass; TBF3CM, total body fat assessed using a three-component model;
TBF2CM, total body fat, assessed using a two-component model.
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Figure 2. A Bland and Altman evaluation of a two-component model 1, based on body 
density, for assessing TBF (%) in women before pregnancy, at gestational weeks 14 and 32 
and 2 weeks postpartum when compared to reference estimates of TBF (%) obtained by 
means of a three-component model 2. The figure shows the average and 2SD of the difference 
between the two estimates and the correlation coefficient (r) and p-value for the relationship 
obtained when (TBF2CM − TBF3CM) (%) (y) is regressed on (TBF2CM + TBF3CM)/2 (%) (x). 
When r is significant (p < 0.05), the regression equation for this relationship is given.  
(A) Before pregnancy, (TBF2CM − TBF3CM) = −1.63%, 2SD = 5.67%, r = 0.39 (p = 0.12);  
(B) Gestational week 14, (TBF2CM − TBF3CM) = −1.39%, 2SD = 7.75%, r = 0.61 (p = 0.009), 
y = 0.27x − 10.2; (C) Gestational week 32, (TBF2CM − TBF3CM) = −0.38%, 2SD = 4.44%,  
r = 0.40 (p = 0.12); (D) 2 weeks postpartum: (TBF2CM − TBF3CM) = −1.39%, 2SD = 5.22%, 
r = 0.63 (p = 0.006), y = 0.22x − 8.9. Using Equation (2) and the fat-free mass density  
1.1 g/mL [6,13]: (TBF2CM − TBF3CM) = −0.25%, 2SD = 5.93%, r = 0.59 (p = 0.014),  
y = 0.19x − 6.6. TBF, total body fat; TBF2CM, total body fat assessed using the two-
component model; TBF3CM, total body fat assessed using the three-component model. 
 
1 The two-component model is based on Equation (2) and the fat-free mass density 1.1 g/mL (before  
pregnancy) [6,13], 1.099 g/mL (gestational week 14) [2], 1.092 g/mL (gestational week 32) [2] and 1.094 g/mL 
(2 weeks postpartum) [5]; 2 n = 17.  
3.2. FFM Density and Its Variability 
Table 2 shows estimated average FFM density and its variability before pregnancy, at gestational 
weeks 14 and 32, and 2 weeks postpartum. FFM density was 1.106, 1.104, 1.093 and 1.099 g/mL, before 
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Figure 2. A Bland and Altman evaluation of a two-component model 1, based on
body density, for assessing TBF (%) in women before pregnancy, at gestational
weeks 14 and 32 and 2 weeks postpartum when compared to reference estimates of
TBF (%) obtained by means of a three-component model 2. The figure shows the
average and 2SD of the difference between the two estimates and the correlation
coefficient (r) and p-value for the relationship obtained when (TBF2CM − TBF3CM)
(%) (y) is regressed on (TBF2CM + TBF3CM)/2 (%) (x). When r is significant (p < 0.05),
the regression equation for this relationship is given. (A) Before pregnancy,
(TBF2CM − TBF3CM) = −1.63%, 2SD = 5.67%, r = 0.39 (p = 0.12); (B) Gestational week
14, (TBF2CM − TBF3CM) = −1.39%, 2SD = 7.75%, r = 0.61 (p = 0.009), y = 0.27x − 10.2;
(C) Gestational week 32, (TBF2CM − TBF3CM) = −0.38%, 2SD = 4.44%, r = 0.40
(p = 0.12); (D) 2 weeks postpartum: (TBF2CM − TBF3CM) = −1.39%, 2SD = 5.22%,
r = 0.63 (p = 0.006), y = 0.22x − 8.9. Using Equation (2) and the fat-free mass
density 1.1 g/mL [6,13]: (TBF2CM − TBF3CM) = −0.25%, 2SD = 5.93%, r = 0.59
(p = 0.014), y = 0.19x − 6.6. TBF, total body fat; TBF2CM, total body fat assessed
using the two-component model; TBF3CM, total body fat assessed using the
three-component model. 1 The two-component model is based on Equation
(2) and the fat-free mass density 1.1 g/mL (before pregnancy) [6,13], 1.099 g/mL
(gestational week 14) [2], 1.092 g/mL (gestational week 32) [2] and 1.094 g/mL
(2 weeks postpartum) [5]; 2 n = 17.
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3.2. FFM Density and Its Variability
Table 2 shows estimated average FFM density and its variability before
pregnancy, at gestational weeks 14 and 32, and 2 weeks postpartum. FFM density
was 1.106, 1.104, 1.093 and 1.099 g/mL, before pregnancy, at gestational weeks 14 and
32, and 2 weeks postpartum, respectively. No significant differences between these
values and the corresponding values published by van Raaij et al. [2] were observed
at gestational weeks 14 or 32. Table 2 also shows the biological variability of FFM
density, estimated on the same occasions and based on the two sets of methodological
errors. These two sets are described in footnotes 3 and 4 of Table 2. Before pregnancy,
biological variability was 0.007 and 0.009 g/mL when using the first and second sets
of assumptions, respectively. The impact of pregnancy on the biological variability
of FFM density was smaller in gestational week 32 than in gestational week 14, and
this was the case for both sets of assumptions.
4. Discussion
The 2CM is considered to be capable of generating useful body composition
results in healthy adult subjects in the general population if a valid figure for FFM
density is used [7]. The data in Figure 1 show that there is considerable agreement
between the 2CM and the 3CM regarding their capacity to assess TBF (%) before,
during and after pregnancy, although the results of the two models may differ for
individual women. Thus our data support previous statements [3,4] that the 2CM,
based on appropriate FFM density values, can provide useful body composition
results also during pregnancy. However, as discussed below, the accuracy of such
results may vary during pregnancy.
In this paper, we use a 3CM to obtain reference estimates of TBF before,
during and after pregnancy, although a four-component model (4CM) is generally
regarded as the best option when evaluating simpler body composition methods [5,6].
A commonly used 4CM calculates TBF from body weight, TBW, DB and body mineral
and has the advantage over a 3CM of avoiding assumptions about the mineral content
of the body [6]. However, the theoretical errors in estimates of TBF (%), associated
with variations in FFM composition, are not very different between the 4CM and
the 3CM [11]. This can be reconciled with results in women showing that the water
content of FFM was significantly related to the difference in TBF (%) assessed by
means of a 2CM versus a 4CM, while the corresponding relationship for the mineral
content of FFM was weaker and not significant [19]. Thus a 3CM, based on TBW,
DB and body weight can provide useful reference estimates of body composition in
healthy women.
Application of a 4CM in pregnant women is not regarded as appropriate since
an assessment of body mineral requires the use of dual-energy X-ray absorptiometry,
a technique that is unacceptable for such subjects due to radiation exposure. The
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body mineral content increases during gestation due to the contribution of the fetus.
In gestational week 32, the fetus increases the contents of osseous and non-osseous
minerals in the pregnant body, by about 1% each [6,20,21]. Such changes have only
a minor impact on TBF (%), calculated by means of the 3CM, since Elia estimated
that increases in the body mineral content as high as 20%–25% affect such estimates
by less than one unit TBF (%) [11]. Furthermore, for women in gestational week 36,
Hopkinson et al. [5] compared the 3CM to the 4CM and found the results to be in
close agreement. In this comparison, the body mineral content required by the 4CM
was measured 2 weeks postpartum and the authors [5] reckoned that the magnitude
of changes in this variable between week 36 of gestation and 2 weeks postpartum
was too small to have any appreciable effect on the results. Based on this evidence,
we conclude that the 3CM provides useful reference estimates of body composition
also in pregnant women.
Our estimated FFM density of women prior to pregnancy is in agreement with
the figure, 1.1 g/mL, which is the value generally regarded as an appropriate average
for the general population [7]. However, it may be relevant to note that the 2CM
underestimated TBF of our women before pregnancy when this FFM density was
used and Fields et al. [19] reported a similar underestimate by the 2CM in their study
on healthy women also using this FFM density. This suggests that women may have
a slightly higher FFM density than 1.100 g/mL, which is the value for the reference
body [6]. However, confirming this suggestion is difficult, since available techniques
for assessing FFM density in vivo may not be accurate enough. Small variations in
this variable between different populations of women may also be present.
We estimated average FFM density 2 weeks postpartum at 1.099 g/mL, which is
slightly higher than 1.094 g/mL as reported by Hopkinson et al. [5]. A consequence
of using this lower value is that the 2CM underestimates TBF (%) postpartum.
Furthermore, as shown by the Bland and Altman evaluation, the magnitude of
the difference between the two models is associated with TBF (%) of the women.
Using an FFM density of 1.1 g/mL 2 weeks postpartum produces more satisfactory
average estimates of TBF (%), but, as indicated in Figure 2, the difference between





















































































































































































































































































































































































































































































































































































































































































































































































































Our results regarding the biological variability of FFM density were obtained
using two sets of methodological errors. As previously discussed [12] we found both
sets to be reasonable and justified and we were not able to determine whether one
was superior to the other. Prior to pregnancy, we found the biological variability
of FFM density to be 0.007 and 0.009 g/mL, respectively, using the two sets of
methodological errors. This is comparable to the published values of 0.0084 g/mL [6]
and 0.0073 g/mL [22]. This rather large biological variability of FFM density has a
negative impact on the accuracy of the 2CM in non-pregnant women. The finding
that the biological variability in FFM density is lower at gestational week 32 but
higher at gestational week 14 when compared to the value before pregnancy is a
corollary of our previous findings [12] regarding the biological variability of FFM
hydration at gestational weeks 14 and 32 versus before pregnancy. These observations
are consistent with data in Figure 2 showing that the 2SD value at gestational week
32 is only 4.44% TBF as opposed to 5.67% and 7.75% TBF before pregnancy and at
gestational week 14, respectively. These observations indicate that the accuracy of
the 2CM, when based on published FFM density values [2], is better at gestational
week 32 than at gestational week 14.
Published values for FFM density in pregnant women [2] are based on data
by Hytten [1], collected in British women several decades ago. Nevertheless, the
differences between these values [2] and our estimates of FFM density during
pregnancy were small and not significant. This supports the conclusion that the
FFM density values by van Raaij et al. [2] produce valid average estimates of TBF
of women when used in a 2CM at gestational weeks 14 and 32. Furthermore,
we suggest that these observations can be reconciled with the statement that the
influence of pregnancy on FFM density and composition is predictable and part of
the regulatory processes needed to meet the physiological changes inherent in this
physiological state.
A limitation of this study is that the number of women is small, while a strength
is that the same women were studied before, during and after pregnancy. This made
it possible to demonstrate how pregnancy influences FFM density and its variability
which is important information for assessing body composition during pregnancy.
It is also relevant to emphasize that our results were obtained in healthy women
being pregnant with one fetus and may not be valid for women not meeting these
criteria. Furthermore, our results were obtained in women with a BMI distribution
typical for Swedish women [14] and may not be appropriate in populations with a
different pattern of body weight.
5. Conclusions
This study confirmed that FFM density values at gestational weeks 14 and 32
are in close agreement with those published by van Raaij et al. [2]. We found the
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corresponding value 2 weeks postpartum to be close to 1.1 g/mL which is the figure
commonly regarded as an appropriate average for healthy non-pregnant adults.
Furthermore, our results showed that a 2CM, based on estimates of DB and the FFM
density values reported by van Raaij et al. [2], is able to generate body composition
results in gestational week 32 that are at least as accurate as those obtained in
the pre-pregnant state with the same methodology when using a FFM density of
1.1 g/mL. Corresponding values obtained in gestational week 14 were found to be
slightly less accurate than those obtained before pregnancy.
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